id	sid	tid	token	lemma	pos
ajlm-1720	1	1	abstract	abstract	ADJ
ajlm-1720	1	2	introduction	introduction	NOUN
ajlm-1720	1	3	methods	method	NOUN
ajlm-1720	1	4	results	result	VERB
ajlm-1720	1	5	discussion	discussion	NOUN
ajlm-1720	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1720	1	7	references	reference	NOUN
ajlm-1720	1	8	about	about	ADP
ajlm-1720	1	9	the	the	DET
ajlm-1720	1	10	author(s	author(s	NOUN
ajlm-1720	1	11	)	)	PUNCT
ajlm-1720	1	12	leanne	leanne	PROPN
ajlm-1720	1	13	swart	swart	PROPN
ajlm-1720	1	14	department	department	PROPN
ajlm-1720	1	15	of	of	ADP
ajlm-1720	1	16	molecular	molecular	ADJ
ajlm-1720	1	17	medicine	medicine	NOUN
ajlm-1720	1	18	and	and	CCONJ
ajlm-1720	1	19	haematology	haematology	NOUN
ajlm-1720	1	20	,	,	PUNCT
ajlm-1720	1	21	charlotte	charlotte	PROPN
ajlm-1720	1	22	maxeke	maxeke	PROPN
ajlm-1720	1	23	johannesburg	johannesburg	PROPN
ajlm-1720	1	24	academic	academic	ADJ
ajlm-1720	1	25	hospital	hospital	NOUN
ajlm-1720	1	26	,	,	PUNCT
ajlm-1720	1	27	national	national	PROPN
ajlm-1720	1	28	health	health	PROPN
ajlm-1720	1	29	laboratory	laboratory	PROPN
ajlm-1720	1	30	service	service	PROPN
ajlm-1720	1	31	,	,	PUNCT
ajlm-1720	1	32	johannesburg	johannesburg	PROPN
ajlm-1720	1	33	,	,	PUNCT
ajlm-1720	1	34	south	south	PROPN
ajlm-1720	1	35	africa	africa	PROPN
ajlm-1720	1	36	department	department	PROPN
ajlm-1720	1	37	of	of	ADP
ajlm-1720	1	38	molecular	molecular	ADJ
ajlm-1720	1	39	medicine	medicine	NOUN
ajlm-1720	1	40	and	and	CCONJ
ajlm-1720	1	41	haematology	haematology	NOUN
ajlm-1720	1	42	,	,	PUNCT
ajlm-1720	1	43	faculty	faculty	NOUN
ajlm-1720	1	44	of	of	ADP
ajlm-1720	1	45	health	health	NOUN
ajlm-1720	1	46	sciences	sciences	PROPN
ajlm-1720	1	47	,	,	PUNCT
ajlm-1720	1	48	university	university	NOUN
ajlm-1720	1	49	of	of	ADP
ajlm-1720	1	50	the	the	DET
ajlm-1720	1	51	witwatersrand	witwatersrand	NOUN
ajlm-1720	1	52	,	,	PUNCT
ajlm-1720	1	53	johannesburg	johannesburg	PROPN
ajlm-1720	1	54	,	,	PUNCT
ajlm-1720	1	55	south	south	PROPN
ajlm-1720	1	56	africa	africa	PROPN
ajlm-1720	1	57	melanie	melanie	PROPN
ajlm-1720	1	58	pretorius	pretorius	PROPN
ajlm-1720	1	59	department	department	PROPN
ajlm-1720	1	60	of	of	ADP
ajlm-1720	1	61	molecular	molecular	ADJ
ajlm-1720	1	62	medicine	medicine	NOUN
ajlm-1720	1	63	and	and	CCONJ
ajlm-1720	1	64	haematology	haematology	NOUN
ajlm-1720	1	65	,	,	PUNCT
ajlm-1720	1	66	charlotte	charlotte	PROPN
ajlm-1720	1	67	maxeke	maxeke	PROPN
ajlm-1720	1	68	johannesburg	johannesburg	PROPN
ajlm-1720	1	69	academic	academic	ADJ
ajlm-1720	1	70	hospital	hospital	NOUN
ajlm-1720	1	71	,	,	PUNCT
ajlm-1720	1	72	national	national	PROPN
ajlm-1720	1	73	health	health	PROPN
ajlm-1720	1	74	laboratory	laboratory	PROPN
ajlm-1720	1	75	service	service	PROPN
ajlm-1720	1	76	,	,	PUNCT
ajlm-1720	1	77	johannesburg	johannesburg	PROPN
ajlm-1720	1	78	,	,	PUNCT
ajlm-1720	1	79	south	south	PROPN
ajlm-1720	1	80	africa	africa	PROPN
ajlm-1720	1	81	department	department	PROPN
ajlm-1720	1	82	of	of	ADP
ajlm-1720	1	83	molecular	molecular	ADJ
ajlm-1720	1	84	medicine	medicine	NOUN
ajlm-1720	1	85	and	and	CCONJ
ajlm-1720	1	86	haematology	haematology	NOUN
ajlm-1720	1	87	,	,	PUNCT
ajlm-1720	1	88	faculty	faculty	NOUN
ajlm-1720	1	89	of	of	ADP
ajlm-1720	1	90	health	health	NOUN
ajlm-1720	1	91	sciences	sciences	PROPN
ajlm-1720	1	92	,	,	PUNCT
ajlm-1720	1	93	university	university	NOUN
ajlm-1720	1	94	of	of	ADP
ajlm-1720	1	95	the	the	DET
ajlm-1720	1	96	witwatersrand	witwatersrand	NOUN
ajlm-1720	1	97	,	,	PUNCT
ajlm-1720	1	98	johannesburg	johannesburg	PROPN
ajlm-1720	1	99	,	,	PUNCT
ajlm-1720	1	100	south	south	PROPN
ajlm-1720	1	101	africa	africa	PROPN
ajlm-1720	1	102	denise	denise	PROPN
ajlm-1720	1	103	lawrie	lawrie	PROPN
ajlm-1720	1	104	department	department	PROPN
ajlm-1720	1	105	of	of	ADP
ajlm-1720	1	106	molecular	molecular	ADJ
ajlm-1720	1	107	medicine	medicine	NOUN
ajlm-1720	1	108	and	and	CCONJ
ajlm-1720	1	109	haematology	haematology	NOUN
ajlm-1720	1	110	,	,	PUNCT
ajlm-1720	1	111	charlotte	charlotte	PROPN
ajlm-1720	1	112	maxeke	maxeke	PROPN
ajlm-1720	1	113	johannesburg	johannesburg	PROPN
ajlm-1720	1	114	academic	academic	ADJ
ajlm-1720	1	115	hospital	hospital	NOUN
ajlm-1720	1	116	,	,	PUNCT
ajlm-1720	1	117	national	national	PROPN
ajlm-1720	1	118	health	health	PROPN
ajlm-1720	1	119	laboratory	laboratory	PROPN
ajlm-1720	1	120	service	service	PROPN
ajlm-1720	1	121	,	,	PUNCT
ajlm-1720	1	122	johannesburg	johannesburg	PROPN
ajlm-1720	1	123	,	,	PUNCT
ajlm-1720	1	124	south	south	PROPN
ajlm-1720	1	125	africa	africa	PROPN
ajlm-1720	1	126	department	department	PROPN
ajlm-1720	1	127	of	of	ADP
ajlm-1720	1	128	molecular	molecular	ADJ
ajlm-1720	1	129	medicine	medicine	NOUN
ajlm-1720	1	130	and	and	CCONJ
ajlm-1720	1	131	haematology	haematology	NOUN
ajlm-1720	1	132	,	,	PUNCT
ajlm-1720	1	133	faculty	faculty	NOUN
ajlm-1720	1	134	of	of	ADP
ajlm-1720	1	135	health	health	NOUN
ajlm-1720	1	136	sciences	sciences	PROPN
ajlm-1720	1	137	,	,	PUNCT
ajlm-1720	1	138	university	university	NOUN
ajlm-1720	1	139	of	of	ADP
ajlm-1720	1	140	the	the	DET
ajlm-1720	1	141	witwatersrand	witwatersrand	NOUN
ajlm-1720	1	142	,	,	PUNCT
ajlm-1720	1	143	johannesburg	johannesburg	PROPN
ajlm-1720	1	144	,	,	PUNCT
ajlm-1720	1	145	south	south	PROPN
ajlm-1720	1	146	africa	africa	PROPN
ajlm-1720	1	147	deborah	deborah	PROPN
ajlm-1720	1	148	k.	k.	PROPN
ajlm-1720	1	149	glencross	glencross	PROPN
ajlm-1720	1	150	department	department	PROPN
ajlm-1720	1	151	of	of	ADP
ajlm-1720	1	152	molecular	molecular	ADJ
ajlm-1720	1	153	medicine	medicine	NOUN
ajlm-1720	1	154	and	and	CCONJ
ajlm-1720	1	155	haematology	haematology	NOUN
ajlm-1720	1	156	,	,	PUNCT
ajlm-1720	1	157	charlotte	charlotte	PROPN
ajlm-1720	1	158	maxeke	maxeke	PROPN
ajlm-1720	1	159	johannesburg	johannesburg	PROPN
ajlm-1720	1	160	academic	academic	ADJ
ajlm-1720	1	161	hospital	hospital	NOUN
ajlm-1720	1	162	,	,	PUNCT
ajlm-1720	1	163	national	national	PROPN
ajlm-1720	1	164	health	health	PROPN
ajlm-1720	1	165	laboratory	laboratory	PROPN
ajlm-1720	1	166	service	service	PROPN
ajlm-1720	1	167	,	,	PUNCT
ajlm-1720	1	168	johannesburg	johannesburg	PROPN
ajlm-1720	1	169	,	,	PUNCT
ajlm-1720	1	170	south	south	PROPN
ajlm-1720	1	171	africa	africa	PROPN
ajlm-1720	1	172	department	department	PROPN
ajlm-1720	1	173	of	of	ADP
ajlm-1720	1	174	molecular	molecular	ADJ
ajlm-1720	1	175	medicine	medicine	NOUN
ajlm-1720	1	176	and	and	CCONJ
ajlm-1720	1	177	haematology	haematology	NOUN
ajlm-1720	1	178	,	,	PUNCT
ajlm-1720	1	179	faculty	faculty	NOUN
ajlm-1720	1	180	of	of	ADP
ajlm-1720	1	181	health	health	NOUN
ajlm-1720	1	182	sciences	sciences	PROPN
ajlm-1720	1	183	,	,	PUNCT
ajlm-1720	1	184	university	university	NOUN
ajlm-1720	1	185	of	of	ADP
ajlm-1720	1	186	the	the	DET
ajlm-1720	1	187	witwatersrand	witwatersrand	NOUN
ajlm-1720	1	188	,	,	PUNCT
ajlm-1720	1	189	johannesburg	johannesburg	PROPN
ajlm-1720	1	190	,	,	PUNCT
ajlm-1720	1	191	south	south	PROPN
ajlm-1720	1	192	africa	africa	PROPN
ajlm-1720	1	193	citation	citation	PROPN
ajlm-1720	1	194	swart	swart	PROPN
ajlm-1720	1	195	l	l	PROPN
ajlm-1720	1	196	,	,	PUNCT
ajlm-1720	1	197	pretorius	pretorius	PROPN
ajlm-1720	1	198	m	m	PROPN
ajlm-1720	1	199	,	,	PUNCT
ajlm-1720	1	200	lawrie	lawrie	PROPN
ajlm-1720	1	201	d	d	PROPN
ajlm-1720	1	202	,	,	PUNCT
ajlm-1720	1	203	glencross	glencross	ADJ
ajlm-1720	1	204	dk	dk	PROPN
ajlm-1720	1	205	.	.	PROPN
ajlm-1720	1	206	commercial	commercial	ADJ
ajlm-1720	1	207	duraclone	duraclone	NOUN
ajlm-1720	1	208	panels	panel	NOUN
ajlm-1720	1	209	for	for	ADP
ajlm-1720	1	210	extending	extend	VERB
ajlm-1720	1	211	the	the	DET
ajlm-1720	1	212	repertoire	repertoire	NOUN
ajlm-1720	1	213	of	of	ADP
ajlm-1720	1	214	multicolour	multicolour	ADJ
ajlm-1720	1	215	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	1	216	panels	panel	NOUN
ajlm-1720	1	217	in	in	ADP
ajlm-1720	1	218	an	an	DET
ajlm-1720	1	219	academic	academic	ADJ
ajlm-1720	1	220	flow	flow	NOUN
ajlm-1720	1	221	cytometry	cytometry	NOUN
ajlm-1720	1	222	laboratory	laboratory	NOUN
ajlm-1720	1	223	in	in	ADP
ajlm-1720	1	224	south	south	PROPN
ajlm-1720	1	225	africa	africa	PROPN
ajlm-1720	1	226	.	.	PUNCT
ajlm-1720	2	1	afr	afr	PROPN
ajlm-1720	2	2	j	j	PROPN
ajlm-1720	2	3	lab	lab	PROPN
ajlm-1720	2	4	med	med	PROPN
ajlm-1720	2	5	.	.	PUNCT
ajlm-1720	3	1	2022;11(1	2022;11(1	NUM
ajlm-1720	3	2	)	)	PUNCT
ajlm-1720	3	3	,	,	PUNCT
ajlm-1720	3	4	a1720	a1720	NOUN
ajlm-1720	3	5	.	.	PUNCT
ajlm-1720	3	6	https://doi.org/10.4102/ajlm.v11i1.1720	https://doi.org/10.4102/ajlm.v11i1.1720	NOUN
ajlm-1720	3	7	original	original	ADJ
ajlm-1720	3	8	research	research	NOUN
ajlm-1720	3	9	commercial	commercial	ADJ
ajlm-1720	3	10	duraclone	duraclone	NOUN
ajlm-1720	3	11	panels	panel	NOUN
ajlm-1720	3	12	for	for	ADP
ajlm-1720	3	13	extending	extend	VERB
ajlm-1720	3	14	the	the	DET
ajlm-1720	3	15	repertoire	repertoire	NOUN
ajlm-1720	3	16	of	of	ADP
ajlm-1720	3	17	multicolour	multicolour	ADJ
ajlm-1720	3	18	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	3	19	panels	panel	NOUN
ajlm-1720	3	20	in	in	ADP
ajlm-1720	3	21	an	an	DET
ajlm-1720	3	22	academic	academic	ADJ
ajlm-1720	3	23	flow	flow	NOUN
ajlm-1720	3	24	cytometry	cytometry	NOUN
ajlm-1720	3	25	laboratory	laboratory	NOUN
ajlm-1720	3	26	in	in	ADP
ajlm-1720	3	27	south	south	PROPN
ajlm-1720	3	28	africa	africa	PROPN
ajlm-1720	3	29	leanne	leanne	PROPN
ajlm-1720	3	30	swart	swart	PROPN
ajlm-1720	3	31	,	,	PUNCT
ajlm-1720	3	32	melanie	melanie	PROPN
ajlm-1720	3	33	pretorius	pretorius	PROPN
ajlm-1720	3	34	,	,	PUNCT
ajlm-1720	3	35	denise	denise	PROPN
ajlm-1720	3	36	lawrie	lawrie	PROPN
ajlm-1720	3	37	,	,	PUNCT
ajlm-1720	3	38	deborah	deborah	PROPN
ajlm-1720	3	39	k.	k.	PROPN
ajlm-1720	3	40	glencross	glencross	PROPN
ajlm-1720	3	41	received	receive	VERB
ajlm-1720	3	42	:	:	PUNCT
ajlm-1720	3	43	31	31	NUM
ajlm-1720	3	44	aug	aug	PROPN
ajlm-1720	3	45	.	.	PROPN
ajlm-1720	3	46	2021	2021	NUM
ajlm-1720	3	47	;	;	PUNCT
ajlm-1720	3	48	accepted	accept	VERB
ajlm-1720	3	49	:	:	PUNCT
ajlm-1720	3	50	28	28	NUM
ajlm-1720	3	51	july	july	PROPN
ajlm-1720	3	52	2022	2022	NUM
ajlm-1720	3	53	;	;	PUNCT
ajlm-1720	3	54	published	publish	VERB
ajlm-1720	3	55	:	:	PUNCT
ajlm-1720	3	56	29	29	NUM
ajlm-1720	3	57	nov	nov	NOUN
ajlm-1720	3	58	.	.	PROPN
ajlm-1720	4	1	2022	2022	NUM
ajlm-1720	4	2	copyright	copyright	NOUN
ajlm-1720	4	3	:	:	PUNCT
ajlm-1720	4	4	©	©	PROPN
ajlm-1720	4	5	2022	2022	NUM
ajlm-1720	4	6	.	.	PUNCT
ajlm-1720	5	1	the	the	DET
ajlm-1720	5	2	author(s	author(s	PROPN
ajlm-1720	5	3	)	)	PUNCT
ajlm-1720	5	4	.	.	PUNCT
ajlm-1720	6	1	licensee	licensee	NOUN
ajlm-1720	6	2	:	:	PUNCT
ajlm-1720	6	3	aosis	aosis	NOUN
ajlm-1720	6	4	.	.	PUNCT
ajlm-1720	7	1	this	this	PRON
ajlm-1720	7	2	is	be	AUX
ajlm-1720	7	3	an	an	DET
ajlm-1720	7	4	open	open	ADJ
ajlm-1720	7	5	access	access	NOUN
ajlm-1720	7	6	article	article	NOUN
ajlm-1720	7	7	distributed	distribute	VERB
ajlm-1720	7	8	under	under	ADP
ajlm-1720	7	9	the	the	DET
ajlm-1720	7	10	terms	term	NOUN
ajlm-1720	7	11	of	of	ADP
ajlm-1720	7	12	the	the	DET
ajlm-1720	7	13	creative	creative	ADJ
ajlm-1720	7	14	commons	common	NOUN
ajlm-1720	7	15	attribution	attribution	NOUN
ajlm-1720	7	16	license	license	NOUN
ajlm-1720	7	17	,	,	PUNCT
ajlm-1720	7	18	which	which	PRON
ajlm-1720	7	19	permits	permit	VERB
ajlm-1720	7	20	unrestricted	unrestricted	ADJ
ajlm-1720	7	21	use	use	NOUN
ajlm-1720	7	22	,	,	PUNCT
ajlm-1720	7	23	distribution	distribution	NOUN
ajlm-1720	7	24	,	,	PUNCT
ajlm-1720	7	25	and	and	CCONJ
ajlm-1720	7	26	reproduction	reproduction	NOUN
ajlm-1720	7	27	in	in	ADP
ajlm-1720	7	28	any	any	DET
ajlm-1720	7	29	medium	medium	NOUN
ajlm-1720	7	30	,	,	PUNCT
ajlm-1720	7	31	provided	provide	VERB
ajlm-1720	7	32	the	the	DET
ajlm-1720	7	33	original	original	ADJ
ajlm-1720	7	34	work	work	NOUN
ajlm-1720	7	35	is	be	AUX
ajlm-1720	7	36	properly	properly	ADV
ajlm-1720	7	37	cited	cite	VERB
ajlm-1720	7	38	.	.	PUNCT
ajlm-1720	8	1	abstract	abstract	ADJ
ajlm-1720	8	2	background	background	NOUN
ajlm-1720	8	3	:	:	PUNCT
ajlm-1720	8	4	commercial	commercial	ADJ
ajlm-1720	8	5	multicolour	multicolour	ADJ
ajlm-1720	8	6	fixed	fix	VERB
ajlm-1720	8	7	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	8	8	panels	panel	NOUN
ajlm-1720	8	9	can	can	AUX
ajlm-1720	8	10	improve	improve	VERB
ajlm-1720	8	11	flow	flow	NOUN
ajlm-1720	8	12	cytometric	cytometric	ADJ
ajlm-1720	8	13	diagnostic	diagnostic	ADJ
ajlm-1720	8	14	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	8	15	repertoire	repertoire	NOUN
ajlm-1720	8	16	.	.	PUNCT
ajlm-1720	9	1	objective	objective	NOUN
ajlm-1720	9	2	:	:	PUNCT
ajlm-1720	9	3	this	this	DET
ajlm-1720	9	4	study	study	NOUN
ajlm-1720	9	5	validated	validate	VERB
ajlm-1720	9	6	the	the	PRON
ajlm-1720	9	7	commercially	commercially	ADV
ajlm-1720	9	8	available	available	ADJ
ajlm-1720	9	9	,	,	PUNCT
ajlm-1720	9	10	standardised	standardised	ADJ
ajlm-1720	9	11	beckman	beckman	PROPN
ajlm-1720	9	12	coulter	coulter	PROPN
ajlm-1720	9	13	lyophilised	lyophilise	VERB
ajlm-1720	9	14	duraclone	duraclone	NOUN
ajlm-1720	9	15	re	re	ADP
ajlm-1720	9	16	panels	panel	NOUN
ajlm-1720	9	17	to	to	PART
ajlm-1720	9	18	discriminate	discriminate	VERB
ajlm-1720	9	19	specific	specific	ADJ
ajlm-1720	9	20	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	9	21	subtypes	subtype	NOUN
ajlm-1720	9	22	.	.	PUNCT
ajlm-1720	10	1	methods	method	NOUN
ajlm-1720	10	2	:	:	PUNCT
ajlm-1720	10	3	we	we	PRON
ajlm-1720	10	4	compared	compare	VERB
ajlm-1720	10	5	the	the	DET
ajlm-1720	10	6	diagnostic	diagnostic	ADJ
ajlm-1720	10	7	capability	capability	NOUN
ajlm-1720	10	8	of	of	ADP
ajlm-1720	10	9	the	the	DET
ajlm-1720	10	10	duraclone	duraclone	NOUN
ajlm-1720	10	11	acute	acute	NOUN
ajlm-1720	10	12	leukaemia	leukaemia	PROPN
ajlm-1720	10	13	b	b	PROPN
ajlm-1720	10	14	(	(	PUNCT
ajlm-1720	10	15	alb	alb	PROPN
ajlm-1720	10	16	)	)	PUNCT
ajlm-1720	10	17	,	,	PUNCT
ajlm-1720	10	18	chronic	chronic	ADJ
ajlm-1720	10	19	leukaemia	leukaemia	NOUN
ajlm-1720	10	20	b	b	PROPN
ajlm-1720	10	21	(	(	PUNCT
ajlm-1720	10	22	clb	clb	NOUN
ajlm-1720	10	23	)	)	PUNCT
ajlm-1720	10	24	,	,	PUNCT
ajlm-1720	10	25	and	and	CCONJ
ajlm-1720	10	26	plasma	plasma	NOUN
ajlm-1720	10	27	cells	cell	NOUN
ajlm-1720	10	28	(	(	PUNCT
ajlm-1720	10	29	pc	pc	NOUN
ajlm-1720	10	30	)	)	PUNCT
ajlm-1720	10	31	panels	panel	NOUN
ajlm-1720	10	32	to	to	ADP
ajlm-1720	10	33	the	the	DET
ajlm-1720	10	34	predicate	predicate	NOUN
ajlm-1720	10	35	second	second	ADJ
ajlm-1720	10	36	-	-	PUNCT
ajlm-1720	10	37	line	line	NOUN
ajlm-1720	10	38	panels	panel	NOUN
ajlm-1720	10	39	in	in	ADP
ajlm-1720	10	40	charlotte	charlotte	PROPN
ajlm-1720	10	41	maxeke	maxeke	PROPN
ajlm-1720	10	42	johannesburg	johannesburg	PROPN
ajlm-1720	10	43	academic	academic	PROPN
ajlm-1720	10	44	hospital	hospital	PROPN
ajlm-1720	10	45	,	,	PUNCT
ajlm-1720	10	46	johannesburg	johannesburg	PROPN
ajlm-1720	10	47	,	,	PUNCT
ajlm-1720	10	48	south	south	PROPN
ajlm-1720	10	49	africa	africa	PROPN
ajlm-1720	10	50	,	,	PUNCT
ajlm-1720	10	51	from	from	ADP
ajlm-1720	10	52	april	april	PROPN
ajlm-1720	10	53	to	to	ADP
ajlm-1720	10	54	august	august	PROPN
ajlm-1720	10	55	2020	2020	NUM
ajlm-1720	10	56	.	.	PUNCT
ajlm-1720	11	1	clinical	clinical	ADJ
ajlm-1720	11	2	diagnostic	diagnostic	ADJ
ajlm-1720	11	3	concordance	concordance	NOUN
ajlm-1720	11	4	between	between	ADP
ajlm-1720	11	5	the	the	DET
ajlm-1720	11	6	in	in	ADP
ajlm-1720	11	7	-	-	PUNCT
ajlm-1720	11	8	house	house	NOUN
ajlm-1720	11	9	second	second	ADJ
ajlm-1720	11	10	-	-	PUNCT
ajlm-1720	11	11	line	line	NOUN
ajlm-1720	11	12	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	11	13	(	(	PUNCT
ajlm-1720	11	14	the	the	DET
ajlm-1720	11	15	predicate	predicate	NOUN
ajlm-1720	11	16	method	method	NOUN
ajlm-1720	11	17	)	)	PUNCT
ajlm-1720	11	18	and	and	CCONJ
ajlm-1720	11	19	duraclone	duraclone	NOUN
ajlm-1720	11	20	was	be	AUX
ajlm-1720	11	21	established	establish	VERB
ajlm-1720	11	22	.	.	PUNCT
ajlm-1720	12	1	the	the	DET
ajlm-1720	12	2	alb	alb	PROPN
ajlm-1720	12	3	panels	panel	NOUN
ajlm-1720	12	4	tested	test	VERB
ajlm-1720	12	5	for	for	ADP
ajlm-1720	12	6	precursor	precursor	NOUN
ajlm-1720	12	7	b	b	NOUN
ajlm-1720	12	8	-	-	PUNCT
ajlm-1720	12	9	cell	cell	NOUN
ajlm-1720	12	10	acute	acute	ADJ
ajlm-1720	12	11	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	12	12	leukaemia	leukaemia	NOUN
ajlm-1720	12	13	(	(	PUNCT
ajlm-1720	12	14	n	n	NOUN
ajlm-1720	12	15	=	=	SYM
ajlm-1720	12	16	11	11	NUM
ajlm-1720	12	17	)	)	PUNCT
ajlm-1720	12	18	or	or	CCONJ
ajlm-1720	12	19	normal	normal	ADJ
ajlm-1720	12	20	bone	bone	NOUN
ajlm-1720	12	21	marrow	marrow	NOUN
ajlm-1720	12	22	haematogones	haematogone	NOUN
ajlm-1720	12	23	(	(	PUNCT
ajlm-1720	12	24	n	n	NOUN
ajlm-1720	12	25	=	=	SYM
ajlm-1720	12	26	9	9	NUM
ajlm-1720	12	27	)	)	PUNCT
ajlm-1720	12	28	;	;	PUNCT
ajlm-1720	12	29	clb	clb	NOUN
ajlm-1720	12	30	panels	panel	NOUN
ajlm-1720	12	31	established	establish	VERB
ajlm-1720	12	32	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	12	33	subtypes	subtype	NOUN
ajlm-1720	12	34	of	of	ADP
ajlm-1720	12	35	mature	mature	ADJ
ajlm-1720	12	36	b	b	NOUN
ajlm-1720	12	37	-	-	PUNCT
ajlm-1720	12	38	cell	cell	NOUN
ajlm-1720	12	39	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	12	40	disorders	disorder	NOUN
ajlm-1720	12	41	(	(	PUNCT
ajlm-1720	12	42	b	b	X
ajlm-1720	12	43	-	-	PUNCT
ajlm-1720	12	44	lpd	lpd	PROPN
ajlm-1720	12	45	)	)	PUNCT
ajlm-1720	12	46	(	(	PUNCT
ajlm-1720	12	47	n	n	NOUN
ajlm-1720	12	48	=	=	SYM
ajlm-1720	12	49	20	20	NUM
ajlm-1720	12	50	)	)	PUNCT
ajlm-1720	12	51	,	,	PUNCT
ajlm-1720	12	52	while	while	SCONJ
ajlm-1720	12	53	pc	pc	NOUN
ajlm-1720	12	54	panels	panel	NOUN
ajlm-1720	12	55	detected	detect	VERB
ajlm-1720	12	56	plasma	plasma	NOUN
ajlm-1720	12	57	cell	cell	NOUN
ajlm-1720	12	58	dyscrasias	dyscrasia	NOUN
ajlm-1720	12	59	(	(	PUNCT
ajlm-1720	12	60	pcd	pcd	NOUN
ajlm-1720	12	61	)	)	PUNCT
ajlm-1720	12	62	(	(	PUNCT
ajlm-1720	12	63	n	n	NOUN
ajlm-1720	12	64	=	=	NUM
ajlm-1720	12	65	17	17	NUM
ajlm-1720	12	66	)	)	PUNCT
ajlm-1720	12	67	.	.	PUNCT
ajlm-1720	13	1	flow	flow	NOUN
ajlm-1720	13	2	cytometer	cytometer	NOUN
ajlm-1720	13	3	setup	setup	NOUN
ajlm-1720	13	4	and	and	CCONJ
ajlm-1720	13	5	data	datum	NOUN
ajlm-1720	13	6	interpretation	interpretation	NOUN
ajlm-1720	13	7	to	to	PART
ajlm-1720	13	8	discriminate	discriminate	VERB
ajlm-1720	13	9	normal	normal	ADJ
ajlm-1720	13	10	and	and	CCONJ
ajlm-1720	13	11	aberrant	aberrant	ADJ
ajlm-1720	13	12	immunophenotypes	immunophenotype	NOUN
ajlm-1720	13	13	were	be	AUX
ajlm-1720	13	14	per	per	ADP
ajlm-1720	13	15	manufacturer	manufacturer	NOUN
ajlm-1720	13	16	’s	’s	PART
ajlm-1720	13	17	instructions	instruction	NOUN
ajlm-1720	13	18	.	.	PUNCT
ajlm-1720	14	1	results	result	NOUN
ajlm-1720	14	2	:	:	PUNCT
ajlm-1720	14	3	there	there	PRON
ajlm-1720	14	4	was	be	VERB
ajlm-1720	14	5	100	100	NUM
ajlm-1720	14	6	%	%	NOUN
ajlm-1720	14	7	clinical	clinical	ADJ
ajlm-1720	14	8	diagnostic	diagnostic	ADJ
ajlm-1720	14	9	concordance	concordance	NOUN
ajlm-1720	14	10	between	between	ADP
ajlm-1720	14	11	the	the	DET
ajlm-1720	14	12	predicate	predicate	NOUN
ajlm-1720	14	13	and	and	CCONJ
ajlm-1720	14	14	the	the	DET
ajlm-1720	14	15	test	test	NOUN
ajlm-1720	14	16	panels	panel	NOUN
ajlm-1720	14	17	for	for	ADP
ajlm-1720	14	18	second	second	ADJ
ajlm-1720	14	19	-	-	PUNCT
ajlm-1720	14	20	line	line	NOUN
ajlm-1720	14	21	diagnostic	diagnostic	ADJ
ajlm-1720	14	22	investigation	investigation	NOUN
ajlm-1720	14	23	of	of	ADP
ajlm-1720	14	24	b	b	X
ajlm-1720	14	25	-	-	PUNCT
ajlm-1720	14	26	all	all	PRON
ajlm-1720	14	27	(	(	PUNCT
ajlm-1720	14	28	with	with	ADP
ajlm-1720	14	29	additional	additional	ADJ
ajlm-1720	14	30	cd56	cd56	PROPN
ajlm-1720	14	31	)	)	PUNCT
ajlm-1720	14	32	,	,	PUNCT
ajlm-1720	14	33	mature	mature	VERB
ajlm-1720	14	34	b	b	PROPN
ajlm-1720	14	35	-	-	PUNCT
ajlm-1720	14	36	lpd	lpd	PROPN
ajlm-1720	14	37	(	(	PUNCT
ajlm-1720	14	38	with	with	ADP
ajlm-1720	14	39	additional	additional	ADJ
ajlm-1720	14	40	discernment	discernment	NOUN
ajlm-1720	14	41	of	of	ADP
ajlm-1720	14	42	cd81	cd81	PROPN
ajlm-1720	14	43	,	,	PUNCT
ajlm-1720	14	44	ror-1	ror-1	NOUN
ajlm-1720	14	45	,	,	PUNCT
ajlm-1720	14	46	cd79b	cd79b	NOUN
ajlm-1720	14	47	and	and	CCONJ
ajlm-1720	14	48	cd43	cd43	PROPN
ajlm-1720	14	49	)	)	PUNCT
ajlm-1720	14	50	and	and	CCONJ
ajlm-1720	14	51	pcd	pcd	PROPN
ajlm-1720	14	52	.	.	PUNCT
ajlm-1720	15	1	conclusion	conclusion	NOUN
ajlm-1720	15	2	:	:	PUNCT
ajlm-1720	15	3	the	the	DET
ajlm-1720	15	4	duraclone	duraclone	NOUN
ajlm-1720	15	5	clb	clb	NOUN
ajlm-1720	15	6	exceeded	exceed	VERB
ajlm-1720	15	7	the	the	DET
ajlm-1720	15	8	predicate	predicate	NOUN
ajlm-1720	15	9	second	second	ADJ
ajlm-1720	15	10	-	-	PUNCT
ajlm-1720	15	11	line	line	NOUN
ajlm-1720	15	12	performance	performance	NOUN
ajlm-1720	15	13	,	,	PUNCT
ajlm-1720	15	14	offering	offer	VERB
ajlm-1720	15	15	extended	extend	VERB
ajlm-1720	15	16	second	second	ADJ
ajlm-1720	15	17	-	-	PUNCT
ajlm-1720	15	18	line	line	NOUN
ajlm-1720	15	19	diagnostic	diagnostic	ADJ
ajlm-1720	15	20	discernment	discernment	NOUN
ajlm-1720	15	21	of	of	ADP
ajlm-1720	15	22	mature	mature	ADJ
ajlm-1720	15	23	b	b	PROPN
ajlm-1720	15	24	-	-	PUNCT
ajlm-1720	15	25	lpd	lpd	PROPN
ajlm-1720	15	26	subtypes	subtype	NOUN
ajlm-1720	15	27	and	and	CCONJ
ajlm-1720	15	28	discernment	discernment	NOUN
ajlm-1720	15	29	of	of	ADP
ajlm-1720	15	30	cd5	cd5	PROPN
ajlm-1720	15	31	+	+	PROPN
ajlm-1720	15	32	b	b	PROPN
ajlm-1720	15	33	-	-	PUNCT
ajlm-1720	15	34	lpd	lpd	PROPN
ajlm-1720	15	35	from	from	ADP
ajlm-1720	15	36	other	other	ADJ
ajlm-1720	15	37	non	non	ADJ
ajlm-1720	15	38	-	-	ADJ
ajlm-1720	15	39	cd5	cd5	ADJ
ajlm-1720	15	40	+	+	CCONJ
ajlm-1720	15	41	(	(	PUNCT
ajlm-1720	15	42	or	or	CCONJ
ajlm-1720	15	43	cd5	cd5	PROPN
ajlm-1720	15	44	–	–	PUNCT
ajlm-1720	15	45	)	)	PUNCT
ajlm-1720	15	46	b	b	PROPN
ajlm-1720	15	47	-	-	PUNCT
ajlm-1720	15	48	lpd	lpd	PROPN
ajlm-1720	15	49	;	;	PUNCT
ajlm-1720	15	50	likewise	likewise	ADV
ajlm-1720	15	51	,	,	PUNCT
ajlm-1720	15	52	the	the	DET
ajlm-1720	15	53	pc	pc	NOUN
ajlm-1720	15	54	panels	panel	NOUN
ajlm-1720	15	55	enabled	enable	VERB
ajlm-1720	15	56	discovery	discovery	NOUN
ajlm-1720	15	57	of	of	ADP
ajlm-1720	15	58	pcd	pcd	PROPN
ajlm-1720	15	59	.	.	PUNCT
ajlm-1720	16	1	while	while	SCONJ
ajlm-1720	16	2	alb	alb	PROPN
ajlm-1720	16	3	testing	testing	NOUN
ajlm-1720	16	4	offered	offer	VERB
ajlm-1720	16	5	no	no	DET
ajlm-1720	16	6	additional	additional	ADJ
ajlm-1720	16	7	diagnostic	diagnostic	ADJ
ajlm-1720	16	8	advantage	advantage	NOUN
ajlm-1720	16	9	over	over	ADP
ajlm-1720	16	10	existing	exist	VERB
ajlm-1720	16	11	predicate	predicate	NOUN
ajlm-1720	16	12	investigation	investigation	NOUN
ajlm-1720	16	13	,	,	PUNCT
ajlm-1720	16	14	cd58	cd58	PROPN
ajlm-1720	16	15	did	do	AUX
ajlm-1720	16	16	offer	offer	VERB
ajlm-1720	16	17	additional	additional	ADJ
ajlm-1720	16	18	information	information	NOUN
ajlm-1720	16	19	to	to	AUX
ajlm-1720	16	20	discern	discern	ADJ
ajlm-1720	16	21	haematogones	haematogone	NOUN
ajlm-1720	16	22	from	from	ADP
ajlm-1720	16	23	b	b	X
ajlm-1720	16	24	-	-	PUNCT
ajlm-1720	16	25	all	all	PRON
ajlm-1720	16	26	.	.	PUNCT
ajlm-1720	17	1	keywords	keyword	NOUN
ajlm-1720	17	2	:	:	PUNCT
ajlm-1720	17	3	flow	flow	NOUN
ajlm-1720	17	4	cytometry	cytometry	NOUN
ajlm-1720	17	5	;	;	PUNCT
ajlm-1720	17	6	multicolour	multicolour	NOUN
ajlm-1720	17	7	;	;	PUNCT
ajlm-1720	17	8	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	17	9	;	;	PUNCT
ajlm-1720	17	10	lymphoma	lymphoma	NOUN
ajlm-1720	17	11	;	;	PUNCT
ajlm-1720	17	12	leukaemia	leukaemia	NOUN
ajlm-1720	17	13	;	;	PUNCT
ajlm-1720	17	14	plasma	plasma	NOUN
ajlm-1720	17	15	cell	cell	NOUN
ajlm-1720	17	16	dyscrasia	dyscrasia	PROPN
ajlm-1720	17	17	;	;	PUNCT
ajlm-1720	17	18	acute	acute	ADJ
ajlm-1720	17	19	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	17	20	leukaemia	leukaemia	NOUN
ajlm-1720	17	21	;	;	PUNCT
ajlm-1720	17	22	b	b	X
ajlm-1720	17	23	-	-	PUNCT
ajlm-1720	17	24	cell	cell	NOUN
ajlm-1720	17	25	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	17	26	disorder	disorder	NOUN
ajlm-1720	17	27	;	;	PUNCT
ajlm-1720	17	28	lyophilised	lyophilise	VERB
ajlm-1720	17	29	reagent	reagent	NOUN
ajlm-1720	17	30	;	;	PUNCT
ajlm-1720	17	31	fixed	fix	VERB
ajlm-1720	17	32	panels	panel	NOUN
ajlm-1720	17	33	.	.	PUNCT
ajlm-1720	18	1	introduction	introduction	NOUN
ajlm-1720	18	2	flow	flow	NOUN
ajlm-1720	18	3	cytometry	cytometry	PROPN
ajlm-1720	18	4	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	18	5	analysis	analysis	NOUN
ajlm-1720	18	6	is	be	AUX
ajlm-1720	18	7	a	a	DET
ajlm-1720	18	8	powerful	powerful	ADJ
ajlm-1720	18	9	diagnostic	diagnostic	ADJ
ajlm-1720	18	10	and	and	CCONJ
ajlm-1720	18	11	research	research	NOUN
ajlm-1720	18	12	tool	tool	NOUN
ajlm-1720	18	13	for	for	ADP
ajlm-1720	18	14	investigating	investigate	VERB
ajlm-1720	18	15	haemato	haemato	NOUN
ajlm-1720	18	16	-	-	PUNCT
ajlm-1720	18	17	lymphoid	lymphoid	NOUN
ajlm-1720	18	18	malignancies	malignancy	NOUN
ajlm-1720	18	19	,	,	PUNCT
ajlm-1720	18	20	such	such	ADJ
ajlm-1720	18	21	as	as	ADP
ajlm-1720	18	22	leukaemia	leukaemia	NOUN
ajlm-1720	18	23	,	,	PUNCT
ajlm-1720	18	24	lymphoma	lymphoma	NOUN
ajlm-1720	18	25	,	,	PUNCT
ajlm-1720	18	26	and	and	CCONJ
ajlm-1720	18	27	plasma	plasma	NOUN
ajlm-1720	18	28	cell	cell	NOUN
ajlm-1720	18	29	dyscrasias	dyscrasia	NOUN
ajlm-1720	18	30	(	(	PUNCT
ajlm-1720	18	31	pcd	pcd	NOUN
ajlm-1720	18	32	)	)	PUNCT
ajlm-1720	18	33	.	.	PUNCT
ajlm-1720	19	1	recently	recently	ADV
ajlm-1720	19	2	,	,	PUNCT
ajlm-1720	19	3	multicolour	multicolour	PROPN
ajlm-1720	19	4	flow	flow	NOUN
ajlm-1720	19	5	cytometric	cytometric	ADJ
ajlm-1720	19	6	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	19	7	has	have	AUX
ajlm-1720	19	8	become	become	VERB
ajlm-1720	19	9	invaluable	invaluable	ADJ
ajlm-1720	19	10	for	for	ADP
ajlm-1720	19	11	improving	improve	VERB
ajlm-1720	19	12	detection	detection	NOUN
ajlm-1720	19	13	and	and	CCONJ
ajlm-1720	19	14	detailed	detailed	ADJ
ajlm-1720	19	15	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	19	16	during	during	ADP
ajlm-1720	19	17	diagnosis	diagnosis	NOUN
ajlm-1720	19	18	and	and	CCONJ
ajlm-1720	19	19	detection	detection	NOUN
ajlm-1720	19	20	of	of	ADP
ajlm-1720	19	21	low	low	ADJ
ajlm-1720	19	22	frequencies	frequency	NOUN
ajlm-1720	19	23	of	of	ADP
ajlm-1720	19	24	abnormal	abnormal	ADJ
ajlm-1720	19	25	or	or	CCONJ
ajlm-1720	19	26	aberrant	aberrant	ADJ
ajlm-1720	19	27	cell	cell	NOUN
ajlm-1720	19	28	populations	population	NOUN
ajlm-1720	19	29	during	during	ADP
ajlm-1720	19	30	minimal	minimal	ADJ
ajlm-1720	19	31	residual	residual	ADJ
ajlm-1720	19	32	disease	disease	NOUN
ajlm-1720	19	33	assessment.1,2	assessment.1,2	ADJ
ajlm-1720	19	34	aberrant	aberrant	ADJ
ajlm-1720	19	35	cell	cell	NOUN
ajlm-1720	19	36	phenotypes	phenotype	NOUN
ajlm-1720	19	37	are	be	AUX
ajlm-1720	19	38	distinguished	distinguish	VERB
ajlm-1720	19	39	from	from	ADP
ajlm-1720	19	40	normal	normal	ADJ
ajlm-1720	19	41	developmental	developmental	ADJ
ajlm-1720	19	42	counterparts2	counterparts2	NOUN
ajlm-1720	19	43	and	and	CCONJ
ajlm-1720	19	44	normal	normal	ADJ
ajlm-1720	19	45	background	background	NOUN
ajlm-1720	19	46	leucocyte	leucocyte	PROPN
ajlm-1720	19	47	populations3	populations3	NOUN
ajlm-1720	19	48	by	by	ADP
ajlm-1720	19	49	analysing	analyse	VERB
ajlm-1720	19	50	and	and	CCONJ
ajlm-1720	19	51	comparing	compare	VERB
ajlm-1720	19	52	several	several	ADJ
ajlm-1720	19	53	simultaneous	simultaneous	ADJ
ajlm-1720	19	54	cell	cell	NOUN
ajlm-1720	19	55	surface	surface	NOUN
ajlm-1720	19	56	and	and	CCONJ
ajlm-1720	19	57	cytoplasmic	cytoplasmic	ADJ
ajlm-1720	19	58	antigen	antigen	ADJ
ajlm-1720	19	59	expression	expression	NOUN
ajlm-1720	19	60	profiles	profile	NOUN
ajlm-1720	19	61	.	.	PUNCT
ajlm-1720	20	1	multicolour	multicolour	ADJ
ajlm-1720	20	2	fluorochrome	fluorochrome	NOUN
ajlm-1720	20	3	-	-	PUNCT
ajlm-1720	20	4	conjugated	conjugate	VERB
ajlm-1720	20	5	antibody	antibody	NOUN
ajlm-1720	20	6	panels	panel	NOUN
ajlm-1720	20	7	generally	generally	ADV
ajlm-1720	20	8	require	require	VERB
ajlm-1720	20	9	antibody	antibody	NOUN
ajlm-1720	20	10	concentrations	concentration	NOUN
ajlm-1720	20	11	and	and	CCONJ
ajlm-1720	20	12	fluorescence	fluorescence	NOUN
ajlm-1720	20	13	intensity	intensity	NOUN
ajlm-1720	20	14	optimisation	optimisation	NOUN
ajlm-1720	20	15	through	through	ADP
ajlm-1720	20	16	titration	titration	NOUN
ajlm-1720	20	17	techniques.4,5	techniques.4,5	NOUN
ajlm-1720	20	18	these	these	DET
ajlm-1720	20	19	assays	assay	NOUN
ajlm-1720	20	20	can	can	AUX
ajlm-1720	20	21	be	be	AUX
ajlm-1720	20	22	technically	technically	ADV
ajlm-1720	20	23	challenging	challenging	ADJ
ajlm-1720	20	24	and	and	CCONJ
ajlm-1720	20	25	error	error	NOUN
ajlm-1720	20	26	-	-	PUNCT
ajlm-1720	20	27	prone	prone	ADJ
ajlm-1720	20	28	due	due	ADP
ajlm-1720	20	29	to	to	ADP
ajlm-1720	20	30	the	the	DET
ajlm-1720	20	31	addition	addition	NOUN
ajlm-1720	20	32	of	of	ADP
ajlm-1720	20	33	multiple	multiple	ADJ
ajlm-1720	20	34	individual	individual	ADJ
ajlm-1720	20	35	liquid	liquid	ADJ
ajlm-1720	20	36	reagents	reagent	NOUN
ajlm-1720	20	37	requiring	require	VERB
ajlm-1720	20	38	manual	manual	ADJ
ajlm-1720	20	39	pipetting,4,6	pipetting,4,6	AUX
ajlm-1720	20	40	thus	thus	ADV
ajlm-1720	20	41	requiring	require	VERB
ajlm-1720	20	42	laboratory	laboratory	NOUN
ajlm-1720	20	43	technicians	technician	NOUN
ajlm-1720	20	44	skilled	skille	VERB
ajlm-1720	20	45	in	in	ADP
ajlm-1720	20	46	titration	titration	NOUN
ajlm-1720	20	47	technique	technique	NOUN
ajlm-1720	20	48	and	and	CCONJ
ajlm-1720	20	49	flow	flow	NOUN
ajlm-1720	20	50	cytometry,4,7	cytometry,4,7	NOUN
ajlm-1720	20	51	including	include	VERB
ajlm-1720	20	52	fluorescence	fluorescence	NOUN
ajlm-1720	20	53	-	-	PUNCT
ajlm-1720	20	54	minus	minus	NOUN
ajlm-1720	20	55	-	-	PUNCT
ajlm-1720	20	56	one	one	NUM
ajlm-1720	20	57	,	,	PUNCT
ajlm-1720	20	58	colour	colour	NOUN
ajlm-1720	20	59	compensation	compensation	NOUN
ajlm-1720	20	60	,	,	PUNCT
ajlm-1720	20	61	and	and	CCONJ
ajlm-1720	20	62	other	other	ADJ
ajlm-1720	20	63	technical	technical	ADJ
ajlm-1720	20	64	flow	flow	NOUN
ajlm-1720	20	65	cytometry	cytometry	NOUN
ajlm-1720	20	66	issues	issue	NOUN
ajlm-1720	20	67	.	.	PUNCT
ajlm-1720	21	1	commercially	commercially	ADV
ajlm-1720	21	2	available	available	ADJ
ajlm-1720	21	3	,	,	PUNCT
ajlm-1720	21	4	standardised	standardised	ADJ
ajlm-1720	21	5	,	,	PUNCT
ajlm-1720	21	6	lyophilised	lyophilise	VERB
ajlm-1720	21	7	,	,	PUNCT
ajlm-1720	21	8	fixed	fixed	ADJ
ajlm-1720	21	9	and	and	CCONJ
ajlm-1720	21	10	pre	pre	ADJ
ajlm-1720	21	11	-	-	ADJ
ajlm-1720	21	12	titrated	titrated	ADJ
ajlm-1720	21	13	antibody	antibody	NOUN
ajlm-1720	21	14	panels,8,9,10,11,12,13	panels,8,9,10,11,12,13	NOUN
ajlm-1720	21	15	like	like	ADP
ajlm-1720	21	16	the	the	DET
ajlm-1720	21	17	beckman	beckman	PROPN
ajlm-1720	21	18	coulter	coulter	PROPN
ajlm-1720	21	19	(	(	PUNCT
ajlm-1720	21	20	bc	bc	PROPN
ajlm-1720	21	21	)	)	PUNCT
ajlm-1720	21	22	duraclone	duraclone	NOUN
ajlm-1720	21	23	inventory	inventory	NOUN
ajlm-1720	21	24	,	,	PUNCT
ajlm-1720	21	25	including	include	VERB
ajlm-1720	21	26	the	the	DET
ajlm-1720	21	27	identification	identification	NOUN
ajlm-1720	21	28	of	of	ADP
ajlm-1720	21	29	normal	normal	ADJ
ajlm-1720	21	30	and	and	CCONJ
ajlm-1720	21	31	abnormal	abnormal	ADJ
ajlm-1720	21	32	b	b	NOUN
ajlm-1720	21	33	progenitor	progenitor	NOUN
ajlm-1720	21	34	cells	cell	NOUN
ajlm-1720	21	35	(	(	PUNCT
ajlm-1720	21	36	re	re	ADP
ajlm-1720	21	37	alb),14	alb),14	ADV
ajlm-1720	21	38	various	various	ADJ
ajlm-1720	21	39	chronic	chronic	ADJ
ajlm-1720	21	40	b	b	X
ajlm-1720	21	41	-	-	PUNCT
ajlm-1720	21	42	cell	cell	NOUN
ajlm-1720	21	43	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	21	44	disorders	disorder	NOUN
ajlm-1720	21	45	including	include	VERB
ajlm-1720	21	46	cd5	cd5	NOUN
ajlm-1720	21	47	+	+	SYM
ajlm-1720	21	48	chronic	chronic	ADJ
ajlm-1720	21	49	lymphocytic	lymphocytic	ADJ
ajlm-1720	21	50	leukaemia	leukaemia	NOUN
ajlm-1720	21	51	(	(	PUNCT
ajlm-1720	21	52	re	re	X
ajlm-1720	21	53	clb)15	clb)15	NOUN
ajlm-1720	21	54	and	and	CCONJ
ajlm-1720	21	55	normal	normal	ADJ
ajlm-1720	21	56	or	or	CCONJ
ajlm-1720	21	57	abnormal	abnormal	ADJ
ajlm-1720	21	58	plasma	plasma	NOUN
ajlm-1720	21	59	cells	cell	NOUN
ajlm-1720	21	60	(	(	PUNCT
ajlm-1720	21	61	re	re	NOUN
ajlm-1720	21	62	pc	pc	NOUN
ajlm-1720	21	63	)	)	PUNCT
ajlm-1720	21	64	panels	panel	NOUN
ajlm-1720	21	65	,	,	PUNCT
ajlm-1720	21	66	offer	offer	VERB
ajlm-1720	21	67	an	an	DET
ajlm-1720	21	68	attractive	attractive	ADJ
ajlm-1720	21	69	alternative	alternative	NOUN
ajlm-1720	21	70	to	to	ADP
ajlm-1720	21	71	the	the	PRON
ajlm-1720	21	72	locally	locally	ADV
ajlm-1720	21	73	developed	develop	VERB
ajlm-1720	21	74	,	,	PUNCT
ajlm-1720	21	75	in	in	ADP
ajlm-1720	21	76	-	-	PUNCT
ajlm-1720	21	77	house	house	NOUN
ajlm-1720	21	78	multicolour	multicolour	NOUN
ajlm-1720	21	79	panels	panel	NOUN
ajlm-1720	21	80	described	describe	VERB
ajlm-1720	21	81	.	.	PUNCT
ajlm-1720	22	1	commercial	commercial	ADJ
ajlm-1720	22	2	multicolour	multicolour	ADJ
ajlm-1720	22	3	panels	panel	NOUN
ajlm-1720	22	4	also	also	ADV
ajlm-1720	22	5	usually	usually	ADV
ajlm-1720	22	6	offer	offer	VERB
ajlm-1720	22	7	the	the	DET
ajlm-1720	22	8	advantage	advantage	NOUN
ajlm-1720	22	9	of	of	ADP
ajlm-1720	22	10	a	a	DET
ajlm-1720	22	11	standardised	standardised	ADJ
ajlm-1720	22	12	instrument	instrument	NOUN
ajlm-1720	22	13	and	and	CCONJ
ajlm-1720	22	14	analysis	analysis	NOUN
ajlm-1720	22	15	protocols	protocol	NOUN
ajlm-1720	22	16	;	;	PUNCT
ajlm-1720	22	17	preset	preset	ADJ
ajlm-1720	22	18	software	software	NOUN
ajlm-1720	22	19	-	-	PUNCT
ajlm-1720	22	20	guided	guide	VERB
ajlm-1720	22	21	controls	control	NOUN
ajlm-1720	22	22	are	be	AUX
ajlm-1720	22	23	available	available	ADJ
ajlm-1720	22	24	to	to	PART
ajlm-1720	22	25	establish	establish	VERB
ajlm-1720	22	26	optimal	optimal	ADJ
ajlm-1720	22	27	standardised	standardised	ADJ
ajlm-1720	22	28	instrument	instrument	NOUN
ajlm-1720	22	29	settings	setting	NOUN
ajlm-1720	22	30	,	,	PUNCT
ajlm-1720	22	31	verified	verify	VERB
ajlm-1720	22	32	with	with	ADP
ajlm-1720	22	33	abnormal	abnormal	ADJ
ajlm-1720	22	34	and	and	CCONJ
ajlm-1720	22	35	normal	normal	ADJ
ajlm-1720	22	36	stabilised	stabilise	VERB
ajlm-1720	22	37	blood	blood	NOUN
ajlm-1720	22	38	material	material	NOUN
ajlm-1720	22	39	controls.9	controls.9	PROPN
ajlm-1720	22	40	in	in	ADP
ajlm-1720	22	41	addition	addition	NOUN
ajlm-1720	22	42	,	,	PUNCT
ajlm-1720	22	43	these	these	DET
ajlm-1720	22	44	commercial	commercial	ADJ
ajlm-1720	22	45	panels	panel	NOUN
ajlm-1720	22	46	are	be	AUX
ajlm-1720	22	47	typically	typically	ADV
ajlm-1720	22	48	fixed	fix	VERB
ajlm-1720	22	49	panels	panel	NOUN
ajlm-1720	22	50	supplied	supply	VERB
ajlm-1720	22	51	in	in	ADP
ajlm-1720	22	52	a	a	DET
ajlm-1720	22	53	stable	stable	ADJ
ajlm-1720	22	54	,	,	PUNCT
ajlm-1720	22	55	dry	dry	ADJ
ajlm-1720	22	56	(	(	PUNCT
ajlm-1720	22	57	lyophilised	lyophilise	VERB
ajlm-1720	22	58	)	)	PUNCT
ajlm-1720	22	59	format	format	NOUN
ajlm-1720	22	60	with	with	ADP
ajlm-1720	22	61	predetermined	predetermine	VERB
ajlm-1720	22	62	antibody	antibody	NOUN
ajlm-1720	22	63	combinations	combination	NOUN
ajlm-1720	22	64	in	in	ADP
ajlm-1720	22	65	a	a	DET
ajlm-1720	22	66	single	single	ADJ
ajlm-1720	22	67	tube9	tube9	NOUN
ajlm-1720	22	68	;	;	PUNCT
ajlm-1720	22	69	these	these	DET
ajlm-1720	22	70	qualities	quality	NOUN
ajlm-1720	22	71	enhance	enhance	VERB
ajlm-1720	22	72	laboratory	laboratory	NOUN
ajlm-1720	22	73	efficiency	efficiency	NOUN
ajlm-1720	22	74	,	,	PUNCT
ajlm-1720	22	75	reduce	reduce	VERB
ajlm-1720	22	76	technical	technical	ADJ
ajlm-1720	22	77	laboratory	laboratory	NOUN
ajlm-1720	22	78	error	error	NOUN
ajlm-1720	22	79	and	and	CCONJ
ajlm-1720	22	80	simplify	simplify	VERB
ajlm-1720	22	81	reagent	reagent	ADJ
ajlm-1720	22	82	inventory	inventory	NOUN
ajlm-1720	22	83	.	.	PUNCT
ajlm-1720	23	1	some	some	DET
ajlm-1720	23	2	commercial	commercial	ADJ
ajlm-1720	23	3	panels	panel	NOUN
ajlm-1720	23	4	also	also	ADV
ajlm-1720	23	5	offer	offer	VERB
ajlm-1720	23	6	some	some	DET
ajlm-1720	23	7	flexibility	flexibility	NOUN
ajlm-1720	23	8	in	in	ADP
ajlm-1720	23	9	marker	marker	NOUN
ajlm-1720	23	10	combinations	combination	NOUN
ajlm-1720	23	11	by	by	ADP
ajlm-1720	23	12	providing	provide	VERB
ajlm-1720	23	13	‘	'	PUNCT
ajlm-1720	23	14	open	open	ADJ
ajlm-1720	23	15	’	'	PUNCT
ajlm-1720	23	16	fluorescence	fluorescence	NOUN
ajlm-1720	23	17	channels14,15	channels14,15	NOUN
ajlm-1720	23	18	so	so	SCONJ
ajlm-1720	23	19	that	that	SCONJ
ajlm-1720	23	20	liquid	liquid	ADJ
ajlm-1720	23	21	drop	drop	NOUN
ajlm-1720	23	22	-	-	PUNCT
ajlm-1720	23	23	in	in	ADP
ajlm-1720	23	24	markers	marker	NOUN
ajlm-1720	23	25	can	can	AUX
ajlm-1720	23	26	be	be	AUX
ajlm-1720	23	27	added	add	VERB
ajlm-1720	23	28	to	to	ADP
ajlm-1720	23	29	the	the	DET
ajlm-1720	23	30	‘	'	PUNCT
ajlm-1720	23	31	fixed	fix	VERB
ajlm-1720	23	32	’	'	PUNCT
ajlm-1720	23	33	panels	panel	NOUN
ajlm-1720	23	34	to	to	PART
ajlm-1720	23	35	accommodate	accommodate	VERB
ajlm-1720	23	36	unique	unique	ADJ
ajlm-1720	23	37	and	and	CCONJ
ajlm-1720	23	38	specific	specific	ADJ
ajlm-1720	23	39	diagnostic	diagnostic	ADJ
ajlm-1720	23	40	requirements	requirement	NOUN
ajlm-1720	23	41	of	of	ADP
ajlm-1720	23	42	the	the	DET
ajlm-1720	23	43	investigating	investigate	VERB
ajlm-1720	23	44	laboratory	laboratory	NOUN
ajlm-1720	23	45	.	.	PUNCT
ajlm-1720	24	1	our	our	PRON
ajlm-1720	24	2	laboratory	laboratory	NOUN
ajlm-1720	24	3	previously	previously	ADV
ajlm-1720	24	4	established	establish	VERB
ajlm-1720	24	5	the	the	DET
ajlm-1720	24	6	positive	positive	ADJ
ajlm-1720	24	7	impact	impact	NOUN
ajlm-1720	24	8	on	on	ADP
ajlm-1720	24	9	quality	quality	NOUN
ajlm-1720	24	10	,	,	PUNCT
ajlm-1720	24	11	laboratory	laboratory	NOUN
ajlm-1720	24	12	workflow	workflow	NOUN
ajlm-1720	24	13	and	and	CCONJ
ajlm-1720	24	14	diagnostic	diagnostic	ADJ
ajlm-1720	24	15	usefulness	usefulness	NOUN
ajlm-1720	24	16	of	of	ADP
ajlm-1720	24	17	the	the	PRON
ajlm-1720	24	18	commercially	commercially	ADV
ajlm-1720	24	19	available	available	ADJ
ajlm-1720	24	20	,	,	PUNCT
ajlm-1720	24	21	fixed	fix	VERB
ajlm-1720	24	22	and	and	CCONJ
ajlm-1720	24	23	standardised	standardise	VERB
ajlm-1720	24	24	bc	bc	PROPN
ajlm-1720	24	25	clearllab	clearllab	PROPN
ajlm-1720	24	26	10c16	10c16	NUM
ajlm-1720	24	27	multicolour	multicolour	PROPN
ajlm-1720	24	28	panel	panel	NOUN
ajlm-1720	24	29	system	system	NOUN
ajlm-1720	24	30	(	(	PUNCT
ajlm-1720	24	31	beckman	beckman	PROPN
ajlm-1720	24	32	coulter	coulter	PROPN
ajlm-1720	24	33	,	,	PUNCT
ajlm-1720	24	34	miami	miami	PROPN
ajlm-1720	24	35	,	,	PUNCT
ajlm-1720	24	36	florida	florida	PROPN
ajlm-1720	24	37	,	,	PUNCT
ajlm-1720	24	38	united	united	PROPN
ajlm-1720	24	39	states	states	PROPN
ajlm-1720	24	40	)	)	PUNCT
ajlm-1720	24	41	.	.	PUNCT
ajlm-1720	25	1	although	although	SCONJ
ajlm-1720	25	2	this	this	DET
ajlm-1720	25	3	method	method	NOUN
ajlm-1720	25	4	provides	provide	VERB
ajlm-1720	25	5	excellent	excellent	ADJ
ajlm-1720	25	6	coverage	coverage	NOUN
ajlm-1720	25	7	to	to	PART
ajlm-1720	25	8	discover	discover	VERB
ajlm-1720	25	9	most	most	ADV
ajlm-1720	25	10	acute	acute	ADJ
ajlm-1720	25	11	leukaemias,9,16	leukaemias,9,16	PROPN
ajlm-1720	25	12	the	the	DET
ajlm-1720	25	13	clearllab	clearllab	NOUN
ajlm-1720	25	14	10c	10c	NOUN
ajlm-1720	25	15	system	system	NOUN
ajlm-1720	25	16	lacks	lack	VERB
ajlm-1720	25	17	additional	additional	ADJ
ajlm-1720	25	18	markers	marker	NOUN
ajlm-1720	25	19	to	to	PART
ajlm-1720	25	20	further	far	ADV
ajlm-1720	25	21	identify	identify	VERB
ajlm-1720	25	22	and	and	CCONJ
ajlm-1720	25	23	discern	discern	VERB
ajlm-1720	25	24	specific	specific	ADJ
ajlm-1720	25	25	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	25	26	subtypes	subtype	NOUN
ajlm-1720	25	27	,	,	PUNCT
ajlm-1720	25	28	especially	especially	ADV
ajlm-1720	25	29	within	within	ADP
ajlm-1720	25	30	the	the	DET
ajlm-1720	25	31	group	group	NOUN
ajlm-1720	25	32	of	of	ADP
ajlm-1720	25	33	mature	mature	ADJ
ajlm-1720	25	34	b	b	NOUN
ajlm-1720	25	35	-	-	PUNCT
ajlm-1720	25	36	cell	cell	NOUN
ajlm-1720	25	37	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	25	38	disorders	disorder	NOUN
ajlm-1720	25	39	and	and	CCONJ
ajlm-1720	25	40	pcd	pcd	PROPN
ajlm-1720	25	41	.	.	PUNCT
ajlm-1720	26	1	specifically	specifically	ADV
ajlm-1720	26	2	,	,	PUNCT
ajlm-1720	26	3	although	although	SCONJ
ajlm-1720	26	4	the	the	DET
ajlm-1720	26	5	bc	bc	PROPN
ajlm-1720	26	6	clearllab	clearllab	PROPN
ajlm-1720	26	7	10c	10c	NOUN
ajlm-1720	26	8	can	can	AUX
ajlm-1720	26	9	easily	easily	ADV
ajlm-1720	26	10	discern	discern	VERB
ajlm-1720	26	11	normal	normal	ADJ
ajlm-1720	26	12	b	b	NOUN
ajlm-1720	26	13	-	-	PUNCT
ajlm-1720	26	14	cell	cell	NOUN
ajlm-1720	26	15	precursors	precursor	NOUN
ajlm-1720	26	16	or	or	CCONJ
ajlm-1720	26	17	haematogones	haematogone	NOUN
ajlm-1720	26	18	from	from	ADP
ajlm-1720	26	19	similar	similar	ADJ
ajlm-1720	26	20	immunophenotypes	immunophenotype	NOUN
ajlm-1720	26	21	present	present	ADJ
ajlm-1720	26	22	in	in	ADP
ajlm-1720	26	23	minimal	minimal	ADJ
ajlm-1720	26	24	residual	residual	ADJ
ajlm-1720	26	25	b	b	NOUN
ajlm-1720	26	26	-	-	PUNCT
ajlm-1720	26	27	cell	cell	NOUN
ajlm-1720	26	28	acute	acute	ADJ
ajlm-1720	26	29	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	26	30	leukaemia	leukaemia	NOUN
ajlm-1720	26	31	(	(	PUNCT
ajlm-1720	26	32	b	b	X
ajlm-1720	26	33	-	-	PUNCT
ajlm-1720	26	34	all	all	PRON
ajlm-1720	26	35	)	)	PUNCT
ajlm-1720	26	36	disease	disease	NOUN
ajlm-1720	26	37	,	,	PUNCT
ajlm-1720	26	38	the	the	DET
ajlm-1720	26	39	cd58	cd58	PROPN
ajlm-1720	26	40	marker	marker	NOUN
ajlm-1720	26	41	is	be	AUX
ajlm-1720	26	42	not	not	PART
ajlm-1720	26	43	included	include	VERB
ajlm-1720	26	44	.	.	PUNCT
ajlm-1720	27	1	however	however	ADV
ajlm-1720	27	2	,	,	PUNCT
ajlm-1720	27	3	it	it	PRON
ajlm-1720	27	4	may	may	AUX
ajlm-1720	27	5	be	be	AUX
ajlm-1720	27	6	helpful	helpful	ADJ
ajlm-1720	27	7	to	to	PART
ajlm-1720	27	8	discriminate	discriminate	VERB
ajlm-1720	27	9	disease	disease	NOUN
ajlm-1720	27	10	from	from	ADP
ajlm-1720	27	11	normal	normal	ADJ
ajlm-1720	27	12	b	b	NOUN
ajlm-1720	27	13	-	-	PUNCT
ajlm-1720	27	14	cell	cell	NOUN
ajlm-1720	27	15	precursors	precursor	NOUN
ajlm-1720	27	16	during	during	ADP
ajlm-1720	27	17	minimal	minimal	ADJ
ajlm-1720	27	18	b	b	X
ajlm-1720	27	19	-	-	PUNCT
ajlm-1720	27	20	all	all	DET
ajlm-1720	27	21	disease	disease	NOUN
ajlm-1720	27	22	assessment.1,2	assessment.1,2	ADP
ajlm-1720	27	23	the	the	DET
ajlm-1720	27	24	clearllab	clearllab	NOUN
ajlm-1720	27	25	10c	10c	NOUN
ajlm-1720	27	26	system	system	NOUN
ajlm-1720	27	27	also	also	ADV
ajlm-1720	27	28	lacks	lack	VERB
ajlm-1720	27	29	markers	marker	NOUN
ajlm-1720	27	30	to	to	PART
ajlm-1720	27	31	discern	discern	VERB
ajlm-1720	27	32	cd5	cd5	NOUN
ajlm-1720	27	33	-	-	PUNCT
ajlm-1720	27	34	positive	positive	ADJ
ajlm-1720	27	35	and	and	CCONJ
ajlm-1720	27	36	cd5	cd5	NOUN
ajlm-1720	27	37	-	-	PUNCT
ajlm-1720	27	38	negative	negative	ADJ
ajlm-1720	27	39	mature	mature	ADJ
ajlm-1720	27	40	b	b	NOUN
ajlm-1720	27	41	-	-	PUNCT
ajlm-1720	27	42	cell	cell	NOUN
ajlm-1720	27	43	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	27	44	disorders	disorder	NOUN
ajlm-1720	27	45	(	(	PUNCT
ajlm-1720	27	46	lpd	lpd	PROPN
ajlm-1720	27	47	)	)	PUNCT
ajlm-1720	27	48	,	,	PUNCT
ajlm-1720	27	49	using	use	VERB
ajlm-1720	27	50	markers	marker	NOUN
ajlm-1720	27	51	such	such	ADJ
ajlm-1720	27	52	as	as	ADP
ajlm-1720	27	53	cd23	cd23	PROPN
ajlm-1720	27	54	,	,	PUNCT
ajlm-1720	27	55	cd43	cd43	PROPN
ajlm-1720	27	56	,	,	PUNCT
ajlm-1720	27	57	cd79b	cd79b	NOUN
ajlm-1720	27	58	,	,	PUNCT
ajlm-1720	27	59	cd81	cd81	PROPN
ajlm-1720	27	60	,	,	PUNCT
ajlm-1720	27	61	and	and	CCONJ
ajlm-1720	27	62	ror-1	ror-1	PUNCT
ajlm-1720	27	63	recommended	recommend	VERB
ajlm-1720	27	64	for	for	ADP
ajlm-1720	27	65	classification	classification	NOUN
ajlm-1720	27	66	by	by	ADP
ajlm-1720	27	67	rawstron	rawstron	PROPN
ajlm-1720	27	68	et	et	PROPN
ajlm-1720	27	69	al.17,18	al.17,18	PROPN
ajlm-1720	27	70	investigation	investigation	NOUN
ajlm-1720	27	71	of	of	ADP
ajlm-1720	27	72	pcd	pcd	PROPN
ajlm-1720	27	73	is	be	AUX
ajlm-1720	27	74	also	also	ADV
ajlm-1720	27	75	limited	limit	VERB
ajlm-1720	27	76	if	if	SCONJ
ajlm-1720	27	77	investigated	investigate	VERB
ajlm-1720	27	78	only	only	ADV
ajlm-1720	27	79	with	with	ADP
ajlm-1720	27	80	the	the	DET
ajlm-1720	27	81	clearllab	clearllab	NOUN
ajlm-1720	27	82	10c	10c	NOUN
ajlm-1720	27	83	system	system	NOUN
ajlm-1720	27	84	which	which	PRON
ajlm-1720	27	85	lacks	lack	VERB
ajlm-1720	27	86	cd138	cd138	PROPN
ajlm-1720	27	87	,	,	PUNCT
ajlm-1720	27	88	an	an	DET
ajlm-1720	27	89	absolute	absolute	ADJ
ajlm-1720	27	90	requirement	requirement	NOUN
ajlm-1720	27	91	for	for	ADP
ajlm-1720	27	92	identifying	identify	VERB
ajlm-1720	27	93	plasma	plasma	NOUN
ajlm-1720	27	94	cells	cell	NOUN
ajlm-1720	27	95	together	together	ADV
ajlm-1720	27	96	with	with	ADP
ajlm-1720	27	97	cd3819	cd3819	NOUN
ajlm-1720	27	98	.	.	PUNCT
ajlm-1720	28	1	in	in	ADP
ajlm-1720	28	2	our	our	PRON
ajlm-1720	28	3	laboratory	laboratory	NOUN
ajlm-1720	28	4	,	,	PUNCT
ajlm-1720	28	5	we	we	PRON
ajlm-1720	28	6	have	have	AUX
ajlm-1720	28	7	developed	develop	VERB
ajlm-1720	28	8	several	several	ADJ
ajlm-1720	28	9	2–4	2–4	NUM
ajlm-1720	28	10	-	-	PUNCT
ajlm-1720	28	11	colour	colour	NOUN
ajlm-1720	28	12	in	in	ADP
ajlm-1720	28	13	-	-	PUNCT
ajlm-1720	28	14	house	house	NOUN
ajlm-1720	28	15	,	,	PUNCT
ajlm-1720	28	16	second	second	ADJ
ajlm-1720	28	17	-	-	PUNCT
ajlm-1720	28	18	line	line	NOUN
ajlm-1720	28	19	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	28	20	panels	panel	NOUN
ajlm-1720	28	21	to	to	PART
ajlm-1720	28	22	identify	identify	VERB
ajlm-1720	28	23	the	the	DET
ajlm-1720	28	24	specific	specific	ADJ
ajlm-1720	28	25	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	28	26	subtypes	subtype	NOUN
ajlm-1720	28	27	mentioned	mention	VERB
ajlm-1720	28	28	,	,	PUNCT
ajlm-1720	28	29	including	include	VERB
ajlm-1720	28	30	markers	marker	NOUN
ajlm-1720	28	31	such	such	ADJ
ajlm-1720	28	32	as	as	ADP
ajlm-1720	28	33	cd23	cd23	PROPN
ajlm-1720	28	34	and	and	CCONJ
ajlm-1720	28	35	fmc-7	fmc-7	PUNCT
ajlm-1720	28	36	for	for	ADP
ajlm-1720	28	37	mature	mature	ADJ
ajlm-1720	28	38	b	b	NOUN
ajlm-1720	28	39	-	-	PUNCT
ajlm-1720	28	40	cell	cell	NOUN
ajlm-1720	28	41	lpd	lpd	PROPN
ajlm-1720	28	42	and	and	CCONJ
ajlm-1720	28	43	cd138	cd138	PROPN
ajlm-1720	28	44	with	with	ADP
ajlm-1720	28	45	cd56	cd56	PROPN
ajlm-1720	28	46	and	and	CCONJ
ajlm-1720	28	47	cd200	cd200	PROPN
ajlm-1720	28	48	,	,	PUNCT
ajlm-1720	28	49	to	to	PART
ajlm-1720	28	50	diagnose	diagnose	VERB
ajlm-1720	28	51	pcd	pcd	NOUN
ajlm-1720	28	52	.	.	PUNCT
ajlm-1720	29	1	these	these	PRON
ajlm-1720	29	2	,	,	PUNCT
ajlm-1720	29	3	however	however	ADV
ajlm-1720	29	4	,	,	PUNCT
ajlm-1720	29	5	require	require	VERB
ajlm-1720	29	6	a	a	DET
ajlm-1720	29	7	separate	separate	ADJ
ajlm-1720	29	8	repertoire	repertoire	NOUN
ajlm-1720	29	9	of	of	ADP
ajlm-1720	29	10	liquid	liquid	ADJ
ajlm-1720	29	11	reagents	reagent	NOUN
ajlm-1720	29	12	and	and	CCONJ
ajlm-1720	29	13	necessary	necessary	ADJ
ajlm-1720	29	14	flow	flow	NOUN
ajlm-1720	29	15	cytometry	cytometry	NOUN
ajlm-1720	29	16	technical	technical	ADJ
ajlm-1720	29	17	expertise	expertise	NOUN
ajlm-1720	29	18	to	to	PART
ajlm-1720	29	19	set	set	VERB
ajlm-1720	29	20	up	up	ADP
ajlm-1720	29	21	and	and	CCONJ
ajlm-1720	29	22	run	run	VERB
ajlm-1720	29	23	the	the	DET
ajlm-1720	29	24	tests	test	NOUN
ajlm-1720	29	25	.	.	PUNCT
ajlm-1720	30	1	for	for	ADP
ajlm-1720	30	2	a	a	DET
ajlm-1720	30	3	busy	busy	ADJ
ajlm-1720	30	4	site	site	NOUN
ajlm-1720	30	5	,	,	PUNCT
ajlm-1720	30	6	such	such	ADJ
ajlm-1720	30	7	as	as	ADP
ajlm-1720	30	8	our	our	PRON
ajlm-1720	30	9	unit	unit	NOUN
ajlm-1720	30	10	,	,	PUNCT
ajlm-1720	30	11	which	which	PRON
ajlm-1720	30	12	processes	process	VERB
ajlm-1720	30	13	over	over	ADV
ajlm-1720	30	14	400	400	NUM
ajlm-1720	30	15	samples	sample	NOUN
ajlm-1720	30	16	per	per	ADP
ajlm-1720	30	17	month	month	NOUN
ajlm-1720	30	18	,	,	PUNCT
ajlm-1720	30	19	standardised	standardise	VERB
ajlm-1720	30	20	commercially	commercially	ADV
ajlm-1720	30	21	available	available	ADJ
ajlm-1720	30	22	panels	panel	NOUN
ajlm-1720	30	23	that	that	PRON
ajlm-1720	30	24	can	can	AUX
ajlm-1720	30	25	supplement	supplement	VERB
ajlm-1720	30	26	second	second	ADJ
ajlm-1720	30	27	-	-	PUNCT
ajlm-1720	30	28	line	line	NOUN
ajlm-1720	30	29	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	30	30	investigation	investigation	NOUN
ajlm-1720	30	31	after	after	SCONJ
ajlm-1720	30	32	clearllab10c	clearllab10c	NOUN
ajlm-1720	30	33	investigation	investigation	NOUN
ajlm-1720	30	34	could	could	AUX
ajlm-1720	30	35	dramatically	dramatically	ADV
ajlm-1720	30	36	increase	increase	VERB
ajlm-1720	30	37	the	the	DET
ajlm-1720	30	38	repertoire	repertoire	NOUN
ajlm-1720	30	39	of	of	ADP
ajlm-1720	30	40	markers	marker	NOUN
ajlm-1720	30	41	tested	test	VERB
ajlm-1720	30	42	and	and	CCONJ
ajlm-1720	30	43	also	also	ADV
ajlm-1720	30	44	improve	improve	VERB
ajlm-1720	30	45	workflow	workflow	NOUN
ajlm-1720	30	46	efficiency	efficiency	NOUN
ajlm-1720	30	47	in	in	ADP
ajlm-1720	30	48	our	our	PRON
ajlm-1720	30	49	site	site	NOUN
ajlm-1720	30	50	.	.	PUNCT
ajlm-1720	31	1	existing	exist	VERB
ajlm-1720	31	2	predicate	predicate	NOUN
ajlm-1720	31	3	second	second	ADJ
ajlm-1720	31	4	-	-	PUNCT
ajlm-1720	31	5	line	line	NOUN
ajlm-1720	31	6	investigation	investigation	NOUN
ajlm-1720	31	7	utilises	utilise	NOUN
ajlm-1720	31	8	locally	locally	ADV
ajlm-1720	31	9	established	establish	VERB
ajlm-1720	31	10	,	,	PUNCT
ajlm-1720	31	11	in	in	ADP
ajlm-1720	31	12	-	-	PUNCT
ajlm-1720	31	13	house	house	NOUN
ajlm-1720	31	14	,	,	PUNCT
ajlm-1720	31	15	non	non	ADJ
ajlm-1720	31	16	-	-	ADJ
ajlm-1720	31	17	standardised	standardised	ADJ
ajlm-1720	31	18	and	and	CCONJ
ajlm-1720	31	19	manually	manually	ADV
ajlm-1720	31	20	assembled	assemble	VERB
ajlm-1720	31	21	liquid	liquid	ADJ
ajlm-1720	31	22	fluorochrome	fluorochrome	NOUN
ajlm-1720	31	23	-	-	PUNCT
ajlm-1720	31	24	conjugated	conjugate	VERB
ajlm-1720	31	25	antibody	antibody	NOUN
ajlm-1720	31	26	panels	panel	NOUN
ajlm-1720	31	27	.	.	PUNCT
ajlm-1720	32	1	the	the	DET
ajlm-1720	32	2	primary	primary	ADJ
ajlm-1720	32	3	aim	aim	NOUN
ajlm-1720	32	4	of	of	ADP
ajlm-1720	32	5	this	this	DET
ajlm-1720	32	6	study	study	NOUN
ajlm-1720	32	7	was	be	AUX
ajlm-1720	32	8	to	to	PART
ajlm-1720	32	9	evaluate	evaluate	VERB
ajlm-1720	32	10	the	the	DET
ajlm-1720	32	11	fixed	fix	VERB
ajlm-1720	32	12	and	and	CCONJ
ajlm-1720	32	13	standardised	standardised	ADJ
ajlm-1720	32	14	,	,	PUNCT
ajlm-1720	32	15	pre	pre	ADJ
ajlm-1720	32	16	-	-	ADJ
ajlm-1720	32	17	titrated	titrated	ADJ
ajlm-1720	32	18	commercially	commercially	ADV
ajlm-1720	32	19	available	available	ADJ
ajlm-1720	32	20	duraclone	duraclone	NOUN
ajlm-1720	32	21	re	re	NOUN
ajlm-1720	32	22	alb	alb	VERB
ajlm-1720	32	23	,	,	PUNCT
ajlm-1720	32	24	re	re	NOUN
ajlm-1720	32	25	clb	clb	NOUN
ajlm-1720	32	26	and	and	CCONJ
ajlm-1720	32	27	re	re	ADJ
ajlm-1720	32	28	pc	pc	NOUN
ajlm-1720	32	29	panels	panel	NOUN
ajlm-1720	32	30	(	(	PUNCT
ajlm-1720	32	31	beckman	beckman	PROPN
ajlm-1720	32	32	coulter	coulter	PROPN
ajlm-1720	32	33	,	,	PUNCT
ajlm-1720	32	34	mumbai	mumbai	PROPN
ajlm-1720	32	35	,	,	PUNCT
ajlm-1720	32	36	india	india	PROPN
ajlm-1720	32	37	)	)	PUNCT
ajlm-1720	32	38	as	as	ADP
ajlm-1720	32	39	a	a	DET
ajlm-1720	32	40	comprehensive	comprehensive	ADJ
ajlm-1720	32	41	and	and	CCONJ
ajlm-1720	32	42	compact	compact	ADJ
ajlm-1720	32	43	alternative	alternative	NOUN
ajlm-1720	32	44	to	to	ADP
ajlm-1720	32	45	our	our	PRON
ajlm-1720	32	46	existing	exist	VERB
ajlm-1720	32	47	second	second	ADJ
ajlm-1720	32	48	-	-	PUNCT
ajlm-1720	32	49	line	line	NOUN
ajlm-1720	32	50	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	32	51	investigation	investigation	NOUN
ajlm-1720	32	52	of	of	ADP
ajlm-1720	32	53	haematological	haematological	ADJ
ajlm-1720	32	54	neoplasms	neoplasm	NOUN
ajlm-1720	32	55	.	.	PUNCT
ajlm-1720	33	1	there	there	PRON
ajlm-1720	33	2	were	be	VERB
ajlm-1720	33	3	two	two	NUM
ajlm-1720	33	4	parts	part	NOUN
ajlm-1720	33	5	to	to	ADP
ajlm-1720	33	6	this	this	DET
ajlm-1720	33	7	study	study	NOUN
ajlm-1720	33	8	.	.	PUNCT
ajlm-1720	34	1	first	first	ADV
ajlm-1720	34	2	,	,	PUNCT
ajlm-1720	34	3	we	we	PRON
ajlm-1720	34	4	compared	compare	VERB
ajlm-1720	34	5	the	the	DET
ajlm-1720	34	6	duraclone	duraclone	NOUN
ajlm-1720	34	7	clb	clb	NOUN
ajlm-1720	34	8	and	and	CCONJ
ajlm-1720	34	9	pc	pc	NOUN
ajlm-1720	34	10	tubes	tube	NOUN
ajlm-1720	34	11	to	to	ADP
ajlm-1720	34	12	the	the	DET
ajlm-1720	34	13	laboratory	laboratory	NOUN
ajlm-1720	34	14	’s	’s	PART
ajlm-1720	34	15	in	in	ADP
ajlm-1720	34	16	-	-	PUNCT
ajlm-1720	34	17	house	house	NOUN
ajlm-1720	34	18	predicate	predicate	NOUN
ajlm-1720	34	19	2–4	2–4	NUM
ajlm-1720	34	20	-	-	PUNCT
ajlm-1720	34	21	colour	colour	NOUN
ajlm-1720	34	22	method	method	NOUN
ajlm-1720	34	23	for	for	ADP
ajlm-1720	34	24	the	the	DET
ajlm-1720	34	25	following	follow	VERB
ajlm-1720	34	26	markers	marker	NOUN
ajlm-1720	34	27	:	:	PUNCT
ajlm-1720	34	28	combinations	combination	NOUN
ajlm-1720	34	29	of	of	ADP
ajlm-1720	34	30	cd10	cd10	PROPN
ajlm-1720	34	31	,	,	PUNCT
ajlm-1720	34	32	cd23	cd23	PROPN
ajlm-1720	34	33	,	,	PUNCT
ajlm-1720	34	34	fmc7	fmc7	PROPN
ajlm-1720	34	35	and	and	CCONJ
ajlm-1720	34	36	cd22	cd22	PROPN
ajlm-1720	34	37	to	to	PART
ajlm-1720	34	38	discern	discern	VERB
ajlm-1720	34	39	mature	mature	ADJ
ajlm-1720	34	40	b	b	NOUN
ajlm-1720	34	41	-	-	PUNCT
ajlm-1720	34	42	cell	cell	NOUN
ajlm-1720	34	43	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	34	44	disorders	disorder	NOUN
ajlm-1720	34	45	,	,	PUNCT
ajlm-1720	34	46	or	or	CCONJ
ajlm-1720	34	47	cd19	cd19	PROPN
ajlm-1720	34	48	,	,	PUNCT
ajlm-1720	34	49	cd38	cd38	PROPN
ajlm-1720	34	50	,	,	PUNCT
ajlm-1720	34	51	cd56	cd56	PROPN
ajlm-1720	34	52	,	,	PUNCT
ajlm-1720	34	53	cd200	cd200	PROPN
ajlm-1720	34	54	and	and	CCONJ
ajlm-1720	34	55	cd138	cd138	NOUN
ajlm-1720	34	56	to	to	AUX
ajlm-1720	34	57	characterise	characterise	VERB
ajlm-1720	34	58	plasma	plasma	NOUN
ajlm-1720	34	59	cells	cell	NOUN
ajlm-1720	34	60	.	.	PUNCT
ajlm-1720	35	1	secondly	secondly	ADV
ajlm-1720	35	2	,	,	PUNCT
ajlm-1720	35	3	we	we	PRON
ajlm-1720	35	4	verified	verify	VERB
ajlm-1720	35	5	manufacturer	manufacturer	NOUN
ajlm-1720	35	6	-	-	PUNCT
ajlm-1720	35	7	described	describe	VERB
ajlm-1720	35	8	expression	expression	NOUN
ajlm-1720	35	9	for	for	ADP
ajlm-1720	35	10	those	those	DET
ajlm-1720	35	11	additional	additional	ADJ
ajlm-1720	35	12	markers	marker	NOUN
ajlm-1720	35	13	that	that	PRON
ajlm-1720	35	14	were	be	AUX
ajlm-1720	35	15	not	not	PART
ajlm-1720	35	16	included	include	VERB
ajlm-1720	35	17	in	in	ADP
ajlm-1720	35	18	the	the	DET
ajlm-1720	35	19	older	old	ADJ
ajlm-1720	35	20	predicate	predicate	NOUN
ajlm-1720	35	21	2–4	2–4	NUM
ajlm-1720	35	22	-	-	PUNCT
ajlm-1720	35	23	colour	colour	NOUN
ajlm-1720	35	24	method	method	NOUN
ajlm-1720	35	25	,	,	PUNCT
ajlm-1720	35	26	such	such	ADJ
ajlm-1720	35	27	as	as	ADP
ajlm-1720	35	28	verifying	verify	VERB
ajlm-1720	35	29	the	the	DET
ajlm-1720	35	30	expression	expression	NOUN
ajlm-1720	35	31	of	of	ADP
ajlm-1720	35	32	cd43	cd43	PROPN
ajlm-1720	35	33	,	,	PUNCT
ajlm-1720	35	34	cd79b	cd79b	ADJ
ajlm-1720	35	35	,	,	PUNCT
ajlm-1720	35	36	cd81	cd81	PROPN
ajlm-1720	35	37	and	and	CCONJ
ajlm-1720	35	38	ror-1	ror-1	PUNCT
ajlm-1720	35	39	in	in	ADP
ajlm-1720	35	40	the	the	DET
ajlm-1720	35	41	clb	clb	NOUN
ajlm-1720	35	42	tube	tube	NOUN
ajlm-1720	35	43	and	and	CCONJ
ajlm-1720	35	44	cd38	cd38	PROPN
ajlm-1720	35	45	and	and	CCONJ
ajlm-1720	35	46	cd138	cd138	PROPN
ajlm-1720	35	47	with	with	ADP
ajlm-1720	35	48	cd27	cd27	PROPN
ajlm-1720	35	49	,	,	PUNCT
ajlm-1720	35	50	cd81	cd81	PROPN
ajlm-1720	35	51	and	and	CCONJ
ajlm-1720	35	52	cd56	cd56	PROPN
ajlm-1720	35	53	included	include	VERB
ajlm-1720	35	54	in	in	ADP
ajlm-1720	35	55	the	the	DET
ajlm-1720	35	56	duraclone	duraclone	NOUN
ajlm-1720	35	57	pc	pc	NOUN
ajlm-1720	35	58	tube	tube	NOUN
ajlm-1720	35	59	against	against	ADP
ajlm-1720	35	60	expected	expect	VERB
ajlm-1720	35	61	expression	expression	NOUN
ajlm-1720	35	62	in	in	ADP
ajlm-1720	35	63	normal	normal	ADJ
ajlm-1720	35	64	leucocyte	leucocyte	NOUN
ajlm-1720	35	65	population	population	NOUN
ajlm-1720	35	66	counterparts	counterpart	NOUN
ajlm-1720	35	67	.	.	PUNCT
ajlm-1720	36	1	we	we	PRON
ajlm-1720	36	2	also	also	ADV
ajlm-1720	36	3	validated	validate	VERB
ajlm-1720	36	4	the	the	DET
ajlm-1720	36	5	overall	overall	ADJ
ajlm-1720	36	6	diagnostic	diagnostic	ADJ
ajlm-1720	36	7	outcome	outcome	NOUN
ajlm-1720	36	8	of	of	ADP
ajlm-1720	36	9	the	the	DET
ajlm-1720	36	10	alb	alb	PROPN
ajlm-1720	36	11	tube	tube	NOUN
ajlm-1720	36	12	;	;	PUNCT
ajlm-1720	36	13	here	here	ADV
ajlm-1720	36	14	,	,	PUNCT
ajlm-1720	36	15	we	we	PRON
ajlm-1720	36	16	asked	ask	VERB
ajlm-1720	36	17	whether	whether	SCONJ
ajlm-1720	36	18	the	the	DET
ajlm-1720	36	19	cd58	cd58	PROPN
ajlm-1720	36	20	included	include	VERB
ajlm-1720	36	21	in	in	ADP
ajlm-1720	36	22	the	the	DET
ajlm-1720	36	23	alb	alb	PROPN
ajlm-1720	36	24	tubes	tube	NOUN
ajlm-1720	36	25	offered	offer	VERB
ajlm-1720	36	26	any	any	DET
ajlm-1720	36	27	additional	additional	ADJ
ajlm-1720	36	28	diagnostic	diagnostic	ADJ
ajlm-1720	36	29	advantage	advantage	NOUN
ajlm-1720	36	30	in	in	ADP
ajlm-1720	36	31	identifying	identify	VERB
ajlm-1720	36	32	a	a	DET
ajlm-1720	36	33	b	b	NOUN
ajlm-1720	36	34	-	-	PUNCT
ajlm-1720	36	35	all	all	PRON
ajlm-1720	36	36	that	that	PRON
ajlm-1720	36	37	had	have	AUX
ajlm-1720	36	38	been	be	AUX
ajlm-1720	36	39	identified	identify	VERB
ajlm-1720	36	40	in	in	ADP
ajlm-1720	36	41	the	the	DET
ajlm-1720	36	42	first	first	ADJ
ajlm-1720	36	43	-	-	PUNCT
ajlm-1720	36	44	line	line	NOUN
ajlm-1720	36	45	clearllab	clearllab	NOUN
ajlm-1720	36	46	10c	10c	PROPN
ajlm-1720	36	47	investigation	investigation	NOUN
ajlm-1720	36	48	.	.	PUNCT
ajlm-1720	37	1	methods	method	NOUN
ajlm-1720	37	2	ethical	ethical	ADJ
ajlm-1720	37	3	considerations	consideration	NOUN
ajlm-1720	37	4	the	the	DET
ajlm-1720	37	5	university	university	NOUN
ajlm-1720	37	6	of	of	ADP
ajlm-1720	37	7	the	the	DET
ajlm-1720	37	8	witwatersrand	witwatersrand	PROPN
ajlm-1720	37	9	health	health	PROPN
ajlm-1720	37	10	research	research	PROPN
ajlm-1720	37	11	ethics	ethic	NOUN
ajlm-1720	37	12	committee	committee	PROPN
ajlm-1720	37	13	approved	approve	VERB
ajlm-1720	37	14	the	the	DET
ajlm-1720	37	15	study	study	NOUN
ajlm-1720	37	16	(	(	PUNCT
ajlm-1720	37	17	ethics	ethic	NOUN
ajlm-1720	37	18	clearance	clearance	NOUN
ajlm-1720	37	19	number	number	NOUN
ajlm-1720	37	20	m1704129	m1704129	PROPN
ajlm-1720	37	21	)	)	PUNCT
ajlm-1720	37	22	.	.	PUNCT
ajlm-1720	38	1	the	the	DET
ajlm-1720	38	2	study	study	NOUN
ajlm-1720	38	3	’s	’s	PART
ajlm-1720	38	4	objective	objective	NOUN
ajlm-1720	38	5	was	be	AUX
ajlm-1720	38	6	to	to	PART
ajlm-1720	38	7	validate	validate	VERB
ajlm-1720	38	8	the	the	DET
ajlm-1720	38	9	commercially	commercially	ADV
ajlm-1720	38	10	available	available	ADJ
ajlm-1720	38	11	beckman	beckman	PROPN
ajlm-1720	38	12	coulter	coulter	PROPN
ajlm-1720	38	13	duraclone	duraclone	PROPN
ajlm-1720	38	14	pc	pc	PROPN
ajlm-1720	38	15	,	,	PUNCT
ajlm-1720	38	16	clb	clb	NOUN
ajlm-1720	38	17	and	and	CCONJ
ajlm-1720	38	18	pc	pc	NOUN
ajlm-1720	38	19	fixed	fix	VERB
ajlm-1720	38	20	-	-	PUNCT
ajlm-1720	38	21	tube	tube	NOUN
ajlm-1720	38	22	,	,	PUNCT
ajlm-1720	38	23	pre	pre	ADJ
ajlm-1720	38	24	-	-	ADJ
ajlm-1720	38	25	titrated	titrated	ADJ
ajlm-1720	38	26	panels	panel	NOUN
ajlm-1720	38	27	as	as	ADP
ajlm-1720	38	28	an	an	DET
ajlm-1720	38	29	alternative	alternative	ADJ
ajlm-1720	38	30	second	second	ADJ
ajlm-1720	38	31	-	-	PUNCT
ajlm-1720	38	32	line	line	NOUN
ajlm-1720	38	33	diagnostic	diagnostic	ADJ
ajlm-1720	38	34	workup	workup	NOUN
ajlm-1720	38	35	to	to	ADP
ajlm-1720	38	36	our	our	PRON
ajlm-1720	38	37	existing	exist	VERB
ajlm-1720	38	38	in	in	ADP
ajlm-1720	38	39	-	-	PUNCT
ajlm-1720	38	40	house	house	NOUN
ajlm-1720	38	41	second	second	ADJ
ajlm-1720	38	42	-	-	PUNCT
ajlm-1720	38	43	line	line	NOUN
ajlm-1720	38	44	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	38	45	investigation	investigation	NOUN
ajlm-1720	38	46	.	.	PUNCT
ajlm-1720	39	1	the	the	DET
ajlm-1720	39	2	interpretation	interpretation	NOUN
ajlm-1720	39	3	of	of	ADP
ajlm-1720	39	4	flow	flow	NOUN
ajlm-1720	39	5	cytometric	cytometric	ADJ
ajlm-1720	39	6	data	datum	NOUN
ajlm-1720	39	7	and	and	CCONJ
ajlm-1720	39	8	consequent	consequent	ADJ
ajlm-1720	39	9	clinical	clinical	ADJ
ajlm-1720	39	10	diagnostic	diagnostic	ADJ
ajlm-1720	39	11	outcomes	outcome	NOUN
ajlm-1720	39	12	of	of	ADP
ajlm-1720	39	13	the	the	DET
ajlm-1720	39	14	existing	exist	VERB
ajlm-1720	39	15	in	in	ADP
ajlm-1720	39	16	-	-	PUNCT
ajlm-1720	39	17	house	house	NOUN
ajlm-1720	39	18	,	,	PUNCT
ajlm-1720	39	19	second	second	ADJ
ajlm-1720	39	20	-	-	PUNCT
ajlm-1720	39	21	line	line	NOUN
ajlm-1720	39	22	,	,	PUNCT
ajlm-1720	39	23	non	non	ADJ
ajlm-1720	39	24	-	-	ADJ
ajlm-1720	39	25	standardised	standardised	ADJ
ajlm-1720	39	26	panels	panel	NOUN
ajlm-1720	39	27	were	be	AUX
ajlm-1720	39	28	compared	compare	VERB
ajlm-1720	39	29	to	to	ADP
ajlm-1720	39	30	the	the	DET
ajlm-1720	39	31	overall	overall	ADJ
ajlm-1720	39	32	clinical	clinical	ADJ
ajlm-1720	39	33	diagnostic	diagnostic	ADJ
ajlm-1720	39	34	outcomes	outcome	NOUN
ajlm-1720	39	35	of	of	ADP
ajlm-1720	39	36	the	the	DET
ajlm-1720	39	37	duraclone	duraclone	NOUN
ajlm-1720	39	38	analyses	analysis	NOUN
ajlm-1720	39	39	.	.	PUNCT
ajlm-1720	40	1	study	study	NOUN
ajlm-1720	40	2	design	design	NOUN
ajlm-1720	40	3	and	and	CCONJ
ajlm-1720	40	4	site	site	NOUN
ajlm-1720	40	5	this	this	DET
ajlm-1720	40	6	study	study	NOUN
ajlm-1720	40	7	was	be	AUX
ajlm-1720	40	8	a	a	DET
ajlm-1720	40	9	prospective	prospective	ADJ
ajlm-1720	40	10	observational	observational	ADJ
ajlm-1720	40	11	cohort	cohort	NOUN
ajlm-1720	40	12	study	study	NOUN
ajlm-1720	40	13	conducted	conduct	VERB
ajlm-1720	40	14	according	accord	VERB
ajlm-1720	40	15	to	to	ADP
ajlm-1720	40	16	the	the	DET
ajlm-1720	40	17	standards	standard	NOUN
ajlm-1720	40	18	for	for	ADP
ajlm-1720	40	19	reporting	report	VERB
ajlm-1720	40	20	diagnostics	diagnostic	NOUN
ajlm-1720	40	21	accuracy.20	accuracy.20	PROPN
ajlm-1720	40	22	the	the	DET
ajlm-1720	40	23	work	work	NOUN
ajlm-1720	40	24	was	be	AUX
ajlm-1720	40	25	undertaken	undertake	VERB
ajlm-1720	40	26	from	from	ADP
ajlm-1720	40	27	april	april	PROPN
ajlm-1720	40	28	2020	2020	NUM
ajlm-1720	40	29	to	to	ADP
ajlm-1720	40	30	august	august	PROPN
ajlm-1720	40	31	2020	2020	NUM
ajlm-1720	40	32	and	and	CCONJ
ajlm-1720	40	33	conducted	conduct	VERB
ajlm-1720	40	34	in	in	ADP
ajlm-1720	40	35	the	the	DET
ajlm-1720	40	36	national	national	PROPN
ajlm-1720	40	37	health	health	PROPN
ajlm-1720	40	38	laboratory	laboratory	PROPN
ajlm-1720	40	39	service	service	NOUN
ajlm-1720	40	40	flow	flow	NOUN
ajlm-1720	40	41	cytometry	cytometry	PROPN
ajlm-1720	40	42	laboratory	laboratory	NOUN
ajlm-1720	40	43	at	at	ADP
ajlm-1720	40	44	the	the	DET
ajlm-1720	40	45	charlotte	charlotte	PROPN
ajlm-1720	40	46	maxeke	maxeke	PROPN
ajlm-1720	40	47	johannesburg	johannesburg	PROPN
ajlm-1720	40	48	academic	academic	ADJ
ajlm-1720	40	49	hospital	hospital	PROPN
ajlm-1720	40	50	in	in	ADP
ajlm-1720	40	51	johannesburg	johannesburg	PROPN
ajlm-1720	40	52	,	,	PUNCT
ajlm-1720	40	53	south	south	PROPN
ajlm-1720	40	54	africa	africa	PROPN
ajlm-1720	40	55	.	.	PUNCT
ajlm-1720	41	1	this	this	DET
ajlm-1720	41	2	laboratory	laboratory	NOUN
ajlm-1720	41	3	performs	perform	VERB
ajlm-1720	41	4	routine	routine	ADJ
ajlm-1720	41	5	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	41	6	investigation	investigation	NOUN
ajlm-1720	41	7	of	of	ADP
ajlm-1720	41	8	leukaemias	leukaemia	NOUN
ajlm-1720	41	9	and	and	CCONJ
ajlm-1720	41	10	lymphomas	lymphoma	NOUN
ajlm-1720	41	11	for	for	ADP
ajlm-1720	41	12	both	both	DET
ajlm-1720	41	13	children	child	NOUN
ajlm-1720	41	14	and	and	CCONJ
ajlm-1720	41	15	adults	adult	NOUN
ajlm-1720	41	16	,	,	PUNCT
ajlm-1720	41	17	referred	refer	VERB
ajlm-1720	41	18	from	from	ADP
ajlm-1720	41	19	charlotte	charlotte	PROPN
ajlm-1720	41	20	maxeke	maxeke	PROPN
ajlm-1720	41	21	johannesburg	johannesburg	PROPN
ajlm-1720	41	22	academic	academic	ADJ
ajlm-1720	41	23	hospital	hospital	NOUN
ajlm-1720	41	24	and	and	CCONJ
ajlm-1720	41	25	other	other	ADJ
ajlm-1720	41	26	hospitals	hospital	NOUN
ajlm-1720	41	27	within	within	ADP
ajlm-1720	41	28	the	the	DET
ajlm-1720	41	29	university	university	NOUN
ajlm-1720	41	30	of	of	ADP
ajlm-1720	41	31	the	the	DET
ajlm-1720	41	32	witwatersrand	witwatersrand	PROPN
ajlm-1720	41	33	service	service	PROPN
ajlm-1720	41	34	precinct	precinct	NOUN
ajlm-1720	41	35	,	,	PUNCT
ajlm-1720	41	36	as	as	ADV
ajlm-1720	41	37	well	well	ADV
ajlm-1720	41	38	as	as	ADP
ajlm-1720	41	39	from	from	ADP
ajlm-1720	41	40	other	other	ADJ
ajlm-1720	41	41	centres	centre	NOUN
ajlm-1720	41	42	around	around	ADP
ajlm-1720	41	43	south	south	PROPN
ajlm-1720	41	44	africa	africa	PROPN
ajlm-1720	41	45	.	.	PUNCT
ajlm-1720	42	1	morphological	morphological	ADJ
ajlm-1720	42	2	assessment	assessment	NOUN
ajlm-1720	42	3	of	of	ADP
ajlm-1720	42	4	peripheral	peripheral	ADJ
ajlm-1720	42	5	blood	blood	NOUN
ajlm-1720	42	6	,	,	PUNCT
ajlm-1720	42	7	bone	bone	NOUN
ajlm-1720	42	8	marrow	marrow	NOUN
ajlm-1720	42	9	and	and	CCONJ
ajlm-1720	42	10	trephine	trephine	NOUN
ajlm-1720	42	11	samples	sample	NOUN
ajlm-1720	42	12	(	(	PUNCT
ajlm-1720	42	13	from	from	ADP
ajlm-1720	42	14	the	the	DET
ajlm-1720	42	15	same	same	ADJ
ajlm-1720	42	16	patients	patient	NOUN
ajlm-1720	42	17	whose	whose	DET
ajlm-1720	42	18	samples	sample	NOUN
ajlm-1720	42	19	are	be	AUX
ajlm-1720	42	20	tested	test	VERB
ajlm-1720	42	21	in	in	ADP
ajlm-1720	42	22	the	the	DET
ajlm-1720	42	23	flow	flow	NOUN
ajlm-1720	42	24	cytometry	cytometry	NOUN
ajlm-1720	42	25	unit	unit	NOUN
ajlm-1720	42	26	)	)	PUNCT
ajlm-1720	42	27	is	be	AUX
ajlm-1720	42	28	performed	perform	VERB
ajlm-1720	42	29	in	in	ADP
ajlm-1720	42	30	the	the	DET
ajlm-1720	42	31	sister	sister	NOUN
ajlm-1720	42	32	haematology	haematology	NOUN
ajlm-1720	42	33	laboratory	laboratory	NOUN
ajlm-1720	42	34	;	;	PUNCT
ajlm-1720	42	35	auxiliary	auxiliary	ADJ
ajlm-1720	42	36	molecular	molecular	ADJ
ajlm-1720	42	37	and	and	CCONJ
ajlm-1720	42	38	cytogenetic	cytogenetic	ADJ
ajlm-1720	42	39	investigations	investigation	NOUN
ajlm-1720	42	40	are	be	AUX
ajlm-1720	42	41	also	also	ADV
ajlm-1720	42	42	performed	perform	VERB
ajlm-1720	42	43	on	on	ADP
ajlm-1720	42	44	site	site	NOUN
ajlm-1720	42	45	.	.	PUNCT
ajlm-1720	43	1	the	the	DET
ajlm-1720	43	2	laboratory	laboratory	NOUN
ajlm-1720	43	3	participates	participate	VERB
ajlm-1720	43	4	in	in	ADP
ajlm-1720	43	5	the	the	DET
ajlm-1720	43	6	united	united	PROPN
ajlm-1720	43	7	kingdom	kingdom	PROPN
ajlm-1720	43	8	national	national	ADJ
ajlm-1720	43	9	external	external	ADJ
ajlm-1720	43	10	quality	quality	NOUN
ajlm-1720	43	11	assurance	assurance	NOUN
ajlm-1720	43	12	scheme	scheme	NOUN
ajlm-1720	43	13	(	(	PUNCT
ajlm-1720	43	14	uk	uk	PROPN
ajlm-1720	43	15	neqas	neqas	PROPN
ajlm-1720	43	16	,	,	PUNCT
ajlm-1720	43	17	sheffield	sheffield	PROPN
ajlm-1720	43	18	,	,	PUNCT
ajlm-1720	43	19	united	united	ADJ
ajlm-1720	43	20	kingdom	kingdom	PROPN
ajlm-1720	43	21	)	)	PUNCT
ajlm-1720	43	22	leukaemia	leukaemia	NOUN
ajlm-1720	43	23	immunophenotyping	immunophenotype	VERB
ajlm-1720	43	24	part	part	NOUN
ajlm-1720	43	25	1	1	NUM
ajlm-1720	43	26	and	and	CCONJ
ajlm-1720	43	27	part	part	NOUN
ajlm-1720	43	28	2	2	NUM
ajlm-1720	43	29	(	(	PUNCT
ajlm-1720	43	30	interpretation	interpretation	NOUN
ajlm-1720	43	31	)	)	PUNCT
ajlm-1720	43	32	proficiency	proficiency	NOUN
ajlm-1720	43	33	testing	testing	NOUN
ajlm-1720	43	34	scheme.21	scheme.21	PROPN
ajlm-1720	43	35	testing	testing	NOUN
ajlm-1720	43	36	approach	approach	NOUN
ajlm-1720	43	37	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	43	38	testing	testing	NOUN
ajlm-1720	43	39	of	of	ADP
ajlm-1720	43	40	all	all	DET
ajlm-1720	43	41	samples	sample	NOUN
ajlm-1720	43	42	at	at	ADP
ajlm-1720	43	43	the	the	DET
ajlm-1720	43	44	charlotte	charlotte	PROPN
ajlm-1720	43	45	maxeke	maxeke	PROPN
ajlm-1720	43	46	johannesburg	johannesburg	PROPN
ajlm-1720	43	47	academic	academic	PROPN
ajlm-1720	43	48	hospital	hospital	PROPN
ajlm-1720	43	49	flow	flow	NOUN
ajlm-1720	43	50	cytometry	cytometry	PROPN
ajlm-1720	43	51	unit	unit	NOUN
ajlm-1720	43	52	is	be	AUX
ajlm-1720	43	53	two	two	NUM
ajlm-1720	43	54	-	-	PUNCT
ajlm-1720	43	55	tiered	tiere	VERB
ajlm-1720	43	56	.	.	PUNCT
ajlm-1720	44	1	firstly	firstly	ADV
ajlm-1720	44	2	,	,	PUNCT
ajlm-1720	44	3	an	an	DET
ajlm-1720	44	4	initial	initial	ADJ
ajlm-1720	44	5	first	first	ADJ
ajlm-1720	44	6	-	-	PUNCT
ajlm-1720	44	7	line	line	NOUN
ajlm-1720	44	8	workup	workup	NOUN
ajlm-1720	44	9	is	be	AUX
ajlm-1720	44	10	performed	perform	VERB
ajlm-1720	44	11	with	with	ADP
ajlm-1720	44	12	bc	bc	PROPN
ajlm-1720	44	13	clearllab	clearllab	PROPN
ajlm-1720	44	14	10	10	NUM
ajlm-1720	44	15	-	-	SYM
ajlm-1720	44	16	c	c	NOUN
ajlm-1720	44	17	(	(	PUNCT
ajlm-1720	44	18	beckman	beckman	PROPN
ajlm-1720	44	19	coulter	coulter	PROPN
ajlm-1720	44	20	,	,	PUNCT
ajlm-1720	44	21	miami	miami	PROPN
ajlm-1720	44	22	,	,	PUNCT
ajlm-1720	44	23	florida	florida	PROPN
ajlm-1720	44	24	,	,	PUNCT
ajlm-1720	44	25	united	united	PROPN
ajlm-1720	44	26	states	states	PROPN
ajlm-1720	44	27	)	)	PUNCT
ajlm-1720	44	28	.	.	PUNCT
ajlm-1720	45	1	the	the	DET
ajlm-1720	45	2	first	first	ADJ
ajlm-1720	45	3	workup	workup	PROPN
ajlm-1720	45	4	identifies	identify	VERB
ajlm-1720	45	5	most	most	ADJ
ajlm-1720	45	6	acute	acute	ADJ
ajlm-1720	45	7	myeloid	myeloid	NOUN
ajlm-1720	45	8	and	and	CCONJ
ajlm-1720	45	9	lymphoid	lymphoid	ADJ
ajlm-1720	45	10	leukaemia	leukaemia	NOUN
ajlm-1720	45	11	subtypes	subtype	NOUN
ajlm-1720	45	12	,	,	PUNCT
ajlm-1720	45	13	distinguishes	distinguish	VERB
ajlm-1720	45	14	early	early	ADV
ajlm-1720	45	15	and	and	CCONJ
ajlm-1720	45	16	mature	mature	VERB
ajlm-1720	45	17	t	t	NOUN
ajlm-1720	45	18	-	-	PUNCT
ajlm-1720	45	19	cell	cell	NOUN
ajlm-1720	45	20	or	or	CCONJ
ajlm-1720	45	21	b	b	NOUN
ajlm-1720	45	22	-	-	PUNCT
ajlm-1720	45	23	cell	cell	NOUN
ajlm-1720	45	24	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	45	25	disorders	disorder	NOUN
ajlm-1720	45	26	,	,	PUNCT
ajlm-1720	45	27	and	and	CCONJ
ajlm-1720	45	28	hints	hint	VERB
ajlm-1720	45	29	at	at	ADP
ajlm-1720	45	30	the	the	DET
ajlm-1720	45	31	presence	presence	NOUN
ajlm-1720	45	32	of	of	ADP
ajlm-1720	45	33	a	a	DET
ajlm-1720	45	34	pcd	pcd	NOUN
ajlm-1720	45	35	(	(	PUNCT
ajlm-1720	45	36	if	if	SCONJ
ajlm-1720	45	37	a	a	DET
ajlm-1720	45	38	population	population	NOUN
ajlm-1720	45	39	of	of	ADP
ajlm-1720	45	40	brightly	brightly	ADV
ajlm-1720	45	41	expressing	express	VERB
ajlm-1720	45	42	cd38	cd38	PROPN
ajlm-1720	45	43	cells	cell	NOUN
ajlm-1720	45	44	is	be	AUX
ajlm-1720	45	45	noted	note	VERB
ajlm-1720	45	46	)	)	PUNCT
ajlm-1720	45	47	.	.	PUNCT
ajlm-1720	46	1	a	a	DET
ajlm-1720	46	2	limitation	limitation	NOUN
ajlm-1720	46	3	of	of	ADP
ajlm-1720	46	4	this	this	DET
ajlm-1720	46	5	clearllab	clearllab	NOUN
ajlm-1720	46	6	10c	10c	NOUN
ajlm-1720	46	7	system	system	NOUN
ajlm-1720	46	8	is	be	AUX
ajlm-1720	46	9	that	that	SCONJ
ajlm-1720	46	10	further	further	ADJ
ajlm-1720	46	11	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	46	12	characterisation	characterisation	NOUN
ajlm-1720	46	13	of	of	ADP
ajlm-1720	46	14	mature	mature	ADJ
ajlm-1720	46	15	b	b	NOUN
ajlm-1720	46	16	-	-	PUNCT
ajlm-1720	46	17	cell	cell	NOUN
ajlm-1720	46	18	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	46	19	disorders17	disorders17	NOUN
ajlm-1720	46	20	or	or	CCONJ
ajlm-1720	46	21	pcd19,22	pcd19,22	ADV
ajlm-1720	46	22	requires	require	VERB
ajlm-1720	46	23	second	second	ADJ
ajlm-1720	46	24	-	-	PUNCT
ajlm-1720	46	25	line	line	NOUN
ajlm-1720	46	26	testing	testing	NOUN
ajlm-1720	46	27	using	use	VERB
ajlm-1720	46	28	markers	marker	NOUN
ajlm-1720	46	29	that	that	PRON
ajlm-1720	46	30	are	be	AUX
ajlm-1720	46	31	not	not	PART
ajlm-1720	46	32	included	include	VERB
ajlm-1720	46	33	in	in	ADP
ajlm-1720	46	34	the	the	DET
ajlm-1720	46	35	first	first	ADJ
ajlm-1720	46	36	-	-	PUNCT
ajlm-1720	46	37	line	line	NOUN
ajlm-1720	46	38	testing	testing	NOUN
ajlm-1720	46	39	.	.	PUNCT
ajlm-1720	47	1	for	for	ADP
ajlm-1720	47	2	this	this	DET
ajlm-1720	47	3	study	study	NOUN
ajlm-1720	47	4	,	,	PUNCT
ajlm-1720	47	5	in	in	ADP
ajlm-1720	47	6	-	-	PUNCT
ajlm-1720	47	7	house	house	NOUN
ajlm-1720	47	8	second	second	ADJ
ajlm-1720	47	9	-	-	PUNCT
ajlm-1720	47	10	line	line	NOUN
ajlm-1720	47	11	testing	testing	NOUN
ajlm-1720	47	12	specifically	specifically	ADV
ajlm-1720	47	13	assessed	assess	VERB
ajlm-1720	47	14	cd23	cd23	PROPN
ajlm-1720	47	15	and	and	CCONJ
ajlm-1720	47	16	fmc-7	fmc-7	X
ajlm-1720	47	17	expression	expression	NOUN
ajlm-1720	47	18	on	on	ADP
ajlm-1720	47	19	mature	mature	ADJ
ajlm-1720	47	20	b	b	NOUN
ajlm-1720	47	21	-	-	PUNCT
ajlm-1720	47	22	cells	cell	NOUN
ajlm-1720	47	23	or	or	CCONJ
ajlm-1720	47	24	cd38	cd38	PROPN
ajlm-1720	47	25	and	and	CCONJ
ajlm-1720	47	26	cd138	cd138	NOUN
ajlm-1720	47	27	expression	expression	NOUN
ajlm-1720	47	28	on	on	ADP
ajlm-1720	47	29	plasma	plasma	NOUN
ajlm-1720	47	30	cells	cell	NOUN
ajlm-1720	47	31	.	.	PUNCT
ajlm-1720	48	1	specifically	specifically	ADV
ajlm-1720	48	2	,	,	PUNCT
ajlm-1720	48	3	in	in	ADP
ajlm-1720	48	4	the	the	DET
ajlm-1720	48	5	context	context	NOUN
ajlm-1720	48	6	of	of	ADP
ajlm-1720	48	7	b	b	PROPN
ajlm-1720	48	8	-	-	PUNCT
ajlm-1720	48	9	lpd	lpd	PROPN
ajlm-1720	48	10	and	and	CCONJ
ajlm-1720	48	11	in	in	ADP
ajlm-1720	48	12	comparison	comparison	NOUN
ajlm-1720	48	13	to	to	ADP
ajlm-1720	48	14	our	our	PRON
ajlm-1720	48	15	in	in	ADP
ajlm-1720	48	16	-	-	PUNCT
ajlm-1720	48	17	house	house	NOUN
ajlm-1720	48	18	second	second	ADJ
ajlm-1720	48	19	-	-	PUNCT
ajlm-1720	48	20	line	line	NOUN
ajlm-1720	48	21	investigation	investigation	NOUN
ajlm-1720	48	22	that	that	PRON
ajlm-1720	48	23	included	include	VERB
ajlm-1720	48	24	cd23	cd23	PROPN
ajlm-1720	48	25	and	and	CCONJ
ajlm-1720	48	26	fmc-7	fmc-7	NOUN
ajlm-1720	48	27	,	,	PUNCT
ajlm-1720	48	28	could	could	AUX
ajlm-1720	48	29	duraclone	duraclone	VERB
ajlm-1720	48	30	clb	clb	NOUN
ajlm-1720	48	31	testing	testing	NOUN
ajlm-1720	48	32	with	with	ADP
ajlm-1720	48	33	ror-1	ror-1	NOUN
ajlm-1720	48	34	,	,	PUNCT
ajlm-1720	48	35	cd20	cd20	PROPN
ajlm-1720	48	36	,	,	PUNCT
ajlm-1720	48	37	cd43	cd43	PROPN
ajlm-1720	48	38	,	,	PUNCT
ajlm-1720	48	39	cd79b	cd79b	NOUN
ajlm-1720	48	40	,	,	PUNCT
ajlm-1720	48	41	and	and	CCONJ
ajlm-1720	48	42	81	81	NUM
ajlm-1720	48	43	replace	replace	NOUN
ajlm-1720	48	44	cd23	cd23	PROPN
ajlm-1720	48	45	and	and	CCONJ
ajlm-1720	48	46	fmc-7	fmc-7	PUNCT
ajlm-1720	48	47	in	in	ADP
ajlm-1720	48	48	discerning	discern	VERB
ajlm-1720	48	49	cd5	cd5	PROPN
ajlm-1720	48	50	b	b	PROPN
ajlm-1720	48	51	-	-	PUNCT
ajlm-1720	48	52	cell	cell	NOUN
ajlm-1720	48	53	chronic	chronic	ADJ
ajlm-1720	48	54	lymphocytic	lymphocytic	ADJ
ajlm-1720	48	55	leukaemia	leukaemia	NOUN
ajlm-1720	48	56	(	(	PUNCT
ajlm-1720	48	57	cll	cll	PROPN
ajlm-1720	48	58	)	)	PUNCT
ajlm-1720	48	59	from	from	ADP
ajlm-1720	48	60	other	other	ADJ
ajlm-1720	48	61	cd5	cd5	PROPN
ajlm-1720	48	62	and	and	CCONJ
ajlm-1720	48	63	non	non	ADJ
ajlm-1720	48	64	-	-	ADJ
ajlm-1720	48	65	cd5	cd5	ADJ
ajlm-1720	48	66	expressing	express	VERB
ajlm-1720	48	67	b	b	PROPN
ajlm-1720	48	68	-	-	PUNCT
ajlm-1720	48	69	lpd.17,18	lpd.17,18	PROPN
ajlm-1720	48	70	samples	sample	NOUN
ajlm-1720	48	71	after	after	ADP
ajlm-1720	48	72	all	all	DET
ajlm-1720	48	73	routine	routine	ADJ
ajlm-1720	48	74	testing	testing	NOUN
ajlm-1720	48	75	with	with	ADP
ajlm-1720	48	76	clearllab	clearllab	NOUN
ajlm-1720	48	77	10c	10c	NOUN
ajlm-1720	48	78	and	and	CCONJ
ajlm-1720	48	79	in	in	ADP
ajlm-1720	48	80	-	-	PUNCT
ajlm-1720	48	81	house	house	NOUN
ajlm-1720	48	82	second	second	ADJ
ajlm-1720	48	83	-	-	PUNCT
ajlm-1720	48	84	line	line	NOUN
ajlm-1720	48	85	testing	testing	NOUN
ajlm-1720	48	86	(	(	PUNCT
ajlm-1720	48	87	table	table	NOUN
ajlm-1720	48	88	1	1	NUM
ajlm-1720	48	89	)	)	PUNCT
ajlm-1720	48	90	,	,	PUNCT
ajlm-1720	48	91	samples	sample	NOUN
ajlm-1720	48	92	having	have	VERB
ajlm-1720	48	93	sufficient	sufficient	ADJ
ajlm-1720	48	94	remnant	remnant	ADJ
ajlm-1720	48	95	prepared	prepare	VERB
ajlm-1720	48	96	-	-	PUNCT
ajlm-1720	48	97	cell	cell	NOUN
ajlm-1720	48	98	-	-	PUNCT
ajlm-1720	48	99	concentrate	concentrate	NOUN
ajlm-1720	48	100	or	or	CCONJ
ajlm-1720	48	101	at	at	ADP
ajlm-1720	48	102	least	least	ADV
ajlm-1720	48	103	1	1	NUM
ajlm-1720	48	104	ml	ml	ADP
ajlm-1720	48	105	remaining	remain	VERB
ajlm-1720	48	106	of	of	ADP
ajlm-1720	48	107	the	the	DET
ajlm-1720	48	108	whole	whole	ADJ
ajlm-1720	48	109	sample	sample	NOUN
ajlm-1720	48	110	were	be	AUX
ajlm-1720	48	111	re	re	VERB
ajlm-1720	48	112	-	-	VERB
ajlm-1720	48	113	tested	test	VERB
ajlm-1720	48	114	using	use	VERB
ajlm-1720	48	115	one	one	NUM
ajlm-1720	48	116	of	of	ADP
ajlm-1720	48	117	the	the	DET
ajlm-1720	48	118	test	test	NOUN
ajlm-1720	48	119	methods	method	NOUN
ajlm-1720	48	120	(	(	PUNCT
ajlm-1720	48	121	either	either	CCONJ
ajlm-1720	48	122	duraclone	duraclone	NOUN
ajlm-1720	48	123	re	re	VERB
ajlm-1720	48	124	alb	alb	VERB
ajlm-1720	48	125	,	,	PUNCT
ajlm-1720	48	126	re	re	NOUN
ajlm-1720	48	127	clb	clb	NOUN
ajlm-1720	48	128	or	or	CCONJ
ajlm-1720	48	129	re	re	NOUN
ajlm-1720	48	130	pc	pc	NOUN
ajlm-1720	48	131	)	)	PUNCT
ajlm-1720	48	132	.	.	PUNCT
ajlm-1720	49	1	the	the	DET
ajlm-1720	49	2	aim	aim	NOUN
ajlm-1720	49	3	was	be	AUX
ajlm-1720	49	4	to	to	PART
ajlm-1720	49	5	collect	collect	VERB
ajlm-1720	49	6	at	at	ADV
ajlm-1720	49	7	least	least	ADV
ajlm-1720	49	8	20	20	NUM
ajlm-1720	49	9	clinical	clinical	ADJ
ajlm-1720	49	10	specimens	specimen	NOUN
ajlm-1720	49	11	for	for	ADP
ajlm-1720	49	12	each	each	DET
ajlm-1720	49	13	validation	validation	NOUN
ajlm-1720	49	14	(	(	PUNCT
ajlm-1720	49	15	estimated	estimate	VERB
ajlm-1720	49	16	to	to	PART
ajlm-1720	49	17	be	be	AUX
ajlm-1720	49	18	60	60	NUM
ajlm-1720	49	19	samples	sample	NOUN
ajlm-1720	49	20	)	)	PUNCT
ajlm-1720	49	21	.	.	PUNCT
ajlm-1720	50	1	all	all	DET
ajlm-1720	50	2	peripheral	peripheral	ADJ
ajlm-1720	50	3	blood	blood	NOUN
ajlm-1720	50	4	and	and	CCONJ
ajlm-1720	50	5	bone	bone	NOUN
ajlm-1720	50	6	marrow	marrow	NOUN
ajlm-1720	50	7	samples	sample	NOUN
ajlm-1720	50	8	were	be	AUX
ajlm-1720	50	9	collected	collect	VERB
ajlm-1720	50	10	by	by	ADP
ajlm-1720	50	11	attending	attend	VERB
ajlm-1720	50	12	physicians	physician	NOUN
ajlm-1720	50	13	into	into	ADP
ajlm-1720	50	14	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-1720	50	15	acid	acid	NOUN
ajlm-1720	50	16	vacutainer	vacutainer	ADJ
ajlm-1720	50	17	tubes	tube	NOUN
ajlm-1720	50	18	;	;	PUNCT
ajlm-1720	50	19	the	the	DET
ajlm-1720	50	20	single	single	ADJ
ajlm-1720	50	21	body	body	NOUN
ajlm-1720	50	22	fluid	fluid	NOUN
ajlm-1720	50	23	sample	sample	NOUN
ajlm-1720	50	24	was	be	AUX
ajlm-1720	50	25	not	not	PART
ajlm-1720	50	26	collected	collect	VERB
ajlm-1720	50	27	into	into	ADP
ajlm-1720	50	28	an	an	DET
ajlm-1720	50	29	anticoagulant	anticoagulant	NOUN
ajlm-1720	50	30	but	but	CCONJ
ajlm-1720	50	31	submitted	submit	VERB
ajlm-1720	50	32	in	in	ADP
ajlm-1720	50	33	a	a	DET
ajlm-1720	50	34	vacutainer	vacutainer	ADJ
ajlm-1720	50	35	tube	tube	NOUN
ajlm-1720	50	36	without	without	ADP
ajlm-1720	50	37	anticoagulant	anticoagulant	NOUN
ajlm-1720	50	38	.	.	PUNCT
ajlm-1720	51	1	at	at	ADP
ajlm-1720	51	2	the	the	DET
ajlm-1720	51	3	end	end	NOUN
ajlm-1720	51	4	of	of	ADP
ajlm-1720	51	5	the	the	DET
ajlm-1720	51	6	study	study	NOUN
ajlm-1720	51	7	period	period	NOUN
ajlm-1720	51	8	,	,	PUNCT
ajlm-1720	51	9	a	a	DET
ajlm-1720	51	10	total	total	NOUN
ajlm-1720	51	11	of	of	ADP
ajlm-1720	51	12	57	57	NUM
ajlm-1720	51	13	anonymised	anonymise	VERB
ajlm-1720	51	14	samples	sample	NOUN
ajlm-1720	51	15	were	be	AUX
ajlm-1720	51	16	identified	identify	VERB
ajlm-1720	51	17	for	for	ADP
ajlm-1720	51	18	second	second	ADJ
ajlm-1720	51	19	-	-	PUNCT
ajlm-1720	51	20	line	line	NOUN
ajlm-1720	51	21	duraclone	duraclone	NOUN
ajlm-1720	51	22	comparison	comparison	NOUN
ajlm-1720	51	23	,	,	PUNCT
ajlm-1720	51	24	including	include	VERB
ajlm-1720	51	25	peripheral	peripheral	ADJ
ajlm-1720	51	26	blood	blood	NOUN
ajlm-1720	51	27	(	(	PUNCT
ajlm-1720	51	28	n	n	NOUN
ajlm-1720	51	29	=	=	SYM
ajlm-1720	51	30	13	13	NUM
ajlm-1720	51	31	)	)	PUNCT
ajlm-1720	51	32	,	,	PUNCT
ajlm-1720	51	33	bone	bone	NOUN
ajlm-1720	51	34	marrow	marrow	NOUN
ajlm-1720	51	35	(	(	PUNCT
ajlm-1720	51	36	n	n	NOUN
ajlm-1720	51	37	=	=	SYM
ajlm-1720	51	38	43	43	NUM
ajlm-1720	51	39	)	)	PUNCT
ajlm-1720	51	40	,	,	PUNCT
ajlm-1720	51	41	and	and	CCONJ
ajlm-1720	51	42	a	a	DET
ajlm-1720	51	43	pleural	pleural	ADJ
ajlm-1720	51	44	fluid	fluid	ADJ
ajlm-1720	51	45	sample	sample	NOUN
ajlm-1720	51	46	(	(	PUNCT
ajlm-1720	51	47	n	n	NOUN
ajlm-1720	51	48	=	=	SYM
ajlm-1720	51	49	1	1	NUM
ajlm-1720	51	50	)	)	PUNCT
ajlm-1720	51	51	collected	collect	VERB
ajlm-1720	51	52	from	from	ADP
ajlm-1720	51	53	paediatric	paediatric	ADJ
ajlm-1720	51	54	and	and	CCONJ
ajlm-1720	51	55	adult	adult	NOUN
ajlm-1720	51	56	patients	patient	NOUN
ajlm-1720	51	57	.	.	PUNCT
ajlm-1720	52	1	for	for	ADP
ajlm-1720	52	2	duraclone	duraclone	NOUN
ajlm-1720	52	3	alb	alb	PROPN
ajlm-1720	52	4	testing	testing	NOUN
ajlm-1720	52	5	,	,	PUNCT
ajlm-1720	52	6	20	20	NUM
ajlm-1720	52	7	bone	bone	NOUN
ajlm-1720	52	8	marrow	marrow	NOUN
ajlm-1720	52	9	aspirate	aspirate	NOUN
ajlm-1720	52	10	samples	sample	NOUN
ajlm-1720	52	11	were	be	AUX
ajlm-1720	52	12	tested	test	VERB
ajlm-1720	52	13	.	.	PUNCT
ajlm-1720	53	1	eleven	eleven	NUM
ajlm-1720	53	2	of	of	ADP
ajlm-1720	53	3	these	these	DET
ajlm-1720	53	4	patients	patient	NOUN
ajlm-1720	53	5	had	have	VERB
ajlm-1720	53	6	a	a	DET
ajlm-1720	53	7	diagnosis	diagnosis	NOUN
ajlm-1720	53	8	of	of	ADP
ajlm-1720	53	9	b	b	NOUN
ajlm-1720	53	10	-	-	PUNCT
ajlm-1720	53	11	all	all	PRON
ajlm-1720	53	12	(	(	PUNCT
ajlm-1720	53	13	n	n	NOUN
ajlm-1720	53	14	=	=	NOUN
ajlm-1720	53	15	11	11	NUM
ajlm-1720	53	16	)	)	PUNCT
ajlm-1720	53	17	,	,	PUNCT
ajlm-1720	53	18	while	while	SCONJ
ajlm-1720	53	19	nine	nine	NUM
ajlm-1720	53	20	had	have	VERB
ajlm-1720	53	21	immunophenotypically	immunophenotypically	ADV
ajlm-1720	53	22	normal	normal	ADJ
ajlm-1720	53	23	haematogones	haematogone	NOUN
ajlm-1720	53	24	.	.	PUNCT
ajlm-1720	54	1	one	one	NUM
ajlm-1720	54	2	of	of	ADP
ajlm-1720	54	3	the	the	DET
ajlm-1720	54	4	nine	nine	NUM
ajlm-1720	54	5	was	be	AUX
ajlm-1720	54	6	a	a	DET
ajlm-1720	54	7	follow	follow	NOUN
ajlm-1720	54	8	-	-	PUNCT
ajlm-1720	54	9	up	up	NOUN
ajlm-1720	54	10	of	of	ADP
ajlm-1720	54	11	a	a	DET
ajlm-1720	54	12	b	b	NOUN
ajlm-1720	54	13	-	-	PUNCT
ajlm-1720	54	14	all	all	ADV
ajlm-1720	54	15	with	with	ADP
ajlm-1720	54	16	normal	normal	ADJ
ajlm-1720	54	17	haematogones	haematogone	NOUN
ajlm-1720	54	18	and	and	CCONJ
ajlm-1720	54	19	no	no	DET
ajlm-1720	54	20	evidence	evidence	NOUN
ajlm-1720	54	21	of	of	ADP
ajlm-1720	54	22	residual	residual	ADJ
ajlm-1720	54	23	disease	disease	NOUN
ajlm-1720	54	24	.	.	PUNCT
ajlm-1720	55	1	twenty	twenty	NUM
ajlm-1720	55	2	samples	sample	NOUN
ajlm-1720	55	3	diagnosed	diagnose	VERB
ajlm-1720	55	4	with	with	ADP
ajlm-1720	55	5	a	a	DET
ajlm-1720	55	6	b	b	NOUN
ajlm-1720	55	7	-	-	PUNCT
ajlm-1720	55	8	cell	cell	NOUN
ajlm-1720	55	9	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	55	10	disorder	disorder	NOUN
ajlm-1720	55	11	by	by	ADP
ajlm-1720	55	12	predicate	predicate	NOUN
ajlm-1720	55	13	clearllab	clearllab	NOUN
ajlm-1720	55	14	10c	10c	NOUN
ajlm-1720	55	15	and	and	CCONJ
ajlm-1720	55	16	in	in	ADP
ajlm-1720	55	17	-	-	PUNCT
ajlm-1720	55	18	house	house	NOUN
ajlm-1720	55	19	second	second	ADJ
ajlm-1720	55	20	-	-	PUNCT
ajlm-1720	55	21	line	line	NOUN
ajlm-1720	55	22	were	be	AUX
ajlm-1720	55	23	referred	refer	VERB
ajlm-1720	55	24	for	for	ADP
ajlm-1720	55	25	duraclone	duraclone	NOUN
ajlm-1720	55	26	clb	clb	NOUN
ajlm-1720	55	27	testing	testing	NOUN
ajlm-1720	55	28	.	.	PUNCT
ajlm-1720	56	1	the	the	DET
ajlm-1720	56	2	clb	clb	NOUN
ajlm-1720	56	3	testing	testing	NOUN
ajlm-1720	56	4	set	set	VERB
ajlm-1720	56	5	comprised	comprise	VERB
ajlm-1720	56	6	12	12	NUM
ajlm-1720	56	7	bone	bone	NOUN
ajlm-1720	56	8	marrow	marrow	NOUN
ajlm-1720	56	9	aspirate	aspirate	NOUN
ajlm-1720	56	10	samples	sample	NOUN
ajlm-1720	56	11	,	,	PUNCT
ajlm-1720	56	12	seven	seven	NUM
ajlm-1720	56	13	peripheral	peripheral	ADJ
ajlm-1720	56	14	blood	blood	NOUN
ajlm-1720	56	15	samples	sample	NOUN
ajlm-1720	56	16	,	,	PUNCT
ajlm-1720	56	17	and	and	CCONJ
ajlm-1720	56	18	a	a	DET
ajlm-1720	56	19	single	single	ADJ
ajlm-1720	56	20	pleural	pleural	ADJ
ajlm-1720	56	21	fluid	fluid	ADJ
ajlm-1720	56	22	sample	sample	NOUN
ajlm-1720	56	23	.	.	PUNCT
ajlm-1720	57	1	due	due	ADP
ajlm-1720	57	2	to	to	ADP
ajlm-1720	57	3	the	the	DET
ajlm-1720	57	4	decommissioning	decommissioning	NOUN
ajlm-1720	57	5	of	of	ADP
ajlm-1720	57	6	the	the	DET
ajlm-1720	57	7	older	old	ADJ
ajlm-1720	57	8	facscalibur	facscalibur	NOUN
ajlm-1720	57	9	flow	flow	NOUN
ajlm-1720	57	10	cytometer	cytometer	NOUN
ajlm-1720	57	11	during	during	ADP
ajlm-1720	57	12	the	the	DET
ajlm-1720	57	13	period	period	NOUN
ajlm-1720	57	14	of	of	ADP
ajlm-1720	57	15	study	study	NOUN
ajlm-1720	57	16	(	(	PUNCT
ajlm-1720	57	17	the	the	DET
ajlm-1720	57	18	instrument	instrument	NOUN
ajlm-1720	57	19	used	use	VERB
ajlm-1720	57	20	to	to	PART
ajlm-1720	57	21	undertake	undertake	VERB
ajlm-1720	57	22	the	the	DET
ajlm-1720	57	23	predicate	predicate	NOUN
ajlm-1720	57	24	in	in	ADP
ajlm-1720	57	25	-	-	PUNCT
ajlm-1720	57	26	house	house	NOUN
ajlm-1720	57	27	second	second	ADJ
ajlm-1720	57	28	-	-	PUNCT
ajlm-1720	57	29	line	line	NOUN
ajlm-1720	57	30	testing	testing	NOUN
ajlm-1720	57	31	)	)	PUNCT
ajlm-1720	57	32	,	,	PUNCT
ajlm-1720	57	33	only	only	ADV
ajlm-1720	57	34	17	17	NUM
ajlm-1720	57	35	samples	sample	NOUN
ajlm-1720	57	36	with	with	ADP
ajlm-1720	57	37	a	a	DET
ajlm-1720	57	38	diagnosis	diagnosis	NOUN
ajlm-1720	57	39	of	of	ADP
ajlm-1720	57	40	a	a	DET
ajlm-1720	57	41	pcd	pcd	NOUN
ajlm-1720	57	42	by	by	ADP
ajlm-1720	57	43	clearllab	clearllab	NOUN
ajlm-1720	57	44	10	10	NUM
ajlm-1720	57	45	-	-	PUNCT
ajlm-1720	57	46	c	c	NOUN
ajlm-1720	57	47	and	and	CCONJ
ajlm-1720	57	48	in	in	ADP
ajlm-1720	57	49	-	-	PUNCT
ajlm-1720	57	50	house	house	NOUN
ajlm-1720	57	51	second	second	ADJ
ajlm-1720	57	52	-	-	PUNCT
ajlm-1720	57	53	line	line	NOUN
ajlm-1720	57	54	investigation	investigation	NOUN
ajlm-1720	57	55	were	be	AUX
ajlm-1720	57	56	tested	test	VERB
ajlm-1720	57	57	by	by	ADP
ajlm-1720	57	58	duraclone	duraclone	NOUN
ajlm-1720	57	59	pc	pc	NOUN
ajlm-1720	57	60	panels	panel	NOUN
ajlm-1720	57	61	.	.	PUNCT
ajlm-1720	58	1	table	table	NOUN
ajlm-1720	58	2	1	1	NUM
ajlm-1720	58	3	:	:	PUNCT
ajlm-1720	58	4	 	 	SPACE
ajlm-1720	58	5	possible	possible	ADJ
ajlm-1720	58	6	reagent	reagent	ADJ
ajlm-1720	58	7	selection	selection	NOUN
ajlm-1720	58	8	for	for	ADP
ajlm-1720	58	9	method	method	ADJ
ajlm-1720	58	10	comparison	comparison	NOUN
ajlm-1720	58	11	according	accord	VERB
ajlm-1720	58	12	to	to	ADP
ajlm-1720	58	13	suspected	suspect	VERB
ajlm-1720	58	14	target	target	NOUN
ajlm-1720	58	15	population	population	NOUN
ajlm-1720	58	16	undertaken	undertake	VERB
ajlm-1720	58	17	from	from	ADP
ajlm-1720	58	18	april	april	PROPN
ajlm-1720	58	19	2020	2020	NUM
ajlm-1720	58	20	to	to	ADP
ajlm-1720	58	21	august	august	PROPN
ajlm-1720	58	22	2020	2020	NUM
ajlm-1720	58	23	at	at	ADP
ajlm-1720	58	24	an	an	DET
ajlm-1720	58	25	academic	academic	ADJ
ajlm-1720	58	26	pathology	pathology	NOUN
ajlm-1720	58	27	service	service	NOUN
ajlm-1720	58	28	in	in	ADP
ajlm-1720	58	29	johannesburg	johannesburg	PROPN
ajlm-1720	58	30	,	,	PUNCT
ajlm-1720	58	31	south	south	PROPN
ajlm-1720	58	32	africa	africa	PROPN
ajlm-1720	58	33	.	.	PUNCT
ajlm-1720	59	1	instruments	instrument	VERB
ajlm-1720	59	2	the	the	DET
ajlm-1720	59	3	naviostm	naviostm	NOUN
ajlm-1720	59	4	(	(	PUNCT
ajlm-1720	59	5	bc	bc	PROPN
ajlm-1720	59	6	,	,	PUNCT
ajlm-1720	59	7	miami	miami	PROPN
ajlm-1720	59	8	,	,	PUNCT
ajlm-1720	59	9	florida	florida	PROPN
ajlm-1720	59	10	,	,	PUNCT
ajlm-1720	59	11	united	united	PROPN
ajlm-1720	59	12	states	states	PROPN
ajlm-1720	59	13	)	)	PUNCT
ajlm-1720	59	14	and	and	CCONJ
ajlm-1720	59	15	the	the	DET
ajlm-1720	59	16	facscalibur	facscalibur	NOUN
ajlm-1720	59	17	flow	flow	NOUN
ajlm-1720	59	18	cytometer	cytometer	NOUN
ajlm-1720	59	19	(	(	PUNCT
ajlm-1720	59	20	becton	becton	PROPN
ajlm-1720	59	21	dickinson	dickinson	PROPN
ajlm-1720	59	22	biosciences	biosciences	PROPN
ajlm-1720	59	23	,	,	PUNCT
ajlm-1720	59	24	san	san	PROPN
ajlm-1720	59	25	jose	jose	PROPN
ajlm-1720	59	26	,	,	PUNCT
ajlm-1720	59	27	california	california	PROPN
ajlm-1720	59	28	,	,	PUNCT
ajlm-1720	59	29	united	united	PROPN
ajlm-1720	59	30	states	states	PROPN
ajlm-1720	59	31	)	)	PUNCT
ajlm-1720	59	32	were	be	AUX
ajlm-1720	59	33	used	use	VERB
ajlm-1720	59	34	during	during	ADP
ajlm-1720	59	35	this	this	DET
ajlm-1720	59	36	study	study	NOUN
ajlm-1720	59	37	.	.	PUNCT
ajlm-1720	60	1	the	the	DET
ajlm-1720	60	2	naviostm	naviostm	NOUN
ajlm-1720	60	3	flow	flow	NOUN
ajlm-1720	60	4	cytometer	cytometer	NOUN
ajlm-1720	60	5	was	be	AUX
ajlm-1720	60	6	used	use	VERB
ajlm-1720	60	7	to	to	PART
ajlm-1720	60	8	analyse	analyse	VERB
ajlm-1720	60	9	the	the	DET
ajlm-1720	60	10	predicate	predicate	NOUN
ajlm-1720	60	11	clearllab	clearllab	NOUN
ajlm-1720	60	12	10c	10c	NOUN
ajlm-1720	60	13	as	as	ADV
ajlm-1720	60	14	well	well	ADV
ajlm-1720	60	15	as	as	ADP
ajlm-1720	60	16	the	the	DET
ajlm-1720	60	17	test	test	NOUN
ajlm-1720	60	18	duraclone	duraclone	NOUN
ajlm-1720	60	19	panels	panel	NOUN
ajlm-1720	60	20	.	.	PUNCT
ajlm-1720	61	1	internal	internal	ADJ
ajlm-1720	61	2	quality	quality	NOUN
ajlm-1720	61	3	control	control	NOUN
ajlm-1720	61	4	on	on	ADP
ajlm-1720	61	5	the	the	DET
ajlm-1720	61	6	naviostm	naviostm	NOUN
ajlm-1720	61	7	included	include	VERB
ajlm-1720	61	8	daily	daily	ADJ
ajlm-1720	61	9	assessment	assessment	NOUN
ajlm-1720	61	10	of	of	ADP
ajlm-1720	61	11	background	background	NOUN
ajlm-1720	61	12	contamination	contamination	NOUN
ajlm-1720	61	13	,	,	PUNCT
ajlm-1720	61	14	cellular	cellular	ADJ
ajlm-1720	61	15	events	event	NOUN
ajlm-1720	61	16	carryover	carryover	NOUN
ajlm-1720	61	17	between	between	ADP
ajlm-1720	61	18	tubes	tube	NOUN
ajlm-1720	61	19	,	,	PUNCT
ajlm-1720	61	20	and	and	CCONJ
ajlm-1720	61	21	fluorospheres	fluorosphere	VERB
ajlm-1720	61	22	acquisition	acquisition	VERB
ajlm-1720	61	23	to	to	PART
ajlm-1720	61	24	verify	verify	VERB
ajlm-1720	61	25	the	the	DET
ajlm-1720	61	26	flow	flow	NOUN
ajlm-1720	61	27	cytometer	cytometer	NOUN
ajlm-1720	61	28	optical	optical	ADJ
ajlm-1720	61	29	alignment	alignment	NOUN
ajlm-1720	61	30	and	and	CCONJ
ajlm-1720	61	31	fluidics	fluidic	NOUN
ajlm-1720	61	32	(	(	PUNCT
ajlm-1720	62	1	flow	flow	NOUN
ajlm-1720	62	2	-	-	PUNCT
ajlm-1720	62	3	check	check	NOUN
ajlm-1720	62	4	pro	pro	ADJ
ajlm-1720	62	5	,	,	PUNCT
ajlm-1720	62	6	bc	bc	PROPN
ajlm-1720	62	7	,	,	PUNCT
ajlm-1720	62	8	lismeehan	lismeehan	PROPN
ajlm-1720	62	9	,	,	PUNCT
ajlm-1720	62	10	ireland	ireland	PROPN
ajlm-1720	62	11	)	)	PUNCT
ajlm-1720	62	12	.	.	PUNCT
ajlm-1720	63	1	in	in	ADP
ajlm-1720	63	2	addition	addition	NOUN
ajlm-1720	63	3	,	,	PUNCT
ajlm-1720	63	4	clearllab	clearllab	NOUN
ajlm-1720	63	5	™	™	VERB
ajlm-1720	63	6	normal	normal	ADJ
ajlm-1720	63	7	and	and	CCONJ
ajlm-1720	63	8	abnormal	abnormal	ADJ
ajlm-1720	63	9	process	process	NOUN
ajlm-1720	63	10	control	control	NOUN
ajlm-1720	63	11	cells	cell	NOUN
ajlm-1720	63	12	(	(	PUNCT
ajlm-1720	63	13	bc	bc	PROPN
ajlm-1720	63	14	,	,	PUNCT
ajlm-1720	63	15	lismeehan	lismeehan	PROPN
ajlm-1720	63	16	,	,	PUNCT
ajlm-1720	63	17	ireland	ireland	PROPN
ajlm-1720	63	18	)	)	PUNCT
ajlm-1720	63	19	were	be	AUX
ajlm-1720	63	20	used	use	VERB
ajlm-1720	63	21	to	to	PART
ajlm-1720	63	22	verify	verify	VERB
ajlm-1720	63	23	sample	sample	NOUN
ajlm-1720	63	24	processing	processing	NOUN
ajlm-1720	63	25	,	,	PUNCT
ajlm-1720	63	26	acquisition	acquisition	NOUN
ajlm-1720	63	27	,	,	PUNCT
ajlm-1720	63	28	and	and	CCONJ
ajlm-1720	63	29	analysis	analysis	NOUN
ajlm-1720	63	30	.	.	PUNCT
ajlm-1720	64	1	clearllab	clearllab	PROPN
ajlm-1720	64	2	10c	10c	PROPN
ajlm-1720	64	3	panel	panel	NOUN
ajlm-1720	64	4	acquisition	acquisition	NOUN
ajlm-1720	64	5	setup	setup	NOUN
ajlm-1720	64	6	was	be	AUX
ajlm-1720	64	7	achieved	achieve	VERB
ajlm-1720	64	8	by	by	ADP
ajlm-1720	64	9	applying	apply	VERB
ajlm-1720	64	10	target	target	NOUN
ajlm-1720	64	11	values	value	NOUN
ajlm-1720	64	12	set	set	VERB
ajlm-1720	64	13	in	in	ADP
ajlm-1720	64	14	the	the	DET
ajlm-1720	64	15	manufacturer	manufacturer	NOUN
ajlm-1720	64	16	manual	manual	NOUN
ajlm-1720	64	17	and	and	CCONJ
ajlm-1720	64	18	using	use	VERB
ajlm-1720	64	19	bc	bc	PROPN
ajlm-1720	64	20	flowset	flowset	VERB
ajlm-1720	64	21	pro	pro	ADJ
ajlm-1720	64	22	beads	bead	NOUN
ajlm-1720	64	23	to	to	PART
ajlm-1720	64	24	adjust	adjust	VERB
ajlm-1720	64	25	the	the	DET
ajlm-1720	64	26	voltages	voltage	NOUN
ajlm-1720	64	27	that	that	PRON
ajlm-1720	64	28	enabled	enable	VERB
ajlm-1720	64	29	optimal	optimal	ADJ
ajlm-1720	64	30	detection	detection	NOUN
ajlm-1720	64	31	and	and	CCONJ
ajlm-1720	64	32	separation	separation	NOUN
ajlm-1720	64	33	of	of	ADP
ajlm-1720	64	34	dim	dim	ADJ
ajlm-1720	64	35	and	and	CCONJ
ajlm-1720	64	36	bright	bright	ADJ
ajlm-1720	64	37	antigens	antigen	NOUN
ajlm-1720	64	38	.	.	PUNCT
ajlm-1720	65	1	after	after	ADP
ajlm-1720	65	2	pilot	pilot	NOUN
ajlm-1720	65	3	testing	testing	NOUN
ajlm-1720	65	4	(	(	PUNCT
ajlm-1720	65	5	data	datum	NOUN
ajlm-1720	65	6	not	not	PART
ajlm-1720	65	7	shown	show	VERB
ajlm-1720	65	8	)	)	PUNCT
ajlm-1720	65	9	,	,	PUNCT
ajlm-1720	65	10	the	the	DET
ajlm-1720	65	11	naviostm	naviostm	NOUN
ajlm-1720	65	12	instrument	instrument	PROPN
ajlm-1720	65	13	clearllab	clearllab	PROPN
ajlm-1720	65	14	10c	10c	NOUN
ajlm-1720	65	15	settings	setting	NOUN
ajlm-1720	65	16	were	be	AUX
ajlm-1720	65	17	deemed	deem	VERB
ajlm-1720	65	18	appropriate	appropriate	ADJ
ajlm-1720	65	19	for	for	ADP
ajlm-1720	65	20	the	the	DET
ajlm-1720	65	21	duraclone	duraclone	NOUN
ajlm-1720	65	22	multicolour	multicolour	PROPN
ajlm-1720	65	23	data	datum	NOUN
ajlm-1720	65	24	acquisition	acquisition	NOUN
ajlm-1720	65	25	and	and	CCONJ
ajlm-1720	65	26	analysis	analysis	NOUN
ajlm-1720	65	27	.	.	PUNCT
ajlm-1720	66	1	the	the	DET
ajlm-1720	66	2	facscalibur	facscalibur	PROPN
ajlm-1720	66	3	flow	flow	NOUN
ajlm-1720	66	4	cytometer	cytometer	NOUN
ajlm-1720	66	5	was	be	AUX
ajlm-1720	66	6	used	use	VERB
ajlm-1720	66	7	to	to	PART
ajlm-1720	66	8	acquire	acquire	VERB
ajlm-1720	66	9	the	the	DET
ajlm-1720	66	10	predicate	predicate	NOUN
ajlm-1720	66	11	in	in	ADP
ajlm-1720	66	12	-	-	PUNCT
ajlm-1720	66	13	house	house	NOUN
ajlm-1720	66	14	second	second	ADJ
ajlm-1720	66	15	-	-	PUNCT
ajlm-1720	66	16	line	line	NOUN
ajlm-1720	66	17	2–4	2–4	NUM
ajlm-1720	66	18	-	-	PUNCT
ajlm-1720	66	19	colour	colour	ADJ
ajlm-1720	66	20	fluorescence	fluorescence	NOUN
ajlm-1720	66	21	panels	panel	NOUN
ajlm-1720	66	22	using	use	VERB
ajlm-1720	66	23	cellquest	cellquest	ADJ
ajlm-1720	66	24	software	software	NOUN
ajlm-1720	66	25	(	(	PUNCT
ajlm-1720	66	26	bd	bd	PROPN
ajlm-1720	66	27	,	,	PUNCT
ajlm-1720	66	28	san	san	PROPN
ajlm-1720	66	29	jose	jose	PROPN
ajlm-1720	66	30	,	,	PUNCT
ajlm-1720	66	31	california	california	PROPN
ajlm-1720	66	32	,	,	PUNCT
ajlm-1720	66	33	united	united	PROPN
ajlm-1720	66	34	states	states	PROPN
ajlm-1720	66	35	)	)	PUNCT
ajlm-1720	66	36	.	.	PUNCT
ajlm-1720	67	1	quality	quality	NOUN
ajlm-1720	67	2	control	control	NOUN
ajlm-1720	67	3	performed	perform	VERB
ajlm-1720	67	4	on	on	ADP
ajlm-1720	67	5	the	the	DET
ajlm-1720	67	6	bd	bd	PROPN
ajlm-1720	67	7	facscalibur	facscalibur	PROPN
ajlm-1720	67	8	included	include	VERB
ajlm-1720	67	9	daily	daily	ADJ
ajlm-1720	67	10	assessment	assessment	NOUN
ajlm-1720	67	11	of	of	ADP
ajlm-1720	67	12	background	background	NOUN
ajlm-1720	67	13	contamination	contamination	NOUN
ajlm-1720	67	14	,	,	PUNCT
ajlm-1720	67	15	carryover	carryover	NOUN
ajlm-1720	67	16	,	,	PUNCT
ajlm-1720	67	17	acquisition	acquisition	NOUN
ajlm-1720	67	18	,	,	PUNCT
ajlm-1720	67	19	and	and	CCONJ
ajlm-1720	67	20	analysis	analysis	NOUN
ajlm-1720	67	21	of	of	ADP
ajlm-1720	67	22	manufacturer	manufacturer	NOUN
ajlm-1720	67	23	-	-	PUNCT
ajlm-1720	67	24	recommended	recommend	VERB
ajlm-1720	67	25	3	3	NUM
ajlm-1720	67	26	-	-	PUNCT
ajlm-1720	67	27	colour	colour	NOUN
ajlm-1720	67	28	and	and	CCONJ
ajlm-1720	67	29	apc	apc	PROPN
ajlm-1720	67	30	calibrite	calibrite	PROPN
ajlm-1720	67	31	beads	bead	NOUN
ajlm-1720	67	32	(	(	PUNCT
ajlm-1720	67	33	becton	becton	PROPN
ajlm-1720	67	34	dickinson	dickinson	PROPN
ajlm-1720	67	35	biosciences	biosciences	PROPN
ajlm-1720	67	36	,	,	PUNCT
ajlm-1720	67	37	san	san	PROPN
ajlm-1720	67	38	jose	jose	PROPN
ajlm-1720	67	39	,	,	PUNCT
ajlm-1720	67	40	california	california	PROPN
ajlm-1720	67	41	,	,	PUNCT
ajlm-1720	67	42	united	united	PROPN
ajlm-1720	67	43	states	states	PROPN
ajlm-1720	67	44	)	)	PUNCT
ajlm-1720	67	45	.	.	PUNCT
ajlm-1720	68	1	further	further	ADJ
ajlm-1720	68	2	acquisition	acquisition	NOUN
ajlm-1720	68	3	and	and	CCONJ
ajlm-1720	68	4	analysis	analysis	NOUN
ajlm-1720	68	5	of	of	ADP
ajlm-1720	68	6	immunotroltm	immunotroltm	NOUN
ajlm-1720	68	7	process	process	NOUN
ajlm-1720	68	8	control	control	NOUN
ajlm-1720	68	9	(	(	PUNCT
ajlm-1720	68	10	bc	bc	PROPN
ajlm-1720	68	11	,	,	PUNCT
ajlm-1720	68	12	brea	brea	PROPN
ajlm-1720	68	13	,	,	PUNCT
ajlm-1720	68	14	california	california	PROPN
ajlm-1720	68	15	,	,	PUNCT
ajlm-1720	68	16	united	united	PROPN
ajlm-1720	68	17	states	states	PROPN
ajlm-1720	68	18	)	)	PUNCT
ajlm-1720	68	19	using	use	VERB
ajlm-1720	68	20	four	four	NUM
ajlm-1720	68	21	monoclonal	monoclonal	NOUN
ajlm-1720	68	22	antibodies	antibody	NOUN
ajlm-1720	68	23	,	,	PUNCT
ajlm-1720	68	24	cd14	cd14	PROPN
ajlm-1720	68	25	fitc	fitc	NOUN
ajlm-1720	68	26	,	,	PUNCT
ajlm-1720	68	27	cd13	cd13	PROPN
ajlm-1720	68	28	pe	pe	PROPN
ajlm-1720	68	29	,	,	PUNCT
ajlm-1720	68	30	cd45	cd45	PROPN
ajlm-1720	68	31	percp	percp	PROPN
ajlm-1720	68	32	and	and	CCONJ
ajlm-1720	68	33	cd3	cd3	PROPN
ajlm-1720	68	34	apc	apc	PROPN
ajlm-1720	68	35	(	(	PUNCT
ajlm-1720	68	36	all	all	DET
ajlm-1720	68	37	becton	becton	PROPN
ajlm-1720	68	38	dickinson	dickinson	PROPN
ajlm-1720	68	39	biosciences	bioscience	NOUN
ajlm-1720	68	40	,	,	PUNCT
ajlm-1720	68	41	san	san	PROPN
ajlm-1720	68	42	jose	jose	PROPN
ajlm-1720	68	43	,	,	PUNCT
ajlm-1720	68	44	california	california	PROPN
ajlm-1720	68	45	,	,	PUNCT
ajlm-1720	68	46	united	united	PROPN
ajlm-1720	68	47	states	states	PROPN
ajlm-1720	68	48	)	)	PUNCT
ajlm-1720	68	49	,	,	PUNCT
ajlm-1720	68	50	was	be	AUX
ajlm-1720	68	51	done	do	VERB
ajlm-1720	68	52	.	.	PUNCT
ajlm-1720	69	1	sample	sample	NOUN
ajlm-1720	69	2	preparation	preparation	NOUN
ajlm-1720	69	3	sample	sample	NOUN
ajlm-1720	69	4	preparation	preparation	NOUN
ajlm-1720	69	5	included	include	VERB
ajlm-1720	69	6	lysing	lyse	VERB
ajlm-1720	69	7	two	two	NUM
ajlm-1720	69	8	or	or	CCONJ
ajlm-1720	69	9	more	more	ADJ
ajlm-1720	69	10	0.5	0.5	NUM
ajlm-1720	69	11	ml	ml	NOUN
ajlm-1720	69	12	sample	sample	NOUN
ajlm-1720	69	13	aliquots	aliquot	NOUN
ajlm-1720	69	14	(	(	PUNCT
ajlm-1720	69	15	dependent	dependent	ADJ
ajlm-1720	69	16	on	on	ADP
ajlm-1720	69	17	the	the	DET
ajlm-1720	69	18	initial	initial	ADJ
ajlm-1720	69	19	white	white	ADJ
ajlm-1720	69	20	cell	cell	NOUN
ajlm-1720	69	21	count	count	NOUN
ajlm-1720	69	22	)	)	PUNCT
ajlm-1720	69	23	with	with	ADP
ajlm-1720	69	24	14.5	14.5	NUM
ajlm-1720	69	25	ml	ml	NOUN
ajlm-1720	69	26	isotonic	isotonic	ADJ
ajlm-1720	69	27	ammonium	ammonium	NOUN
ajlm-1720	69	28	chloride	chloride	NOUN
ajlm-1720	69	29	ph	ph	NOUN
ajlm-1720	69	30	7.1–7.4	7.1–7.4	NOUN
ajlm-1720	69	31	(	(	PUNCT
ajlm-1720	69	32	8.99	8.99	NUM
ajlm-1720	69	33	%	%	NOUN
ajlm-1720	69	34	nh4cl	nh4cl	NUM
ajlm-1720	69	35	,	,	PUNCT
ajlm-1720	69	36	0.84	0.84	NUM
ajlm-1720	69	37	%	%	NOUN
ajlm-1720	69	38	nahco3	nahco3	NOUN
ajlm-1720	69	39	and	and	CCONJ
ajlm-1720	69	40	0.0372	0.0372	NUM
ajlm-1720	69	41	%	%	NOUN
ajlm-1720	69	42	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-1720	69	43	acid	acid	NOUN
ajlm-1720	69	44	;	;	PUNCT
ajlm-1720	69	45	merck	merck	PROPN
ajlm-1720	69	46	,	,	PUNCT
ajlm-1720	69	47	darmstadt	darmstadt	PROPN
ajlm-1720	69	48	,	,	PUNCT
ajlm-1720	69	49	germany	germany	PROPN
ajlm-1720	69	50	)	)	PUNCT
ajlm-1720	69	51	in	in	ADP
ajlm-1720	69	52	a	a	DET
ajlm-1720	69	53	15	15	NUM
ajlm-1720	69	54	ml	ml	NOUN
ajlm-1720	69	55	conical	conical	NOUN
ajlm-1720	69	56	centrifuge	centrifuge	NOUN
ajlm-1720	69	57	tube	tube	NOUN
ajlm-1720	69	58	for	for	ADP
ajlm-1720	69	59	15	15	NUM
ajlm-1720	69	60	min	min	NOUN
ajlm-1720	69	61	at	at	ADP
ajlm-1720	69	62	room	room	NOUN
ajlm-1720	69	63	temperature	temperature	NOUN
ajlm-1720	69	64	.	.	PUNCT
ajlm-1720	70	1	after	after	ADP
ajlm-1720	70	2	incubation	incubation	NOUN
ajlm-1720	70	3	,	,	PUNCT
ajlm-1720	70	4	samples	sample	NOUN
ajlm-1720	70	5	were	be	AUX
ajlm-1720	70	6	spun	spin	VERB
ajlm-1720	70	7	at	at	ADP
ajlm-1720	70	8	3000	3000	NUM
ajlm-1720	70	9	g	g	NOUN
ajlm-1720	70	10	for	for	ADP
ajlm-1720	70	11	3	3	NUM
ajlm-1720	70	12	min	min	NOUN
ajlm-1720	70	13	,	,	PUNCT
ajlm-1720	70	14	the	the	DET
ajlm-1720	70	15	supernatant	supernatant	NOUN
ajlm-1720	70	16	was	be	AUX
ajlm-1720	70	17	decanted	decant	VERB
ajlm-1720	70	18	,	,	PUNCT
ajlm-1720	70	19	while	while	SCONJ
ajlm-1720	70	20	the	the	DET
ajlm-1720	70	21	pellet	pellet	NOUN
ajlm-1720	70	22	was	be	AUX
ajlm-1720	70	23	washed	wash	VERB
ajlm-1720	70	24	four	four	NUM
ajlm-1720	70	25	times	time	NOUN
ajlm-1720	70	26	with	with	ADP
ajlm-1720	70	27	14	14	NUM
ajlm-1720	70	28	ml	ml	NOUN
ajlm-1720	70	29	phosphate	phosphate	NOUN
ajlm-1720	70	30	-	-	PUNCT
ajlm-1720	70	31	buffered	buffer	VERB
ajlm-1720	70	32	saline	saline	NOUN
ajlm-1720	70	33	at	at	ADP
ajlm-1720	70	34	ph	ph	PROPN
ajlm-1720	70	35	7.3	7.3	NUM
ajlm-1720	70	36	±	±	NUM
ajlm-1720	70	37	2	2	NUM
ajlm-1720	70	38	(	(	PUNCT
ajlm-1720	70	39	oxoid	oxoid	PROPN
ajlm-1720	70	40	ltd	ltd	PROPN
ajlm-1720	70	41	,	,	PUNCT
ajlm-1720	70	42	basingstoke	basingstoke	PROPN
ajlm-1720	70	43	,	,	PUNCT
ajlm-1720	70	44	united	united	ADJ
ajlm-1720	70	45	kingdom	kingdom	PROPN
ajlm-1720	70	46	)	)	PUNCT
ajlm-1720	70	47	containing	contain	VERB
ajlm-1720	70	48	0.09	0.09	NUM
ajlm-1720	70	49	%	%	NOUN
ajlm-1720	70	50	sodium	sodium	NOUN
ajlm-1720	70	51	azide	azide	NOUN
ajlm-1720	70	52	(	(	PUNCT
ajlm-1720	70	53	nan3	nan3	PROPN
ajlm-1720	70	54	)	)	PUNCT
ajlm-1720	70	55	(	(	PUNCT
ajlm-1720	70	56	merck	merck	PROPN
ajlm-1720	70	57	,	,	PUNCT
ajlm-1720	70	58	darmstadt	darmstadt	PROPN
ajlm-1720	70	59	,	,	PUNCT
ajlm-1720	70	60	germany	germany	PROPN
ajlm-1720	70	61	)	)	PUNCT
ajlm-1720	70	62	and	and	CCONJ
ajlm-1720	70	63	0.2	0.2	NUM
ajlm-1720	70	64	%	%	NOUN
ajlm-1720	70	65	bovine	bovine	NOUN
ajlm-1720	70	66	serum	serum	NOUN
ajlm-1720	70	67	albumin	albumin	PROPN
ajlm-1720	70	68	(	(	PUNCT
ajlm-1720	70	69	biowest	biow	ADJ
ajlm-1720	70	70	,	,	PUNCT
ajlm-1720	70	71	nuaille	nuaille	PROPN
ajlm-1720	70	72	,	,	PUNCT
ajlm-1720	70	73	france	france	PROPN
ajlm-1720	70	74	)	)	PUNCT
ajlm-1720	70	75	.	.	PUNCT
ajlm-1720	71	1	following	follow	VERB
ajlm-1720	71	2	washing	washing	NOUN
ajlm-1720	71	3	,	,	PUNCT
ajlm-1720	71	4	samples	sample	NOUN
ajlm-1720	71	5	were	be	AUX
ajlm-1720	71	6	reconstituted	reconstitute	VERB
ajlm-1720	71	7	to	to	ADP
ajlm-1720	71	8	0.5	0.5	NUM
ajlm-1720	71	9	ml	ml	NOUN
ajlm-1720	71	10	with	with	ADP
ajlm-1720	71	11	phosphate	phosphate	NOUN
ajlm-1720	71	12	-	-	PUNCT
ajlm-1720	71	13	buffered	buffer	VERB
ajlm-1720	71	14	saline	saline	NOUN
ajlm-1720	71	15	,	,	PUNCT
ajlm-1720	71	16	and	and	CCONJ
ajlm-1720	71	17	the	the	DET
ajlm-1720	71	18	white	white	ADJ
ajlm-1720	71	19	cell	cell	NOUN
ajlm-1720	71	20	count	count	NOUN
ajlm-1720	71	21	was	be	AUX
ajlm-1720	71	22	determined	determine	VERB
ajlm-1720	71	23	.	.	PUNCT
ajlm-1720	72	1	cells	cell	NOUN
ajlm-1720	72	2	were	be	AUX
ajlm-1720	72	3	then	then	ADV
ajlm-1720	72	4	diluted	dilute	VERB
ajlm-1720	72	5	(	(	PUNCT
ajlm-1720	72	6	or	or	CCONJ
ajlm-1720	72	7	concentrated	concentrate	VERB
ajlm-1720	72	8	)	)	PUNCT
ajlm-1720	72	9	to	to	PART
ajlm-1720	72	10	achieve	achieve	VERB
ajlm-1720	72	11	the	the	DET
ajlm-1720	72	12	recommended	recommend	VERB
ajlm-1720	72	13	cellular	cellular	ADJ
ajlm-1720	72	14	concentration	concentration	NOUN
ajlm-1720	72	15	of	of	ADP
ajlm-1720	72	16	≤	≤	NUM
ajlm-1720	72	17	10	10	NUM
ajlm-1720	72	18	000	000	NUM
ajlm-1720	72	19	cells/µl	cells/µl	NOUN
ajlm-1720	72	20	for	for	ADP
ajlm-1720	72	21	monoclonal	monoclonal	NOUN
ajlm-1720	72	22	antibody	antibody	NOUN
ajlm-1720	72	23	incubation	incubation	NOUN
ajlm-1720	72	24	.	.	PUNCT
ajlm-1720	73	1	subsequently	subsequently	ADV
ajlm-1720	73	2	,	,	PUNCT
ajlm-1720	73	3	100	100	NUM
ajlm-1720	73	4	µl	µl	ADP
ajlm-1720	73	5	of	of	ADP
ajlm-1720	73	6	this	this	DET
ajlm-1720	73	7	cell	cell	NOUN
ajlm-1720	73	8	concentrate	concentrate	NOUN
ajlm-1720	73	9	,	,	PUNCT
ajlm-1720	73	10	which	which	PRON
ajlm-1720	73	11	contained	contain	VERB
ajlm-1720	73	12	approximately	approximately	ADV
ajlm-1720	73	13	106	106	NUM
ajlm-1720	73	14	cells	cell	NOUN
ajlm-1720	73	15	,	,	PUNCT
ajlm-1720	73	16	was	be	AUX
ajlm-1720	73	17	added	add	VERB
ajlm-1720	73	18	to	to	ADP
ajlm-1720	73	19	the	the	DET
ajlm-1720	73	20	clearllab	clearllab	NOUN
ajlm-1720	73	21	10c	10c	NOUN
ajlm-1720	73	22	and	and	CCONJ
ajlm-1720	73	23	in	in	ADP
ajlm-1720	73	24	-	-	PUNCT
ajlm-1720	73	25	house	house	NOUN
ajlm-1720	73	26	panels	panel	NOUN
ajlm-1720	73	27	(	(	PUNCT
ajlm-1720	73	28	see	see	VERB
ajlm-1720	73	29	table	table	NOUN
ajlm-1720	73	30	1	1	NUM
ajlm-1720	73	31	)	)	PUNCT
ajlm-1720	73	32	.	.	PUNCT
ajlm-1720	74	1	if	if	SCONJ
ajlm-1720	74	2	the	the	DET
ajlm-1720	74	3	sample	sample	NOUN
ajlm-1720	74	4	was	be	AUX
ajlm-1720	74	5	deemed	deem	VERB
ajlm-1720	74	6	to	to	PART
ajlm-1720	74	7	be	be	AUX
ajlm-1720	74	8	suitable	suitable	ADJ
ajlm-1720	74	9	for	for	ADP
ajlm-1720	74	10	inclusion	inclusion	NOUN
ajlm-1720	74	11	in	in	ADP
ajlm-1720	74	12	the	the	DET
ajlm-1720	74	13	study	study	NOUN
ajlm-1720	74	14	(	(	PUNCT
ajlm-1720	74	15	i.e.	i.e.	X
ajlm-1720	74	16	had	have	VERB
ajlm-1720	74	17	an	an	DET
ajlm-1720	74	18	established	establish	VERB
ajlm-1720	74	19	diagnosis	diagnosis	NOUN
ajlm-1720	74	20	by	by	ADP
ajlm-1720	74	21	predicate	predicate	NOUN
ajlm-1720	74	22	clearllab	clearllab	NOUN
ajlm-1720	74	23	10c	10c	NOUN
ajlm-1720	74	24	)	)	PUNCT
ajlm-1720	74	25	,	,	PUNCT
ajlm-1720	74	26	and	and	CCONJ
ajlm-1720	74	27	if	if	SCONJ
ajlm-1720	74	28	there	there	PRON
ajlm-1720	74	29	was	be	VERB
ajlm-1720	74	30	sufficient	sufficient	ADJ
ajlm-1720	74	31	remaining	remain	VERB
ajlm-1720	74	32	material	material	NOUN
ajlm-1720	74	33	,	,	PUNCT
ajlm-1720	74	34	100	100	NUM
ajlm-1720	74	35	µl	µl	NOUN
ajlm-1720	74	36	of	of	ADP
ajlm-1720	74	37	the	the	DET
ajlm-1720	74	38	remaining	remain	VERB
ajlm-1720	74	39	cell	cell	NOUN
ajlm-1720	74	40	concentrate	concentrate	NOUN
ajlm-1720	74	41	was	be	AUX
ajlm-1720	74	42	tested	test	VERB
ajlm-1720	74	43	with	with	ADP
ajlm-1720	74	44	either	either	CCONJ
ajlm-1720	74	45	duraclone	duraclone	NOUN
ajlm-1720	74	46	alb	alb	NOUN
ajlm-1720	74	47	,	,	PUNCT
ajlm-1720	74	48	clb	clb	NOUN
ajlm-1720	74	49	or	or	CCONJ
ajlm-1720	74	50	pc	pc	NOUN
ajlm-1720	74	51	panels	panel	NOUN
ajlm-1720	74	52	(	(	PUNCT
ajlm-1720	74	53	table	table	NOUN
ajlm-1720	74	54	1	1	NUM
ajlm-1720	74	55	)	)	PUNCT
ajlm-1720	74	56	.	.	PUNCT
ajlm-1720	75	1	details	detail	NOUN
ajlm-1720	75	2	of	of	ADP
ajlm-1720	75	3	the	the	DET
ajlm-1720	75	4	markers	marker	NOUN
ajlm-1720	75	5	included	include	VERB
ajlm-1720	75	6	in	in	ADP
ajlm-1720	75	7	these	these	DET
ajlm-1720	75	8	duraclone	duraclone	NOUN
ajlm-1720	75	9	panels	panel	NOUN
ajlm-1720	75	10	are	be	AUX
ajlm-1720	75	11	outlined	outline	VERB
ajlm-1720	75	12	in	in	ADP
ajlm-1720	75	13	table	table	NOUN
ajlm-1720	75	14	2	2	NUM
ajlm-1720	75	15	.	.	PUNCT
ajlm-1720	76	1	each	each	DET
ajlm-1720	76	2	duraclone	duraclone	NOUN
ajlm-1720	76	3	panel	panel	NOUN
ajlm-1720	76	4	has	have	VERB
ajlm-1720	76	5	a	a	DET
ajlm-1720	76	6	‘	'	PUNCT
ajlm-1720	76	7	spare	spare	ADJ
ajlm-1720	76	8	’	'	PUNCT
ajlm-1720	76	9	capacity	capacity	NOUN
ajlm-1720	76	10	for	for	ADP
ajlm-1720	76	11	additional	additional	ADJ
ajlm-1720	76	12	markers	marker	NOUN
ajlm-1720	76	13	per	per	ADP
ajlm-1720	76	14	the	the	DET
ajlm-1720	76	15	investigator	investigator	NOUN
ajlm-1720	76	16	’s	’s	PART
ajlm-1720	76	17	need	need	NOUN
ajlm-1720	76	18	.	.	PUNCT
ajlm-1720	77	1	in	in	ADP
ajlm-1720	77	2	our	our	PRON
ajlm-1720	77	3	study	study	NOUN
ajlm-1720	77	4	,	,	PUNCT
ajlm-1720	77	5	in	in	ADP
ajlm-1720	77	6	two	two	NUM
ajlm-1720	77	7	cases	case	NOUN
ajlm-1720	77	8	of	of	ADP
ajlm-1720	77	9	precursor	precursor	NOUN
ajlm-1720	77	10	b	b	NOUN
ajlm-1720	77	11	-	-	PUNCT
ajlm-1720	77	12	all	all	PRON
ajlm-1720	77	13	,	,	PUNCT
ajlm-1720	77	14	the	the	DET
ajlm-1720	77	15	marker	marker	NOUN
ajlm-1720	77	16	cd22	cd22	PROPN
ajlm-1720	77	17	(	(	PUNCT
ajlm-1720	77	18	apc	apc	PROPN
ajlm-1720	77	19	)	)	PUNCT
ajlm-1720	77	20	(	(	PUNCT
ajlm-1720	77	21	bc	bc	PROPN
ajlm-1720	77	22	,	,	PUNCT
ajlm-1720	77	23	miami	miami	PROPN
ajlm-1720	77	24	,	,	PUNCT
ajlm-1720	77	25	florida	florida	PROPN
ajlm-1720	77	26	,	,	PUNCT
ajlm-1720	77	27	united	united	PROPN
ajlm-1720	77	28	states	states	PROPN
ajlm-1720	77	29	)	)	PUNCT
ajlm-1720	77	30	was	be	AUX
ajlm-1720	77	31	added	add	VERB
ajlm-1720	77	32	in	in	ADP
ajlm-1720	77	33	liquid	liquid	ADJ
ajlm-1720	77	34	format	format	NOUN
ajlm-1720	77	35	to	to	ADP
ajlm-1720	77	36	the	the	DET
ajlm-1720	77	37	alb	alb	PROPN
ajlm-1720	77	38	panel	panel	NOUN
ajlm-1720	77	39	to	to	PART
ajlm-1720	77	40	occupy	occupy	VERB
ajlm-1720	77	41	the	the	DET
ajlm-1720	77	42	free	free	PROPN
ajlm-1720	77	43	apc	apc	PROPN
ajlm-1720	77	44	channel	channel	PROPN
ajlm-1720	77	45	(	(	PUNCT
ajlm-1720	77	46	see	see	VERB
ajlm-1720	77	47	table	table	NOUN
ajlm-1720	77	48	2	2	NUM
ajlm-1720	77	49	,	,	PUNCT
ajlm-1720	77	50	duraclone	duraclone	NOUN
ajlm-1720	77	51	re	re	NOUN
ajlm-1720	77	52	alb	alb	PROPN
ajlm-1720	77	53	panel	panel	PROPN
ajlm-1720	77	54	)	)	PUNCT
ajlm-1720	77	55	to	to	PART
ajlm-1720	77	56	verify	verify	VERB
ajlm-1720	77	57	cd22	cd22	PROPN
ajlm-1720	77	58	expression	expression	NOUN
ajlm-1720	77	59	in	in	ADP
ajlm-1720	77	60	the	the	DET
ajlm-1720	77	61	context	context	NOUN
ajlm-1720	77	62	of	of	ADP
ajlm-1720	77	63	a	a	DET
ajlm-1720	77	64	b	b	NOUN
ajlm-1720	77	65	-	-	PUNCT
ajlm-1720	77	66	all	all	PRON
ajlm-1720	77	67	.	.	PUNCT
ajlm-1720	78	1	in	in	ADP
ajlm-1720	78	2	a	a	DET
ajlm-1720	78	3	single	single	ADJ
ajlm-1720	78	4	case	case	NOUN
ajlm-1720	78	5	of	of	ADP
ajlm-1720	78	6	a	a	DET
ajlm-1720	78	7	suspected	suspect	VERB
ajlm-1720	78	8	pcd	pcd	NOUN
ajlm-1720	78	9	,	,	PUNCT
ajlm-1720	78	10	liquid	liquid	NOUN
ajlm-1720	78	11	cd117	cd117	PROPN
ajlm-1720	78	12	ecd	ecd	PROPN
ajlm-1720	78	13	(	(	PUNCT
ajlm-1720	78	14	bc	bc	PROPN
ajlm-1720	78	15	,	,	PUNCT
ajlm-1720	78	16	miami	miami	PROPN
ajlm-1720	78	17	,	,	PUNCT
ajlm-1720	78	18	florida	florida	PROPN
ajlm-1720	78	19	,	,	PUNCT
ajlm-1720	78	20	united	united	PROPN
ajlm-1720	78	21	states	states	PROPN
ajlm-1720	78	22	)	)	PUNCT
ajlm-1720	78	23	was	be	AUX
ajlm-1720	78	24	added	add	VERB
ajlm-1720	78	25	to	to	ADP
ajlm-1720	78	26	the	the	DET
ajlm-1720	78	27	duraclone	duraclone	NOUN
ajlm-1720	78	28	re	re	NOUN
ajlm-1720	78	29	pc	pc	NOUN
ajlm-1720	78	30	tube	tube	NOUN
ajlm-1720	78	31	in	in	ADP
ajlm-1720	78	32	the	the	DET
ajlm-1720	78	33	‘	'	PUNCT
ajlm-1720	78	34	free	free	ADJ
ajlm-1720	78	35	’	'	PUNCT
ajlm-1720	78	36	ecd	ecd	PROPN
ajlm-1720	78	37	channel	channel	PROPN
ajlm-1720	78	38	to	to	PART
ajlm-1720	78	39	demonstrate	demonstrate	VERB
ajlm-1720	78	40	expression	expression	NOUN
ajlm-1720	78	41	of	of	ADP
ajlm-1720	78	42	cd117	cd117	PROPN
ajlm-1720	78	43	in	in	ADP
ajlm-1720	78	44	a	a	DET
ajlm-1720	78	45	case	case	NOUN
ajlm-1720	78	46	of	of	ADP
ajlm-1720	78	47	multiple	multiple	ADJ
ajlm-1720	78	48	myeloma	myeloma	NOUN
ajlm-1720	78	49	.	.	PUNCT
ajlm-1720	79	1	after	after	ADP
ajlm-1720	79	2	adding	add	VERB
ajlm-1720	79	3	the	the	DET
ajlm-1720	79	4	cell	cell	NOUN
ajlm-1720	79	5	aliquot	aliquot	NOUN
ajlm-1720	79	6	into	into	ADP
ajlm-1720	79	7	panels	panel	NOUN
ajlm-1720	79	8	,	,	PUNCT
ajlm-1720	79	9	and	and	CCONJ
ajlm-1720	79	10	,	,	PUNCT
ajlm-1720	79	11	where	where	SCONJ
ajlm-1720	79	12	applicable	applicable	ADJ
ajlm-1720	79	13	,	,	PUNCT
ajlm-1720	79	14	the	the	DET
ajlm-1720	79	15	addition	addition	NOUN
ajlm-1720	79	16	of	of	ADP
ajlm-1720	79	17	liquid	liquid	ADJ
ajlm-1720	79	18	monoclonal	monoclonal	NOUN
ajlm-1720	79	19	reagent	reagent	NOUN
ajlm-1720	79	20	,	,	PUNCT
ajlm-1720	79	21	all	all	DET
ajlm-1720	79	22	samples	sample	NOUN
ajlm-1720	79	23	were	be	AUX
ajlm-1720	79	24	incubated	incubate	VERB
ajlm-1720	79	25	at	at	ADP
ajlm-1720	79	26	room	room	NOUN
ajlm-1720	79	27	temperature	temperature	NOUN
ajlm-1720	79	28	(	(	PUNCT
ajlm-1720	79	29	average	average	ADJ
ajlm-1720	79	30	20	20	NUM
ajlm-1720	79	31	°	°	ADP
ajlm-1720	79	32	c	c	NOUN
ajlm-1720	79	33	–	–	PUNCT
ajlm-1720	79	34	22	22	NUM
ajlm-1720	79	35	°	°	SYM
ajlm-1720	79	36	c	c	NOUN
ajlm-1720	79	37	)	)	PUNCT
ajlm-1720	79	38	in	in	ADP
ajlm-1720	79	39	the	the	DET
ajlm-1720	79	40	dark	dark	NOUN
ajlm-1720	79	41	for	for	ADP
ajlm-1720	79	42	15	15	NUM
ajlm-1720	79	43	min	min	NOUN
ajlm-1720	79	44	.	.	PROPN
ajlm-1720	80	1	after	after	ADP
ajlm-1720	80	2	incubation	incubation	NOUN
ajlm-1720	80	3	,	,	PUNCT
ajlm-1720	80	4	all	all	DET
ajlm-1720	80	5	samples	sample	NOUN
ajlm-1720	80	6	were	be	AUX
ajlm-1720	80	7	washed	wash	VERB
ajlm-1720	80	8	once	once	ADV
ajlm-1720	80	9	with	with	ADP
ajlm-1720	80	10	phosphate	phosphate	NOUN
ajlm-1720	80	11	-	-	PUNCT
ajlm-1720	80	12	buffered	buffer	VERB
ajlm-1720	80	13	saline	saline	NOUN
ajlm-1720	80	14	and	and	CCONJ
ajlm-1720	80	15	reconstituted	reconstitute	VERB
ajlm-1720	80	16	to	to	ADP
ajlm-1720	80	17	0.5	0.5	NUM
ajlm-1720	80	18	ml	ml	NOUN
ajlm-1720	80	19	.	.	PUNCT
ajlm-1720	80	20	table	table	NOUN
ajlm-1720	80	21	2	2	NUM
ajlm-1720	80	22	:	:	PUNCT
ajlm-1720	80	23	 	 	SPACE
ajlm-1720	80	24	possible	possible	ADJ
ajlm-1720	80	25	reagent	reagent	ADJ
ajlm-1720	80	26	selection	selection	NOUN
ajlm-1720	80	27	for	for	ADP
ajlm-1720	80	28	method	method	ADJ
ajlm-1720	80	29	comparison	comparison	NOUN
ajlm-1720	80	30	according	accord	VERB
ajlm-1720	80	31	to	to	ADP
ajlm-1720	80	32	suspected	suspect	VERB
ajlm-1720	80	33	target	target	NOUN
ajlm-1720	80	34	population	population	NOUN
ajlm-1720	80	35	validated	validate	VERB
ajlm-1720	80	36	at	at	ADP
ajlm-1720	80	37	the	the	DET
ajlm-1720	80	38	charlotte	charlotte	PROPN
ajlm-1720	80	39	maxeke	maxeke	PROPN
ajlm-1720	80	40	johannesburg	johannesburg	PROPN
ajlm-1720	80	41	academic	academic	PROPN
ajlm-1720	80	42	hospital	hospital	PROPN
ajlm-1720	80	43	flow	flow	NOUN
ajlm-1720	80	44	cytometry	cytometry	PROPN
ajlm-1720	80	45	laboratory	laboratory	NOUN
ajlm-1720	80	46	in	in	ADP
ajlm-1720	80	47	johannesburg	johannesburg	PROPN
ajlm-1720	80	48	,	,	PUNCT
ajlm-1720	80	49	south	south	PROPN
ajlm-1720	80	50	africa	africa	PROPN
ajlm-1720	80	51	,	,	PUNCT
ajlm-1720	80	52	april	april	PROPN
ajlm-1720	80	53	2020	2020	NUM
ajlm-1720	80	54	to	to	ADP
ajlm-1720	80	55	august	august	PROPN
ajlm-1720	80	56	2020	2020	NUM
ajlm-1720	80	57	.	.	PUNCT
ajlm-1720	81	1	data	datum	NOUN
ajlm-1720	81	2	acquisition	acquisition	NOUN
ajlm-1720	81	3	and	and	CCONJ
ajlm-1720	81	4	interpretation	interpretation	NOUN
ajlm-1720	81	5	of	of	ADP
ajlm-1720	81	6	flow	flow	NOUN
ajlm-1720	81	7	cytometric	cytometric	ADJ
ajlm-1720	81	8	case	case	NOUN
ajlm-1720	81	9	data	datum	NOUN
ajlm-1720	81	10	all	all	DET
ajlm-1720	81	11	samples	sample	NOUN
ajlm-1720	81	12	were	be	AUX
ajlm-1720	81	13	acquired	acquire	VERB
ajlm-1720	81	14	on	on	ADP
ajlm-1720	81	15	a	a	DET
ajlm-1720	81	16	flow	flow	NOUN
ajlm-1720	81	17	cytometer	cytometer	NOUN
ajlm-1720	81	18	to	to	PART
ajlm-1720	81	19	acquire	acquire	VERB
ajlm-1720	81	20	raw	raw	ADJ
ajlm-1720	81	21	flow	flow	NOUN
ajlm-1720	81	22	cytometric	cytometric	ADJ
ajlm-1720	81	23	listmode	listmode	PROPN
ajlm-1720	81	24	data	datum	NOUN
ajlm-1720	81	25	.	.	PUNCT
ajlm-1720	82	1	for	for	ADP
ajlm-1720	82	2	the	the	DET
ajlm-1720	82	3	predicate	predicate	NOUN
ajlm-1720	82	4	in	in	ADP
ajlm-1720	82	5	-	-	PUNCT
ajlm-1720	82	6	house	house	NOUN
ajlm-1720	82	7	panels	panel	NOUN
ajlm-1720	82	8	acquired	acquire	VERB
ajlm-1720	82	9	on	on	ADP
ajlm-1720	82	10	the	the	DET
ajlm-1720	82	11	facscalibur	facscalibur	NOUN
ajlm-1720	82	12	,	,	PUNCT
ajlm-1720	82	13	5000	5000	NUM
ajlm-1720	82	14	(	(	PUNCT
ajlm-1720	82	15	.fcs	.fcs	PUNCT
ajlm-1720	82	16	data	datum	NOUN
ajlm-1720	82	17	)	)	PUNCT
ajlm-1720	82	18	events	event	NOUN
ajlm-1720	82	19	were	be	AUX
ajlm-1720	82	20	collected	collect	VERB
ajlm-1720	82	21	.	.	PUNCT
ajlm-1720	83	1	paint	paint	NOUN
ajlm-1720	83	2	-	-	PUNCT
ajlm-1720	83	3	a	a	DET
ajlm-1720	83	4	-	-	PUNCT
ajlm-1720	83	5	gate	gate	NOUN
ajlm-1720	83	6	software	software	NOUN
ajlm-1720	83	7	(	(	PUNCT
ajlm-1720	83	8	becton	becton	PROPN
ajlm-1720	83	9	dickinson	dickinson	PROPN
ajlm-1720	83	10	biosciences	biosciences	PROPN
ajlm-1720	83	11	,	,	PUNCT
ajlm-1720	83	12	san	san	PROPN
ajlm-1720	83	13	jose	jose	PROPN
ajlm-1720	83	14	,	,	PUNCT
ajlm-1720	83	15	california	california	PROPN
ajlm-1720	83	16	,	,	PUNCT
ajlm-1720	83	17	united	united	PROPN
ajlm-1720	83	18	states	states	PROPN
ajlm-1720	83	19	)	)	PUNCT
ajlm-1720	83	20	was	be	AUX
ajlm-1720	83	21	used	use	VERB
ajlm-1720	83	22	for	for	ADP
ajlm-1720	83	23	analysis	analysis	NOUN
ajlm-1720	83	24	of	of	ADP
ajlm-1720	83	25	raw	raw	ADJ
ajlm-1720	83	26	facscalibur	facscalibur	NOUN
ajlm-1720	83	27	flow	flow	NOUN
ajlm-1720	83	28	cytometric	cytometric	ADJ
ajlm-1720	83	29	data	datum	NOUN
ajlm-1720	83	30	with	with	ADP
ajlm-1720	83	31	a	a	DET
ajlm-1720	83	32	primary	primary	ADJ
ajlm-1720	83	33	gating	gate	VERB
ajlm-1720	83	34	focus	focus	NOUN
ajlm-1720	83	35	using	use	VERB
ajlm-1720	83	36	cd45	cd45	PROPN
ajlm-1720	83	37	and	and	CCONJ
ajlm-1720	83	38	side	side	NOUN
ajlm-1720	83	39	scatter	scatter	NOUN
ajlm-1720	83	40	.	.	PUNCT
ajlm-1720	84	1	for	for	ADP
ajlm-1720	84	2	both	both	CCONJ
ajlm-1720	84	3	the	the	DET
ajlm-1720	84	4	clearllab	clearllab	NOUN
ajlm-1720	84	5	10c	10c	NOUN
ajlm-1720	84	6	and	and	CCONJ
ajlm-1720	84	7	duraclone	duraclone	NOUN
ajlm-1720	84	8	panels	panel	NOUN
ajlm-1720	84	9	,	,	PUNCT
ajlm-1720	84	10	at	at	ADP
ajlm-1720	84	11	least	least	ADJ
ajlm-1720	84	12	50	50	NUM
ajlm-1720	84	13	000	000	NUM
ajlm-1720	84	14	(	(	PUNCT
ajlm-1720	84	15	listmode	listmode	PROPN
ajlm-1720	84	16	data	data	PROPN
ajlm-1720	84	17	)	)	PUNCT
ajlm-1720	84	18	events	event	NOUN
ajlm-1720	84	19	were	be	AUX
ajlm-1720	84	20	acquired	acquire	VERB
ajlm-1720	84	21	on	on	ADP
ajlm-1720	84	22	the	the	DET
ajlm-1720	84	23	navios	navio	NOUN
ajlm-1720	84	24	.	.	PUNCT
ajlm-1720	85	1	kaluza	kaluza	PROPN
ajlm-1720	85	2	c	c	VERB
ajlm-1720	85	3	™	™	VERB
ajlm-1720	85	4	version	version	NOUN
ajlm-1720	85	5	1.1	1.1	NUM
ajlm-1720	85	6	(	(	PUNCT
ajlm-1720	85	7	bc	bc	PROPN
ajlm-1720	85	8	,	,	PUNCT
ajlm-1720	85	9	miami	miami	PROPN
ajlm-1720	85	10	,	,	PUNCT
ajlm-1720	85	11	florida	florida	PROPN
ajlm-1720	85	12	,	,	PUNCT
ajlm-1720	85	13	united	united	PROPN
ajlm-1720	85	14	states	states	PROPN
ajlm-1720	85	15	)	)	PUNCT
ajlm-1720	85	16	software	software	NOUN
ajlm-1720	85	17	was	be	AUX
ajlm-1720	85	18	used	use	VERB
ajlm-1720	85	19	to	to	PART
ajlm-1720	85	20	analyse	analyse	VERB
ajlm-1720	85	21	all	all	DET
ajlm-1720	85	22	raw	raw	ADJ
ajlm-1720	85	23	listmode	listmode	NOUN
ajlm-1720	85	24	data	datum	NOUN
ajlm-1720	85	25	to	to	PART
ajlm-1720	85	26	facilitate	facilitate	VERB
ajlm-1720	85	27	clinical	clinical	ADJ
ajlm-1720	85	28	interpretation	interpretation	NOUN
ajlm-1720	85	29	.	.	PUNCT
ajlm-1720	86	1	kaluza	kaluza	PROPN
ajlm-1720	86	2	c	c	PUNCT
ajlm-1720	86	3	™	™	VERB
ajlm-1720	86	4	clearllab	clearllab	NOUN
ajlm-1720	86	5	b	b	PROPN
ajlm-1720	86	6	,	,	PUNCT
ajlm-1720	86	7	t	t	PROPN
ajlm-1720	86	8	,	,	PUNCT
ajlm-1720	86	9	m1	m1	PROPN
ajlm-1720	86	10	and	and	CCONJ
ajlm-1720	86	11	m2	m2	PROPN
ajlm-1720	86	12	,	,	PUNCT
ajlm-1720	86	13	and	and	CCONJ
ajlm-1720	86	14	duraclone	duraclone	NOUN
ajlm-1720	86	15	panel	panel	NOUN
ajlm-1720	86	16	analysis	analysis	NOUN
ajlm-1720	86	17	protocols	protocol	NOUN
ajlm-1720	86	18	were	be	AUX
ajlm-1720	86	19	developed	develop	VERB
ajlm-1720	86	20	according	accord	VERB
ajlm-1720	86	21	to	to	ADP
ajlm-1720	86	22	manufacturer	manufacturer	NOUN
ajlm-1720	86	23	specifications.23	specifications.23	PROPN
ajlm-1720	86	24	first	first	ADV
ajlm-1720	86	25	,	,	PUNCT
ajlm-1720	86	26	doublets	doublet	NOUN
ajlm-1720	86	27	,	,	PUNCT
ajlm-1720	86	28	debris	debris	NOUN
ajlm-1720	86	29	and	and	CCONJ
ajlm-1720	86	30	unlysed	unlysed	ADJ
ajlm-1720	86	31	red	red	ADJ
ajlm-1720	86	32	blood	blood	NOUN
ajlm-1720	86	33	cells	cell	NOUN
ajlm-1720	86	34	were	be	AUX
ajlm-1720	86	35	excluded	exclude	VERB
ajlm-1720	86	36	,	,	PUNCT
ajlm-1720	86	37	and	and	CCONJ
ajlm-1720	86	38	,	,	PUNCT
ajlm-1720	86	39	where	where	SCONJ
ajlm-1720	86	40	possible	possible	ADJ
ajlm-1720	86	41	,	,	PUNCT
ajlm-1720	86	42	a	a	DET
ajlm-1720	86	43	neoplastic	neoplastic	ADJ
ajlm-1720	86	44	target	target	NOUN
ajlm-1720	86	45	population	population	NOUN
ajlm-1720	86	46	was	be	AUX
ajlm-1720	86	47	identified	identify	VERB
ajlm-1720	86	48	in	in	ADP
ajlm-1720	86	49	a	a	DET
ajlm-1720	86	50	primary	primary	ADJ
ajlm-1720	86	51	gate	gate	NOUN
ajlm-1720	86	52	using	use	VERB
ajlm-1720	86	53	cd45	cd45	PROPN
ajlm-1720	86	54	and	and	CCONJ
ajlm-1720	86	55	side	side	NOUN
ajlm-1720	86	56	scatter	scatter	NOUN
ajlm-1720	86	57	.	.	PUNCT
ajlm-1720	87	1	thereafter	thereafter	ADV
ajlm-1720	87	2	,	,	PUNCT
ajlm-1720	87	3	secondary	secondary	ADJ
ajlm-1720	87	4	gating	gating	NOUN
ajlm-1720	87	5	focused	focus	VERB
ajlm-1720	87	6	on	on	ADP
ajlm-1720	87	7	identifying	identify	VERB
ajlm-1720	87	8	the	the	DET
ajlm-1720	87	9	same	same	ADJ
ajlm-1720	87	10	target	target	NOUN
ajlm-1720	87	11	immunophenotype	immunophenotype	NOUN
ajlm-1720	87	12	across	across	ADP
ajlm-1720	87	13	each	each	PRON
ajlm-1720	87	14	of	of	ADP
ajlm-1720	87	15	the	the	DET
ajlm-1720	87	16	t	t	PROPN
ajlm-1720	87	17	,	,	PUNCT
ajlm-1720	87	18	m1	m1	PROPN
ajlm-1720	87	19	and	and	CCONJ
ajlm-1720	87	20	m2	m2	PROPN
ajlm-1720	87	21	panels.9,16	panels.9,16	PROPN
ajlm-1720	87	22	finally	finally	ADV
ajlm-1720	87	23	,	,	PUNCT
ajlm-1720	87	24	simultaneous	simultaneous	ADJ
ajlm-1720	87	25	identification	identification	NOUN
ajlm-1720	87	26	of	of	ADP
ajlm-1720	87	27	normal	normal	ADJ
ajlm-1720	87	28	populations	population	NOUN
ajlm-1720	87	29	in	in	ADP
ajlm-1720	87	30	the	the	DET
ajlm-1720	87	31	background	background	NOUN
ajlm-1720	87	32	was	be	AUX
ajlm-1720	87	33	based	base	VERB
ajlm-1720	87	34	on	on	ADP
ajlm-1720	87	35	local	local	ADJ
ajlm-1720	87	36	in	in	ADP
ajlm-1720	87	37	-	-	PUNCT
ajlm-1720	87	38	house	house	NOUN
ajlm-1720	87	39	developed	develop	VERB
ajlm-1720	87	40	gating	gate	VERB
ajlm-1720	87	41	strategies	strategy	NOUN
ajlm-1720	87	42	to	to	PART
ajlm-1720	87	43	identify	identify	VERB
ajlm-1720	87	44	granulocytes	granulocyte	NOUN
ajlm-1720	87	45	,	,	PUNCT
ajlm-1720	87	46	monocytes	monocyte	NOUN
ajlm-1720	87	47	and	and	CCONJ
ajlm-1720	87	48	mature	mature	ADJ
ajlm-1720	87	49	lymphocytes	lymphocyte	NOUN
ajlm-1720	87	50	using	use	VERB
ajlm-1720	87	51	cd45	cd45	PROPN
ajlm-1720	87	52	,	,	PUNCT
ajlm-1720	87	53	side	side	NOUN
ajlm-1720	87	54	scatter	scatter	NOUN
ajlm-1720	87	55	characteristics	characteristic	NOUN
ajlm-1720	87	56	and	and	CCONJ
ajlm-1720	87	57	specific	specific	ADJ
ajlm-1720	87	58	regular	regular	ADJ
ajlm-1720	87	59	expression	expression	NOUN
ajlm-1720	87	60	of	of	ADP
ajlm-1720	87	61	the	the	DET
ajlm-1720	87	62	markers	marker	NOUN
ajlm-1720	87	63	studied	study	VERB
ajlm-1720	87	64	(	(	PUNCT
ajlm-1720	87	65	figure	figure	NOUN
ajlm-1720	87	66	1	1	NUM
ajlm-1720	87	67	and	and	CCONJ
ajlm-1720	87	68	figure	figure	VERB
ajlm-1720	87	69	2	2	NUM
ajlm-1720	87	70	)	)	PUNCT
ajlm-1720	87	71	.	.	PUNCT
ajlm-1720	88	1	figure	figure	VERB
ajlm-1720	88	2	1	1	NUM
ajlm-1720	88	3	:	:	PUNCT
ajlm-1720	88	4	relative	relative	ADJ
ajlm-1720	88	5	expression	expression	NOUN
ajlm-1720	88	6	of	of	ADP
ajlm-1720	88	7	cd81	cd81	PROPN
ajlm-1720	88	8	relative	relative	ADJ
ajlm-1720	88	9	to	to	ADP
ajlm-1720	88	10	normal	normal	ADJ
ajlm-1720	88	11	t	t	PROPN
ajlm-1720	88	12	-	-	PUNCT
ajlm-1720	88	13	cells	cell	NOUN
ajlm-1720	88	14	and	and	CCONJ
ajlm-1720	88	15	granulocytes	granulocyte	NOUN
ajlm-1720	88	16	in	in	ADP
ajlm-1720	88	17	the	the	DET
ajlm-1720	88	18	clb	clb	NOUN
ajlm-1720	88	19	tube	tube	NOUN
ajlm-1720	88	20	validated	validate	VERB
ajlm-1720	88	21	at	at	ADP
ajlm-1720	88	22	the	the	DET
ajlm-1720	88	23	charlotte	charlotte	PROPN
ajlm-1720	88	24	maxeke	maxeke	PROPN
ajlm-1720	88	25	johannesburg	johannesburg	PROPN
ajlm-1720	88	26	academic	academic	PROPN
ajlm-1720	88	27	hospital	hospital	PROPN
ajlm-1720	88	28	flow	flow	NOUN
ajlm-1720	88	29	cytometry	cytometry	PROPN
ajlm-1720	88	30	laboratory	laboratory	NOUN
ajlm-1720	88	31	in	in	ADP
ajlm-1720	88	32	johannesburg	johannesburg	PROPN
ajlm-1720	88	33	,	,	PUNCT
ajlm-1720	88	34	south	south	PROPN
ajlm-1720	88	35	africa	africa	PROPN
ajlm-1720	88	36	,	,	PUNCT
ajlm-1720	88	37	april	april	PROPN
ajlm-1720	88	38	2020	2020	NUM
ajlm-1720	88	39	to	to	ADP
ajlm-1720	88	40	august	august	PROPN
ajlm-1720	88	41	2020	2020	NUM
ajlm-1720	88	42	.	.	PUNCT
ajlm-1720	89	1	each	each	DET
ajlm-1720	89	2	plot	plot	NOUN
ajlm-1720	89	3	(	(	PUNCT
ajlm-1720	89	4	a	a	PRON
ajlm-1720	89	5	,	,	PUNCT
ajlm-1720	89	6	b	b	PROPN
ajlm-1720	89	7	and	and	CCONJ
ajlm-1720	89	8	c	c	NOUN
ajlm-1720	89	9	)	)	PUNCT
ajlm-1720	89	10	shows	show	VERB
ajlm-1720	89	11	cd81	cd81	PROPN
ajlm-1720	89	12	expression	expression	NOUN
ajlm-1720	89	13	(	(	PUNCT
ajlm-1720	89	14	x	x	NOUN
ajlm-1720	89	15	-	-	NOUN
ajlm-1720	89	16	axis	axis	ADJ
ajlm-1720	89	17	)	)	PUNCT
ajlm-1720	89	18	versus	versus	ADP
ajlm-1720	89	19	frequency	frequency	NOUN
ajlm-1720	89	20	(	(	PUNCT
ajlm-1720	89	21	y	y	NOUN
ajlm-1720	89	22	-	-	PUNCT
ajlm-1720	89	23	axis	axis	NOUN
ajlm-1720	89	24	)	)	PUNCT
ajlm-1720	89	25	.	.	PUNCT
ajlm-1720	90	1	in	in	ADP
ajlm-1720	90	2	a	a	PRON
ajlm-1720	90	3	,	,	PUNCT
ajlm-1720	90	4	there	there	PRON
ajlm-1720	90	5	is	be	VERB
ajlm-1720	90	6	relative	relative	ADJ
ajlm-1720	90	7	(	(	PUNCT
ajlm-1720	90	8	weak	weak	ADJ
ajlm-1720	90	9	)	)	PUNCT
ajlm-1720	90	10	under	under	ADP
ajlm-1720	90	11	-	-	PUNCT
ajlm-1720	90	12	expression	expression	NOUN
ajlm-1720	90	13	of	of	ADP
ajlm-1720	90	14	cd81	cd81	PROPN
ajlm-1720	90	15	in	in	ADP
ajlm-1720	90	16	a	a	DET
ajlm-1720	90	17	patient	patient	NOUN
ajlm-1720	90	18	with	with	ADP
ajlm-1720	90	19	cll	cll	PROPN
ajlm-1720	90	20	gated	gate	VERB
ajlm-1720	90	21	on	on	ADP
ajlm-1720	90	22	cd19+|cd5	cd19+|cd5	PROPN
ajlm-1720	90	23	+	+	PROPN
ajlm-1720	90	24	;	;	PUNCT
ajlm-1720	90	25	in	in	ADP
ajlm-1720	90	26	b	b	NUM
ajlm-1720	90	27	,	,	PUNCT
ajlm-1720	90	28	there	there	PRON
ajlm-1720	90	29	is	be	VERB
ajlm-1720	90	30	relative	relative	ADJ
ajlm-1720	90	31	over	over	ADP
ajlm-1720	90	32	-	-	PUNCT
ajlm-1720	90	33	expression	expression	NOUN
ajlm-1720	90	34	of	of	ADP
ajlm-1720	90	35	cd81	cd81	PROPN
ajlm-1720	90	36	in	in	ADP
ajlm-1720	90	37	a	a	DET
ajlm-1720	90	38	patient	patient	NOUN
ajlm-1720	90	39	with	with	ADP
ajlm-1720	90	40	follicular	follicular	ADJ
ajlm-1720	90	41	lymphoma	lymphoma	NOUN
ajlm-1720	90	42	gated	gate	VERB
ajlm-1720	90	43	on	on	ADP
ajlm-1720	90	44	cd19+|cd10	cd19+|cd10	PROPN
ajlm-1720	90	45	+	+	PROPN
ajlm-1720	90	46	c	c	PROPN
ajlm-1720	90	47	is	be	AUX
ajlm-1720	90	48	a	a	DET
ajlm-1720	90	49	control	control	NOUN
ajlm-1720	90	50	experiment	experiment	NOUN
ajlm-1720	90	51	of	of	ADP
ajlm-1720	90	52	a	a	DET
ajlm-1720	90	53	paediatric	paediatric	ADJ
ajlm-1720	90	54	sample	sample	NOUN
ajlm-1720	90	55	with	with	ADP
ajlm-1720	90	56	20	20	NUM
ajlm-1720	90	57	%	%	NOUN
ajlm-1720	90	58	haematogones	haematogone	NOUN
ajlm-1720	90	59	showing	show	VERB
ajlm-1720	90	60	bright	bright	ADJ
ajlm-1720	90	61	expression	expression	NOUN
ajlm-1720	90	62	of	of	ADP
ajlm-1720	90	63	cd81	cd81	PROPN
ajlm-1720	90	64	on	on	ADP
ajlm-1720	90	65	normal	normal	ADJ
ajlm-1720	90	66	precursor	precursor	NOUN
ajlm-1720	90	67	b	b	NOUN
ajlm-1720	90	68	-	-	PUNCT
ajlm-1720	90	69	cells	cell	NOUN
ajlm-1720	90	70	gated	gate	VERB
ajlm-1720	90	71	on	on	ADP
ajlm-1720	90	72	weak	weak	ADJ
ajlm-1720	90	73	cd45+|	cd45+|	PROPN
ajlm-1720	90	74	cd19	cd19	PROPN
ajlm-1720	90	75	+	+	PROPN
ajlm-1720	90	76	.	.	PROPN
ajlm-1720	90	77	orange	orange	PROPN
ajlm-1720	90	78	represents	represent	VERB
ajlm-1720	90	79	the	the	DET
ajlm-1720	90	80	b	b	NOUN
ajlm-1720	90	81	-	-	PUNCT
ajlm-1720	90	82	cells	cell	NOUN
ajlm-1720	90	83	identified	identify	VERB
ajlm-1720	90	84	with	with	ADP
ajlm-1720	90	85	cd19	cd19	PROPN
ajlm-1720	90	86	;	;	PUNCT
ajlm-1720	90	87	the	the	DET
ajlm-1720	90	88	blue	blue	ADJ
ajlm-1720	90	89	population	population	NOUN
ajlm-1720	90	90	represents	represent	VERB
ajlm-1720	90	91	background	background	NOUN
ajlm-1720	90	92	granulocytes	granulocyte	NOUN
ajlm-1720	90	93	identified	identify	VERB
ajlm-1720	90	94	with	with	ADP
ajlm-1720	90	95	cd45	cd45	PROPN
ajlm-1720	90	96	and	and	CCONJ
ajlm-1720	90	97	side	side	NOUN
ajlm-1720	90	98	scatter	scatter	NOUN
ajlm-1720	90	99	,	,	PUNCT
ajlm-1720	90	100	and	and	CCONJ
ajlm-1720	90	101	red	red	NOUN
ajlm-1720	90	102	represents	represent	VERB
ajlm-1720	90	103	background	background	NOUN
ajlm-1720	90	104	t	t	PROPN
ajlm-1720	90	105	-	-	PUNCT
ajlm-1720	90	106	cells	cell	NOUN
ajlm-1720	90	107	gated	gate	VERB
ajlm-1720	90	108	on	on	ADP
ajlm-1720	90	109	cd5	cd5	PROPN
ajlm-1720	90	110	(	(	PUNCT
ajlm-1720	90	111	all	all	DET
ajlm-1720	90	112	markers	marker	NOUN
ajlm-1720	90	113	are	be	AUX
ajlm-1720	90	114	included	include	VERB
ajlm-1720	90	115	in	in	ADP
ajlm-1720	90	116	the	the	DET
ajlm-1720	90	117	clb	clb	NOUN
ajlm-1720	90	118	panel	panel	NOUN
ajlm-1720	90	119	)	)	PUNCT
ajlm-1720	90	120	.	.	PUNCT
ajlm-1720	91	1	figure	figure	VERB
ajlm-1720	91	2	2	2	NUM
ajlm-1720	91	3	:	:	PUNCT
ajlm-1720	91	4	identification	identification	NOUN
ajlm-1720	91	5	of	of	ADP
ajlm-1720	91	6	plasma	plasma	NOUN
ajlm-1720	91	7	cells	cell	NOUN
ajlm-1720	91	8	using	use	VERB
ajlm-1720	91	9	the	the	DET
ajlm-1720	91	10	duraclone	duraclone	NOUN
ajlm-1720	91	11	pc	pc	NOUN
ajlm-1720	91	12	tube	tube	NOUN
ajlm-1720	91	13	validated	validate	VERB
ajlm-1720	91	14	at	at	ADP
ajlm-1720	91	15	the	the	DET
ajlm-1720	91	16	charlotte	charlotte	PROPN
ajlm-1720	91	17	maxeke	maxeke	PROPN
ajlm-1720	91	18	johannesburg	johannesburg	PROPN
ajlm-1720	91	19	academic	academic	PROPN
ajlm-1720	91	20	hospital	hospital	PROPN
ajlm-1720	91	21	flow	flow	NOUN
ajlm-1720	91	22	cytometry	cytometry	PROPN
ajlm-1720	91	23	laboratory	laboratory	NOUN
ajlm-1720	91	24	in	in	ADP
ajlm-1720	91	25	johannesburg	johannesburg	PROPN
ajlm-1720	91	26	,	,	PUNCT
ajlm-1720	91	27	south	south	PROPN
ajlm-1720	91	28	africa	africa	PROPN
ajlm-1720	91	29	,	,	PUNCT
ajlm-1720	91	30	april	april	PROPN
ajlm-1720	91	31	2020	2020	NUM
ajlm-1720	91	32	to	to	ADP
ajlm-1720	91	33	august	august	PROPN
ajlm-1720	91	34	2020	2020	NUM
ajlm-1720	91	35	.	.	PUNCT
ajlm-1720	92	1	in	in	ADP
ajlm-1720	92	2	histogram	histogram	PROPN
ajlm-1720	92	3	a	a	DET
ajlm-1720	92	4	,	,	PUNCT
ajlm-1720	92	5	negative	negative	ADJ
ajlm-1720	92	6	cd45	cd45	PROPN
ajlm-1720	92	7	expression	expression	NOUN
ajlm-1720	92	8	of	of	ADP
ajlm-1720	92	9	plasma	plasma	NOUN
ajlm-1720	92	10	cells	cell	NOUN
ajlm-1720	92	11	is	be	AUX
ajlm-1720	92	12	shown	show	VERB
ajlm-1720	92	13	(	(	PUNCT
ajlm-1720	92	14	purple	purple	ADJ
ajlm-1720	92	15	)	)	PUNCT
ajlm-1720	92	16	,	,	PUNCT
ajlm-1720	92	17	with	with	SCONJ
ajlm-1720	92	18	cd45	cd45	PROPN
ajlm-1720	92	19	positive	positive	ADJ
ajlm-1720	92	20	(	(	PUNCT
ajlm-1720	92	21	background	background	NOUN
ajlm-1720	92	22	)	)	PUNCT
ajlm-1720	92	23	expression	expression	NOUN
ajlm-1720	92	24	noted	note	VERB
ajlm-1720	92	25	amongst	amongst	ADP
ajlm-1720	92	26	granulocytes	granulocyte	NOUN
ajlm-1720	92	27	(	(	PUNCT
ajlm-1720	92	28	blue	blue	NOUN
ajlm-1720	92	29	)	)	PUNCT
ajlm-1720	92	30	,	,	PUNCT
ajlm-1720	92	31	monocytes	monocyte	VERB
ajlm-1720	92	32	(	(	PUNCT
ajlm-1720	92	33	green	green	ADJ
ajlm-1720	92	34	)	)	PUNCT
ajlm-1720	92	35	and	and	CCONJ
ajlm-1720	92	36	mature	mature	ADJ
ajlm-1720	92	37	lymphocytes	lymphocyte	NOUN
ajlm-1720	92	38	(	(	PUNCT
ajlm-1720	92	39	red	red	ADJ
ajlm-1720	92	40	)	)	PUNCT
ajlm-1720	92	41	.	.	PUNCT
ajlm-1720	93	1	the	the	DET
ajlm-1720	93	2	target	target	NOUN
ajlm-1720	93	3	plasma	plasma	NOUN
ajlm-1720	93	4	cell	cell	NOUN
ajlm-1720	93	5	population	population	NOUN
ajlm-1720	93	6	were	be	AUX
ajlm-1720	93	7	primary	primary	ADV
ajlm-1720	93	8	-	-	PUNCT
ajlm-1720	93	9	gated	gate	VERB
ajlm-1720	93	10	on	on	ADP
ajlm-1720	93	11	bright	bright	ADJ
ajlm-1720	93	12	cd138	cd138	NOUN
ajlm-1720	93	13	and	and	CCONJ
ajlm-1720	93	14	cd38	cd38	PROPN
ajlm-1720	93	15	to	to	PART
ajlm-1720	93	16	reveal	reveal	VERB
ajlm-1720	93	17	aberrant	aberrant	ADJ
ajlm-1720	93	18	cd117	cd117	PROPN
ajlm-1720	93	19	expression	expression	NOUN
ajlm-1720	93	20	(	(	PUNCT
ajlm-1720	93	21	b	b	NOUN
ajlm-1720	93	22	)	)	PUNCT
ajlm-1720	93	23	and	and	CCONJ
ajlm-1720	93	24	under	under	NOUN
ajlm-1720	93	25	-	-	PUNCT
ajlm-1720	93	26	expression	expression	NOUN
ajlm-1720	93	27	of	of	ADP
ajlm-1720	93	28	cd81	cd81	PROPN
ajlm-1720	93	29	(	(	PUNCT
ajlm-1720	93	30	c	c	NOUN
ajlm-1720	93	31	)	)	PUNCT
ajlm-1720	93	32	and	and	CCONJ
ajlm-1720	93	33	cd27	cd27	PROPN
ajlm-1720	93	34	(	(	PUNCT
ajlm-1720	93	35	d	d	NOUN
ajlm-1720	93	36	)	)	PUNCT
ajlm-1720	93	37	.	.	PUNCT
ajlm-1720	94	1	a	a	DET
ajlm-1720	94	2	similar	similar	ADJ
ajlm-1720	94	3	approach	approach	NOUN
ajlm-1720	94	4	was	be	AUX
ajlm-1720	94	5	used	use	VERB
ajlm-1720	94	6	for	for	ADP
ajlm-1720	94	7	each	each	PRON
ajlm-1720	94	8	of	of	ADP
ajlm-1720	94	9	the	the	DET
ajlm-1720	94	10	comparative	comparative	ADJ
ajlm-1720	94	11	second	second	ADJ
ajlm-1720	94	12	-	-	PUNCT
ajlm-1720	94	13	line	line	NOUN
ajlm-1720	94	14	duraclone	duraclone	NOUN
ajlm-1720	94	15	re	re	AUX
ajlm-1720	94	16	alb	alb	VERB
ajlm-1720	94	17	,	,	PUNCT
ajlm-1720	94	18	re	re	X
ajlm-1720	94	19	clb	clb	NOUN
ajlm-1720	94	20	,	,	PUNCT
ajlm-1720	94	21	and	and	CCONJ
ajlm-1720	94	22	re	re	ADP
ajlm-1720	94	23	pc	pc	NOUN
ajlm-1720	94	24	listmode	listmode	NOUN
ajlm-1720	94	25	data	datum	NOUN
ajlm-1720	94	26	analysis	analysis	NOUN
ajlm-1720	94	27	but	but	CCONJ
ajlm-1720	94	28	additionally	additionally	ADV
ajlm-1720	94	29	incorporated	incorporated	ADJ
ajlm-1720	94	30	manufacturer	manufacturer	NOUN
ajlm-1720	94	31	-	-	PUNCT
ajlm-1720	94	32	recommended	recommend	VERB
ajlm-1720	94	33	gating	gate	VERB
ajlm-1720	94	34	strategies	strategy	NOUN
ajlm-1720	94	35	for	for	ADP
ajlm-1720	94	36	clinical	clinical	ADJ
ajlm-1720	94	37	interpretation	interpretation	NOUN
ajlm-1720	94	38	of	of	ADP
ajlm-1720	94	39	data.23	data.23	PROPN
ajlm-1720	94	40	the	the	DET
ajlm-1720	94	41	relative	relative	ADJ
ajlm-1720	94	42	intensity	intensity	NOUN
ajlm-1720	94	43	of	of	ADP
ajlm-1720	94	44	expression	expression	NOUN
ajlm-1720	94	45	of	of	ADP
ajlm-1720	94	46	cell	cell	NOUN
ajlm-1720	94	47	surface	surface	NOUN
ajlm-1720	94	48	antigens	antigen	NOUN
ajlm-1720	94	49	was	be	AUX
ajlm-1720	94	50	used	use	VERB
ajlm-1720	94	51	to	to	PART
ajlm-1720	94	52	discriminate	discriminate	VERB
ajlm-1720	94	53	between	between	ADP
ajlm-1720	94	54	normal	normal	ADJ
ajlm-1720	94	55	and	and	CCONJ
ajlm-1720	94	56	aberrant	aberrant	ADJ
ajlm-1720	94	57	immunophenotypes	immunophenotype	NOUN
ajlm-1720	94	58	according	accord	VERB
ajlm-1720	94	59	to	to	ADP
ajlm-1720	94	60	manufacturer	manufacturer	NOUN
ajlm-1720	94	61	specifications	specification	NOUN
ajlm-1720	94	62	.	.	PUNCT
ajlm-1720	95	1	positivity	positivity	NOUN
ajlm-1720	95	2	(	(	PUNCT
ajlm-1720	95	3	or	or	CCONJ
ajlm-1720	95	4	no	no	DET
ajlm-1720	95	5	expression	expression	NOUN
ajlm-1720	95	6	)	)	PUNCT
ajlm-1720	95	7	of	of	ADP
ajlm-1720	95	8	individual	individual	ADJ
ajlm-1720	95	9	markers	marker	NOUN
ajlm-1720	95	10	was	be	AUX
ajlm-1720	95	11	established	establish	VERB
ajlm-1720	95	12	,	,	PUNCT
ajlm-1720	95	13	and	and	CCONJ
ajlm-1720	95	14	overall	overall	ADJ
ajlm-1720	95	15	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	95	16	immunophenotypes	immunophenotype	NOUN
ajlm-1720	95	17	sub	sub	ADJ
ajlm-1720	95	18	-	-	ADJ
ajlm-1720	95	19	classified	classified	ADJ
ajlm-1720	95	20	according	accord	VERB
ajlm-1720	95	21	to	to	ADP
ajlm-1720	95	22	the	the	DET
ajlm-1720	95	23	established	establish	VERB
ajlm-1720	95	24	positive	positive	ADJ
ajlm-1720	95	25	markers	marker	NOUN
ajlm-1720	95	26	outlined	outline	VERB
ajlm-1720	95	27	in	in	ADP
ajlm-1720	95	28	the	the	DET
ajlm-1720	95	29	world	world	NOUN
ajlm-1720	95	30	health	health	NOUN
ajlm-1720	95	31	organization	organization	NOUN
ajlm-1720	95	32	(	(	PUNCT
ajlm-1720	95	33	who	who	PRON
ajlm-1720	95	34	)	)	PUNCT
ajlm-1720	95	35	2016	2016	NUM
ajlm-1720	95	36	classification	classification	NOUN
ajlm-1720	95	37	of	of	ADP
ajlm-1720	95	38	tumours	tumour	NOUN
ajlm-1720	95	39	of	of	ADP
ajlm-1720	95	40	haemopoietic	haemopoietic	ADJ
ajlm-1720	95	41	and	and	CCONJ
ajlm-1720	95	42	lymphoid	lymphoid	ADJ
ajlm-1720	95	43	tissues.24	tissues.24	NOUN
ajlm-1720	95	44	specifically	specifically	ADV
ajlm-1720	95	45	,	,	PUNCT
ajlm-1720	95	46	expression	expression	NOUN
ajlm-1720	95	47	of	of	ADP
ajlm-1720	95	48	cd27	cd27	PROPN
ajlm-1720	95	49	,	,	PUNCT
ajlm-1720	95	50	cd43	cd43	PROPN
ajlm-1720	95	51	,	,	PUNCT
ajlm-1720	95	52	cd56	cd56	PROPN
ajlm-1720	95	53	,	,	PUNCT
ajlm-1720	95	54	cd58	cd58	PROPN
ajlm-1720	95	55	,	,	PUNCT
ajlm-1720	95	56	and	and	CCONJ
ajlm-1720	95	57	cd81	cd81	PROPN
ajlm-1720	95	58	,	,	PUNCT
ajlm-1720	95	59	which	which	PRON
ajlm-1720	95	60	were	be	AUX
ajlm-1720	95	61	not	not	PART
ajlm-1720	95	62	included	include	VERB
ajlm-1720	95	63	in	in	ADP
ajlm-1720	95	64	the	the	DET
ajlm-1720	95	65	predicate	predicate	NOUN
ajlm-1720	95	66	clearllab	clearllab	NOUN
ajlm-1720	95	67	10c	10c	NOUN
ajlm-1720	95	68	and	and	CCONJ
ajlm-1720	95	69	in	in	ADP
ajlm-1720	95	70	-	-	PUNCT
ajlm-1720	95	71	house	house	NOUN
ajlm-1720	95	72	second	second	ADJ
ajlm-1720	95	73	-	-	PUNCT
ajlm-1720	95	74	line	line	NOUN
ajlm-1720	95	75	panel	panel	NOUN
ajlm-1720	95	76	analysis	analysis	NOUN
ajlm-1720	95	77	,	,	PUNCT
ajlm-1720	95	78	were	be	AUX
ajlm-1720	95	79	verified	verify	VERB
ajlm-1720	95	80	on	on	ADP
ajlm-1720	95	81	background	background	NOUN
ajlm-1720	95	82	(	(	PUNCT
ajlm-1720	95	83	normal	normal	ADJ
ajlm-1720	95	84	)	)	PUNCT
ajlm-1720	95	85	populations	population	NOUN
ajlm-1720	95	86	as	as	ADP
ajlm-1720	95	87	evidence	evidence	NOUN
ajlm-1720	95	88	of	of	ADP
ajlm-1720	95	89	a	a	DET
ajlm-1720	95	90	satisfactory	satisfactory	ADJ
ajlm-1720	95	91	internal	internal	ADJ
ajlm-1720	95	92	positive	positive	ADJ
ajlm-1720	95	93	control	control	NOUN
ajlm-1720	95	94	and	and	CCONJ
ajlm-1720	95	95	proof	proof	NOUN
ajlm-1720	95	96	that	that	SCONJ
ajlm-1720	95	97	the	the	DET
ajlm-1720	95	98	reagents	reagent	NOUN
ajlm-1720	95	99	met	meet	VERB
ajlm-1720	95	100	the	the	DET
ajlm-1720	95	101	manufacturer	manufacturer	NOUN
ajlm-1720	95	102	’s	’s	PART
ajlm-1720	95	103	performance	performance	NOUN
ajlm-1720	95	104	specifications	specification	NOUN
ajlm-1720	95	105	.	.	PUNCT
ajlm-1720	96	1	in	in	ADP
ajlm-1720	96	2	the	the	DET
ajlm-1720	96	3	alb	alb	PROPN
ajlm-1720	96	4	analyses	analysis	NOUN
ajlm-1720	96	5	,	,	PUNCT
ajlm-1720	96	6	typical	typical	ADJ
ajlm-1720	96	7	secondary	secondary	ADJ
ajlm-1720	96	8	backbone	backbone	NOUN
ajlm-1720	96	9	markers	marker	NOUN
ajlm-1720	96	10	,	,	PUNCT
ajlm-1720	96	11	including	include	VERB
ajlm-1720	96	12	co	co	NOUN
ajlm-1720	96	13	-	-	NOUN
ajlm-1720	96	14	expression	expression	NOUN
ajlm-1720	96	15	of	of	ADP
ajlm-1720	96	16	cd19	cd19	PROPN
ajlm-1720	96	17	/	/	SYM
ajlm-1720	96	18	cd10	cd10	PROPN
ajlm-1720	96	19	/	/	SYM
ajlm-1720	96	20	cd34	cd34	PROPN
ajlm-1720	96	21	enabled	enable	VERB
ajlm-1720	96	22	further	further	ADJ
ajlm-1720	96	23	characterisation	characterisation	NOUN
ajlm-1720	96	24	of	of	ADP
ajlm-1720	96	25	markers	marker	NOUN
ajlm-1720	96	26	cd20	cd20	PROPN
ajlm-1720	96	27	,	,	PUNCT
ajlm-1720	96	28	cd38	cd38	PROPN
ajlm-1720	96	29	,	,	PUNCT
ajlm-1720	96	30	and	and	CCONJ
ajlm-1720	96	31	cd58	cd58	PROPN
ajlm-1720	96	32	and	and	CCONJ
ajlm-1720	96	33	established	establish	VERB
ajlm-1720	96	34	the	the	DET
ajlm-1720	96	35	presence	presence	NOUN
ajlm-1720	96	36	of	of	ADP
ajlm-1720	96	37	normal	normal	ADJ
ajlm-1720	96	38	precursor	precursor	NOUN
ajlm-1720	96	39	b	b	NOUN
ajlm-1720	96	40	-	-	PUNCT
ajlm-1720	96	41	cells	cell	NOUN
ajlm-1720	96	42	(	(	PUNCT
ajlm-1720	96	43	haematogones	haematogone	NOUN
ajlm-1720	96	44	)	)	PUNCT
ajlm-1720	96	45	or	or	CCONJ
ajlm-1720	96	46	abnormal	abnormal	ADJ
ajlm-1720	96	47	precursor	precursor	NOUN
ajlm-1720	96	48	b	b	NOUN
ajlm-1720	96	49	-	-	PUNCT
ajlm-1720	96	50	cells	cell	NOUN
ajlm-1720	96	51	.	.	PUNCT
ajlm-1720	97	1	likewise	likewise	ADV
ajlm-1720	97	2	,	,	PUNCT
ajlm-1720	97	3	for	for	ADP
ajlm-1720	97	4	the	the	DET
ajlm-1720	97	5	duraclone	duraclone	PROPN
ajlm-1720	97	6	re	re	X
ajlm-1720	97	7	clb	clb	NOUN
ajlm-1720	97	8	,	,	PUNCT
ajlm-1720	97	9	dual	dual	ADJ
ajlm-1720	97	10	expression	expression	NOUN
ajlm-1720	97	11	of	of	ADP
ajlm-1720	97	12	either	either	CCONJ
ajlm-1720	97	13	cd19	cd19	PROPN
ajlm-1720	97	14	/	/	SYM
ajlm-1720	97	15	cd5	cd5	PROPN
ajlm-1720	97	16	or	or	CCONJ
ajlm-1720	97	17	cd19	cd19	PROPN
ajlm-1720	97	18	/	/	SYM
ajlm-1720	97	19	cd20	cd20	PROPN
ajlm-1720	97	20	was	be	AUX
ajlm-1720	97	21	used	use	VERB
ajlm-1720	97	22	to	to	PART
ajlm-1720	97	23	identify	identify	VERB
ajlm-1720	97	24	the	the	DET
ajlm-1720	97	25	‘	'	PUNCT
ajlm-1720	97	26	target	target	NOUN
ajlm-1720	97	27	’	'	PUNCT
ajlm-1720	97	28	or	or	CCONJ
ajlm-1720	97	29	neoplastic	neoplastic	ADJ
ajlm-1720	97	30	b	b	NOUN
ajlm-1720	97	31	-	-	PUNCT
ajlm-1720	97	32	cell	cell	NOUN
ajlm-1720	97	33	population	population	NOUN
ajlm-1720	97	34	before	before	ADP
ajlm-1720	97	35	specific	specific	ADJ
ajlm-1720	97	36	characterisation	characterisation	NOUN
ajlm-1720	97	37	of	of	ADP
ajlm-1720	97	38	cd43	cd43	PROPN
ajlm-1720	97	39	,	,	PUNCT
ajlm-1720	97	40	cd79b	cd79b	ADJ
ajlm-1720	97	41	,	,	PUNCT
ajlm-1720	97	42	cd81	cd81	PROPN
ajlm-1720	97	43	and	and	CCONJ
ajlm-1720	97	44	ror1	ror1	ADJ
ajlm-1720	97	45	expression	expression	NOUN
ajlm-1720	97	46	.	.	PUNCT
ajlm-1720	98	1	plasma	plasma	NOUN
ajlm-1720	98	2	cells	cell	NOUN
ajlm-1720	98	3	were	be	AUX
ajlm-1720	98	4	defined	define	VERB
ajlm-1720	98	5	in	in	ADP
ajlm-1720	98	6	the	the	DET
ajlm-1720	98	7	duraclone	duraclone	NOUN
ajlm-1720	98	8	re	re	NOUN
ajlm-1720	98	9	pc	pc	NOUN
ajlm-1720	98	10	panel	panel	NOUN
ajlm-1720	98	11	by	by	ADP
ajlm-1720	98	12	the	the	DET
ajlm-1720	98	13	dual	dual	ADJ
ajlm-1720	98	14	expression	expression	NOUN
ajlm-1720	98	15	of	of	ADP
ajlm-1720	98	16	both	both	DET
ajlm-1720	98	17	cd38	cd38	PROPN
ajlm-1720	98	18	and	and	CCONJ
ajlm-1720	98	19	cd138	cd138	PROPN
ajlm-1720	98	20	;	;	PUNCT
ajlm-1720	98	21	a	a	DET
ajlm-1720	98	22	normal	normal	ADJ
ajlm-1720	98	23	or	or	CCONJ
ajlm-1720	98	24	malignant	malignant	ADJ
ajlm-1720	98	25	plasma	plasma	NOUN
ajlm-1720	98	26	cell	cell	NOUN
ajlm-1720	98	27	immunophenotype	immunophenotype	NOUN
ajlm-1720	98	28	was	be	AUX
ajlm-1720	98	29	subsequently	subsequently	ADV
ajlm-1720	98	30	noted	note	VERB
ajlm-1720	98	31	following	follow	VERB
ajlm-1720	98	32	interrogation	interrogation	NOUN
ajlm-1720	98	33	of	of	ADP
ajlm-1720	98	34	markers	marker	NOUN
ajlm-1720	98	35	including	include	VERB
ajlm-1720	98	36	cd81	cd81	PROPN
ajlm-1720	98	37	,	,	PUNCT
ajlm-1720	98	38	cd27	cd27	PROPN
ajlm-1720	98	39	,	,	PUNCT
ajlm-1720	98	40	cd19	cd19	PROPN
ajlm-1720	98	41	,	,	PUNCT
ajlm-1720	98	42	cd200	cd200	PROPN
ajlm-1720	98	43	,	,	PUNCT
ajlm-1720	98	44	cd56	cd56	PROPN
ajlm-1720	98	45	,	,	PUNCT
ajlm-1720	98	46	and	and	CCONJ
ajlm-1720	98	47	cd45	cd45	PROPN
ajlm-1720	98	48	.	.	PUNCT
ajlm-1720	99	1	statistical	statistical	ADJ
ajlm-1720	99	2	analysis	analysis	NOUN
ajlm-1720	99	3	clinical	clinical	ADJ
ajlm-1720	99	4	diagnostic	diagnostic	ADJ
ajlm-1720	99	5	outcomes	outcome	NOUN
ajlm-1720	99	6	were	be	AUX
ajlm-1720	99	7	collated	collate	VERB
ajlm-1720	99	8	into	into	ADP
ajlm-1720	99	9	microsoft	microsoft	PROPN
ajlm-1720	99	10	excel	excel	PROPN
ajlm-1720	99	11	(	(	PUNCT
ajlm-1720	99	12	redmond	redmond	PROPN
ajlm-1720	99	13	,	,	PUNCT
ajlm-1720	99	14	washington	washington	PROPN
ajlm-1720	99	15	,	,	PUNCT
ajlm-1720	99	16	united	united	PROPN
ajlm-1720	99	17	states	states	PROPN
ajlm-1720	99	18	)	)	PUNCT
ajlm-1720	99	19	spreadsheets	spreadsheet	NOUN
ajlm-1720	99	20	.	.	PUNCT
ajlm-1720	100	1	marker	marker	NOUN
ajlm-1720	100	2	expressions	expression	NOUN
ajlm-1720	100	3	and	and	CCONJ
ajlm-1720	100	4	specific	specific	ADJ
ajlm-1720	100	5	clinical	clinical	ADJ
ajlm-1720	100	6	diagnoses	diagnosis	NOUN
ajlm-1720	100	7	noted	note	VERB
ajlm-1720	100	8	for	for	ADP
ajlm-1720	100	9	the	the	DET
ajlm-1720	100	10	duraclone	duraclone	NOUN
ajlm-1720	100	11	re	re	NOUN
ajlm-1720	100	12	alb	alb	VERB
ajlm-1720	100	13	,	,	PUNCT
ajlm-1720	100	14	re	re	X
ajlm-1720	100	15	clb	clb	NOUN
ajlm-1720	100	16	,	,	PUNCT
ajlm-1720	100	17	and	and	CCONJ
ajlm-1720	100	18	re	re	PUNCT
ajlm-1720	100	19	pc	pc	NOUN
ajlm-1720	100	20	panels	panel	NOUN
ajlm-1720	100	21	were	be	AUX
ajlm-1720	100	22	compared	compare	VERB
ajlm-1720	100	23	to	to	ADP
ajlm-1720	100	24	the	the	DET
ajlm-1720	100	25	clinical	clinical	ADJ
ajlm-1720	100	26	diagnostic	diagnostic	ADJ
ajlm-1720	100	27	outcomes	outcome	NOUN
ajlm-1720	100	28	from	from	ADP
ajlm-1720	100	29	the	the	DET
ajlm-1720	100	30	existing	exist	VERB
ajlm-1720	100	31	in	in	ADP
ajlm-1720	100	32	-	-	PUNCT
ajlm-1720	100	33	house	house	NOUN
ajlm-1720	100	34	2–4	2–4	NOUN
ajlm-1720	100	35	-	-	PUNCT
ajlm-1720	100	36	colour	colour	ADJ
ajlm-1720	100	37	antibody	antibody	NOUN
ajlm-1720	100	38	panels	panel	NOUN
ajlm-1720	100	39	described	describe	VERB
ajlm-1720	100	40	(	(	PUNCT
ajlm-1720	100	41	table	table	NOUN
ajlm-1720	100	42	2	2	NUM
ajlm-1720	100	43	)	)	PUNCT
ajlm-1720	100	44	.	.	PUNCT
ajlm-1720	101	1	the	the	DET
ajlm-1720	101	2	agreement	agreement	NOUN
ajlm-1720	101	3	between	between	ADP
ajlm-1720	101	4	methods	method	NOUN
ajlm-1720	101	5	(	(	PUNCT
ajlm-1720	101	6	comparing	compare	VERB
ajlm-1720	101	7	the	the	DET
ajlm-1720	101	8	final	final	ADJ
ajlm-1720	101	9	diagnostic	diagnostic	ADJ
ajlm-1720	101	10	outcome	outcome	NOUN
ajlm-1720	101	11	)	)	PUNCT
ajlm-1720	101	12	was	be	AUX
ajlm-1720	101	13	assessed	assess	VERB
ajlm-1720	101	14	using	use	VERB
ajlm-1720	101	15	contingency	contingency	NOUN
ajlm-1720	101	16	tables	table	NOUN
ajlm-1720	101	17	to	to	PART
ajlm-1720	101	18	determine	determine	VERB
ajlm-1720	101	19	sensitivity	sensitivity	NOUN
ajlm-1720	101	20	and	and	CCONJ
ajlm-1720	101	21	specificity	specificity	NOUN
ajlm-1720	101	22	.	.	PUNCT
ajlm-1720	102	1	true	true	ADJ
ajlm-1720	102	2	positives	positive	NOUN
ajlm-1720	102	3	were	be	AUX
ajlm-1720	102	4	regarded	regard	VERB
ajlm-1720	102	5	as	as	ADP
ajlm-1720	102	6	clinical	clinical	ADJ
ajlm-1720	102	7	diagnostic	diagnostic	ADJ
ajlm-1720	102	8	outcomes	outcome	NOUN
ajlm-1720	102	9	matching	match	VERB
ajlm-1720	102	10	the	the	DET
ajlm-1720	102	11	predicate	predicate	NOUN
ajlm-1720	102	12	clearllab	clearllab	NOUN
ajlm-1720	102	13	10	10	NUM
ajlm-1720	102	14	-	-	PUNCT
ajlm-1720	102	15	c	c	NOUN
ajlm-1720	102	16	with	with	ADP
ajlm-1720	102	17	in	in	ADP
ajlm-1720	102	18	-	-	PUNCT
ajlm-1720	102	19	house	house	NOUN
ajlm-1720	102	20	panels	panel	NOUN
ajlm-1720	102	21	,	,	PUNCT
ajlm-1720	102	22	and	and	CCONJ
ajlm-1720	102	23	test	test	NOUN
ajlm-1720	102	24	system	system	NOUN
ajlm-1720	102	25	outcomes	outcome	NOUN
ajlm-1720	102	26	using	use	VERB
ajlm-1720	102	27	alb	alb	PROPN
ajlm-1720	102	28	,	,	PUNCT
ajlm-1720	102	29	clb	clb	NOUN
ajlm-1720	102	30	or	or	CCONJ
ajlm-1720	102	31	pc	pc	NOUN
ajlm-1720	102	32	.	.	PUNCT
ajlm-1720	103	1	for	for	ADP
ajlm-1720	103	2	example	example	NOUN
ajlm-1720	103	3	,	,	PUNCT
ajlm-1720	103	4	when	when	SCONJ
ajlm-1720	103	5	a	a	DET
ajlm-1720	103	6	b	b	NOUN
ajlm-1720	103	7	-	-	PUNCT
ajlm-1720	103	8	cell	cell	NOUN
ajlm-1720	103	9	cll	cll	PROPN
ajlm-1720	103	10	was	be	AUX
ajlm-1720	103	11	diagnosed	diagnose	VERB
ajlm-1720	103	12	on	on	ADP
ajlm-1720	103	13	the	the	DET
ajlm-1720	103	14	initial	initial	ADJ
ajlm-1720	103	15	clearllab	clearllab	NOUN
ajlm-1720	103	16	investigation	investigation	NOUN
ajlm-1720	103	17	with	with	ADP
ajlm-1720	103	18	cd23	cd23	PROPN
ajlm-1720	103	19	expression	expression	NOUN
ajlm-1720	103	20	by	by	ADP
ajlm-1720	103	21	predicate	predicate	NOUN
ajlm-1720	103	22	second	second	ADJ
ajlm-1720	103	23	-	-	PUNCT
ajlm-1720	103	24	line	line	NOUN
ajlm-1720	103	25	testing	testing	NOUN
ajlm-1720	103	26	,	,	PUNCT
ajlm-1720	103	27	a	a	DET
ajlm-1720	103	28	diagnosis	diagnosis	NOUN
ajlm-1720	103	29	of	of	ADP
ajlm-1720	103	30	a	a	DET
ajlm-1720	103	31	b	b	NOUN
ajlm-1720	103	32	-	-	PUNCT
ajlm-1720	103	33	cell	cell	NOUN
ajlm-1720	103	34	cll	cll	PROPN
ajlm-1720	103	35	was	be	AUX
ajlm-1720	103	36	confirmed	confirm	VERB
ajlm-1720	103	37	in	in	ADP
ajlm-1720	103	38	the	the	DET
ajlm-1720	103	39	clb	clb	NOUN
ajlm-1720	103	40	tube	tube	NOUN
ajlm-1720	103	41	with	with	ADP
ajlm-1720	103	42	positive	positive	ADJ
ajlm-1720	103	43	ror-1	ror-1	ADJ
ajlm-1720	103	44	and	and	CCONJ
ajlm-1720	103	45	cd43	cd43	PROPN
ajlm-1720	103	46	expression	expression	NOUN
ajlm-1720	103	47	.	.	PUNCT
ajlm-1720	104	1	true	true	ADJ
ajlm-1720	104	2	negatives	negative	NOUN
ajlm-1720	104	3	were	be	AUX
ajlm-1720	104	4	those	those	DET
ajlm-1720	104	5	cases	case	NOUN
ajlm-1720	104	6	where	where	SCONJ
ajlm-1720	104	7	there	there	PRON
ajlm-1720	104	8	was	be	VERB
ajlm-1720	104	9	no	no	DET
ajlm-1720	104	10	disease	disease	NOUN
ajlm-1720	104	11	noted	note	VERB
ajlm-1720	104	12	,	,	PUNCT
ajlm-1720	104	13	either	either	CCONJ
ajlm-1720	104	14	by	by	ADP
ajlm-1720	104	15	predicate	predicate	NOUN
ajlm-1720	104	16	clearllab	clearllab	NOUN
ajlm-1720	104	17	and	and	CCONJ
ajlm-1720	104	18	second	second	ADJ
ajlm-1720	104	19	-	-	PUNCT
ajlm-1720	104	20	line	line	NOUN
ajlm-1720	104	21	testing	testing	NOUN
ajlm-1720	104	22	or	or	CCONJ
ajlm-1720	104	23	by	by	ADP
ajlm-1720	104	24	test	test	NOUN
ajlm-1720	104	25	method	method	NOUN
ajlm-1720	104	26	with	with	ADP
ajlm-1720	104	27	duraclone	duraclone	NOUN
ajlm-1720	104	28	panel	panel	NOUN
ajlm-1720	104	29	testing	testing	NOUN
ajlm-1720	104	30	.	.	PUNCT
ajlm-1720	105	1	false	false	ADJ
ajlm-1720	105	2	positives	positive	NOUN
ajlm-1720	105	3	were	be	AUX
ajlm-1720	105	4	defined	define	VERB
ajlm-1720	105	5	as	as	ADP
ajlm-1720	105	6	those	those	DET
ajlm-1720	105	7	cases	case	NOUN
ajlm-1720	105	8	where	where	SCONJ
ajlm-1720	105	9	there	there	PRON
ajlm-1720	105	10	was	be	VERB
ajlm-1720	105	11	no	no	DET
ajlm-1720	105	12	disease	disease	NOUN
ajlm-1720	105	13	noted	note	VERB
ajlm-1720	105	14	on	on	ADP
ajlm-1720	105	15	predicate	predicate	NOUN
ajlm-1720	105	16	clearllab	clearllab	NOUN
ajlm-1720	105	17	with	with	ADP
ajlm-1720	105	18	in	in	ADP
ajlm-1720	105	19	-	-	PUNCT
ajlm-1720	105	20	house	house	NOUN
ajlm-1720	105	21	second	second	ADJ
ajlm-1720	105	22	-	-	PUNCT
ajlm-1720	105	23	line	line	NOUN
ajlm-1720	105	24	testing	testing	NOUN
ajlm-1720	105	25	,	,	PUNCT
ajlm-1720	105	26	but	but	CCONJ
ajlm-1720	105	27	the	the	DET
ajlm-1720	105	28	disease	disease	NOUN
ajlm-1720	105	29	was	be	AUX
ajlm-1720	105	30	noted	note	VERB
ajlm-1720	105	31	by	by	ADP
ajlm-1720	105	32	respective	respective	ADJ
ajlm-1720	105	33	duraclone	duraclone	NOUN
ajlm-1720	105	34	analysis	analysis	NOUN
ajlm-1720	105	35	.	.	PUNCT
ajlm-1720	106	1	likewise	likewise	ADV
ajlm-1720	106	2	,	,	PUNCT
ajlm-1720	106	3	false	false	ADJ
ajlm-1720	106	4	negatives	negative	NOUN
ajlm-1720	106	5	were	be	AUX
ajlm-1720	106	6	defined	define	VERB
ajlm-1720	106	7	as	as	ADP
ajlm-1720	106	8	disease	disease	NOUN
ajlm-1720	106	9	on	on	ADP
ajlm-1720	106	10	predicate	predicate	NOUN
ajlm-1720	106	11	first	first	ADJ
ajlm-1720	106	12	-	-	PUNCT
ajlm-1720	106	13	line	line	NOUN
ajlm-1720	106	14	clearllab	clearllab	NOUN
ajlm-1720	106	15	and	and	CCONJ
ajlm-1720	106	16	second	second	ADJ
ajlm-1720	106	17	-	-	PUNCT
ajlm-1720	106	18	line	line	NOUN
ajlm-1720	106	19	testing	testing	NOUN
ajlm-1720	106	20	,	,	PUNCT
ajlm-1720	106	21	but	but	CCONJ
ajlm-1720	106	22	no	no	DET
ajlm-1720	106	23	disease	disease	NOUN
ajlm-1720	106	24	by	by	ADP
ajlm-1720	106	25	respective	respective	ADJ
ajlm-1720	106	26	duraclone	duraclone	NOUN
ajlm-1720	106	27	panel	panel	NOUN
ajlm-1720	106	28	testing	testing	NOUN
ajlm-1720	106	29	.	.	PUNCT
ajlm-1720	107	1	results	result	VERB
ajlm-1720	107	2	normal	normal	ADJ
ajlm-1720	107	3	and	and	CCONJ
ajlm-1720	107	4	abnormal	abnormal	ADJ
ajlm-1720	107	5	b	b	NOUN
ajlm-1720	107	6	progenitor	progenitor	NOUN
ajlm-1720	107	7	cells	cell	NOUN
ajlm-1720	107	8	panel	panel	NOUN
ajlm-1720	107	9	twenty	twenty	NUM
ajlm-1720	107	10	samples	sample	NOUN
ajlm-1720	107	11	were	be	AUX
ajlm-1720	107	12	tested	test	VERB
ajlm-1720	107	13	with	with	ADP
ajlm-1720	107	14	the	the	DET
ajlm-1720	107	15	duraclone	duraclone	NOUN
ajlm-1720	107	16	alb	alb	PROPN
ajlm-1720	107	17	panel	panel	NOUN
ajlm-1720	107	18	.	.	PUNCT
ajlm-1720	108	1	the	the	DET
ajlm-1720	108	2	duraclone	duraclone	NOUN
ajlm-1720	108	3	re	re	VERB
ajlm-1720	108	4	alb	alb	VERB
ajlm-1720	108	5	evaluation	evaluation	NOUN
ajlm-1720	108	6	on	on	ADP
ajlm-1720	108	7	both	both	CCONJ
ajlm-1720	108	8	routine	routine	ADJ
ajlm-1720	108	9	diagnostic	diagnostic	ADJ
ajlm-1720	108	10	precursor	precursor	NOUN
ajlm-1720	108	11	b	b	NOUN
ajlm-1720	108	12	-	-	PUNCT
ajlm-1720	108	13	all	all	DET
ajlm-1720	108	14	samples	sample	NOUN
ajlm-1720	108	15	,	,	PUNCT
ajlm-1720	108	16	and	and	CCONJ
ajlm-1720	108	17	patient	patient	ADJ
ajlm-1720	108	18	samples	sample	NOUN
ajlm-1720	108	19	who	who	PRON
ajlm-1720	108	20	were	be	AUX
ajlm-1720	108	21	being	be	AUX
ajlm-1720	108	22	followed	follow	VERB
ajlm-1720	108	23	up	up	ADP
ajlm-1720	108	24	after	after	ADP
ajlm-1720	108	25	therapy	therapy	NOUN
ajlm-1720	108	26	for	for	ADP
ajlm-1720	108	27	precursor	precursor	NOUN
ajlm-1720	108	28	b	b	NOUN
ajlm-1720	108	29	-	-	PUNCT
ajlm-1720	108	30	all	all	PRON
ajlm-1720	108	31	,	,	PUNCT
ajlm-1720	108	32	revealed	reveal	VERB
ajlm-1720	108	33	100	100	NUM
ajlm-1720	108	34	%	%	NOUN
ajlm-1720	108	35	positive	positive	ADJ
ajlm-1720	108	36	and	and	CCONJ
ajlm-1720	108	37	negative	negative	ADJ
ajlm-1720	108	38	agreement	agreement	NOUN
ajlm-1720	108	39	to	to	PART
ajlm-1720	108	40	clearllab	clearllab	PROPN
ajlm-1720	108	41	10c	10c	NOUN
ajlm-1720	108	42	reported	report	VERB
ajlm-1720	108	43	outcomes	outcome	NOUN
ajlm-1720	108	44	(	(	PUNCT
ajlm-1720	108	45	table	table	NOUN
ajlm-1720	108	46	3	3	NUM
ajlm-1720	108	47	)	)	PUNCT
ajlm-1720	108	48	.	.	PUNCT
ajlm-1720	109	1	the	the	DET
ajlm-1720	109	2	estimated	estimate	VERB
ajlm-1720	109	3	sensitivity	sensitivity	NOUN
ajlm-1720	109	4	and	and	CCONJ
ajlm-1720	109	5	specificity	specificity	NOUN
ajlm-1720	109	6	rates	rate	NOUN
ajlm-1720	109	7	were	be	AUX
ajlm-1720	109	8	both	both	PRON
ajlm-1720	109	9	100	100	NUM
ajlm-1720	109	10	%	%	NOUN
ajlm-1720	109	11	.	.	PUNCT
ajlm-1720	110	1	cd58	cd58	VERB
ajlm-1720	110	2	expression	expression	NOUN
ajlm-1720	110	3	(	(	PUNCT
ajlm-1720	110	4	an	an	DET
ajlm-1720	110	5	additional	additional	ADJ
ajlm-1720	110	6	marker	marker	NOUN
ajlm-1720	110	7	included	include	VERB
ajlm-1720	110	8	in	in	ADP
ajlm-1720	110	9	the	the	DET
ajlm-1720	110	10	duraclone	duraclone	NOUN
ajlm-1720	110	11	alb	alb	PROPN
ajlm-1720	110	12	tube	tube	NOUN
ajlm-1720	110	13	,	,	PUNCT
ajlm-1720	110	14	but	but	CCONJ
ajlm-1720	110	15	not	not	PART
ajlm-1720	110	16	clearllab	clearllab	NOUN
ajlm-1720	110	17	tubes	tube	NOUN
ajlm-1720	110	18	)	)	PUNCT
ajlm-1720	110	19	enabled	enable	VERB
ajlm-1720	110	20	further	further	ADJ
ajlm-1720	110	21	confirmation	confirmation	NOUN
ajlm-1720	110	22	of	of	ADP
ajlm-1720	110	23	the	the	DET
ajlm-1720	110	24	diagnostic	diagnostic	ADJ
ajlm-1720	110	25	outcome	outcome	NOUN
ajlm-1720	110	26	reported	report	VERB
ajlm-1720	110	27	;	;	PUNCT
ajlm-1720	110	28	here	here	ADV
ajlm-1720	110	29	,	,	PUNCT
ajlm-1720	110	30	there	there	PRON
ajlm-1720	110	31	was	be	VERB
ajlm-1720	110	32	consistent	consistent	ADJ
ajlm-1720	110	33	under	under	ADP
ajlm-1720	110	34	-	-	PUNCT
ajlm-1720	110	35	expression	expression	NOUN
ajlm-1720	110	36	of	of	ADP
ajlm-1720	110	37	cd58	cd58	PROPN
ajlm-1720	110	38	noted	note	VERB
ajlm-1720	110	39	on	on	ADP
ajlm-1720	110	40	haematogones	haematogone	NOUN
ajlm-1720	110	41	and	and	CCONJ
ajlm-1720	110	42	consistent	consistent	ADJ
ajlm-1720	110	43	over	over	ADP
ajlm-1720	110	44	-	-	PUNCT
ajlm-1720	110	45	expression	expression	NOUN
ajlm-1720	110	46	seen	see	VERB
ajlm-1720	110	47	on	on	ADP
ajlm-1720	110	48	abnormal	abnormal	ADJ
ajlm-1720	110	49	precursor	precursor	NOUN
ajlm-1720	110	50	b	b	NOUN
ajlm-1720	110	51	-	-	PUNCT
ajlm-1720	110	52	cells	cell	NOUN
ajlm-1720	110	53	(	(	PUNCT
ajlm-1720	110	54	blasts	blast	NOUN
ajlm-1720	110	55	)	)	PUNCT
ajlm-1720	110	56	,	,	PUNCT
ajlm-1720	110	57	verifying	verify	VERB
ajlm-1720	110	58	manufacturer	manufacturer	NOUN
ajlm-1720	110	59	-	-	PUNCT
ajlm-1720	110	60	described	describe	VERB
ajlm-1720	110	61	cd58	cd58	PROPN
ajlm-1720	110	62	expression	expression	NOUN
ajlm-1720	110	63	.	.	PUNCT
ajlm-1720	111	1	cd22	cd22	PROPN
ajlm-1720	111	2	apc	apc	PROPN
ajlm-1720	111	3	expression	expression	NOUN
ajlm-1720	111	4	(	(	PUNCT
ajlm-1720	111	5	that	that	PRON
ajlm-1720	111	6	was	be	AUX
ajlm-1720	111	7	added	add	VERB
ajlm-1720	111	8	as	as	ADP
ajlm-1720	111	9	an	an	DET
ajlm-1720	111	10	additional	additional	ADJ
ajlm-1720	111	11	marker	marker	NOUN
ajlm-1720	111	12	panel	panel	NOUN
ajlm-1720	111	13	in	in	ADP
ajlm-1720	111	14	two	two	NUM
ajlm-1720	111	15	precursor	precursor	NOUN
ajlm-1720	111	16	b	b	NOUN
ajlm-1720	111	17	-	-	PUNCT
ajlm-1720	111	18	all	all	DET
ajlm-1720	111	19	cases	case	NOUN
ajlm-1720	111	20	to	to	PART
ajlm-1720	111	21	demonstrate	demonstrate	VERB
ajlm-1720	111	22	that	that	SCONJ
ajlm-1720	111	23	the	the	DET
ajlm-1720	111	24	addition	addition	NOUN
ajlm-1720	111	25	was	be	AUX
ajlm-1720	111	26	possible	possible	ADJ
ajlm-1720	111	27	)	)	PUNCT
ajlm-1720	111	28	was	be	AUX
ajlm-1720	111	29	verified	verify	VERB
ajlm-1720	111	30	against	against	ADP
ajlm-1720	111	31	the	the	DET
ajlm-1720	111	32	expected	expect	VERB
ajlm-1720	111	33	disease	disease	NOUN
ajlm-1720	111	34	outcome	outcome	NOUN
ajlm-1720	111	35	(	(	PUNCT
ajlm-1720	111	36	positive	positive	ADJ
ajlm-1720	111	37	in	in	ADP
ajlm-1720	111	38	two	two	NUM
ajlm-1720	111	39	cases	case	NOUN
ajlm-1720	111	40	of	of	ADP
ajlm-1720	111	41	b	b	NOUN
ajlm-1720	111	42	-	-	PUNCT
ajlm-1720	111	43	all	all	PRON
ajlm-1720	111	44	)	)	PUNCT
ajlm-1720	111	45	and	and	CCONJ
ajlm-1720	111	46	met	meet	VERB
ajlm-1720	111	47	the	the	DET
ajlm-1720	111	48	manufacturer	manufacturer	NOUN
ajlm-1720	111	49	’s	’s	PART
ajlm-1720	111	50	specifications	specification	NOUN
ajlm-1720	111	51	in	in	ADP
ajlm-1720	111	52	the	the	DET
ajlm-1720	111	53	duraclone	duraclone	NOUN
ajlm-1720	111	54	re	re	ADP
ajlm-1720	111	55	alb	alb	PROPN
ajlm-1720	111	56	(	(	PUNCT
ajlm-1720	111	57	table	table	NOUN
ajlm-1720	111	58	3	3	NUM
ajlm-1720	111	59	)	)	PUNCT
ajlm-1720	111	60	.	.	PUNCT
ajlm-1720	112	1	table	table	NOUN
ajlm-1720	112	2	3	3	NUM
ajlm-1720	112	3	:	:	PUNCT
ajlm-1720	112	4	 	 	SPACE
ajlm-1720	112	5	comparison	comparison	NOUN
ajlm-1720	112	6	of	of	ADP
ajlm-1720	112	7	predicate	predicate	NOUN
ajlm-1720	112	8	reagents	reagent	NOUN
ajlm-1720	112	9	and	and	CCONJ
ajlm-1720	112	10	duraclone	duraclone	NOUN
ajlm-1720	112	11	re	re	PART
ajlm-1720	112	12	alb	alb	VERB
ajlm-1720	112	13	reagent	reagent	NOUN
ajlm-1720	112	14	during	during	ADP
ajlm-1720	112	15	the	the	DET
ajlm-1720	112	16	assessment	assessment	NOUN
ajlm-1720	112	17	of	of	ADP
ajlm-1720	112	18	normal	normal	ADJ
ajlm-1720	112	19	and	and	CCONJ
ajlm-1720	112	20	abnormal	abnormal	ADJ
ajlm-1720	112	21	precursor	precursor	NOUN
ajlm-1720	112	22	b	b	NOUN
ajlm-1720	112	23	-	-	PUNCT
ajlm-1720	112	24	cells	cell	NOUN
ajlm-1720	112	25	undertaken	undertake	VERB
ajlm-1720	112	26	at	at	ADP
ajlm-1720	112	27	the	the	DET
ajlm-1720	112	28	charlotte	charlotte	PROPN
ajlm-1720	112	29	maxeke	maxeke	PROPN
ajlm-1720	112	30	johannesburg	johannesburg	PROPN
ajlm-1720	112	31	academic	academic	PROPN
ajlm-1720	112	32	hospital	hospital	PROPN
ajlm-1720	112	33	flow	flow	NOUN
ajlm-1720	112	34	cytometry	cytometry	PROPN
ajlm-1720	112	35	laboratory	laboratory	NOUN
ajlm-1720	112	36	in	in	ADP
ajlm-1720	112	37	johannesburg	johannesburg	PROPN
ajlm-1720	112	38	,	,	PUNCT
ajlm-1720	112	39	south	south	PROPN
ajlm-1720	112	40	africa	africa	PROPN
ajlm-1720	112	41	,	,	PUNCT
ajlm-1720	112	42	april	april	PROPN
ajlm-1720	112	43	2020	2020	NUM
ajlm-1720	112	44	to	to	ADP
ajlm-1720	112	45	august	august	PROPN
ajlm-1720	112	46	2020	2020	NUM
ajlm-1720	112	47	.	.	PUNCT
ajlm-1720	113	1	chronic	chronic	ADJ
ajlm-1720	113	2	b	b	X
ajlm-1720	113	3	-	-	PUNCT
ajlm-1720	113	4	cell	cell	NOUN
ajlm-1720	113	5	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	113	6	disorder	disorder	NOUN
ajlm-1720	113	7	panel	panel	NOUN
ajlm-1720	113	8	the	the	DET
ajlm-1720	113	9	duraclone	duraclone	NOUN
ajlm-1720	113	10	re	re	PART
ajlm-1720	113	11	clb	clb	NOUN
ajlm-1720	113	12	panel	panel	NOUN
ajlm-1720	113	13	identified	identify	VERB
ajlm-1720	113	14	the	the	DET
ajlm-1720	113	15	b	b	NOUN
ajlm-1720	113	16	-	-	PUNCT
ajlm-1720	113	17	cell	cell	NOUN
ajlm-1720	113	18	target	target	NOUN
ajlm-1720	113	19	population	population	NOUN
ajlm-1720	113	20	using	use	VERB
ajlm-1720	113	21	a	a	DET
ajlm-1720	113	22	combination	combination	NOUN
ajlm-1720	113	23	of	of	ADP
ajlm-1720	113	24	cd19	cd19	PROPN
ajlm-1720	113	25	and	and	CCONJ
ajlm-1720	113	26	cd5	cd5	PROPN
ajlm-1720	113	27	or	or	CCONJ
ajlm-1720	113	28	cd20	cd20	PROPN
ajlm-1720	113	29	,	,	PUNCT
ajlm-1720	113	30	as	as	ADV
ajlm-1720	113	31	well	well	ADV
ajlm-1720	113	32	as	as	ADP
ajlm-1720	113	33	surface	surface	NOUN
ajlm-1720	113	34	cd81	cd81	PROPN
ajlm-1720	113	35	,	,	PUNCT
ajlm-1720	113	36	ror1	ror1	NOUN
ajlm-1720	113	37	,	,	PUNCT
ajlm-1720	113	38	cd79b	cd79b	ADJ
ajlm-1720	113	39	,	,	PUNCT
ajlm-1720	113	40	and	and	CCONJ
ajlm-1720	113	41	cd43	cd43	PROPN
ajlm-1720	113	42	expression	expression	NOUN
ajlm-1720	113	43	.	.	PUNCT
ajlm-1720	114	1	twenty	twenty	NUM
ajlm-1720	114	2	samples	sample	NOUN
ajlm-1720	114	3	were	be	AUX
ajlm-1720	114	4	tested	test	VERB
ajlm-1720	114	5	with	with	ADP
ajlm-1720	114	6	the	the	DET
ajlm-1720	114	7	duraclone	duraclone	NOUN
ajlm-1720	114	8	clb	clb	NOUN
ajlm-1720	114	9	panel	panel	NOUN
ajlm-1720	114	10	.	.	PUNCT
ajlm-1720	115	1	the	the	DET
ajlm-1720	115	2	calculated	calculate	VERB
ajlm-1720	115	3	sensitivity	sensitivity	NOUN
ajlm-1720	115	4	and	and	CCONJ
ajlm-1720	115	5	specificity	specificity	NOUN
ajlm-1720	115	6	were	be	AUX
ajlm-1720	115	7	100	100	NUM
ajlm-1720	115	8	%	%	NOUN
ajlm-1720	115	9	,	,	PUNCT
ajlm-1720	115	10	with	with	ADP
ajlm-1720	115	11	full	full	ADJ
ajlm-1720	115	12	diagnostic	diagnostic	ADJ
ajlm-1720	115	13	concordance	concordance	NOUN
ajlm-1720	115	14	noted	note	VERB
ajlm-1720	115	15	across	across	ADP
ajlm-1720	115	16	all	all	DET
ajlm-1720	115	17	cases	case	NOUN
ajlm-1720	115	18	evaluated	evaluate	VERB
ajlm-1720	115	19	(	(	PUNCT
ajlm-1720	115	20	n	n	NOUN
ajlm-1720	115	21	=	=	NUM
ajlm-1720	115	22	20	20	NUM
ajlm-1720	115	23	)	)	PUNCT
ajlm-1720	115	24	.	.	PUNCT
ajlm-1720	116	1	all	all	DET
ajlm-1720	116	2	cll	cll	PROPN
ajlm-1720	116	3	cases	case	NOUN
ajlm-1720	116	4	(	(	PUNCT
ajlm-1720	116	5	n	n	NOUN
ajlm-1720	116	6	=	=	SYM
ajlm-1720	116	7	16/20	16/20	NUM
ajlm-1720	116	8	)	)	PUNCT
ajlm-1720	116	9	showed	show	VERB
ajlm-1720	116	10	under	under	ADP
ajlm-1720	116	11	-	-	PUNCT
ajlm-1720	116	12	expression	expression	NOUN
ajlm-1720	116	13	(	(	PUNCT
ajlm-1720	116	14	weak	weak	ADJ
ajlm-1720	116	15	)	)	PUNCT
ajlm-1720	116	16	of	of	ADP
ajlm-1720	116	17	cd81	cd81	PROPN
ajlm-1720	116	18	,	,	PUNCT
ajlm-1720	116	19	cd79b	cd79b	NOUN
ajlm-1720	116	20	and	and	CCONJ
ajlm-1720	116	21	cd20	cd20	PROPN
ajlm-1720	116	22	(	(	PUNCT
ajlm-1720	116	23	table	table	NOUN
ajlm-1720	116	24	4	4	NUM
ajlm-1720	116	25	)	)	PUNCT
ajlm-1720	116	26	.	.	PUNCT
ajlm-1720	117	1	further	far	ADV
ajlm-1720	117	2	,	,	PUNCT
ajlm-1720	117	3	surface	surface	ADJ
ajlm-1720	117	4	ror1	ror1	NOUN
ajlm-1720	117	5	expression	expression	NOUN
ajlm-1720	117	6	was	be	AUX
ajlm-1720	117	7	detected	detect	VERB
ajlm-1720	117	8	in	in	ADP
ajlm-1720	117	9	15	15	NUM
ajlm-1720	117	10	of	of	ADP
ajlm-1720	117	11	the	the	DET
ajlm-1720	117	12	16	16	NUM
ajlm-1720	117	13	(	(	PUNCT
ajlm-1720	117	14	93.75	93.75	NUM
ajlm-1720	117	15	%	%	NOUN
ajlm-1720	117	16	)	)	PUNCT
ajlm-1720	118	1	cd5	cd5	NOUN
ajlm-1720	118	2	-	-	PUNCT
ajlm-1720	118	3	expressing	express	VERB
ajlm-1720	118	4	cll	cll	PROPN
ajlm-1720	118	5	cases	case	NOUN
ajlm-1720	118	6	;	;	PUNCT
ajlm-1720	118	7	all	all	DET
ajlm-1720	118	8	cll	cll	PROPN
ajlm-1720	118	9	showed	show	VERB
ajlm-1720	118	10	expression	expression	NOUN
ajlm-1720	118	11	of	of	ADP
ajlm-1720	118	12	cd43	cd43	PROPN
ajlm-1720	118	13	.	.	PUNCT
ajlm-1720	119	1	a	a	DET
ajlm-1720	119	2	single	single	ADJ
ajlm-1720	119	3	case	case	NOUN
ajlm-1720	119	4	of	of	ADP
ajlm-1720	119	5	follicular	follicular	ADJ
ajlm-1720	119	6	lymphoma	lymphoma	NOUN
ajlm-1720	119	7	(	(	PUNCT
ajlm-1720	119	8	n	n	NOUN
ajlm-1720	119	9	=	=	SYM
ajlm-1720	119	10	1	1	X
ajlm-1720	119	11	)	)	PUNCT
ajlm-1720	119	12	showed	show	VERB
ajlm-1720	119	13	a	a	DET
ajlm-1720	119	14	bright	bright	ADJ
ajlm-1720	119	15	expression	expression	NOUN
ajlm-1720	119	16	of	of	ADP
ajlm-1720	119	17	cd79b	cd79b	ADJ
ajlm-1720	119	18	.	.	PUNCT
ajlm-1720	120	1	three	three	NUM
ajlm-1720	120	2	cases	case	NOUN
ajlm-1720	120	3	(	(	PUNCT
ajlm-1720	120	4	15	15	NUM
ajlm-1720	120	5	%	%	NOUN
ajlm-1720	120	6	)	)	PUNCT
ajlm-1720	120	7	evaluated	evaluate	VERB
ajlm-1720	120	8	could	could	AUX
ajlm-1720	120	9	not	not	PART
ajlm-1720	120	10	be	be	AUX
ajlm-1720	120	11	definitively	definitively	ADV
ajlm-1720	120	12	sub	sub	ADJ
ajlm-1720	120	13	-	-	ADJ
ajlm-1720	120	14	classified	classified	ADJ
ajlm-1720	120	15	with	with	ADP
ajlm-1720	120	16	the	the	DET
ajlm-1720	120	17	in	in	ADP
ajlm-1720	120	18	-	-	PUNCT
ajlm-1720	120	19	house	house	NOUN
ajlm-1720	120	20	second	second	ADJ
ajlm-1720	120	21	-	-	PUNCT
ajlm-1720	120	22	line	line	NOUN
ajlm-1720	120	23	panel	panel	NOUN
ajlm-1720	120	24	analysis	analysis	NOUN
ajlm-1720	120	25	or	or	CCONJ
ajlm-1720	120	26	the	the	DET
ajlm-1720	120	27	duraclone	duraclone	NOUN
ajlm-1720	120	28	re	re	NOUN
ajlm-1720	120	29	clb	clb	NOUN
ajlm-1720	120	30	reagents	reagent	NOUN
ajlm-1720	120	31	.	.	PUNCT
ajlm-1720	121	1	an	an	DET
ajlm-1720	121	2	additional	additional	ADJ
ajlm-1720	121	3	control	control	NOUN
ajlm-1720	121	4	sample	sample	NOUN
ajlm-1720	121	5	(	(	PUNCT
ajlm-1720	121	6	not	not	PART
ajlm-1720	121	7	included	include	VERB
ajlm-1720	121	8	in	in	ADP
ajlm-1720	121	9	table	table	NOUN
ajlm-1720	121	10	2	2	NUM
ajlm-1720	121	11	)	)	PUNCT
ajlm-1720	121	12	,	,	PUNCT
ajlm-1720	121	13	with	with	ADP
ajlm-1720	121	14	confirmed	confirm	VERB
ajlm-1720	121	15	20	20	NUM
ajlm-1720	121	16	%	%	NOUN
ajlm-1720	121	17	of	of	ADP
ajlm-1720	121	18	b	b	NOUN
ajlm-1720	121	19	-	-	PUNCT
ajlm-1720	121	20	cell	cell	NOUN
ajlm-1720	121	21	precursors	precursor	NOUN
ajlm-1720	121	22	,	,	PUNCT
ajlm-1720	121	23	revealed	reveal	VERB
ajlm-1720	121	24	and	and	CCONJ
ajlm-1720	121	25	confirmed	confirm	VERB
ajlm-1720	121	26	bright	bright	ADJ
ajlm-1720	121	27	cd81	cd81	PROPN
ajlm-1720	121	28	on	on	ADP
ajlm-1720	121	29	the	the	DET
ajlm-1720	121	30	normal	normal	ADJ
ajlm-1720	121	31	precursor	precursor	NOUN
ajlm-1720	121	32	b	b	NOUN
ajlm-1720	121	33	-	-	PUNCT
ajlm-1720	121	34	cells	cell	NOUN
ajlm-1720	121	35	(	(	PUNCT
ajlm-1720	121	36	figure	figure	NOUN
ajlm-1720	121	37	1	1	NUM
ajlm-1720	121	38	)	)	PUNCT
ajlm-1720	121	39	.	.	PUNCT
ajlm-1720	122	1	table	table	NOUN
ajlm-1720	122	2	4	4	NUM
ajlm-1720	122	3	:	:	PUNCT
ajlm-1720	122	4	 	 	SPACE
ajlm-1720	122	5	comparison	comparison	NOUN
ajlm-1720	122	6	of	of	ADP
ajlm-1720	122	7	predicate	predicate	NOUN
ajlm-1720	122	8	reagents	reagent	NOUN
ajlm-1720	122	9	and	and	CCONJ
ajlm-1720	122	10	duraclone	duraclone	NOUN
ajlm-1720	122	11	re	re	PART
ajlm-1720	122	12	clb	clb	VERB
ajlm-1720	122	13	reagent	reagent	NOUN
ajlm-1720	122	14	during	during	ADP
ajlm-1720	122	15	the	the	DET
ajlm-1720	122	16	assessment	assessment	NOUN
ajlm-1720	122	17	of	of	ADP
ajlm-1720	122	18	mature	mature	ADJ
ajlm-1720	122	19	b	b	NOUN
ajlm-1720	122	20	-	-	PUNCT
ajlm-1720	122	21	cell	cell	NOUN
ajlm-1720	122	22	lymphoid	lymphoid	NOUN
ajlm-1720	122	23	proliferations	proliferation	NOUN
ajlm-1720	122	24	undertaken	undertake	VERB
ajlm-1720	122	25	at	at	ADP
ajlm-1720	122	26	the	the	DET
ajlm-1720	122	27	charlotte	charlotte	PROPN
ajlm-1720	122	28	maxeke	maxeke	PROPN
ajlm-1720	122	29	johannesburg	johannesburg	PROPN
ajlm-1720	122	30	academic	academic	PROPN
ajlm-1720	122	31	hospital	hospital	PROPN
ajlm-1720	122	32	flow	flow	NOUN
ajlm-1720	122	33	cytometry	cytometry	PROPN
ajlm-1720	122	34	laboratory	laboratory	NOUN
ajlm-1720	122	35	in	in	ADP
ajlm-1720	122	36	johannesburg	johannesburg	PROPN
ajlm-1720	122	37	,	,	PUNCT
ajlm-1720	122	38	south	south	PROPN
ajlm-1720	122	39	africa	africa	PROPN
ajlm-1720	122	40	,	,	PUNCT
ajlm-1720	122	41	april	april	PROPN
ajlm-1720	122	42	2020	2020	NUM
ajlm-1720	122	43	to	to	ADP
ajlm-1720	122	44	august	august	PROPN
ajlm-1720	122	45	2020	2020	NUM
ajlm-1720	122	46	.	.	PUNCT
ajlm-1720	123	1	normal	normal	ADJ
ajlm-1720	123	2	and	and	CCONJ
ajlm-1720	123	3	abnormal	abnormal	ADJ
ajlm-1720	123	4	plasma	plasma	NOUN
ajlm-1720	123	5	cells	cell	NOUN
ajlm-1720	123	6	panel	panel	NOUN
ajlm-1720	123	7	seventeen	seventeen	NUM
ajlm-1720	123	8	samples	sample	NOUN
ajlm-1720	123	9	were	be	AUX
ajlm-1720	123	10	tested	test	VERB
ajlm-1720	123	11	with	with	ADP
ajlm-1720	123	12	the	the	DET
ajlm-1720	123	13	duraclone	duraclone	NOUN
ajlm-1720	123	14	pc	pc	NOUN
ajlm-1720	123	15	panel	panel	NOUN
ajlm-1720	123	16	.	.	PUNCT
ajlm-1720	124	1	a	a	DET
ajlm-1720	124	2	plasma	plasma	NOUN
ajlm-1720	124	3	cell	cell	NOUN
ajlm-1720	124	4	population	population	NOUN
ajlm-1720	124	5	was	be	AUX
ajlm-1720	124	6	identified	identify	VERB
ajlm-1720	124	7	by	by	ADP
ajlm-1720	124	8	backbone	backbone	NOUN
ajlm-1720	124	9	markers	marker	NOUN
ajlm-1720	124	10	cd138	cd138	PROPN
ajlm-1720	124	11	and	and	CCONJ
ajlm-1720	124	12	cd38	cd38	PROPN
ajlm-1720	124	13	in	in	ADP
ajlm-1720	124	14	the	the	DET
ajlm-1720	124	15	duraclone	duraclone	NOUN
ajlm-1720	124	16	re	re	NOUN
ajlm-1720	124	17	pc	pc	NOUN
ajlm-1720	124	18	panel	panel	NOUN
ajlm-1720	124	19	,	,	PUNCT
ajlm-1720	124	20	with	with	ADP
ajlm-1720	124	21	subsequent	subsequent	ADJ
ajlm-1720	124	22	determination	determination	NOUN
ajlm-1720	124	23	of	of	ADP
ajlm-1720	124	24	expression	expression	NOUN
ajlm-1720	124	25	of	of	ADP
ajlm-1720	124	26	cd19	cd19	PROPN
ajlm-1720	124	27	,	,	PUNCT
ajlm-1720	124	28	cd27	cd27	PROPN
ajlm-1720	124	29	,	,	PUNCT
ajlm-1720	124	30	cd45	cd45	PROPN
ajlm-1720	124	31	,	,	PUNCT
ajlm-1720	124	32	cd56	cd56	PROPN
ajlm-1720	124	33	and	and	CCONJ
ajlm-1720	124	34	cd200	cd200	PROPN
ajlm-1720	124	35	.	.	PUNCT
ajlm-1720	125	1	there	there	PRON
ajlm-1720	125	2	was	be	VERB
ajlm-1720	125	3	cross	cross	ADJ
ajlm-1720	125	4	-	-	ADJ
ajlm-1720	125	5	panel	panel	NOUN
ajlm-1720	125	6	marker	marker	NOUN
ajlm-1720	125	7	equivalency	equivalency	NOUN
ajlm-1720	125	8	to	to	ADP
ajlm-1720	125	9	the	the	DET
ajlm-1720	125	10	existing	exist	VERB
ajlm-1720	125	11	in	in	ADP
ajlm-1720	125	12	-	-	PUNCT
ajlm-1720	125	13	house	house	NOUN
ajlm-1720	125	14	panels	panel	NOUN
ajlm-1720	125	15	(	(	PUNCT
ajlm-1720	125	16	table	table	NOUN
ajlm-1720	125	17	5	5	NUM
ajlm-1720	125	18	)	)	PUNCT
ajlm-1720	125	19	and	and	CCONJ
ajlm-1720	125	20	clinical	clinical	ADJ
ajlm-1720	125	21	outcomes	outcome	NOUN
ajlm-1720	125	22	,	,	PUNCT
ajlm-1720	125	23	with	with	ADP
ajlm-1720	125	24	100	100	NUM
ajlm-1720	125	25	%	%	NOUN
ajlm-1720	125	26	agreement	agreement	NOUN
ajlm-1720	125	27	achieved	achieve	VERB
ajlm-1720	125	28	,	,	PUNCT
ajlm-1720	125	29	and	and	CCONJ
ajlm-1720	125	30	estimated	estimate	VERB
ajlm-1720	125	31	sensitivity	sensitivity	NOUN
ajlm-1720	125	32	and	and	CCONJ
ajlm-1720	125	33	specificity	specificity	NOUN
ajlm-1720	125	34	rates	rate	NOUN
ajlm-1720	125	35	of	of	ADP
ajlm-1720	125	36	100	100	NUM
ajlm-1720	125	37	%	%	NOUN
ajlm-1720	125	38	.	.	PUNCT
ajlm-1720	126	1	in	in	ADP
ajlm-1720	126	2	addition	addition	NOUN
ajlm-1720	126	3	,	,	PUNCT
ajlm-1720	126	4	the	the	DET
ajlm-1720	126	5	assessment	assessment	NOUN
ajlm-1720	126	6	of	of	ADP
ajlm-1720	126	7	cd27	cd27	PROPN
ajlm-1720	126	8	and	and	CCONJ
ajlm-1720	126	9	cd81	cd81	PROPN
ajlm-1720	126	10	on	on	ADP
ajlm-1720	126	11	target	target	NOUN
ajlm-1720	126	12	plasma	plasma	NOUN
ajlm-1720	126	13	cells	cell	NOUN
ajlm-1720	126	14	revealed	reveal	VERB
ajlm-1720	126	15	consistent	consistent	ADJ
ajlm-1720	126	16	under	under	ADP
ajlm-1720	126	17	-	-	PUNCT
ajlm-1720	126	18	expression	expression	NOUN
ajlm-1720	126	19	of	of	ADP
ajlm-1720	126	20	cd81	cd81	PROPN
ajlm-1720	126	21	or	or	CCONJ
ajlm-1720	126	22	cd27	cd27	PROPN
ajlm-1720	126	23	(	(	PUNCT
ajlm-1720	126	24	n	n	NOUN
ajlm-1720	126	25	=	=	SYM
ajlm-1720	126	26	14/14	14/14	NUM
ajlm-1720	126	27	)	)	PUNCT
ajlm-1720	126	28	(	(	PUNCT
ajlm-1720	126	29	figure	figure	NOUN
ajlm-1720	126	30	2	2	NUM
ajlm-1720	126	31	)	)	PUNCT
ajlm-1720	126	32	.	.	PUNCT
ajlm-1720	127	1	a	a	DET
ajlm-1720	127	2	single	single	ADJ
ajlm-1720	127	3	(	(	PUNCT
ajlm-1720	127	4	n	n	NOUN
ajlm-1720	127	5	=	=	SYM
ajlm-1720	127	6	1	1	X
ajlm-1720	127	7	)	)	PUNCT
ajlm-1720	127	8	pcd	pcd	NOUN
ajlm-1720	127	9	had	have	VERB
ajlm-1720	127	10	positive	positive	ADJ
ajlm-1720	127	11	surface	surface	NOUN
ajlm-1720	127	12	cd117	cd117	PROPN
ajlm-1720	127	13	expression	expression	NOUN
ajlm-1720	127	14	(	(	PUNCT
ajlm-1720	127	15	figure	figure	NOUN
ajlm-1720	127	16	2	2	NUM
ajlm-1720	127	17	)	)	PUNCT
ajlm-1720	127	18	on	on	ADP
ajlm-1720	127	19	the	the	DET
ajlm-1720	127	20	aberrant	aberrant	NOUN
ajlm-1720	127	21	identified	identify	VERB
ajlm-1720	127	22	plasma	plasma	NOUN
ajlm-1720	127	23	cell	cell	NOUN
ajlm-1720	127	24	population	population	NOUN
ajlm-1720	127	25	,	,	PUNCT
ajlm-1720	127	26	in	in	ADP
ajlm-1720	127	27	agreement	agreement	NOUN
ajlm-1720	127	28	with	with	ADP
ajlm-1720	127	29	cd117	cd117	PROPN
ajlm-1720	127	30	expression	expression	NOUN
ajlm-1720	127	31	noted	note	VERB
ajlm-1720	127	32	in	in	ADP
ajlm-1720	127	33	the	the	DET
ajlm-1720	127	34	matching	matching	ADJ
ajlm-1720	127	35	clearllab	clearllab	NOUN
ajlm-1720	127	36	10c	10c	NUM
ajlm-1720	128	1	m2	m2	PROPN
ajlm-1720	128	2	analysis	analysis	NOUN
ajlm-1720	128	3	.	.	PUNCT
ajlm-1720	129	1	table	table	NOUN
ajlm-1720	129	2	5	5	NUM
ajlm-1720	129	3	:	:	PUNCT
ajlm-1720	129	4	 	 	SPACE
ajlm-1720	129	5	comparison	comparison	NOUN
ajlm-1720	129	6	of	of	ADP
ajlm-1720	129	7	predicate	predicate	NOUN
ajlm-1720	129	8	reagents	reagent	NOUN
ajlm-1720	129	9	and	and	CCONJ
ajlm-1720	129	10	duraclone	duraclone	NOUN
ajlm-1720	129	11	re	re	AUX
ajlm-1720	129	12	pc	pc	VERB
ajlm-1720	129	13	reagent	reagent	NOUN
ajlm-1720	129	14	during	during	ADP
ajlm-1720	129	15	assessment	assessment	NOUN
ajlm-1720	129	16	of	of	ADP
ajlm-1720	129	17	normal	normal	ADJ
ajlm-1720	129	18	and	and	CCONJ
ajlm-1720	129	19	abnormal	abnormal	ADJ
ajlm-1720	129	20	plasma	plasma	NOUN
ajlm-1720	129	21	cell	cell	NOUN
ajlm-1720	129	22	populations	population	NOUN
ajlm-1720	129	23	undertaken	undertake	VERB
ajlm-1720	129	24	at	at	ADP
ajlm-1720	129	25	the	the	DET
ajlm-1720	129	26	charlotte	charlotte	PROPN
ajlm-1720	129	27	maxeke	maxeke	PROPN
ajlm-1720	129	28	johannesburg	johannesburg	PROPN
ajlm-1720	129	29	academic	academic	PROPN
ajlm-1720	129	30	hospital	hospital	PROPN
ajlm-1720	129	31	flow	flow	NOUN
ajlm-1720	129	32	cytometry	cytometry	PROPN
ajlm-1720	129	33	laboratory	laboratory	NOUN
ajlm-1720	129	34	in	in	ADP
ajlm-1720	129	35	johannesburg	johannesburg	PROPN
ajlm-1720	129	36	,	,	PUNCT
ajlm-1720	129	37	south	south	PROPN
ajlm-1720	129	38	africa	africa	PROPN
ajlm-1720	129	39	,	,	PUNCT
ajlm-1720	129	40	april	april	PROPN
ajlm-1720	129	41	2020	2020	NUM
ajlm-1720	129	42	to	to	ADP
ajlm-1720	129	43	august	august	PROPN
ajlm-1720	129	44	2020	2020	NUM
ajlm-1720	129	45	.	.	PUNCT
ajlm-1720	130	1	discussion	discussion	NOUN
ajlm-1720	130	2	the	the	DET
ajlm-1720	130	3	recently	recently	ADV
ajlm-1720	130	4	evaluated,9,16	evaluated,9,16	PROPN
ajlm-1720	130	5	fixed	fix	VERB
ajlm-1720	130	6	-	-	PUNCT
ajlm-1720	130	7	tube	tube	NOUN
ajlm-1720	130	8	,	,	PUNCT
ajlm-1720	130	9	standardised	standardise	VERB
ajlm-1720	130	10	,	,	PUNCT
ajlm-1720	130	11	pre	pre	ADJ
ajlm-1720	130	12	-	-	ADJ
ajlm-1720	130	13	titrated	titrated	ADJ
ajlm-1720	130	14	reagent	reagent	ADJ
ajlm-1720	130	15	system	system	NOUN
ajlm-1720	130	16	,	,	PUNCT
ajlm-1720	130	17	clearllab	clearllab	NOUN
ajlm-1720	130	18	10c	10c	NOUN
ajlm-1720	130	19	(	(	PUNCT
ajlm-1720	130	20	including	include	VERB
ajlm-1720	130	21	the	the	DET
ajlm-1720	130	22	b	b	NOUN
ajlm-1720	130	23	-	-	PUNCT
ajlm-1720	130	24	cell	cell	NOUN
ajlm-1720	130	25	,	,	PUNCT
ajlm-1720	130	26	t	t	NOUN
ajlm-1720	130	27	-	-	PUNCT
ajlm-1720	130	28	cell	cell	NOUN
ajlm-1720	130	29	and	and	CCONJ
ajlm-1720	130	30	m1	m1	PROPN
ajlm-1720	130	31	and	and	CCONJ
ajlm-1720	130	32	m2	m2	PROPN
ajlm-1720	130	33	tubes	tube	NOUN
ajlm-1720	130	34	)	)	PUNCT
ajlm-1720	130	35	,	,	PUNCT
ajlm-1720	130	36	and	and	CCONJ
ajlm-1720	130	37	clearllab	clearllab	PROPN
ajlm-1720	130	38	ls11	ls11	PROPN
ajlm-1720	130	39	were	be	AUX
ajlm-1720	130	40	recently	recently	ADV
ajlm-1720	130	41	implemented	implement	VERB
ajlm-1720	130	42	to	to	PART
ajlm-1720	130	43	replace	replace	VERB
ajlm-1720	130	44	our	our	PRON
ajlm-1720	130	45	outdated	outdated	ADJ
ajlm-1720	130	46	facscalibur	facscalibur	NOUN
ajlm-1720	130	47	/	/	SYM
ajlm-1720	130	48	paint	paint	NOUN
ajlm-1720	130	49	-	-	PUNCT
ajlm-1720	130	50	a	a	DET
ajlm-1720	130	51	-	-	PUNCT
ajlm-1720	130	52	gate	gate	NOUN
ajlm-1720	130	53	method	method	NOUN
ajlm-1720	130	54	for	for	ADP
ajlm-1720	130	55	routine	routine	ADJ
ajlm-1720	130	56	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	130	57	investigation	investigation	NOUN
ajlm-1720	130	58	of	of	ADP
ajlm-1720	130	59	haematological	haematological	ADJ
ajlm-1720	130	60	neoplasms	neoplasm	NOUN
ajlm-1720	130	61	at	at	ADP
ajlm-1720	130	62	our	our	PRON
ajlm-1720	130	63	laboratory	laboratory	NOUN
ajlm-1720	130	64	.	.	PUNCT
ajlm-1720	131	1	this	this	DET
ajlm-1720	131	2	new	new	ADJ
ajlm-1720	131	3	system	system	NOUN
ajlm-1720	131	4	provides	provide	VERB
ajlm-1720	131	5	flow	flow	NOUN
ajlm-1720	131	6	cytometric	cytometric	ADJ
ajlm-1720	131	7	workup	workup	NOUN
ajlm-1720	131	8	for	for	ADP
ajlm-1720	131	9	haematological	haematological	ADJ
ajlm-1720	131	10	neoplasms	neoplasm	NOUN
ajlm-1720	131	11	and	and	CCONJ
ajlm-1720	131	12	enables	enable	VERB
ajlm-1720	131	13	processing	process	VERB
ajlm-1720	131	14	up	up	ADP
ajlm-1720	131	15	to	to	PART
ajlm-1720	131	16	400	400	NUM
ajlm-1720	131	17	samples	sample	NOUN
ajlm-1720	131	18	a	a	DET
ajlm-1720	131	19	month	month	NOUN
ajlm-1720	131	20	.	.	PUNCT
ajlm-1720	132	1	previously	previously	ADV
ajlm-1720	132	2	,	,	PUNCT
ajlm-1720	132	3	leukaemia	leukaemia	NOUN
ajlm-1720	132	4	flow	flow	NOUN
ajlm-1720	132	5	cytometry	cytometry	NOUN
ajlm-1720	132	6	testing	testing	NOUN
ajlm-1720	132	7	was	be	AUX
ajlm-1720	132	8	limited	limit	VERB
ajlm-1720	132	9	to	to	ADP
ajlm-1720	132	10	simple	simple	ADJ
ajlm-1720	132	11	2–4	2–4	NUM
ajlm-1720	132	12	-	-	PUNCT
ajlm-1720	132	13	colour	colour	NOUN
ajlm-1720	132	14	analysis	analysis	NOUN
ajlm-1720	132	15	;	;	PUNCT
ajlm-1720	132	16	sample	sample	NOUN
ajlm-1720	132	17	setup	setup	NOUN
ajlm-1720	132	18	was	be	AUX
ajlm-1720	132	19	manually	manually	ADV
ajlm-1720	132	20	intensive	intensive	ADJ
ajlm-1720	132	21	and	and	CCONJ
ajlm-1720	132	22	error	error	NOUN
ajlm-1720	132	23	-	-	PUNCT
ajlm-1720	132	24	prone	prone	ADJ
ajlm-1720	132	25	.	.	PUNCT
ajlm-1720	133	1	systems	system	NOUN
ajlm-1720	133	2	previously	previously	ADV
ajlm-1720	133	3	implemented	implement	VERB
ajlm-1720	133	4	into	into	ADP
ajlm-1720	133	5	our	our	PRON
ajlm-1720	133	6	laboratory	laboratory	NOUN
ajlm-1720	133	7	streamlined	streamline	VERB
ajlm-1720	133	8	standardised	standardised	ADJ
ajlm-1720	133	9	and	and	CCONJ
ajlm-1720	133	10	automated	automate	VERB
ajlm-1720	133	11	testing	testing	NOUN
ajlm-1720	133	12	and	and	CCONJ
ajlm-1720	133	13	improved	improve	VERB
ajlm-1720	133	14	workflow	workflow	NOUN
ajlm-1720	133	15	and	and	CCONJ
ajlm-1720	133	16	quality	quality	NOUN
ajlm-1720	133	17	of	of	ADP
ajlm-1720	133	18	reporting.25,26,27	reporting.25,26,27	NOUN
ajlm-1720	133	19	similarly	similarly	ADV
ajlm-1720	133	20	,	,	PUNCT
ajlm-1720	133	21	implementing	implement	VERB
ajlm-1720	133	22	the	the	DET
ajlm-1720	133	23	clearllab	clearllab	NOUN
ajlm-1720	133	24	10c	10c	NOUN
ajlm-1720	133	25	and	and	CCONJ
ajlm-1720	133	26	ls	ls	ADJ
ajlm-1720	133	27	system	system	NOUN
ajlm-1720	133	28	in	in	ADP
ajlm-1720	133	29	our	our	PRON
ajlm-1720	133	30	laboratory16	laboratory16	NOUN
ajlm-1720	133	31	has	have	AUX
ajlm-1720	133	32	markedly	markedly	ADV
ajlm-1720	133	33	improved	improve	VERB
ajlm-1720	133	34	workflow	workflow	NOUN
ajlm-1720	133	35	and	and	CCONJ
ajlm-1720	133	36	minimised	minimised	ADJ
ajlm-1720	133	37	errors	error	NOUN
ajlm-1720	133	38	while	while	SCONJ
ajlm-1720	133	39	providing	provide	VERB
ajlm-1720	133	40	standardised	standardised	ADJ
ajlm-1720	133	41	and	and	CCONJ
ajlm-1720	133	42	substantially	substantially	ADV
ajlm-1720	133	43	better	well	ADJ
ajlm-1720	133	44	quality	quality	NOUN
ajlm-1720	133	45	-	-	PUNCT
ajlm-1720	133	46	controlled	control	VERB
ajlm-1720	133	47	sample	sample	NOUN
ajlm-1720	133	48	and	and	CCONJ
ajlm-1720	133	49	data	datum	NOUN
ajlm-1720	133	50	acquisition	acquisition	NOUN
ajlm-1720	133	51	and	and	CCONJ
ajlm-1720	133	52	comprehensive	comprehensive	ADJ
ajlm-1720	133	53	data	datum	NOUN
ajlm-1720	133	54	.	.	PUNCT
ajlm-1720	134	1	the	the	DET
ajlm-1720	134	2	latter	latter	ADJ
ajlm-1720	134	3	allows	allow	VERB
ajlm-1720	134	4	for	for	ADP
ajlm-1720	134	5	improved	improved	ADJ
ajlm-1720	134	6	target	target	NOUN
ajlm-1720	134	7	population	population	NOUN
ajlm-1720	134	8	identification	identification	NOUN
ajlm-1720	134	9	,	,	PUNCT
ajlm-1720	134	10	especially	especially	ADV
ajlm-1720	134	11	for	for	ADP
ajlm-1720	134	12	small	small	ADJ
ajlm-1720	134	13	populations	population	NOUN
ajlm-1720	134	14	.	.	PUNCT
ajlm-1720	135	1	complementary	complementary	ADJ
ajlm-1720	135	2	and	and	CCONJ
ajlm-1720	135	3	supplementary	supplementary	ADJ
ajlm-1720	135	4	multicolour	multicolour	PROPN
ajlm-1720	135	5	panel	panel	NOUN
ajlm-1720	135	6	options	option	NOUN
ajlm-1720	135	7	are	be	AUX
ajlm-1720	135	8	published3,4,10,19,28	published3,4,10,19,28	ADJ
ajlm-1720	135	9	and	and	CCONJ
ajlm-1720	135	10	could	could	AUX
ajlm-1720	135	11	theoretically	theoretically	ADV
ajlm-1720	135	12	be	be	AUX
ajlm-1720	135	13	assembled	assemble	VERB
ajlm-1720	135	14	as	as	ADP
ajlm-1720	135	15	required	require	VERB
ajlm-1720	135	16	in	in	ADP
ajlm-1720	135	17	the	the	DET
ajlm-1720	135	18	lab	lab	NOUN
ajlm-1720	135	19	to	to	PART
ajlm-1720	135	20	provide	provide	VERB
ajlm-1720	135	21	additional	additional	ADJ
ajlm-1720	135	22	marker	marker	NOUN
ajlm-1720	135	23	panels	panel	NOUN
ajlm-1720	135	24	needed	need	VERB
ajlm-1720	135	25	to	to	PART
ajlm-1720	135	26	complete	complete	VERB
ajlm-1720	135	27	full	full	ADJ
ajlm-1720	135	28	patient	patient	ADJ
ajlm-1720	135	29	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	135	30	investigation	investigation	NOUN
ajlm-1720	135	31	.	.	PUNCT
ajlm-1720	136	1	however	however	ADV
ajlm-1720	136	2	,	,	PUNCT
ajlm-1720	136	3	setting	set	VERB
ajlm-1720	136	4	up	up	ADP
ajlm-1720	136	5	quality	quality	NOUN
ajlm-1720	136	6	-	-	PUNCT
ajlm-1720	136	7	controlled	control	VERB
ajlm-1720	136	8	multicolour	multicolour	NOUN
ajlm-1720	136	9	panels	panel	NOUN
ajlm-1720	136	10	in	in	ADP
ajlm-1720	136	11	lowand	lowand	ADJ
ajlm-1720	136	12	middle	middle	ADJ
ajlm-1720	136	13	-	-	PUNCT
ajlm-1720	136	14	income	income	NOUN
ajlm-1720	136	15	countries	country	NOUN
ajlm-1720	136	16	is	be	AUX
ajlm-1720	136	17	both	both	PRON
ajlm-1720	136	18	challenging	challenging	ADJ
ajlm-1720	136	19	and	and	CCONJ
ajlm-1720	136	20	less	less	ADJ
ajlm-1720	136	21	reliable16	reliable16	NOUN
ajlm-1720	136	22	.	.	PUNCT
ajlm-1720	137	1	the	the	DET
ajlm-1720	137	2	clearllab	clearllab	NOUN
ajlm-1720	137	3	system	system	NOUN
ajlm-1720	137	4	facilitates	facilitate	VERB
ajlm-1720	137	5	detailed	detailed	ADJ
ajlm-1720	137	6	diagnosis	diagnosis	NOUN
ajlm-1720	137	7	across	across	ADP
ajlm-1720	137	8	a	a	DET
ajlm-1720	137	9	broad	broad	ADJ
ajlm-1720	137	10	range	range	NOUN
ajlm-1720	137	11	of	of	ADP
ajlm-1720	137	12	acute	acute	NOUN
ajlm-1720	137	13	leukaemias	leukaemia	NOUN
ajlm-1720	137	14	,	,	PUNCT
ajlm-1720	137	15	and	and	CCONJ
ajlm-1720	137	16	is	be	AUX
ajlm-1720	137	17	sufficiently	sufficiently	ADV
ajlm-1720	137	18	sensitive	sensitive	ADJ
ajlm-1720	137	19	to	to	PART
ajlm-1720	137	20	detect	detect	VERB
ajlm-1720	137	21	the	the	DET
ajlm-1720	137	22	presence	presence	NOUN
ajlm-1720	137	23	of	of	ADP
ajlm-1720	137	24	a	a	DET
ajlm-1720	137	25	mature	mature	ADJ
ajlm-1720	137	26	b	b	NOUN
ajlm-1720	137	27	-	-	PUNCT
ajlm-1720	137	28	cell	cell	NOUN
ajlm-1720	137	29	lpd	lpd	PROPN
ajlm-1720	137	30	,	,	PUNCT
ajlm-1720	137	31	but	but	CCONJ
ajlm-1720	137	32	it	it	PRON
ajlm-1720	137	33	lacks	lack	VERB
ajlm-1720	137	34	specificity	specificity	NOUN
ajlm-1720	137	35	to	to	PART
ajlm-1720	137	36	discern	discern	VERB
ajlm-1720	137	37	and	and	CCONJ
ajlm-1720	137	38	diagnose	diagnose	VERB
ajlm-1720	137	39	different	different	ADJ
ajlm-1720	137	40	mature	mature	ADJ
ajlm-1720	137	41	b	b	NOUN
ajlm-1720	137	42	-	-	PUNCT
ajlm-1720	137	43	cell	cell	NOUN
ajlm-1720	137	44	lpd9	lpd9	NOUN
ajlm-1720	137	45	or	or	CCONJ
ajlm-1720	137	46	confirm	confirm	VERB
ajlm-1720	137	47	pcds	pcds	NOUN
ajlm-1720	137	48	.	.	PUNCT
ajlm-1720	138	1	for	for	ADP
ajlm-1720	138	2	example	example	NOUN
ajlm-1720	138	3	,	,	PUNCT
ajlm-1720	138	4	although	although	SCONJ
ajlm-1720	138	5	the	the	DET
ajlm-1720	138	6	b	b	NOUN
ajlm-1720	138	7	-	-	PUNCT
ajlm-1720	138	8	cell	cell	NOUN
ajlm-1720	138	9	panel	panel	NOUN
ajlm-1720	138	10	is	be	AUX
ajlm-1720	138	11	useful	useful	ADJ
ajlm-1720	138	12	to	to	PART
ajlm-1720	138	13	differentiate	differentiate	VERB
ajlm-1720	138	14	precursor	precursor	NOUN
ajlm-1720	138	15	b	b	NOUN
ajlm-1720	138	16	-	-	NOUN
ajlm-1720	138	17	cell	cell	NOUN
ajlm-1720	138	18	from	from	ADP
ajlm-1720	138	19	more	more	ADV
ajlm-1720	138	20	mature	mature	ADJ
ajlm-1720	138	21	b	b	NOUN
ajlm-1720	138	22	-	-	PUNCT
ajlm-1720	138	23	cell	cell	NOUN
ajlm-1720	138	24	lpd	lpd	PROPN
ajlm-1720	138	25	,	,	PUNCT
ajlm-1720	138	26	the	the	DET
ajlm-1720	138	27	panel	panel	NOUN
ajlm-1720	138	28	does	do	AUX
ajlm-1720	138	29	not	not	PART
ajlm-1720	138	30	accommodate	accommodate	VERB
ajlm-1720	138	31	sufficient	sufficient	ADJ
ajlm-1720	138	32	markers	marker	NOUN
ajlm-1720	138	33	to	to	PART
ajlm-1720	138	34	discern	discern	VERB
ajlm-1720	138	35	different	different	ADJ
ajlm-1720	138	36	types	type	NOUN
ajlm-1720	138	37	of	of	ADP
ajlm-1720	138	38	mature	mature	ADJ
ajlm-1720	138	39	lpds	lpd	NOUN
ajlm-1720	138	40	,	,	PUNCT
ajlm-1720	138	41	including	include	VERB
ajlm-1720	138	42	cd23	cd23	PROPN
ajlm-1720	138	43	,	,	PUNCT
ajlm-1720	138	44	cd43	cd43	PROPN
ajlm-1720	138	45	,	,	PUNCT
ajlm-1720	138	46	cd79b	cd79b	NOUN
ajlm-1720	138	47	and	and	CCONJ
ajlm-1720	138	48	fmc-7	fmc-7	PUNCT
ajlm-1720	138	49	markers	marker	NOUN
ajlm-1720	138	50	necessary	necessary	ADJ
ajlm-1720	138	51	to	to	PART
ajlm-1720	138	52	distinguish	distinguish	VERB
ajlm-1720	138	53	b	b	NUM
ajlm-1720	138	54	-	-	PUNCT
ajlm-1720	138	55	cell	cell	NOUN
ajlm-1720	138	56	lpd	lpd	PROPN
ajlm-1720	138	57	per	per	ADP
ajlm-1720	138	58	the	the	PRON
ajlm-1720	138	59	who	who	PRON
ajlm-1720	138	60	classification.24	classification.24	VERB
ajlm-1720	138	61	likewise	likewise	ADV
ajlm-1720	138	62	,	,	PUNCT
ajlm-1720	138	63	markers	marker	NOUN
ajlm-1720	138	64	,	,	PUNCT
ajlm-1720	138	65	such	such	ADJ
ajlm-1720	138	66	as	as	ADP
ajlm-1720	138	67	cd58	cd58	PROPN
ajlm-1720	138	68	,	,	PUNCT
ajlm-1720	138	69	for	for	ADP
ajlm-1720	138	70	diagnosis	diagnosis	NOUN
ajlm-1720	138	71	for	for	ADP
ajlm-1720	138	72	subsequent	subsequent	ADJ
ajlm-1720	138	73	follow	follow	NOUN
ajlm-1720	138	74	-	-	PUNCT
ajlm-1720	138	75	up	up	NOUN
ajlm-1720	138	76	of	of	ADP
ajlm-1720	138	77	precursor	precursor	NOUN
ajlm-1720	138	78	b	b	NOUN
ajlm-1720	138	79	-	-	PUNCT
ajlm-1720	138	80	all	all	PRON
ajlm-1720	138	81	,	,	PUNCT
ajlm-1720	138	82	or	or	CCONJ
ajlm-1720	138	83	cd79a	cd79a	NOUN
ajlm-1720	138	84	and	and	CCONJ
ajlm-1720	138	85	cd81	cd81	PROPN
ajlm-1720	138	86	,	,	PUNCT
ajlm-1720	138	87	would	would	AUX
ajlm-1720	138	88	be	be	AUX
ajlm-1720	138	89	of	of	ADP
ajlm-1720	138	90	value	value	NOUN
ajlm-1720	138	91	in	in	ADP
ajlm-1720	138	92	the	the	DET
ajlm-1720	138	93	b	b	NOUN
ajlm-1720	138	94	-	-	PUNCT
ajlm-1720	138	95	cell	cell	NOUN
ajlm-1720	138	96	panel	panel	NOUN
ajlm-1720	138	97	to	to	PART
ajlm-1720	138	98	discern	discern	VERB
ajlm-1720	138	99	neoplasm	neoplasm	NOUN
ajlm-1720	138	100	from	from	ADP
ajlm-1720	138	101	haematogones	haematogone	NOUN
ajlm-1720	138	102	.	.	PUNCT
ajlm-1720	139	1	plasma	plasma	NOUN
ajlm-1720	139	2	cell	cell	NOUN
ajlm-1720	139	3	dyscrasias	dyscrasia	NOUN
ajlm-1720	139	4	are	be	AUX
ajlm-1720	139	5	also	also	ADV
ajlm-1720	139	6	not	not	PART
ajlm-1720	139	7	easily	easily	ADV
ajlm-1720	139	8	identified	identify	VERB
ajlm-1720	139	9	in	in	ADP
ajlm-1720	139	10	the	the	DET
ajlm-1720	139	11	clearllab	clearllab	NOUN
ajlm-1720	139	12	system	system	NOUN
ajlm-1720	139	13	,	,	PUNCT
ajlm-1720	139	14	which	which	PRON
ajlm-1720	139	15	lacks	lack	VERB
ajlm-1720	139	16	cd138	cd138	PROPN
ajlm-1720	139	17	and	and	CCONJ
ajlm-1720	139	18	other	other	ADJ
ajlm-1720	139	19	markers	marker	NOUN
ajlm-1720	139	20	useful	useful	ADJ
ajlm-1720	139	21	for	for	ADP
ajlm-1720	139	22	diagnoses	diagnosis	NOUN
ajlm-1720	139	23	and	and	CCONJ
ajlm-1720	139	24	follow	follow	VERB
ajlm-1720	139	25	-	-	PUNCT
ajlm-1720	139	26	up	up	NOUN
ajlm-1720	139	27	of	of	ADP
ajlm-1720	139	28	pcd.22,29,30	pcd.22,29,30	NOUN
ajlm-1720	139	29	although	although	SCONJ
ajlm-1720	139	30	cd38	cd38	PROPN
ajlm-1720	139	31	,	,	PUNCT
ajlm-1720	139	32	cd56	cd56	PROPN
ajlm-1720	139	33	,	,	PUNCT
ajlm-1720	139	34	and	and	CCONJ
ajlm-1720	139	35	cd45	cd45	PROPN
ajlm-1720	139	36	,	,	PUNCT
ajlm-1720	139	37	used	use	VERB
ajlm-1720	139	38	to	to	PART
ajlm-1720	139	39	identify	identify	VERB
ajlm-1720	139	40	plasma	plasma	NOUN
ajlm-1720	139	41	cells	cell	NOUN
ajlm-1720	139	42	,	,	PUNCT
ajlm-1720	139	43	are	be	AUX
ajlm-1720	139	44	included	include	VERB
ajlm-1720	139	45	in	in	ADP
ajlm-1720	139	46	the	the	DET
ajlm-1720	139	47	clearllab	clearllab	NOUN
ajlm-1720	139	48	panels	panel	NOUN
ajlm-1720	139	49	,	,	PUNCT
ajlm-1720	139	50	plasma	plasma	NOUN
ajlm-1720	139	51	cell	cell	NOUN
ajlm-1720	139	52	identification	identification	NOUN
ajlm-1720	139	53	is	be	AUX
ajlm-1720	139	54	not	not	PART
ajlm-1720	139	55	definitive	definitive	ADJ
ajlm-1720	139	56	.	.	PUNCT
ajlm-1720	140	1	specifically	specifically	ADV
ajlm-1720	140	2	,	,	PUNCT
ajlm-1720	140	3	cd56	cd56	PROPN
ajlm-1720	140	4	,	,	PUNCT
ajlm-1720	140	5	included	include	VERB
ajlm-1720	140	6	in	in	ADP
ajlm-1720	140	7	the	the	DET
ajlm-1720	140	8	t	t	PROPN
ajlm-1720	140	9	-	-	PUNCT
ajlm-1720	140	10	cell	cell	NOUN
ajlm-1720	140	11	panel	panel	NOUN
ajlm-1720	140	12	,	,	PUNCT
ajlm-1720	140	13	is	be	AUX
ajlm-1720	140	14	assessed	assess	VERB
ajlm-1720	140	15	separately	separately	ADV
ajlm-1720	140	16	from	from	ADP
ajlm-1720	140	17	cd38	cd38	PROPN
ajlm-1720	140	18	(	(	PUNCT
ajlm-1720	140	19	included	include	VERB
ajlm-1720	140	20	in	in	ADP
ajlm-1720	140	21	the	the	DET
ajlm-1720	140	22	b	b	NOUN
ajlm-1720	140	23	-	-	PUNCT
ajlm-1720	140	24	cell	cell	NOUN
ajlm-1720	140	25	and	and	CCONJ
ajlm-1720	140	26	m2	m2	PROPN
ajlm-1720	140	27	panels	panel	NOUN
ajlm-1720	140	28	)	)	PUNCT
ajlm-1720	140	29	.	.	PUNCT
ajlm-1720	141	1	a	a	DET
ajlm-1720	141	2	pre	pre	ADJ
ajlm-1720	141	3	-	-	ADJ
ajlm-1720	141	4	titrated	titrated	ADJ
ajlm-1720	141	5	-	-	PUNCT
ajlm-1720	141	6	monoclonal	monoclonal	NOUN
ajlm-1720	141	7	panel	panel	NOUN
ajlm-1720	141	8	including	include	VERB
ajlm-1720	141	9	all	all	DET
ajlm-1720	141	10	three	three	NUM
ajlm-1720	141	11	markers	marker	NOUN
ajlm-1720	141	12	would	would	AUX
ajlm-1720	141	13	suitably	suitably	ADV
ajlm-1720	141	14	enhance	enhance	VERB
ajlm-1720	141	15	the	the	DET
ajlm-1720	141	16	clearllab	clearllab	NOUN
ajlm-1720	141	17	system	system	NOUN
ajlm-1720	141	18	;	;	PUNCT
ajlm-1720	141	19	the	the	DET
ajlm-1720	141	20	duraclone	duraclone	NOUN
ajlm-1720	141	21	panels	panel	NOUN
ajlm-1720	141	22	used	use	VERB
ajlm-1720	141	23	in	in	ADP
ajlm-1720	141	24	this	this	DET
ajlm-1720	141	25	study	study	NOUN
ajlm-1720	141	26	provided	provide	VERB
ajlm-1720	141	27	this	this	DET
ajlm-1720	141	28	supplement	supplement	NOUN
ajlm-1720	141	29	format	format	NOUN
ajlm-1720	141	30	.	.	PUNCT
ajlm-1720	142	1	normal	normal	ADJ
ajlm-1720	142	2	and	and	CCONJ
ajlm-1720	142	3	abnormal	abnormal	ADJ
ajlm-1720	142	4	b	b	NOUN
ajlm-1720	142	5	progenitor	progenitor	NOUN
ajlm-1720	142	6	cells	cell	NOUN
ajlm-1720	142	7	panel	panel	VERB
ajlm-1720	142	8	the	the	DET
ajlm-1720	142	9	expression	expression	NOUN
ajlm-1720	142	10	of	of	ADP
ajlm-1720	142	11	cd10	cd10	PROPN
ajlm-1720	142	12	,	,	PUNCT
ajlm-1720	142	13	cd19	cd19	PROPN
ajlm-1720	142	14	,	,	PUNCT
ajlm-1720	142	15	cd34	cd34	PROPN
ajlm-1720	142	16	,	,	PUNCT
ajlm-1720	142	17	cd38	cd38	PROPN
ajlm-1720	142	18	,	,	PUNCT
ajlm-1720	142	19	cd20	cd20	PROPN
ajlm-1720	142	20	and	and	CCONJ
ajlm-1720	142	21	cd45	cd45	PROPN
ajlm-1720	142	22	in	in	ADP
ajlm-1720	142	23	the	the	DET
ajlm-1720	142	24	duraclone	duraclone	NOUN
ajlm-1720	142	25	re	re	PART
ajlm-1720	142	26	alb	alb	PROPN
ajlm-1720	142	27	panel	panel	NOUN
ajlm-1720	142	28	showed	show	VERB
ajlm-1720	142	29	excellent	excellent	ADJ
ajlm-1720	142	30	cross	cross	ADJ
ajlm-1720	142	31	-	-	ADJ
ajlm-1720	142	32	panel	panel	NOUN
ajlm-1720	142	33	marker	marker	NOUN
ajlm-1720	142	34	expression	expression	NOUN
ajlm-1720	142	35	equivalency	equivalency	NOUN
ajlm-1720	142	36	and	and	CCONJ
ajlm-1720	142	37	concordant	concordant	ADJ
ajlm-1720	142	38	clinical	clinical	ADJ
ajlm-1720	142	39	diagnostic	diagnostic	ADJ
ajlm-1720	142	40	outcome	outcome	NOUN
ajlm-1720	142	41	when	when	SCONJ
ajlm-1720	142	42	compared	compare	VERB
ajlm-1720	142	43	to	to	ADP
ajlm-1720	142	44	clearllab	clearllab	PROPN
ajlm-1720	142	45	10c	10c	PROPN
ajlm-1720	142	46	b	b	SYM
ajlm-1720	142	47	-	-	PUNCT
ajlm-1720	142	48	cell	cell	NOUN
ajlm-1720	142	49	panel	panel	NOUN
ajlm-1720	142	50	expression	expression	NOUN
ajlm-1720	142	51	.	.	PUNCT
ajlm-1720	143	1	cd58	cd58	PROPN
ajlm-1720	143	2	together	together	ADV
ajlm-1720	143	3	with	with	ADP
ajlm-1720	143	4	cd38	cd38	PROPN
ajlm-1720	143	5	,	,	PUNCT
ajlm-1720	143	6	cd10	cd10	PROPN
ajlm-1720	143	7	,	,	PUNCT
ajlm-1720	143	8	cd19	cd19	PROPN
ajlm-1720	143	9	,	,	PUNCT
ajlm-1720	143	10	cd34	cd34	PROPN
ajlm-1720	143	11	,	,	PUNCT
ajlm-1720	143	12	cd20	cd20	PROPN
ajlm-1720	143	13	and	and	CCONJ
ajlm-1720	143	14	cd45	cd45	PROPN
ajlm-1720	143	15	has	have	VERB
ajlm-1720	143	16	potential	potential	NOUN
ajlm-1720	143	17	for	for	ADP
ajlm-1720	143	18	sensitive	sensitive	ADJ
ajlm-1720	143	19	minimal	minimal	ADJ
ajlm-1720	143	20	residual	residual	ADJ
ajlm-1720	143	21	disease	disease	NOUN
ajlm-1720	143	22	assessment31,32	assessment31,32	VERB
ajlm-1720	143	23	along	along	ADP
ajlm-1720	143	24	with	with	ADP
ajlm-1720	143	25	cd81	cd81	PROPN
ajlm-1720	143	26	expression.31	expression.31	PROPN
ajlm-1720	144	1	cd58	cd58	PROPN
ajlm-1720	144	2	in	in	ADP
ajlm-1720	144	3	the	the	DET
ajlm-1720	144	4	index	index	NOUN
ajlm-1720	144	5	test	test	NOUN
ajlm-1720	144	6	alb	alb	PROPN
ajlm-1720	144	7	tube	tube	PROPN
ajlm-1720	144	8	proved	prove	VERB
ajlm-1720	144	9	to	to	PART
ajlm-1720	144	10	be	be	AUX
ajlm-1720	144	11	an	an	DET
ajlm-1720	144	12	excellent	excellent	ADJ
ajlm-1720	144	13	adjunct	adjunct	ADJ
ajlm-1720	144	14	for	for	ADP
ajlm-1720	144	15	assessing	assess	VERB
ajlm-1720	144	16	precursor	precursor	NOUN
ajlm-1720	144	17	b	b	NOUN
ajlm-1720	144	18	-	-	NOUN
ajlm-1720	144	19	cells	cell	NOUN
ajlm-1720	144	20	and	and	CCONJ
ajlm-1720	144	21	was	be	AUX
ajlm-1720	144	22	helpful	helpful	ADJ
ajlm-1720	144	23	in	in	ADP
ajlm-1720	144	24	discerning	discern	VERB
ajlm-1720	144	25	abnormal	abnormal	ADJ
ajlm-1720	144	26	precursor	precursor	NOUN
ajlm-1720	144	27	b	b	NOUN
ajlm-1720	144	28	-	-	NOUN
ajlm-1720	144	29	cells	cell	NOUN
ajlm-1720	144	30	from	from	ADP
ajlm-1720	144	31	normal	normal	ADJ
ajlm-1720	144	32	precursor	precursor	NOUN
ajlm-1720	144	33	b	b	NOUN
ajlm-1720	144	34	-	-	PUNCT
ajlm-1720	144	35	cells	cell	NOUN
ajlm-1720	144	36	(	(	PUNCT
ajlm-1720	144	37	haematogones)31	haematogones)31	PROPN
ajlm-1720	144	38	.	.	PUNCT
ajlm-1720	145	1	distinct	distinct	ADJ
ajlm-1720	145	2	discordant	discordant	ADJ
ajlm-1720	145	3	cd123	cd123	PROPN
ajlm-1720	145	4	and	and	CCONJ
ajlm-1720	145	5	cd34	cd34	PROPN
ajlm-1720	145	6	expression	expression	NOUN
ajlm-1720	145	7	patterns	pattern	NOUN
ajlm-1720	145	8	have	have	AUX
ajlm-1720	145	9	also	also	ADV
ajlm-1720	145	10	been	be	AUX
ajlm-1720	145	11	described	describe	VERB
ajlm-1720	145	12	on	on	ADP
ajlm-1720	145	13	haematogones	haematogone	NOUN
ajlm-1720	145	14	and	and	CCONJ
ajlm-1720	145	15	can	can	AUX
ajlm-1720	145	16	be	be	AUX
ajlm-1720	145	17	used	use	VERB
ajlm-1720	145	18	in	in	ADP
ajlm-1720	145	19	a	a	DET
ajlm-1720	145	20	strategy	strategy	NOUN
ajlm-1720	145	21	to	to	PART
ajlm-1720	145	22	determine	determine	VERB
ajlm-1720	145	23	b	b	X
ajlm-1720	145	24	-	-	PUNCT
ajlm-1720	145	25	all	all	DET
ajlm-1720	145	26	minimal	minimal	ADJ
ajlm-1720	145	27	residual	residual	ADJ
ajlm-1720	145	28	disease.32	disease.32	NOUN
ajlm-1720	145	29	cd123	cd123	PROPN
ajlm-1720	145	30	was	be	AUX
ajlm-1720	145	31	not	not	PART
ajlm-1720	145	32	however	however	ADV
ajlm-1720	145	33	included	include	VERB
ajlm-1720	145	34	in	in	ADP
ajlm-1720	145	35	the	the	DET
ajlm-1720	145	36	alb	alb	PROPN
ajlm-1720	145	37	tube	tube	NOUN
ajlm-1720	145	38	.	.	PUNCT
ajlm-1720	146	1	in	in	ADP
ajlm-1720	146	2	our	our	PRON
ajlm-1720	146	3	predicate	predicate	NOUN
ajlm-1720	146	4	method	method	NOUN
ajlm-1720	146	5	,	,	PUNCT
ajlm-1720	146	6	the	the	DET
ajlm-1720	146	7	clearllab	clearllab	NOUN
ajlm-1720	146	8	10c	10c	NOUN
ajlm-1720	146	9	system	system	NOUN
ajlm-1720	146	10	,	,	PUNCT
ajlm-1720	146	11	co	co	NOUN
ajlm-1720	146	12	-	-	NOUN
ajlm-1720	146	13	expression	expression	NOUN
ajlm-1720	146	14	of	of	ADP
ajlm-1720	146	15	cd123	cd123	PROPN
ajlm-1720	146	16	with	with	ADP
ajlm-1720	146	17	cd34	cd34	PROPN
ajlm-1720	146	18	and	and	CCONJ
ajlm-1720	146	19	cd19	cd19	PROPN
ajlm-1720	146	20	assessment	assessment	NOUN
ajlm-1720	146	21	within	within	ADP
ajlm-1720	146	22	the	the	DET
ajlm-1720	146	23	clearllab	clearllab	NOUN
ajlm-1720	146	24	m2	m2	PROPN
ajlm-1720	146	25	panel	panel	NOUN
ajlm-1720	146	26	,	,	PUNCT
ajlm-1720	146	27	used	use	VERB
ajlm-1720	146	28	to	to	PART
ajlm-1720	146	29	identify	identify	VERB
ajlm-1720	146	30	precursor	precursor	NOUN
ajlm-1720	146	31	b	b	NOUN
ajlm-1720	146	32	-	-	PUNCT
ajlm-1720	146	33	cells	cell	NOUN
ajlm-1720	146	34	,	,	PUNCT
ajlm-1720	146	35	together	together	ADV
ajlm-1720	146	36	with	with	ADP
ajlm-1720	146	37	cd19	cd19	PROPN
ajlm-1720	146	38	,	,	PUNCT
ajlm-1720	146	39	cd10	cd10	PROPN
ajlm-1720	146	40	and	and	CCONJ
ajlm-1720	146	41	cd34	cd34	PROPN
ajlm-1720	146	42	co	co	NOUN
ajlm-1720	146	43	-	-	NOUN
ajlm-1720	146	44	expression	expression	NOUN
ajlm-1720	146	45	in	in	ADP
ajlm-1720	146	46	the	the	DET
ajlm-1720	146	47	clearllab	clearllab	NOUN
ajlm-1720	146	48	b	b	NOUN
ajlm-1720	146	49	-	-	PUNCT
ajlm-1720	146	50	cell	cell	NOUN
ajlm-1720	146	51	tube	tube	NOUN
ajlm-1720	146	52	,	,	PUNCT
ajlm-1720	146	53	therefore	therefore	ADV
ajlm-1720	146	54	offers	offer	VERB
ajlm-1720	146	55	more	more	ADJ
ajlm-1720	146	56	diagnostic	diagnostic	ADJ
ajlm-1720	146	57	information	information	NOUN
ajlm-1720	146	58	than	than	ADP
ajlm-1720	146	59	the	the	DET
ajlm-1720	146	60	duraclone	duraclone	NOUN
ajlm-1720	146	61	alb	alb	NOUN
ajlm-1720	146	62	tube	tube	NOUN
ajlm-1720	146	63	alone	alone	ADV
ajlm-1720	146	64	for	for	ADP
ajlm-1720	146	65	the	the	DET
ajlm-1720	146	66	follow	follow	NOUN
ajlm-1720	146	67	-	-	PUNCT
ajlm-1720	146	68	up	up	NOUN
ajlm-1720	146	69	of	of	ADP
ajlm-1720	146	70	precursor	precursor	NOUN
ajlm-1720	146	71	b	b	NOUN
ajlm-1720	146	72	-	-	PUNCT
ajlm-1720	146	73	all	all	PRON
ajlm-1720	146	74	and	and	CCONJ
ajlm-1720	146	75	residual	residual	ADJ
ajlm-1720	146	76	disease	disease	NOUN
ajlm-1720	146	77	assessment	assessment	NOUN
ajlm-1720	146	78	.	.	PUNCT
ajlm-1720	147	1	the	the	DET
ajlm-1720	147	2	clearllab	clearllab	NOUN
ajlm-1720	147	3	10c	10c	NOUN
ajlm-1720	147	4	system	system	NOUN
ajlm-1720	147	5	was	be	AUX
ajlm-1720	147	6	developed	develop	VERB
ajlm-1720	147	7	to	to	PART
ajlm-1720	147	8	diagnose	diagnose	VERB
ajlm-1720	147	9	early	early	ADJ
ajlm-1720	147	10	and	and	CCONJ
ajlm-1720	147	11	later	later	ADJ
ajlm-1720	147	12	b	b	X
ajlm-1720	147	13	-	-	PUNCT
ajlm-1720	147	14	cell	cell	NOUN
ajlm-1720	147	15	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	147	16	disorders	disorder	NOUN
ajlm-1720	147	17	;	;	PUNCT
ajlm-1720	147	18	these	these	DET
ajlm-1720	147	19	10	10	NUM
ajlm-1720	147	20	-	-	PUNCT
ajlm-1720	147	21	colour	colour	NOUN
ajlm-1720	147	22	panels	panel	NOUN
ajlm-1720	147	23	are	be	AUX
ajlm-1720	147	24	fixed	fix	VERB
ajlm-1720	147	25	.	.	PUNCT
ajlm-1720	148	1	thus	thus	ADV
ajlm-1720	148	2	,	,	PUNCT
ajlm-1720	148	3	additional	additional	ADJ
ajlm-1720	148	4	markers	marker	NOUN
ajlm-1720	148	5	can	can	AUX
ajlm-1720	148	6	not	not	PART
ajlm-1720	148	7	be	be	AUX
ajlm-1720	148	8	tested	test	VERB
ajlm-1720	148	9	for	for	ADP
ajlm-1720	148	10	in	in	ADP
ajlm-1720	148	11	the	the	DET
ajlm-1720	148	12	panels	panel	NOUN
ajlm-1720	148	13	.	.	PUNCT
ajlm-1720	149	1	however	however	ADV
ajlm-1720	149	2	,	,	PUNCT
ajlm-1720	149	3	additional	additional	ADJ
ajlm-1720	149	4	markers	marker	NOUN
ajlm-1720	149	5	can	can	AUX
ajlm-1720	149	6	be	be	AUX
ajlm-1720	149	7	added	add	VERB
ajlm-1720	149	8	to	to	ADP
ajlm-1720	149	9	the	the	DET
ajlm-1720	149	10	re	re	X
ajlm-1720	149	11	alb	alb	PROPN
ajlm-1720	149	12	,	,	PUNCT
ajlm-1720	149	13	fine	fine	ADV
ajlm-1720	149	14	-	-	PUNCT
ajlm-1720	149	15	tuned	tune	VERB
ajlm-1720	149	16	toward	toward	ADP
ajlm-1720	149	17	detecting	detect	VERB
ajlm-1720	149	18	early	early	ADJ
ajlm-1720	149	19	b	b	NOUN
ajlm-1720	149	20	-	-	PUNCT
ajlm-1720	149	21	cell	cell	NOUN
ajlm-1720	149	22	precursors	precursor	NOUN
ajlm-1720	149	23	only	only	ADV
ajlm-1720	149	24	.	.	PUNCT
ajlm-1720	150	1	cd22	cd22	PROPN
ajlm-1720	150	2	and	and	CCONJ
ajlm-1720	150	3	cd123	cd123	PROPN
ajlm-1720	150	4	could	could	AUX
ajlm-1720	150	5	be	be	AUX
ajlm-1720	150	6	valuable	valuable	ADJ
ajlm-1720	150	7	additions	addition	NOUN
ajlm-1720	150	8	to	to	ADP
ajlm-1720	150	9	the	the	DET
ajlm-1720	150	10	alb	alb	PROPN
ajlm-1720	150	11	panel	panel	NOUN
ajlm-1720	150	12	.	.	PUNCT
ajlm-1720	151	1	for	for	ADP
ajlm-1720	151	2	example	example	NOUN
ajlm-1720	151	3	,	,	PUNCT
ajlm-1720	151	4	a	a	DET
ajlm-1720	151	5	liquid	liquid	ADJ
ajlm-1720	151	6	reagent	reagent	ADJ
ajlm-1720	151	7	drop	drop	NOUN
ajlm-1720	151	8	-	-	PUNCT
ajlm-1720	151	9	in	in	NOUN
ajlm-1720	151	10	of	of	ADP
ajlm-1720	151	11	cd22	cd22	PROPN
ajlm-1720	151	12	-	-	PUNCT
ajlm-1720	151	13	apc	apc	PROPN
ajlm-1720	151	14	in	in	ADP
ajlm-1720	151	15	the	the	DET
ajlm-1720	151	16	free	free	PROPN
ajlm-1720	151	17	apc	apc	PROPN
ajlm-1720	151	18	fluorescence	fluorescence	PROPN
ajlm-1720	151	19	channel	channel	NOUN
ajlm-1720	151	20	of	of	ADP
ajlm-1720	151	21	the	the	DET
ajlm-1720	151	22	duraclone	duraclone	NOUN
ajlm-1720	151	23	re	re	PART
ajlm-1720	151	24	alb	alb	PROPN
ajlm-1720	151	25	panel	panel	NOUN
ajlm-1720	151	26	could	could	AUX
ajlm-1720	151	27	provide	provide	VERB
ajlm-1720	151	28	a	a	DET
ajlm-1720	151	29	baseline	baseline	ADJ
ajlm-1720	151	30	assessment	assessment	NOUN
ajlm-1720	151	31	of	of	ADP
ajlm-1720	151	32	cd22	cd22	PROPN
ajlm-1720	151	33	expression	expression	NOUN
ajlm-1720	151	34	on	on	ADP
ajlm-1720	151	35	b	b	X
ajlm-1720	151	36	-	-	PUNCT
ajlm-1720	151	37	all	all	DET
ajlm-1720	151	38	blasts	blast	NOUN
ajlm-1720	151	39	,	,	PUNCT
ajlm-1720	151	40	which	which	PRON
ajlm-1720	151	41	would	would	AUX
ajlm-1720	151	42	be	be	AUX
ajlm-1720	151	43	useful	useful	ADJ
ajlm-1720	151	44	for	for	ADP
ajlm-1720	151	45	deciding	decide	VERB
ajlm-1720	151	46	on	on	ADP
ajlm-1720	151	47	anti	anti	ADJ
ajlm-1720	151	48	-	-	ADJ
ajlm-1720	151	49	cd22	cd22	ADJ
ajlm-1720	151	50	targeted	target	VERB
ajlm-1720	151	51	therapy	therapy	NOUN
ajlm-1720	151	52	in	in	ADP
ajlm-1720	151	53	b	b	NOUN
ajlm-1720	151	54	-	-	PUNCT
ajlm-1720	151	55	all	all	DET
ajlm-1720	151	56	patients	patient	NOUN
ajlm-1720	151	57	.	.	PUNCT
ajlm-1720	152	1	cd123	cd123	PROPN
ajlm-1720	152	2	could	could	AUX
ajlm-1720	152	3	also	also	ADV
ajlm-1720	152	4	be	be	AUX
ajlm-1720	152	5	added	add	VERB
ajlm-1720	152	6	in	in	ADP
ajlm-1720	152	7	a	a	DET
ajlm-1720	152	8	second	second	ADJ
ajlm-1720	152	9	available	available	ADJ
ajlm-1720	152	10	channel	channel	NOUN
ajlm-1720	152	11	to	to	PART
ajlm-1720	152	12	enable	enable	VERB
ajlm-1720	152	13	further	further	ADJ
ajlm-1720	152	14	discrimination	discrimination	NOUN
ajlm-1720	152	15	of	of	ADP
ajlm-1720	152	16	disease	disease	NOUN
ajlm-1720	152	17	(	(	PUNCT
ajlm-1720	152	18	b	b	X
ajlm-1720	152	19	-	-	PUNCT
ajlm-1720	152	20	all	all	PRON
ajlm-1720	152	21	)	)	PUNCT
ajlm-1720	152	22	from	from	ADP
ajlm-1720	152	23	normal	normal	ADJ
ajlm-1720	152	24	haematogones	haematogone	NOUN
ajlm-1720	152	25	(	(	PUNCT
ajlm-1720	152	26	see	see	VERB
ajlm-1720	152	27	table	table	NOUN
ajlm-1720	152	28	2	2	NUM
ajlm-1720	152	29	)	)	PUNCT
ajlm-1720	152	30	.	.	PUNCT
ajlm-1720	153	1	chronic	chronic	ADJ
ajlm-1720	153	2	b	b	X
ajlm-1720	153	3	-	-	PUNCT
ajlm-1720	153	4	cell	cell	NOUN
ajlm-1720	153	5	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	153	6	disorder	disorder	NOUN
ajlm-1720	153	7	panel	panel	NOUN
ajlm-1720	153	8	the	the	DET
ajlm-1720	153	9	expression	expression	NOUN
ajlm-1720	153	10	of	of	ADP
ajlm-1720	153	11	cd5	cd5	PROPN
ajlm-1720	153	12	,	,	PUNCT
ajlm-1720	153	13	cd19	cd19	PROPN
ajlm-1720	153	14	,	,	PUNCT
ajlm-1720	153	15	cd20	cd20	PROPN
ajlm-1720	153	16	and	and	CCONJ
ajlm-1720	153	17	cd45	cd45	PROPN
ajlm-1720	153	18	in	in	ADP
ajlm-1720	153	19	the	the	DET
ajlm-1720	153	20	duraclone	duraclone	NOUN
ajlm-1720	153	21	re	re	PART
ajlm-1720	153	22	clb	clb	NOUN
ajlm-1720	153	23	reagent	reagent	NOUN
ajlm-1720	153	24	showed	show	VERB
ajlm-1720	153	25	excellent	excellent	ADJ
ajlm-1720	153	26	cross	cross	ADJ
ajlm-1720	153	27	-	-	ADJ
ajlm-1720	153	28	panel	panel	NOUN
ajlm-1720	153	29	marker	marker	NOUN
ajlm-1720	153	30	expression	expression	NOUN
ajlm-1720	153	31	,	,	PUNCT
ajlm-1720	153	32	equivalent	equivalent	ADJ
ajlm-1720	153	33	to	to	ADP
ajlm-1720	153	34	clearllab	clearllab	PROPN
ajlm-1720	153	35	10c	10c	NOUN
ajlm-1720	153	36	b	b	NOUN
ajlm-1720	153	37	panel	panel	NOUN
ajlm-1720	153	38	expression	expression	NOUN
ajlm-1720	153	39	,	,	PUNCT
ajlm-1720	153	40	with	with	ADP
ajlm-1720	153	41	100	100	NUM
ajlm-1720	153	42	%	%	NOUN
ajlm-1720	153	43	(	(	PUNCT
ajlm-1720	153	44	n	n	NOUN
ajlm-1720	153	45	=	=	SYM
ajlm-1720	153	46	20/20	20/20	NUM
ajlm-1720	153	47	)	)	PUNCT
ajlm-1720	153	48	and	and	CCONJ
ajlm-1720	153	49	clinical	clinical	ADJ
ajlm-1720	153	50	diagnostic	diagnostic	ADJ
ajlm-1720	153	51	outcomes	outcome	NOUN
ajlm-1720	153	52	agreement	agreement	NOUN
ajlm-1720	153	53	.	.	PUNCT
ajlm-1720	154	1	the	the	DET
ajlm-1720	154	2	additional	additional	ADJ
ajlm-1720	154	3	markers	marker	NOUN
ajlm-1720	154	4	in	in	ADP
ajlm-1720	154	5	the	the	DET
ajlm-1720	154	6	duraclone	duraclone	NOUN
ajlm-1720	154	7	re	re	X
ajlm-1720	154	8	clb	clb	NOUN
ajlm-1720	154	9	panel	panel	NOUN
ajlm-1720	154	10	,	,	PUNCT
ajlm-1720	154	11	including	include	VERB
ajlm-1720	154	12	cd81	cd81	PROPN
ajlm-1720	154	13	,	,	PUNCT
ajlm-1720	154	14	ror1	ror1	NOUN
ajlm-1720	154	15	,	,	PUNCT
ajlm-1720	154	16	cd79b	cd79b	NOUN
ajlm-1720	154	17	and	and	CCONJ
ajlm-1720	154	18	cd43	cd43	PROPN
ajlm-1720	154	19	which	which	PRON
ajlm-1720	154	20	are	be	AUX
ajlm-1720	154	21	not	not	PART
ajlm-1720	154	22	included	include	VERB
ajlm-1720	154	23	in	in	ADP
ajlm-1720	154	24	the	the	DET
ajlm-1720	154	25	laboratory	laboratory	NOUN
ajlm-1720	154	26	predicate	predicate	NOUN
ajlm-1720	154	27	clearllab	clearllab	NOUN
ajlm-1720	154	28	system	system	NOUN
ajlm-1720	154	29	,	,	PUNCT
ajlm-1720	154	30	specifically	specifically	ADV
ajlm-1720	154	31	the	the	DET
ajlm-1720	154	32	b	b	NOUN
ajlm-1720	154	33	-	-	PUNCT
ajlm-1720	154	34	cell	cell	NOUN
ajlm-1720	154	35	tube	tube	NOUN
ajlm-1720	154	36	,	,	PUNCT
ajlm-1720	154	37	met	meet	VERB
ajlm-1720	154	38	the	the	DET
ajlm-1720	154	39	requirements	requirement	NOUN
ajlm-1720	154	40	for	for	ADP
ajlm-1720	154	41	intended	intended	ADJ
ajlm-1720	154	42	use	use	NOUN
ajlm-1720	154	43	and	and	CCONJ
ajlm-1720	154	44	the	the	DET
ajlm-1720	154	45	manufacturer	manufacturer	NOUN
ajlm-1720	154	46	performance	performance	NOUN
ajlm-1720	154	47	specifications	specification	NOUN
ajlm-1720	154	48	.	.	PUNCT
ajlm-1720	155	1	the	the	DET
ajlm-1720	155	2	duraclone	duraclone	PROPN
ajlm-1720	155	3	re	re	ADP
ajlm-1720	155	4	clb	clb	NOUN
ajlm-1720	155	5	panel	panel	NOUN
ajlm-1720	155	6	proved	prove	VERB
ajlm-1720	155	7	to	to	PART
ajlm-1720	155	8	be	be	AUX
ajlm-1720	155	9	an	an	DET
ajlm-1720	155	10	excellent	excellent	ADJ
ajlm-1720	155	11	fixed	fix	VERB
ajlm-1720	155	12	supplementary	supplementary	ADJ
ajlm-1720	155	13	panel	panel	NOUN
ajlm-1720	155	14	to	to	PART
ajlm-1720	155	15	replace	replace	VERB
ajlm-1720	155	16	our	our	PRON
ajlm-1720	155	17	outdated	outdated	ADJ
ajlm-1720	155	18	second	second	ADJ
ajlm-1720	155	19	-	-	PUNCT
ajlm-1720	155	20	line	line	NOUN
ajlm-1720	155	21	investigation	investigation	NOUN
ajlm-1720	155	22	for	for	ADP
ajlm-1720	155	23	the	the	DET
ajlm-1720	155	24	workup	workup	NOUN
ajlm-1720	155	25	of	of	ADP
ajlm-1720	155	26	mature	mature	ADJ
ajlm-1720	155	27	b	b	NOUN
ajlm-1720	155	28	-	-	PUNCT
ajlm-1720	155	29	cell	cell	NOUN
ajlm-1720	155	30	lymphoid	lymphoid	NOUN
ajlm-1720	155	31	proliferations	proliferation	NOUN
ajlm-1720	155	32	and	and	CCONJ
ajlm-1720	155	33	proved	prove	VERB
ajlm-1720	155	34	to	to	PART
ajlm-1720	155	35	be	be	AUX
ajlm-1720	155	36	especially	especially	ADV
ajlm-1720	155	37	useful	useful	ADJ
ajlm-1720	155	38	for	for	ADP
ajlm-1720	155	39	discerning	discern	VERB
ajlm-1720	155	40	cd19	cd19	PROPN
ajlm-1720	155	41	/	/	SYM
ajlm-1720	155	42	cd5	cd5	PROPN
ajlm-1720	155	43	positive	positive	ADJ
ajlm-1720	155	44	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	155	45	disease	disease	NOUN
ajlm-1720	155	46	subtypes	subtype	NOUN
ajlm-1720	155	47	.	.	PUNCT
ajlm-1720	156	1	the	the	DET
ajlm-1720	156	2	surface	surface	NOUN
ajlm-1720	156	3	cd81	cd81	PROPN
ajlm-1720	156	4	,	,	PUNCT
ajlm-1720	156	5	cd79b	cd79b	NOUN
ajlm-1720	156	6	and	and	CCONJ
ajlm-1720	156	7	cd20	cd20	PROPN
ajlm-1720	156	8	showed	show	VERB
ajlm-1720	156	9	consistent	consistent	ADJ
ajlm-1720	156	10	under	under	ADP
ajlm-1720	156	11	-	-	PUNCT
ajlm-1720	156	12	expression	expression	NOUN
ajlm-1720	156	13	in	in	ADP
ajlm-1720	156	14	cll	cll	PROPN
ajlm-1720	156	15	,	,	PUNCT
ajlm-1720	156	16	while	while	SCONJ
ajlm-1720	156	17	the	the	DET
ajlm-1720	156	18	presence	presence	NOUN
ajlm-1720	156	19	of	of	ADP
ajlm-1720	156	20	ror1	ror1	PROPN
ajlm-1720	156	21	was	be	AUX
ajlm-1720	156	22	also	also	ADV
ajlm-1720	156	23	helpful	helpful	ADJ
ajlm-1720	156	24	in	in	ADP
ajlm-1720	156	25	discerning	discern	VERB
ajlm-1720	156	26	cll	cll	PROPN
ajlm-1720	156	27	over	over	ADP
ajlm-1720	156	28	mantle	mantle	ADJ
ajlm-1720	156	29	cell	cell	NOUN
ajlm-1720	156	30	lymphoma	lymphoma	NOUN
ajlm-1720	156	31	as	as	SCONJ
ajlm-1720	156	32	described	describe	VERB
ajlm-1720	156	33	in	in	ADP
ajlm-1720	156	34	previous	previous	ADJ
ajlm-1720	156	35	studies,17,18,33	studies,17,18,33	PROPN
ajlm-1720	156	36	especially	especially	ADV
ajlm-1720	156	37	when	when	SCONJ
ajlm-1720	156	38	interpreted	interpret	VERB
ajlm-1720	156	39	in	in	ADP
ajlm-1720	156	40	conjunction	conjunction	NOUN
ajlm-1720	156	41	with	with	ADP
ajlm-1720	156	42	cd200	cd200	PROPN
ajlm-1720	156	43	expression	expression	NOUN
ajlm-1720	156	44	in	in	ADP
ajlm-1720	156	45	the	the	DET
ajlm-1720	156	46	clearllab	clearllab	NOUN
ajlm-1720	156	47	b	b	NOUN
ajlm-1720	156	48	-	-	PUNCT
ajlm-1720	156	49	cell	cell	NOUN
ajlm-1720	156	50	panel.34,35	panel.34,35	NOUN
ajlm-1720	156	51	in	in	ADP
ajlm-1720	156	52	the	the	DET
ajlm-1720	156	53	event	event	NOUN
ajlm-1720	156	54	of	of	ADP
ajlm-1720	156	55	a	a	DET
ajlm-1720	156	56	cd19	cd19	PROPN
ajlm-1720	156	57	/	/	SYM
ajlm-1720	156	58	cd10	cd10	PROPN
ajlm-1720	156	59	co	co	VERB
ajlm-1720	156	60	-	-	VERB
ajlm-1720	156	61	expressing	express	VERB
ajlm-1720	156	62	mature	mature	ADJ
ajlm-1720	156	63	b	b	NOUN
ajlm-1720	156	64	-	-	PUNCT
ajlm-1720	156	65	cell	cell	NOUN
ajlm-1720	156	66	lymphoid	lymphoid	NOUN
ajlm-1720	156	67	proliferation	proliferation	NOUN
ajlm-1720	156	68	,	,	PUNCT
ajlm-1720	156	69	cd43	cd43	PROPN
ajlm-1720	156	70	in	in	ADP
ajlm-1720	156	71	the	the	DET
ajlm-1720	156	72	duraclone	duraclone	NOUN
ajlm-1720	156	73	re	re	PART
ajlm-1720	156	74	clb	clb	NOUN
ajlm-1720	156	75	panel	panel	NOUN
ajlm-1720	156	76	was	be	AUX
ajlm-1720	156	77	shown	show	VERB
ajlm-1720	156	78	to	to	PART
ajlm-1720	156	79	be	be	AUX
ajlm-1720	156	80	a	a	DET
ajlm-1720	156	81	useful	useful	ADJ
ajlm-1720	156	82	cell	cell	NOUN
ajlm-1720	156	83	surface	surface	NOUN
ajlm-1720	156	84	marker	marker	NOUN
ajlm-1720	156	85	to	to	PART
ajlm-1720	156	86	discriminate	discriminate	VERB
ajlm-1720	156	87	follicular	follicular	ADJ
ajlm-1720	156	88	lymphoma	lymphoma	NOUN
ajlm-1720	156	89	from	from	ADP
ajlm-1720	156	90	a	a	DET
ajlm-1720	156	91	high	high	ADJ
ajlm-1720	156	92	-	-	PUNCT
ajlm-1720	156	93	grade	grade	NOUN
ajlm-1720	156	94	b	b	NOUN
ajlm-1720	156	95	-	-	PUNCT
ajlm-1720	156	96	cell	cell	NOUN
ajlm-1720	156	97	lymphoma	lymphoma	NOUN
ajlm-1720	156	98	.	.	PUNCT
ajlm-1720	157	1	similarly	similarly	ADV
ajlm-1720	157	2	,	,	PUNCT
ajlm-1720	157	3	cd79b	cd79b	X
ajlm-1720	157	4	within	within	ADP
ajlm-1720	157	5	the	the	DET
ajlm-1720	157	6	duraclone	duraclone	NOUN
ajlm-1720	157	7	re	re	X
ajlm-1720	157	8	clb	clb	NOUN
ajlm-1720	157	9	panel	panel	NOUN
ajlm-1720	157	10	,	,	PUNCT
ajlm-1720	157	11	read	read	VERB
ajlm-1720	157	12	together	together	ADV
ajlm-1720	157	13	with	with	ADP
ajlm-1720	157	14	cd38	cd38	PROPN
ajlm-1720	157	15	expression	expression	NOUN
ajlm-1720	157	16	in	in	ADP
ajlm-1720	157	17	the	the	DET
ajlm-1720	157	18	clearllab	clearllab	NOUN
ajlm-1720	157	19	b	b	NOUN
ajlm-1720	157	20	-	-	PUNCT
ajlm-1720	157	21	cell	cell	NOUN
ajlm-1720	157	22	tube	tube	NOUN
ajlm-1720	157	23	,	,	PUNCT
ajlm-1720	157	24	identifies	identify	VERB
ajlm-1720	157	25	a	a	DET
ajlm-1720	157	26	mature	mature	ADJ
ajlm-1720	157	27	b	b	NOUN
ajlm-1720	157	28	-	-	PUNCT
ajlm-1720	157	29	cell	cell	NOUN
ajlm-1720	157	30	lymphoid	lymphoid	NOUN
ajlm-1720	157	31	proliferation	proliferation	NOUN
ajlm-1720	157	32	with	with	ADP
ajlm-1720	157	33	plasmacytoid	plasmacytoid	NOUN
ajlm-1720	157	34	differentiation	differentiation	NOUN
ajlm-1720	157	35	.	.	PUNCT
ajlm-1720	158	1	as	as	ADP
ajlm-1720	158	2	for	for	ADP
ajlm-1720	158	3	the	the	DET
ajlm-1720	158	4	alb	alb	PROPN
ajlm-1720	158	5	panel	panel	NOUN
ajlm-1720	158	6	,	,	PUNCT
ajlm-1720	158	7	free	free	ADJ
ajlm-1720	158	8	channels	channel	NOUN
ajlm-1720	158	9	in	in	ADP
ajlm-1720	158	10	the	the	DET
ajlm-1720	158	11	panel	panel	NOUN
ajlm-1720	158	12	allow	allow	VERB
ajlm-1720	158	13	for	for	ADP
ajlm-1720	158	14	additional	additional	ADJ
ajlm-1720	158	15	flexibility	flexibility	NOUN
ajlm-1720	158	16	to	to	PART
ajlm-1720	158	17	investigate	investigate	VERB
ajlm-1720	158	18	related	related	ADJ
ajlm-1720	158	19	markers	marker	NOUN
ajlm-1720	158	20	that	that	PRON
ajlm-1720	158	21	are	be	AUX
ajlm-1720	158	22	regarded	regard	VERB
ajlm-1720	158	23	as	as	ADP
ajlm-1720	158	24	useful	useful	ADJ
ajlm-1720	158	25	to	to	PART
ajlm-1720	158	26	discern	discern	VERB
ajlm-1720	158	27	mature	mature	ADJ
ajlm-1720	158	28	b	b	NOUN
ajlm-1720	158	29	-	-	PUNCT
ajlm-1720	158	30	cell	cell	NOUN
ajlm-1720	158	31	haematolymphoid	haematolymphoid	ADJ
ajlm-1720	158	32	subtypes	subtype	NOUN
ajlm-1720	158	33	.	.	PUNCT
ajlm-1720	159	1	a	a	DET
ajlm-1720	159	2	liquid	liquid	ADJ
ajlm-1720	159	3	reagent	reagent	ADJ
ajlm-1720	159	4	drop	drop	NOUN
ajlm-1720	159	5	-	-	PUNCT
ajlm-1720	159	6	in	in	NOUN
ajlm-1720	159	7	of	of	ADP
ajlm-1720	159	8	cd23	cd23	PROPN
ajlm-1720	159	9	-	-	PUNCT
ajlm-1720	159	10	ecd	ecd	PROPN
ajlm-1720	159	11	in	in	ADP
ajlm-1720	159	12	the	the	DET
ajlm-1720	159	13	duraclone	duraclone	NOUN
ajlm-1720	159	14	re	re	PART
ajlm-1720	159	15	clb	clb	NOUN
ajlm-1720	159	16	panel	panel	NOUN
ajlm-1720	159	17	could	could	AUX
ajlm-1720	159	18	further	far	ADV
ajlm-1720	159	19	confirm	confirm	VERB
ajlm-1720	159	20	b	b	NOUN
ajlm-1720	159	21	-	-	PUNCT
ajlm-1720	159	22	cell	cell	NOUN
ajlm-1720	159	23	cll	cll	NOUN
ajlm-1720	159	24	and	and	CCONJ
ajlm-1720	159	25	discern	discern	ADJ
ajlm-1720	159	26	b	b	NOUN
ajlm-1720	159	27	-	-	PUNCT
ajlm-1720	159	28	cell	cell	NOUN
ajlm-1720	159	29	cll	cll	NOUN
ajlm-1720	159	30	from	from	ADP
ajlm-1720	159	31	other	other	ADJ
ajlm-1720	159	32	cd19	cd19	PROPN
ajlm-1720	159	33	/	/	SYM
ajlm-1720	159	34	cd5	cd5	PROPN
ajlm-1720	159	35	co	co	NOUN
ajlm-1720	159	36	-	-	ADJ
ajlm-1720	159	37	expressing	express	VERB
ajlm-1720	159	38	target	target	NOUN
ajlm-1720	159	39	populations.17,18,33	populations.17,18,33	X
ajlm-1720	159	40	normal	normal	ADJ
ajlm-1720	159	41	and	and	CCONJ
ajlm-1720	159	42	abnormal	abnormal	ADJ
ajlm-1720	159	43	plasma	plasma	NOUN
ajlm-1720	159	44	cells	cell	NOUN
ajlm-1720	159	45	panel	panel	VERB
ajlm-1720	159	46	the	the	DET
ajlm-1720	159	47	cd38	cd38	PROPN
ajlm-1720	159	48	,	,	PUNCT
ajlm-1720	159	49	cd138	cd138	PROPN
ajlm-1720	159	50	,	,	PUNCT
ajlm-1720	159	51	cd45	cd45	PROPN
ajlm-1720	159	52	,	,	PUNCT
ajlm-1720	159	53	cd19	cd19	PROPN
ajlm-1720	159	54	,	,	PUNCT
ajlm-1720	159	55	cd56	cd56	PROPN
ajlm-1720	159	56	,	,	PUNCT
ajlm-1720	159	57	and	and	CCONJ
ajlm-1720	159	58	cd200	cd200	NOUN
ajlm-1720	159	59	expressions	expression	NOUN
ajlm-1720	159	60	in	in	ADP
ajlm-1720	159	61	the	the	DET
ajlm-1720	159	62	duraclone	duraclone	NOUN
ajlm-1720	159	63	re	re	NOUN
ajlm-1720	159	64	pc	pc	NOUN
ajlm-1720	159	65	panel	panel	NOUN
ajlm-1720	159	66	showed	show	VERB
ajlm-1720	159	67	excellent	excellent	ADJ
ajlm-1720	159	68	cross	cross	ADJ
ajlm-1720	159	69	-	-	ADJ
ajlm-1720	159	70	panel	panel	NOUN
ajlm-1720	159	71	marker	marker	NOUN
ajlm-1720	159	72	expression	expression	NOUN
ajlm-1720	159	73	and	and	CCONJ
ajlm-1720	159	74	equivalent	equivalent	ADJ
ajlm-1720	159	75	diagnostic	diagnostic	ADJ
ajlm-1720	159	76	outcome	outcome	NOUN
ajlm-1720	159	77	and	and	CCONJ
ajlm-1720	159	78	facscalibur	facscalibur	PROPN
ajlm-1720	159	79	/	/	SYM
ajlm-1720	159	80	pag	pag	PROPN
ajlm-1720	159	81	analysis	analysis	NOUN
ajlm-1720	159	82	outcomes	outcome	NOUN
ajlm-1720	159	83	,	,	PUNCT
ajlm-1720	159	84	with	with	ADP
ajlm-1720	159	85	100	100	NUM
ajlm-1720	159	86	%	%	NOUN
ajlm-1720	159	87	(	(	PUNCT
ajlm-1720	159	88	n	n	NOUN
ajlm-1720	159	89	=	=	SYM
ajlm-1720	159	90	17/17	17/17	NUM
ajlm-1720	159	91	)	)	PUNCT
ajlm-1720	159	92	clinical	clinical	ADJ
ajlm-1720	159	93	diagnostic	diagnostic	ADJ
ajlm-1720	159	94	concordance	concordance	NOUN
ajlm-1720	159	95	(	(	PUNCT
ajlm-1720	159	96	agreement	agreement	NOUN
ajlm-1720	159	97	)	)	PUNCT
ajlm-1720	159	98	.	.	PUNCT
ajlm-1720	160	1	in	in	ADP
ajlm-1720	160	2	addition	addition	NOUN
ajlm-1720	160	3	,	,	PUNCT
ajlm-1720	160	4	as	as	ADP
ajlm-1720	160	5	previously	previously	ADV
ajlm-1720	160	6	described,29	described,29	NOUN
ajlm-1720	160	7	cd27	cd27	PROPN
ajlm-1720	160	8	and	and	CCONJ
ajlm-1720	160	9	cd8130	cd8130	NOUN
ajlm-1720	160	10	proved	prove	VERB
ajlm-1720	160	11	to	to	PART
ajlm-1720	160	12	be	be	AUX
ajlm-1720	160	13	valuable	valuable	ADJ
ajlm-1720	160	14	markers	marker	NOUN
ajlm-1720	160	15	to	to	PART
ajlm-1720	160	16	discern	discern	VERB
ajlm-1720	160	17	aberrant	aberrant	ADJ
ajlm-1720	160	18	plasma	plasma	NOUN
ajlm-1720	160	19	cells	cell	NOUN
ajlm-1720	160	20	over	over	ADP
ajlm-1720	160	21	normal	normal	ADJ
ajlm-1720	160	22	plasma	plasma	NOUN
ajlm-1720	160	23	cells	cell	NOUN
ajlm-1720	160	24	.	.	PUNCT
ajlm-1720	161	1	finally	finally	ADV
ajlm-1720	161	2	,	,	PUNCT
ajlm-1720	161	3	the	the	DET
ajlm-1720	161	4	usefulness	usefulness	NOUN
ajlm-1720	161	5	of	of	ADP
ajlm-1720	161	6	the	the	DET
ajlm-1720	161	7	re	re	X
ajlm-1720	161	8	pc	pc	NOUN
ajlm-1720	161	9	panel	panel	NOUN
ajlm-1720	161	10	can	can	AUX
ajlm-1720	161	11	be	be	AUX
ajlm-1720	161	12	further	far	ADV
ajlm-1720	161	13	extended	extend	VERB
ajlm-1720	161	14	by	by	ADP
ajlm-1720	161	15	adding	add	VERB
ajlm-1720	161	16	cd117	cd117	PROPN
ajlm-1720	161	17	-	-	PUNCT
ajlm-1720	161	18	ecd30	ecd30	PROPN
ajlm-1720	161	19	reagents	reagent	NOUN
ajlm-1720	161	20	.	.	PUNCT
ajlm-1720	162	1	for	for	ADP
ajlm-1720	162	2	one	one	NUM
ajlm-1720	162	3	sample	sample	NOUN
ajlm-1720	162	4	,	,	PUNCT
ajlm-1720	162	5	we	we	PRON
ajlm-1720	162	6	added	add	VERB
ajlm-1720	162	7	cd117	cd117	PROPN
ajlm-1720	162	8	-	-	PUNCT
ajlm-1720	162	9	ecd	ecd	PROPN
ajlm-1720	162	10	reagents	reagent	NOUN
ajlm-1720	162	11	to	to	ADP
ajlm-1720	162	12	the	the	DET
ajlm-1720	162	13	pc	pc	NOUN
ajlm-1720	162	14	tube	tube	NOUN
ajlm-1720	162	15	,	,	PUNCT
ajlm-1720	162	16	confirming	confirm	VERB
ajlm-1720	162	17	the	the	DET
ajlm-1720	162	18	presence	presence	NOUN
ajlm-1720	162	19	of	of	ADP
ajlm-1720	162	20	malignant	malignant	ADJ
ajlm-1720	162	21	plasma	plasma	NOUN
ajlm-1720	162	22	cells	cell	NOUN
ajlm-1720	162	23	and	and	CCONJ
ajlm-1720	162	24	minimal	minimal	ADJ
ajlm-1720	162	25	residual	residual	ADJ
ajlm-1720	162	26	disease	disease	NOUN
ajlm-1720	162	27	assessment.14,30	assessment.14,30	NOUN
ajlm-1720	162	28	.	.	PUNCT
ajlm-1720	163	1	limitations	limitation	NOUN
ajlm-1720	163	2	firstly	firstly	ADV
ajlm-1720	163	3	,	,	PUNCT
ajlm-1720	163	4	the	the	DET
ajlm-1720	163	5	sample	sample	NOUN
ajlm-1720	163	6	size	size	NOUN
ajlm-1720	163	7	per	per	ADP
ajlm-1720	163	8	panel	panel	NOUN
ajlm-1720	163	9	evaluated	evaluate	VERB
ajlm-1720	163	10	is	be	AUX
ajlm-1720	163	11	small	small	ADJ
ajlm-1720	163	12	,	,	PUNCT
ajlm-1720	163	13	and	and	CCONJ
ajlm-1720	163	14	further	further	ADJ
ajlm-1720	163	15	studies	study	NOUN
ajlm-1720	163	16	are	be	AUX
ajlm-1720	163	17	needed	need	VERB
ajlm-1720	163	18	to	to	PART
ajlm-1720	163	19	confirm	confirm	VERB
ajlm-1720	163	20	the	the	DET
ajlm-1720	163	21	outcomes	outcome	NOUN
ajlm-1720	163	22	reported	report	VERB
ajlm-1720	163	23	here	here	ADV
ajlm-1720	163	24	.	.	PUNCT
ajlm-1720	164	1	secondly	secondly	ADV
ajlm-1720	164	2	,	,	PUNCT
ajlm-1720	164	3	the	the	DET
ajlm-1720	164	4	fluorochromes	fluorochrome	NOUN
ajlm-1720	164	5	used	use	VERB
ajlm-1720	164	6	in	in	ADP
ajlm-1720	164	7	the	the	DET
ajlm-1720	164	8	panels	panel	NOUN
ajlm-1720	164	9	are	be	AUX
ajlm-1720	164	10	specifically	specifically	ADV
ajlm-1720	164	11	designed	design	VERB
ajlm-1720	164	12	for	for	ADP
ajlm-1720	164	13	use	use	NOUN
ajlm-1720	164	14	on	on	ADP
ajlm-1720	164	15	a	a	DET
ajlm-1720	164	16	bc	bc	PROPN
ajlm-1720	164	17	navios	navio	NOUN
ajlm-1720	164	18	instrument	instrument	NOUN
ajlm-1720	164	19	.	.	PUNCT
ajlm-1720	165	1	therefore	therefore	ADV
ajlm-1720	165	2	,	,	PUNCT
ajlm-1720	165	3	the	the	DET
ajlm-1720	165	4	products	product	NOUN
ajlm-1720	165	5	could	could	AUX
ajlm-1720	165	6	be	be	AUX
ajlm-1720	165	7	used	use	VERB
ajlm-1720	165	8	on	on	ADP
ajlm-1720	165	9	alternative	alternative	ADJ
ajlm-1720	165	10	instruments	instrument	NOUN
ajlm-1720	165	11	only	only	ADV
ajlm-1720	165	12	if	if	SCONJ
ajlm-1720	165	13	the	the	DET
ajlm-1720	165	14	respective	respective	ADJ
ajlm-1720	165	15	filter	filter	NOUN
ajlm-1720	165	16	setups23	setups23	NOUN
ajlm-1720	165	17	(	(	PUNCT
ajlm-1720	165	18	of	of	ADP
ajlm-1720	165	19	the	the	DET
ajlm-1720	165	20	particular	particular	ADJ
ajlm-1720	165	21	laboratory	laboratory	NOUN
ajlm-1720	165	22	’s	’s	PART
ajlm-1720	165	23	flow	flow	NOUN
ajlm-1720	165	24	cytometer	cytometer	NOUN
ajlm-1720	165	25	)	)	PUNCT
ajlm-1720	165	26	can	can	AUX
ajlm-1720	165	27	accommodate	accommodate	VERB
ajlm-1720	165	28	data	datum	NOUN
ajlm-1720	165	29	collection	collection	NOUN
ajlm-1720	165	30	from	from	ADP
ajlm-1720	165	31	the	the	DET
ajlm-1720	165	32	fluorochromes	fluorochrome	NOUN
ajlm-1720	165	33	used	use	VERB
ajlm-1720	165	34	in	in	ADP
ajlm-1720	165	35	the	the	DET
ajlm-1720	165	36	clearllab	clearllab	NOUN
ajlm-1720	165	37	10c	10c	NOUN
ajlm-1720	165	38	or	or	CCONJ
ajlm-1720	165	39	duraclone	duraclone	NOUN
ajlm-1720	165	40	panels	panel	NOUN
ajlm-1720	165	41	.	.	PUNCT
ajlm-1720	166	1	conclusion	conclusion	NOUN
ajlm-1720	166	2	this	this	DET
ajlm-1720	166	3	study	study	NOUN
ajlm-1720	166	4	confirms	confirm	VERB
ajlm-1720	166	5	that	that	SCONJ
ajlm-1720	166	6	the	the	DET
ajlm-1720	166	7	bc	bc	PROPN
ajlm-1720	166	8	duraclone	duraclone	PROPN
ajlm-1720	166	9	alb	alb	NOUN
ajlm-1720	166	10	and	and	CCONJ
ajlm-1720	166	11	clb	clb	NOUN
ajlm-1720	166	12	panels	panel	NOUN
ajlm-1720	166	13	are	be	AUX
ajlm-1720	166	14	suitable	suitable	ADJ
ajlm-1720	166	15	to	to	PART
ajlm-1720	166	16	provide	provide	VERB
ajlm-1720	166	17	additional	additional	ADJ
ajlm-1720	166	18	second	second	ADJ
ajlm-1720	166	19	-	-	PUNCT
ajlm-1720	166	20	line	line	NOUN
ajlm-1720	166	21	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	166	22	workup	workup	NOUN
ajlm-1720	166	23	of	of	ADP
ajlm-1720	166	24	precursor	precursor	NOUN
ajlm-1720	166	25	b	b	NOUN
ajlm-1720	166	26	-	-	PUNCT
ajlm-1720	166	27	all	all	PRON
ajlm-1720	166	28	and	and	CCONJ
ajlm-1720	166	29	mature	mature	VERB
ajlm-1720	166	30	b	b	NOUN
ajlm-1720	166	31	-	-	PUNCT
ajlm-1720	166	32	cell	cell	NOUN
ajlm-1720	166	33	lymphoproliferative	lymphoproliferative	ADJ
ajlm-1720	166	34	disorders	disorder	NOUN
ajlm-1720	166	35	resepectively	resepectively	ADV
ajlm-1720	166	36	,	,	PUNCT
ajlm-1720	166	37	at	at	ADP
ajlm-1720	166	38	disease	disease	NOUN
ajlm-1720	166	39	presentation	presentation	NOUN
ajlm-1720	166	40	and	and	CCONJ
ajlm-1720	166	41	are	be	AUX
ajlm-1720	166	42	suitable	suitable	ADJ
ajlm-1720	166	43	to	to	PART
ajlm-1720	166	44	supplement	supplement	VERB
ajlm-1720	166	45	first	first	ADJ
ajlm-1720	166	46	-	-	PUNCT
ajlm-1720	166	47	line	line	NOUN
ajlm-1720	166	48	clearllab	clearllab	NOUN
ajlm-1720	166	49	10c	10c	NUM
ajlm-1720	166	50	laboratory	laboratory	NOUN
ajlm-1720	166	51	predicate	predicate	NOUN
ajlm-1720	166	52	method	method	NOUN
ajlm-1720	166	53	testing	testing	NOUN
ajlm-1720	166	54	.	.	PUNCT
ajlm-1720	167	1	the	the	DET
ajlm-1720	167	2	under	under	NOUN
ajlm-1720	167	3	-	-	PUNCT
ajlm-1720	167	4	expression	expression	NOUN
ajlm-1720	167	5	of	of	ADP
ajlm-1720	167	6	cd81	cd81	PROPN
ajlm-1720	167	7	,	,	PUNCT
ajlm-1720	167	8	cd79b	cd79b	ADJ
ajlm-1720	167	9	,	,	PUNCT
ajlm-1720	167	10	and	and	CCONJ
ajlm-1720	167	11	positive	positive	ADJ
ajlm-1720	167	12	cd43	cd43	PROPN
ajlm-1720	167	13	and	and	CCONJ
ajlm-1720	167	14	ror1	ror1	ADJ
ajlm-1720	167	15	expression	expression	NOUN
ajlm-1720	167	16	,	,	PUNCT
ajlm-1720	167	17	noted	note	VERB
ajlm-1720	167	18	in	in	ADP
ajlm-1720	167	19	the	the	DET
ajlm-1720	167	20	duraclone	duraclone	NOUN
ajlm-1720	167	21	clb	clb	NOUN
ajlm-1720	167	22	panel	panel	NOUN
ajlm-1720	167	23	specifically	specifically	ADV
ajlm-1720	167	24	assists	assist	VERB
ajlm-1720	167	25	in	in	ADP
ajlm-1720	167	26	distinguishing	distinguish	VERB
ajlm-1720	167	27	b	b	NOUN
ajlm-1720	167	28	-	-	PUNCT
ajlm-1720	167	29	cell	cell	NOUN
ajlm-1720	167	30	cll	cll	NOUN
ajlm-1720	167	31	from	from	ADP
ajlm-1720	167	32	mantle	mantle	ADJ
ajlm-1720	167	33	cell	cell	NOUN
ajlm-1720	167	34	lymphoma	lymphoma	NOUN
ajlm-1720	167	35	and	and	CCONJ
ajlm-1720	167	36	other	other	ADJ
ajlm-1720	167	37	cd5	cd5	PROPN
ajlm-1720	167	38	negative	negative	ADJ
ajlm-1720	167	39	b	b	NOUN
ajlm-1720	167	40	-	-	PUNCT
ajlm-1720	167	41	cell	cell	NOUN
ajlm-1720	167	42	lpds	lpd	NOUN
ajlm-1720	167	43	.	.	PUNCT
ajlm-1720	168	1	the	the	DET
ajlm-1720	168	2	duraclone	duraclone	NOUN
ajlm-1720	168	3	re	re	NOUN
ajlm-1720	168	4	pc	pc	NOUN
ajlm-1720	168	5	panel	panel	NOUN
ajlm-1720	168	6	is	be	AUX
ajlm-1720	168	7	suitable	suitable	ADJ
ajlm-1720	168	8	for	for	ADP
ajlm-1720	168	9	the	the	DET
ajlm-1720	168	10	second	second	ADJ
ajlm-1720	168	11	-	-	PUNCT
ajlm-1720	168	12	line	line	NOUN
ajlm-1720	168	13	investigation	investigation	NOUN
ajlm-1720	168	14	of	of	ADP
ajlm-1720	168	15	pcd	pcd	PROPN
ajlm-1720	168	16	.	.	PUNCT
ajlm-1720	169	1	cd27	cd27	PROPN
ajlm-1720	169	2	,	,	PUNCT
ajlm-1720	169	3	cd56	cd56	PROPN
ajlm-1720	169	4	,	,	PUNCT
ajlm-1720	169	5	cd81	cd81	PROPN
ajlm-1720	169	6	and	and	CCONJ
ajlm-1720	169	7	cd200	cd200	PROPN
ajlm-1720	169	8	,	,	PUNCT
ajlm-1720	169	9	together	together	ADV
ajlm-1720	169	10	with	with	ADP
ajlm-1720	169	11	cd19	cd19	PROPN
ajlm-1720	169	12	,	,	PUNCT
ajlm-1720	169	13	cd38	cd38	PROPN
ajlm-1720	169	14	and	and	CCONJ
ajlm-1720	169	15	cd138	cd138	PROPN
ajlm-1720	169	16	in	in	ADP
ajlm-1720	169	17	a	a	DET
ajlm-1720	169	18	single	single	ADJ
ajlm-1720	169	19	analysis	analysis	NOUN
ajlm-1720	169	20	,	,	PUNCT
ajlm-1720	169	21	were	be	AUX
ajlm-1720	169	22	efficient	efficient	ADJ
ajlm-1720	169	23	in	in	ADP
ajlm-1720	169	24	identifying	identify	VERB
ajlm-1720	169	25	aberrant	aberrant	ADJ
ajlm-1720	169	26	plasma	plasma	NOUN
ajlm-1720	169	27	cells	cell	NOUN
ajlm-1720	169	28	.	.	PUNCT
ajlm-1720	170	1	although	although	SCONJ
ajlm-1720	170	2	there	there	PRON
ajlm-1720	170	3	was	be	VERB
ajlm-1720	170	4	diagnostic	diagnostic	ADJ
ajlm-1720	170	5	and	and	CCONJ
ajlm-1720	170	6	individual	individual	ADJ
ajlm-1720	170	7	marker	marker	NOUN
ajlm-1720	170	8	concordance	concordance	NOUN
ajlm-1720	170	9	,	,	PUNCT
ajlm-1720	170	10	we	we	PRON
ajlm-1720	170	11	did	do	AUX
ajlm-1720	170	12	not	not	PART
ajlm-1720	170	13	find	find	VERB
ajlm-1720	170	14	the	the	DET
ajlm-1720	170	15	alb	alb	NOUN
ajlm-1720	170	16	more	more	ADV
ajlm-1720	170	17	useful	useful	ADJ
ajlm-1720	170	18	for	for	ADP
ajlm-1720	170	19	diagnosing	diagnose	VERB
ajlm-1720	170	20	b	b	X
ajlm-1720	170	21	-	-	PUNCT
ajlm-1720	170	22	all	all	ADV
ajlm-1720	170	23	over	over	ADP
ajlm-1720	170	24	our	our	PRON
ajlm-1720	170	25	existing	exist	VERB
ajlm-1720	170	26	clearllab	clearllab	NOUN
ajlm-1720	170	27	system	system	NOUN
ajlm-1720	170	28	(	(	PUNCT
ajlm-1720	170	29	utilising	utilise	VERB
ajlm-1720	170	30	the	the	DET
ajlm-1720	170	31	b	b	NOUN
ajlm-1720	170	32	-	-	PUNCT
ajlm-1720	170	33	cell	cell	NOUN
ajlm-1720	170	34	and	and	CCONJ
ajlm-1720	170	35	m2	m2	PROPN
ajlm-1720	170	36	tubes	tube	NOUN
ajlm-1720	170	37	)	)	PUNCT
ajlm-1720	170	38	.	.	PUNCT
ajlm-1720	171	1	the	the	DET
ajlm-1720	171	2	inclusion	inclusion	NOUN
ajlm-1720	171	3	of	of	ADP
ajlm-1720	171	4	cd5831	cd5831	PROPN
ajlm-1720	171	5	in	in	ADP
ajlm-1720	171	6	the	the	DET
ajlm-1720	171	7	re	re	ADJ
ajlm-1720	171	8	alb	alb	PROPN
ajlm-1720	171	9	tube	tube	NOUN
ajlm-1720	171	10	may	may	AUX
ajlm-1720	171	11	however	however	ADV
ajlm-1720	171	12	be	be	AUX
ajlm-1720	171	13	a	a	DET
ajlm-1720	171	14	valuable	valuable	ADJ
ajlm-1720	171	15	adjunct	adjunct	ADJ
ajlm-1720	171	16	for	for	ADP
ajlm-1720	171	17	discerning	discern	VERB
ajlm-1720	171	18	normal	normal	ADJ
ajlm-1720	171	19	reactive	reactive	ADJ
ajlm-1720	171	20	b	b	NOUN
ajlm-1720	171	21	-	-	PUNCT
ajlm-1720	171	22	cell	cell	NOUN
ajlm-1720	171	23	precursors	precursor	NOUN
ajlm-1720	171	24	from	from	ADP
ajlm-1720	171	25	the	the	DET
ajlm-1720	171	26	minimal	minimal	ADJ
ajlm-1720	171	27	residual	residual	ADJ
ajlm-1720	171	28	disease	disease	NOUN
ajlm-1720	171	29	at	at	ADP
ajlm-1720	171	30	follow	follow	NOUN
ajlm-1720	171	31	-	-	PUNCT
ajlm-1720	171	32	up	up	NOUN
ajlm-1720	171	33	.	.	PUNCT
ajlm-1720	172	1	lastly	lastly	ADV
ajlm-1720	172	2	,	,	PUNCT
ajlm-1720	172	3	the	the	DET
ajlm-1720	172	4	potential	potential	ADJ
ajlm-1720	172	5	benefit	benefit	NOUN
ajlm-1720	172	6	of	of	ADP
ajlm-1720	172	7	using	use	VERB
ajlm-1720	172	8	commercialised	commercialise	VERB
ajlm-1720	172	9	multicolour	multicolour	ADJ
ajlm-1720	172	10	lyophilised	lyophilise	VERB
ajlm-1720	172	11	fixed	fix	VERB
ajlm-1720	172	12	panel	panel	NOUN
ajlm-1720	172	13	preparations	preparation	NOUN
ajlm-1720	172	14	having	have	VERB
ajlm-1720	172	15	stable	stable	ADJ
ajlm-1720	172	16	,	,	PUNCT
ajlm-1720	172	17	standardised	standardised	ADJ
ajlm-1720	172	18	antibody	antibody	NOUN
ajlm-1720	172	19	reagents	reagent	NOUN
ajlm-1720	172	20	reduces	reduce	VERB
ajlm-1720	172	21	the	the	DET
ajlm-1720	172	22	risks	risk	NOUN
ajlm-1720	172	23	of	of	ADP
ajlm-1720	172	24	technical	technical	ADJ
ajlm-1720	172	25	error	error	NOUN
ajlm-1720	172	26	,	,	PUNCT
ajlm-1720	172	27	improves	improve	VERB
ajlm-1720	172	28	laboratory	laboratory	NOUN
ajlm-1720	172	29	efficiency	efficiency	NOUN
ajlm-1720	172	30	,	,	PUNCT
ajlm-1720	172	31	and	and	CCONJ
ajlm-1720	172	32	simplifies	simplify	VERB
ajlm-1720	172	33	reagent	reagent	ADJ
ajlm-1720	172	34	inventory	inventory	NOUN
ajlm-1720	172	35	.	.	PUNCT
ajlm-1720	173	1	in	in	ADP
ajlm-1720	173	2	addition	addition	NOUN
ajlm-1720	173	3	,	,	PUNCT
ajlm-1720	173	4	the	the	DET
ajlm-1720	173	5	duraclone	duraclone	NOUN
ajlm-1720	173	6	‘	'	PUNCT
ajlm-1720	173	7	free	free	ADJ
ajlm-1720	173	8	fluorescence	fluorescence	NOUN
ajlm-1720	173	9	channels	channel	NOUN
ajlm-1720	173	10	’	'	PUNCT
ajlm-1720	173	11	provide	provide	VERB
ajlm-1720	173	12	some	some	DET
ajlm-1720	173	13	additional	additional	ADJ
ajlm-1720	173	14	flexibility	flexibility	NOUN
ajlm-1720	173	15	for	for	ADP
ajlm-1720	173	16	a	a	DET
ajlm-1720	173	17	laboratory	laboratory	NOUN
ajlm-1720	173	18	to	to	PART
ajlm-1720	173	19	use	use	VERB
ajlm-1720	173	20	their	their	PRON
ajlm-1720	173	21	preferred	prefer	VERB
ajlm-1720	173	22	markers	marker	NOUN
ajlm-1720	173	23	to	to	PART
ajlm-1720	173	24	establish	establish	VERB
ajlm-1720	173	25	diseases	disease	NOUN
ajlm-1720	173	26	(	(	PUNCT
ajlm-1720	173	27	or	or	CCONJ
ajlm-1720	173	28	not	not	PART
ajlm-1720	173	29	)	)	PUNCT
ajlm-1720	173	30	of	of	ADP
ajlm-1720	173	31	their	their	PRON
ajlm-1720	173	32	choice	choice	NOUN
ajlm-1720	173	33	.	.	PUNCT
ajlm-1720	174	1	acknowledgements	acknowledgement	NOUN
ajlm-1720	174	2	d.k.g	d.k.g	PROPN
ajlm-1720	174	3	.	.	PUNCT
ajlm-1720	175	1	and	and	CCONJ
ajlm-1720	175	2	d.l	d.l	PROPN
ajlm-1720	175	3	.	.	PROPN
ajlm-1720	175	4	thank	thank	PROPN
ajlm-1720	175	5	mrs	mrs	PROPN
ajlm-1720	175	6	merriam	merriam	PROPN
ajlm-1720	175	7	machaba	machaba	PROPN
ajlm-1720	175	8	at	at	ADP
ajlm-1720	175	9	charlotte	charlotte	PROPN
ajlm-1720	175	10	maxeke	maxeke	PROPN
ajlm-1720	175	11	johannesburg	johannesburg	PROPN
ajlm-1720	175	12	academic	academic	PROPN
ajlm-1720	175	13	hospital	hospital	PROPN
ajlm-1720	175	14	flow	flow	NOUN
ajlm-1720	175	15	cytometry	cytometry	NOUN
ajlm-1720	175	16	.	.	PUNCT
ajlm-1720	176	1	competing	compete	VERB
ajlm-1720	176	2	interests	interest	NOUN
ajlm-1720	176	3	the	the	DET
ajlm-1720	176	4	authors	author	NOUN
ajlm-1720	176	5	declare	declare	VERB
ajlm-1720	176	6	that	that	SCONJ
ajlm-1720	176	7	they	they	PRON
ajlm-1720	176	8	have	have	VERB
ajlm-1720	176	9	no	no	DET
ajlm-1720	176	10	financial	financial	ADJ
ajlm-1720	176	11	or	or	CCONJ
ajlm-1720	176	12	personal	personal	ADJ
ajlm-1720	176	13	relationships	relationship	NOUN
ajlm-1720	176	14	that	that	PRON
ajlm-1720	176	15	may	may	AUX
ajlm-1720	176	16	have	have	AUX
ajlm-1720	176	17	inappropriately	inappropriately	ADV
ajlm-1720	176	18	influenced	influence	VERB
ajlm-1720	176	19	them	they	PRON
ajlm-1720	176	20	in	in	ADP
ajlm-1720	176	21	writing	write	VERB
ajlm-1720	176	22	this	this	DET
ajlm-1720	176	23	article	article	NOUN
ajlm-1720	176	24	.	.	PUNCT
ajlm-1720	177	1	authors	author	NOUN
ajlm-1720	177	2	’	’	PART
ajlm-1720	177	3	contributions	contribution	NOUN
ajlm-1720	177	4	d.k.g	d.k.g	ADV
ajlm-1720	177	5	.	.	PUNCT
ajlm-1720	177	6	conceptualised	conceptualise	VERB
ajlm-1720	177	7	,	,	PUNCT
ajlm-1720	177	8	led	lead	VERB
ajlm-1720	177	9	and	and	CCONJ
ajlm-1720	177	10	funded	fund	VERB
ajlm-1720	177	11	the	the	DET
ajlm-1720	177	12	study	study	NOUN
ajlm-1720	177	13	,	,	PUNCT
ajlm-1720	177	14	provided	provide	VERB
ajlm-1720	177	15	project	project	NOUN
ajlm-1720	177	16	administration	administration	NOUN
ajlm-1720	177	17	and	and	CCONJ
ajlm-1720	177	18	project	project	NOUN
ajlm-1720	177	19	supervision	supervision	NOUN
ajlm-1720	177	20	as	as	ADV
ajlm-1720	177	21	well	well	ADV
ajlm-1720	177	22	as	as	ADP
ajlm-1720	177	23	supervision	supervision	NOUN
ajlm-1720	177	24	of	of	ADP
ajlm-1720	177	25	all	all	DET
ajlm-1720	177	26	laboratory	laboratory	NOUN
ajlm-1720	177	27	testing	testing	NOUN
ajlm-1720	177	28	and	and	CCONJ
ajlm-1720	177	29	data	datum	NOUN
ajlm-1720	177	30	analysis	analysis	NOUN
ajlm-1720	177	31	.	.	PUNCT
ajlm-1720	178	1	d.l	d.l	PROPN
ajlm-1720	178	2	.	.	PROPN
ajlm-1720	179	1	and	and	CCONJ
ajlm-1720	179	2	d.k.g	d.k.g	PROPN
ajlm-1720	179	3	.	.	PUNCT
ajlm-1720	180	1	oversaw	oversaw	PROPN
ajlm-1720	180	2	technical	technical	ADJ
ajlm-1720	180	3	aspects	aspect	NOUN
ajlm-1720	180	4	and	and	CCONJ
ajlm-1720	180	5	the	the	DET
ajlm-1720	180	6	setup	setup	NOUN
ajlm-1720	180	7	of	of	ADP
ajlm-1720	180	8	protocols	protocol	NOUN
ajlm-1720	180	9	for	for	ADP
ajlm-1720	180	10	flow	flow	NOUN
ajlm-1720	180	11	cytometric	cytometric	ADJ
ajlm-1720	180	12	data	datum	NOUN
ajlm-1720	180	13	acquisition	acquisition	NOUN
ajlm-1720	180	14	and	and	CCONJ
ajlm-1720	180	15	data	datum	NOUN
ajlm-1720	180	16	analysis	analysis	NOUN
ajlm-1720	180	17	.	.	PUNCT
ajlm-1720	181	1	l.s	l.s	NOUN
ajlm-1720	181	2	.	.	PROPN
ajlm-1720	182	1	and	and	CCONJ
ajlm-1720	182	2	m.p	m.p	PROPN
ajlm-1720	182	3	.	.	PROPN
ajlm-1720	182	4	analysed	analyse	VERB
ajlm-1720	182	5	flow	flow	NOUN
ajlm-1720	182	6	cytometric	cytometric	ADJ
ajlm-1720	182	7	data	datum	NOUN
ajlm-1720	182	8	and	and	CCONJ
ajlm-1720	182	9	recorded	record	VERB
ajlm-1720	182	10	the	the	DET
ajlm-1720	182	11	outcomes	outcome	NOUN
ajlm-1720	182	12	in	in	ADP
ajlm-1720	182	13	spreadsheets	spreadsheet	NOUN
ajlm-1720	182	14	for	for	ADP
ajlm-1720	182	15	analysis	analysis	NOUN
ajlm-1720	182	16	comparison	comparison	NOUN
ajlm-1720	182	17	.	.	PUNCT
ajlm-1720	183	1	d.k.g	d.k.g	ADJ
ajlm-1720	183	2	.	.	PUNCT
ajlm-1720	184	1	undertook	undertake	VERB
ajlm-1720	184	2	final	final	ADJ
ajlm-1720	184	3	checking	checking	NOUN
ajlm-1720	184	4	of	of	ADP
ajlm-1720	184	5	data	datum	NOUN
ajlm-1720	184	6	and	and	CCONJ
ajlm-1720	184	7	compiled	compile	VERB
ajlm-1720	184	8	the	the	DET
ajlm-1720	184	9	final	final	ADJ
ajlm-1720	184	10	laboratory	laboratory	NOUN
ajlm-1720	184	11	validation	validation	NOUN
ajlm-1720	184	12	report	report	NOUN
ajlm-1720	184	13	.	.	PUNCT
ajlm-1720	185	1	l.s	l.s	NOUN
ajlm-1720	185	2	.	.	PROPN
ajlm-1720	185	3	and	and	CCONJ
ajlm-1720	185	4	d.k.g	d.k.g	PROPN
ajlm-1720	185	5	.	.	PROPN
ajlm-1720	185	6	translated	translate	VERB
ajlm-1720	185	7	the	the	DET
ajlm-1720	185	8	validation	validation	NOUN
ajlm-1720	185	9	report	report	NOUN
ajlm-1720	185	10	into	into	ADP
ajlm-1720	185	11	a	a	DET
ajlm-1720	185	12	first	first	ADJ
ajlm-1720	185	13	draft	draft	NOUN
ajlm-1720	185	14	for	for	ADP
ajlm-1720	185	15	publication	publication	NOUN
ajlm-1720	185	16	format	format	NOUN
ajlm-1720	185	17	.	.	PUNCT
ajlm-1720	186	1	all	all	DET
ajlm-1720	186	2	subsequent	subsequent	ADJ
ajlm-1720	186	3	drafts	draft	NOUN
ajlm-1720	186	4	were	be	AUX
ajlm-1720	186	5	written	write	VERB
ajlm-1720	186	6	by	by	ADP
ajlm-1720	186	7	d.k.g	d.k.g	NOUN
ajlm-1720	186	8	.	.	PUNCT
ajlm-1720	187	1	sources	source	NOUN
ajlm-1720	187	2	of	of	ADP
ajlm-1720	187	3	support	support	NOUN
ajlm-1720	187	4	funding	funding	NOUN
ajlm-1720	187	5	for	for	ADP
ajlm-1720	187	6	this	this	DET
ajlm-1720	187	7	study	study	NOUN
ajlm-1720	187	8	was	be	AUX
ajlm-1720	187	9	made	make	VERB
ajlm-1720	187	10	possible	possible	ADJ
ajlm-1720	187	11	with	with	ADP
ajlm-1720	187	12	research	research	NOUN
ajlm-1720	187	13	incentive	incentive	NOUN
ajlm-1720	187	14	funds	fund	NOUN
ajlm-1720	187	15	accrued	accrue	VERB
ajlm-1720	187	16	to	to	PART
ajlm-1720	187	17	d.k.g	d.k.g	VERB
ajlm-1720	187	18	.	.	PUNCT
ajlm-1720	188	1	through	through	ADP
ajlm-1720	188	2	the	the	DET
ajlm-1720	188	3	university	university	NOUN
ajlm-1720	188	4	of	of	ADP
ajlm-1720	188	5	the	the	DET
ajlm-1720	188	6	witwatersrand	witwatersrand	NOUN
ajlm-1720	188	7	.	.	PUNCT
ajlm-1720	189	1	data	datum	NOUN
ajlm-1720	189	2	availability	availability	NOUN
ajlm-1720	189	3	all	all	DET
ajlm-1720	189	4	outcomes	outcome	NOUN
ajlm-1720	189	5	are	be	AUX
ajlm-1720	189	6	anonymised	anonymise	VERB
ajlm-1720	189	7	and	and	CCONJ
ajlm-1720	189	8	published	publish	VERB
ajlm-1720	189	9	in	in	ADP
ajlm-1720	189	10	the	the	DET
ajlm-1720	189	11	maunscript	maunscript	NOUN
ajlm-1720	189	12	.	.	PUNCT
ajlm-1720	190	1	individal	individal	ADJ
ajlm-1720	190	2	raw	raw	ADJ
ajlm-1720	190	3	flow	flow	NOUN
ajlm-1720	190	4	cytometric	cytometric	PROPN
ajlm-1720	190	5	listmode	listmode	PROPN
ajlm-1720	190	6	data	datum	NOUN
ajlm-1720	190	7	files	file	NOUN
ajlm-1720	190	8	are	be	AUX
ajlm-1720	190	9	available	available	ADJ
ajlm-1720	190	10	on	on	ADP
ajlm-1720	190	11	request	request	NOUN
ajlm-1720	190	12	from	from	ADP
ajlm-1720	190	13	the	the	DET
ajlm-1720	190	14	corresponding	corresponding	ADJ
ajlm-1720	190	15	author	author	NOUN
ajlm-1720	190	16	,	,	PUNCT
ajlm-1720	190	17	d.k.g	d.k.g	PROPN
ajlm-1720	190	18	.	.	PUNCT
ajlm-1720	191	1	disclaimer	disclaimer	VERB
ajlm-1720	191	2	the	the	DET
ajlm-1720	191	3	views	view	NOUN
ajlm-1720	191	4	and	and	CCONJ
ajlm-1720	191	5	opinions	opinion	NOUN
ajlm-1720	191	6	expressed	express	VERB
ajlm-1720	191	7	in	in	ADP
ajlm-1720	191	8	this	this	DET
ajlm-1720	191	9	article	article	NOUN
ajlm-1720	191	10	are	be	AUX
ajlm-1720	191	11	those	those	PRON
ajlm-1720	191	12	of	of	ADP
ajlm-1720	191	13	the	the	DET
ajlm-1720	191	14	authors	author	NOUN
ajlm-1720	191	15	and	and	CCONJ
ajlm-1720	191	16	do	do	AUX
ajlm-1720	191	17	not	not	PART
ajlm-1720	191	18	necessarily	necessarily	ADV
ajlm-1720	191	19	reflect	reflect	VERB
ajlm-1720	191	20	the	the	DET
ajlm-1720	191	21	official	official	ADJ
ajlm-1720	191	22	policy	policy	NOUN
ajlm-1720	191	23	or	or	CCONJ
ajlm-1720	191	24	position	position	NOUN
ajlm-1720	191	25	of	of	ADP
ajlm-1720	191	26	any	any	PRON
ajlm-1720	191	27	of	of	ADP
ajlm-1720	191	28	the	the	DET
ajlm-1720	191	29	affiliated	affiliated	ADJ
ajlm-1720	191	30	agencies	agency	NOUN
ajlm-1720	191	31	of	of	ADP
ajlm-1720	191	32	the	the	DET
ajlm-1720	191	33	authors	author	NOUN
ajlm-1720	191	34	.	.	PUNCT
ajlm-1720	192	1	references	reference	NOUN
ajlm-1720	192	2	borowitz	borowitz	PROPN
ajlm-1720	192	3	mj	mj	PROPN
ajlm-1720	192	4	,	,	PUNCT
ajlm-1720	192	5	wood	wood	PROPN
ajlm-1720	192	6	bl	bl	PROPN
ajlm-1720	192	7	,	,	PUNCT
ajlm-1720	192	8	devidas	devidas	PROPN
ajlm-1720	192	9	m	m	PRON
ajlm-1720	192	10	,	,	PUNCT
ajlm-1720	192	11	et	et	PROPN
ajlm-1720	192	12	al	al	PROPN
ajlm-1720	192	13	.	.	PUNCT
ajlm-1720	193	1	prognostic	prognostic	ADJ
ajlm-1720	193	2	significance	significance	NOUN
ajlm-1720	193	3	of	of	ADP
ajlm-1720	193	4	minimal	minimal	ADJ
ajlm-1720	193	5	residual	residual	ADJ
ajlm-1720	193	6	disease	disease	NOUN
ajlm-1720	193	7	in	in	ADP
ajlm-1720	193	8	high	high	ADJ
ajlm-1720	193	9	risk	risk	NOUN
ajlm-1720	193	10	b	b	NOUN
ajlm-1720	193	11	-	-	PUNCT
ajlm-1720	193	12	all	all	PRON
ajlm-1720	193	13	:	:	PUNCT
ajlm-1720	193	14	a	a	DET
ajlm-1720	193	15	report	report	NOUN
ajlm-1720	193	16	from	from	ADP
ajlm-1720	193	17	children	child	NOUN
ajlm-1720	193	18	’s	’s	PART
ajlm-1720	193	19	oncology	oncology	NOUN
ajlm-1720	193	20	group	group	PROPN
ajlm-1720	193	21	study	study	PROPN
ajlm-1720	193	22	aall0232	aall0232	PROPN
ajlm-1720	193	23	.	.	PUNCT
ajlm-1720	194	1	blood	blood	NOUN
ajlm-1720	194	2	.	.	PUNCT
ajlm-1720	195	1	2015;126(8):964–971	2015;126(8):964–971	NUM
ajlm-1720	195	2	.	.	PUNCT
ajlm-1720	195	3	https://doi.org/10.1182/blood-2015-03-633685	https://doi.org/10.1182/blood-2015-03-633685	NUM
ajlm-1720	195	4	theunissen	theunissen	ADJ
ajlm-1720	195	5	p	p	NOUN
ajlm-1720	195	6	,	,	PUNCT
ajlm-1720	195	7	mejstrikova	mejstrikova	PROPN
ajlm-1720	195	8	e	e	PROPN
ajlm-1720	195	9	,	,	PUNCT
ajlm-1720	195	10	sedek	sedek	NOUN
ajlm-1720	195	11	l	l	PROPN
ajlm-1720	195	12	,	,	PUNCT
ajlm-1720	195	13	et	et	PROPN
ajlm-1720	195	14	al	al	PROPN
ajlm-1720	195	15	.	.	PROPN
ajlm-1720	195	16	standardized	standardize	VERB
ajlm-1720	195	17	flow	flow	NOUN
ajlm-1720	195	18	cytometry	cytometry	NOUN
ajlm-1720	195	19	for	for	ADP
ajlm-1720	195	20	highly	highly	ADV
ajlm-1720	195	21	sensitive	sensitive	ADJ
ajlm-1720	195	22	mrd	mrd	ADJ
ajlm-1720	195	23	measurements	measurement	NOUN
ajlm-1720	195	24	in	in	ADP
ajlm-1720	195	25	b	b	NOUN
ajlm-1720	195	26	-	-	PUNCT
ajlm-1720	195	27	cell	cell	NOUN
ajlm-1720	195	28	acute	acute	ADJ
ajlm-1720	195	29	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	195	30	leukemia	leukemia	NOUN
ajlm-1720	195	31	.	.	PUNCT
ajlm-1720	196	1	blood	blood	NOUN
ajlm-1720	196	2	.	.	PUNCT
ajlm-1720	197	1	2017;129(3):347–357	2017;129(3):347–357	X
ajlm-1720	197	2	.	.	PUNCT
ajlm-1720	197	3	https://doi.org/10.1182/blood-2016-07-726307	https://doi.org/10.1182/blood-2016-07-726307	NUM
ajlm-1720	197	4	van	van	PROPN
ajlm-1720	197	5	dongen	dongen	PROPN
ajlm-1720	197	6	jj	jj	PROPN
ajlm-1720	197	7	,	,	PUNCT
ajlm-1720	197	8	lhermitte	lhermitte	PROPN
ajlm-1720	197	9	l	l	PROPN
ajlm-1720	197	10	,	,	PUNCT
ajlm-1720	197	11	bottcher	bottcher	PROPN
ajlm-1720	197	12	s	s	PROPN
ajlm-1720	197	13	,	,	PUNCT
ajlm-1720	197	14	et	et	PROPN
ajlm-1720	197	15	al	al	PROPN
ajlm-1720	197	16	.	.	PROPN
ajlm-1720	197	17	euroflow	euroflow	ADJ
ajlm-1720	197	18	antibody	antibody	NOUN
ajlm-1720	197	19	panels	panel	NOUN
ajlm-1720	197	20	for	for	ADP
ajlm-1720	197	21	standardized	standardized	ADJ
ajlm-1720	197	22	n	n	CCONJ
ajlm-1720	197	23	-	-	PUNCT
ajlm-1720	197	24	dimensional	dimensional	ADJ
ajlm-1720	197	25	flow	flow	NOUN
ajlm-1720	197	26	cytometric	cytometric	ADJ
ajlm-1720	197	27	immunophenotyping	immunophenotyping	NOUN
ajlm-1720	197	28	of	of	ADP
ajlm-1720	197	29	normal	normal	ADJ
ajlm-1720	197	30	,	,	PUNCT
ajlm-1720	197	31	reactive	reactive	ADJ
ajlm-1720	197	32	and	and	CCONJ
ajlm-1720	197	33	malignant	malignant	ADJ
ajlm-1720	197	34	leukocytes	leukocyte	NOUN
ajlm-1720	197	35	.	.	PUNCT
ajlm-1720	198	1	leukemia	leukemia	NOUN
ajlm-1720	198	2	.	.	PUNCT
ajlm-1720	199	1	2012;26(9):1908–1975	2012;26(9):1908–1975	NUM
ajlm-1720	199	2	.	.	PUNCT
ajlm-1720	200	1	https://doi.org/10.1038/leu.2012.120	https://doi.org/10.1038/leu.2012.120	PROPN
ajlm-1720	200	2	kalina	kalina	PROPN
ajlm-1720	200	3	t	t	PROPN
ajlm-1720	200	4	,	,	PUNCT
ajlm-1720	200	5	flores	flores	PROPN
ajlm-1720	200	6	-	-	PUNCT
ajlm-1720	200	7	montero	montero	PROPN
ajlm-1720	200	8	j	j	PROPN
ajlm-1720	200	9	,	,	PUNCT
ajlm-1720	200	10	van	van	PROPN
ajlm-1720	200	11	der	der	PROPN
ajlm-1720	200	12	velden	velden	PROPN
ajlm-1720	200	13	vh	vh	PROPN
ajlm-1720	200	14	,	,	PUNCT
ajlm-1720	200	15	et	et	PROPN
ajlm-1720	200	16	al	al	PROPN
ajlm-1720	200	17	.	.	PROPN
ajlm-1720	200	18	euroflow	euroflow	ADJ
ajlm-1720	200	19	standardization	standardization	NOUN
ajlm-1720	200	20	of	of	ADP
ajlm-1720	200	21	flow	flow	NOUN
ajlm-1720	200	22	cytometer	cytometer	NOUN
ajlm-1720	200	23	instrument	instrument	NOUN
ajlm-1720	200	24	settings	setting	NOUN
ajlm-1720	200	25	and	and	CCONJ
ajlm-1720	200	26	immunophenotyping	immunophenotype	VERB
ajlm-1720	200	27	protocols	protocol	NOUN
ajlm-1720	200	28	.	.	PUNCT
ajlm-1720	201	1	leukemia	leukemia	NOUN
ajlm-1720	201	2	.	.	PUNCT
ajlm-1720	202	1	2012;26(9):1986–2010	2012;26(9):1986–2010	NUM
ajlm-1720	202	2	.	.	PUNCT
ajlm-1720	203	1	https://doi.org/10.1038/leu.2012.122	https://doi.org/10.1038/leu.2012.122	X
ajlm-1720	203	2	glier	glier	ADJ
ajlm-1720	203	3	h	h	NOUN
ajlm-1720	203	4	,	,	PUNCT
ajlm-1720	203	5	heijnen	heijnen	PROPN
ajlm-1720	204	1	i	i	PRON
ajlm-1720	204	2	,	,	PUNCT
ajlm-1720	204	3	hauwel	hauwel	PROPN
ajlm-1720	204	4	m	m	PROPN
ajlm-1720	204	5	,	,	PUNCT
ajlm-1720	204	6	et	et	PROPN
ajlm-1720	204	7	al	al	PROPN
ajlm-1720	204	8	.	.	PUNCT
ajlm-1720	204	9	standardization	standardization	NOUN
ajlm-1720	204	10	of	of	ADP
ajlm-1720	204	11	8	8	NUM
ajlm-1720	204	12	-	-	PUNCT
ajlm-1720	204	13	color	color	NOUN
ajlm-1720	204	14	flow	flow	NOUN
ajlm-1720	204	15	cytometry	cytometry	NOUN
ajlm-1720	204	16	across	across	ADP
ajlm-1720	204	17	different	different	ADJ
ajlm-1720	204	18	flow	flow	NOUN
ajlm-1720	204	19	cytometer	cytometer	NOUN
ajlm-1720	204	20	instruments	instrument	NOUN
ajlm-1720	204	21	:	:	PUNCT
ajlm-1720	204	22	a	a	DET
ajlm-1720	204	23	feasibility	feasibility	NOUN
ajlm-1720	204	24	study	study	NOUN
ajlm-1720	204	25	in	in	ADP
ajlm-1720	204	26	clinical	clinical	ADJ
ajlm-1720	204	27	laboratories	laboratory	NOUN
ajlm-1720	204	28	in	in	ADP
ajlm-1720	204	29	switzerland	switzerland	PROPN
ajlm-1720	204	30	.	.	PUNCT
ajlm-1720	205	1	j	j	PROPN
ajlm-1720	205	2	immunol	immunol	NOUN
ajlm-1720	205	3	methods	method	NOUN
ajlm-1720	205	4	.	.	PUNCT
ajlm-1720	206	1	2019;475:112348	2019;475:112348	NUM
ajlm-1720	206	2	.	.	PUNCT
ajlm-1720	207	1	https://doi.org/10.1016/j.jim.2017.07.013	https://doi.org/10.1016/j.jim.2017.07.013	PROPN
ajlm-1720	207	2	kalina	kalina	PROPN
ajlm-1720	207	3	t	t	PROPN
ajlm-1720	207	4	,	,	PUNCT
ajlm-1720	207	5	brdickova	brdickova	PROPN
ajlm-1720	207	6	n	n	CCONJ
ajlm-1720	207	7	,	,	PUNCT
ajlm-1720	207	8	glier	glier	ADJ
ajlm-1720	207	9	h	h	NOUN
ajlm-1720	207	10	,	,	PUNCT
ajlm-1720	207	11	et	et	PROPN
ajlm-1720	207	12	al	al	PROPN
ajlm-1720	207	13	.	.	PUNCT
ajlm-1720	207	14	frequent	frequent	ADJ
ajlm-1720	207	15	issues	issue	NOUN
ajlm-1720	207	16	and	and	CCONJ
ajlm-1720	207	17	lessons	lesson	NOUN
ajlm-1720	207	18	learned	learn	VERB
ajlm-1720	207	19	from	from	ADP
ajlm-1720	207	20	euroflow	euroflow	PROPN
ajlm-1720	207	21	qa	qa	PROPN
ajlm-1720	207	22	.	.	PUNCT
ajlm-1720	208	1	j	j	PROPN
ajlm-1720	208	2	immunol	immunol	NOUN
ajlm-1720	208	3	methods	method	NOUN
ajlm-1720	208	4	.	.	PUNCT
ajlm-1720	209	1	2019;475:112520	2019;475:112520	X
ajlm-1720	209	2	.	.	PUNCT
ajlm-1720	210	1	https://doi.org/10.1016/j.jim.2018.09.008	https://doi.org/10.1016/j.jim.2018.09.008	PROPN
ajlm-1720	210	2	davis	davis	PROPN
ajlm-1720	210	3	bh	bh	PROPN
ajlm-1720	210	4	,	,	PUNCT
ajlm-1720	210	5	holden	holden	PROPN
ajlm-1720	210	6	jt	jt	PROPN
ajlm-1720	210	7	,	,	PUNCT
ajlm-1720	210	8	bene	bene	PROPN
ajlm-1720	210	9	mc	mc	PROPN
ajlm-1720	210	10	,	,	PUNCT
ajlm-1720	210	11	et	et	PROPN
ajlm-1720	210	12	al	al	PROPN
ajlm-1720	210	13	.	.	PROPN
ajlm-1720	210	14	2006	2006	NUM
ajlm-1720	210	15	bethesda	bethesda	PROPN
ajlm-1720	210	16	international	international	ADJ
ajlm-1720	210	17	consensus	consensus	NOUN
ajlm-1720	210	18	recommendations	recommendation	NOUN
ajlm-1720	210	19	on	on	ADP
ajlm-1720	210	20	the	the	DET
ajlm-1720	210	21	flow	flow	NOUN
ajlm-1720	210	22	cytometric	cytometric	ADJ
ajlm-1720	210	23	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	210	24	analysis	analysis	NOUN
ajlm-1720	210	25	of	of	ADP
ajlm-1720	210	26	hematolymphoid	hematolymphoid	ADJ
ajlm-1720	210	27	neoplasia	neoplasia	NOUN
ajlm-1720	210	28	:	:	PUNCT
ajlm-1720	210	29	medical	medical	ADJ
ajlm-1720	210	30	indications	indication	NOUN
ajlm-1720	210	31	.	.	PUNCT
ajlm-1720	211	1	cytometry	cytometry	PROPN
ajlm-1720	211	2	b	b	PROPN
ajlm-1720	211	3	clin	clin	PROPN
ajlm-1720	211	4	cytom	cytom	PROPN
ajlm-1720	211	5	.	.	PUNCT
ajlm-1720	212	1	2007;72	2007;72	NUM
ajlm-1720	212	2	suppl	suppl	ADJ
ajlm-1720	212	3	1	1	NUM
ajlm-1720	212	4	:	:	PUNCT
ajlm-1720	212	5	s5	s5	PROPN
ajlm-1720	212	6	–	–	PUNCT
ajlm-1720	212	7	s13	s13	NOUN
ajlm-1720	212	8	.	.	PUNCT
ajlm-1720	213	1	https://doi.org/10.1002/cyto.b.20365	https://doi.org/10.1002/cyto.b.20365	VERB
ajlm-1720	213	2	hedley	hedley	PROPN
ajlm-1720	213	3	bd	bd	PROPN
ajlm-1720	213	4	,	,	PUNCT
ajlm-1720	213	5	cheng	cheng	PROPN
ajlm-1720	213	6	g	g	PROPN
ajlm-1720	213	7	,	,	PUNCT
ajlm-1720	213	8	luider	luider	PROPN
ajlm-1720	213	9	j	j	PROPN
ajlm-1720	213	10	,	,	PUNCT
ajlm-1720	213	11	et	et	PROPN
ajlm-1720	213	12	al	al	PROPN
ajlm-1720	213	13	.	.	PROPN
ajlm-1720	214	1	initial	initial	ADJ
ajlm-1720	214	2	flow	flow	NOUN
ajlm-1720	214	3	cytometric	cytometric	ADJ
ajlm-1720	214	4	evaluation	evaluation	NOUN
ajlm-1720	214	5	of	of	ADP
ajlm-1720	214	6	the	the	DET
ajlm-1720	214	7	clearllab	clearllab	NOUN
ajlm-1720	214	8	lymphoid	lymphoid	NOUN
ajlm-1720	214	9	screen	screen	NOUN
ajlm-1720	214	10	.	.	PUNCT
ajlm-1720	215	1	cytometry	cytometry	PROPN
ajlm-1720	215	2	b	b	PROPN
ajlm-1720	215	3	clin	clin	PROPN
ajlm-1720	215	4	cytom	cytom	PROPN
ajlm-1720	215	5	.	.	PUNCT
ajlm-1720	216	1	2018;94(5):707–713	2018;94(5):707–713	NUM
ajlm-1720	216	2	.	.	PUNCT
ajlm-1720	216	3	https://doi.org/10.1002/cyto.b.21603	https://doi.org/10.1002/cyto.b.21603	VERB
ajlm-1720	216	4	hedley	hedley	PROPN
ajlm-1720	216	5	bd	bd	PROPN
ajlm-1720	216	6	,	,	PUNCT
ajlm-1720	216	7	cheng	cheng	PROPN
ajlm-1720	216	8	g	g	PROPN
ajlm-1720	216	9	,	,	PUNCT
ajlm-1720	216	10	keeney	keeney	PROPN
ajlm-1720	216	11	m	m	PROPN
ajlm-1720	216	12	,	,	PUNCT
ajlm-1720	216	13	et	et	PROPN
ajlm-1720	216	14	al	al	PROPN
ajlm-1720	216	15	.	.	PUNCT
ajlm-1720	217	1	a	a	DET
ajlm-1720	217	2	multicenter	multicenter	ADJ
ajlm-1720	217	3	study	study	NOUN
ajlm-1720	217	4	evaluation	evaluation	NOUN
ajlm-1720	217	5	of	of	ADP
ajlm-1720	217	6	the	the	DET
ajlm-1720	217	7	clearllab	clearllab	NOUN
ajlm-1720	217	8	10c	10c	NUM
ajlm-1720	217	9	panels	panel	NOUN
ajlm-1720	217	10	.	.	PUNCT
ajlm-1720	218	1	cytometry	cytometry	PROPN
ajlm-1720	218	2	b	b	PROPN
ajlm-1720	218	3	clin	clin	PROPN
ajlm-1720	218	4	cytom	cytom	PROPN
ajlm-1720	218	5	.	.	PUNCT
ajlm-1720	219	1	2020	2020	NUM
ajlm-1720	219	2	.	.	PUNCT
ajlm-1720	220	1	flores	flores	PROPN
ajlm-1720	220	2	-	-	PUNCT
ajlm-1720	220	3	montero	montero	PROPN
ajlm-1720	220	4	j	j	PROPN
ajlm-1720	220	5	,	,	PUNCT
ajlm-1720	220	6	grigore	grigore	VERB
ajlm-1720	220	7	g	g	NOUN
ajlm-1720	220	8	,	,	PUNCT
ajlm-1720	220	9	fluxa	fluxa	NOUN
ajlm-1720	220	10	r	r	NOUN
ajlm-1720	220	11	,	,	PUNCT
ajlm-1720	220	12	et	et	PROPN
ajlm-1720	220	13	al	al	PROPN
ajlm-1720	220	14	.	.	PROPN
ajlm-1720	220	15	euroflow	euroflow	PROPN
ajlm-1720	220	16	lymphoid	lymphoid	NOUN
ajlm-1720	220	17	screening	screen	VERB
ajlm-1720	220	18	tube	tube	NOUN
ajlm-1720	220	19	(	(	PUNCT
ajlm-1720	220	20	lst	lst	NOUN
ajlm-1720	220	21	)	)	PUNCT
ajlm-1720	220	22	data	datum	NOUN
ajlm-1720	220	23	base	base	NOUN
ajlm-1720	220	24	for	for	ADP
ajlm-1720	220	25	automated	automate	VERB
ajlm-1720	220	26	identification	identification	NOUN
ajlm-1720	220	27	of	of	ADP
ajlm-1720	220	28	blood	blood	NOUN
ajlm-1720	220	29	lymphocyte	lymphocyte	ADJ
ajlm-1720	220	30	subsets	subset	NOUN
ajlm-1720	220	31	.	.	PUNCT
ajlm-1720	221	1	j	j	PROPN
ajlm-1720	221	2	immunol	immunol	NOUN
ajlm-1720	221	3	methods	method	NOUN
ajlm-1720	221	4	.	.	PUNCT
ajlm-1720	222	1	2019;475:112662	2019;475:112662	NUM
ajlm-1720	222	2	.	.	PUNCT
ajlm-1720	223	1	https://doi.org/10.1016/j.jim.2019.112662	https://doi.org/10.1016/j.jim.2019.112662	X
ajlm-1720	223	2	hedley	hedley	PROPN
ajlm-1720	223	3	bd	bd	PROPN
ajlm-1720	223	4	,	,	PUNCT
ajlm-1720	223	5	keeney	keeney	PROPN
ajlm-1720	223	6	m	m	PROPN
ajlm-1720	223	7	,	,	PUNCT
ajlm-1720	223	8	popma	popma	PROPN
ajlm-1720	223	9	j	j	PROPN
ajlm-1720	223	10	,	,	PUNCT
ajlm-1720	223	11	chin	chin	PROPN
ajlm-1720	223	12	-	-	PUNCT
ajlm-1720	223	13	yee	yee	PROPN
ajlm-1720	223	14	i.	i.	PROPN
ajlm-1720	223	15	novel	novel	PROPN
ajlm-1720	223	16	lymphocyte	lymphocyte	NOUN
ajlm-1720	223	17	screening	screen	VERB
ajlm-1720	223	18	tube	tube	NOUN
ajlm-1720	223	19	using	use	VERB
ajlm-1720	223	20	dried	dry	VERB
ajlm-1720	223	21	monoclonal	monoclonal	NOUN
ajlm-1720	223	22	antibody	antibody	NOUN
ajlm-1720	223	23	reagents	reagent	NOUN
ajlm-1720	223	24	.	.	PUNCT
ajlm-1720	224	1	cytometry	cytometry	PROPN
ajlm-1720	224	2	b	b	PROPN
ajlm-1720	224	3	clin	clin	PROPN
ajlm-1720	224	4	cytom	cytom	PROPN
ajlm-1720	224	5	.	.	PUNCT
ajlm-1720	225	1	2015;88(6):361–370	2015;88(6):361–370	NUM
ajlm-1720	225	2	.	.	PUNCT
ajlm-1720	226	1	https://doi.org/10.1002/cyto.b.21251	https://doi.org/10.1002/cyto.b.21251	X
ajlm-1720	226	2	van	van	PROPN
ajlm-1720	226	3	der	der	PROPN
ajlm-1720	226	4	velden	velden	PROPN
ajlm-1720	226	5	vhj	vhj	PROPN
ajlm-1720	226	6	,	,	PUNCT
ajlm-1720	226	7	flores	flores	PROPN
ajlm-1720	226	8	-	-	PUNCT
ajlm-1720	226	9	montero	montero	PROPN
ajlm-1720	226	10	j	j	PROPN
ajlm-1720	226	11	,	,	PUNCT
ajlm-1720	226	12	perez	perez	PROPN
ajlm-1720	226	13	-	-	PUNCT
ajlm-1720	226	14	andres	andres	PROPN
ajlm-1720	226	15	m	m	PROPN
ajlm-1720	226	16	,	,	PUNCT
ajlm-1720	226	17	et	et	PROPN
ajlm-1720	226	18	al	al	PROPN
ajlm-1720	226	19	.	.	PUNCT
ajlm-1720	226	20	optimization	optimization	NOUN
ajlm-1720	226	21	and	and	CCONJ
ajlm-1720	226	22	testing	testing	NOUN
ajlm-1720	226	23	of	of	ADP
ajlm-1720	226	24	dried	dry	VERB
ajlm-1720	226	25	antibody	antibody	NOUN
ajlm-1720	226	26	tube	tube	NOUN
ajlm-1720	226	27	:	:	PUNCT
ajlm-1720	226	28	the	the	DET
ajlm-1720	226	29	euroflow	euroflow	ADJ
ajlm-1720	226	30	lst	lst	NOUN
ajlm-1720	226	31	and	and	CCONJ
ajlm-1720	226	32	pidot	pidot	NOUN
ajlm-1720	226	33	tubes	tube	NOUN
ajlm-1720	226	34	as	as	ADP
ajlm-1720	226	35	examples	example	NOUN
ajlm-1720	226	36	.	.	PUNCT
ajlm-1720	227	1	j	j	PROPN
ajlm-1720	227	2	immunol	immunol	NOUN
ajlm-1720	227	3	methods	method	NOUN
ajlm-1720	227	4	.	.	PUNCT
ajlm-1720	228	1	2019;475:112287	2019;475:112287	NUM
ajlm-1720	228	2	.	.	PUNCT
ajlm-1720	229	1	https://doi.org/10.1016/j.jim.2017.03.011	https://doi.org/10.1016/j.jim.2017.03.011	PROPN
ajlm-1720	229	2	correia	correia	PROPN
ajlm-1720	229	3	rp	rp	PROPN
ajlm-1720	229	4	,	,	PUNCT
ajlm-1720	229	5	rajab	rajab	VERB
ajlm-1720	229	6	a	a	PRON
ajlm-1720	229	7	,	,	PUNCT
ajlm-1720	229	8	bento	bento	NOUN
ajlm-1720	229	9	lc	lc	PROPN
ajlm-1720	229	10	,	,	PUNCT
ajlm-1720	229	11	et	et	PROPN
ajlm-1720	229	12	al	al	PROPN
ajlm-1720	229	13	.	.	PUNCT
ajlm-1720	230	1	a	a	DET
ajlm-1720	230	2	ten	ten	NUM
ajlm-1720	230	3	-	-	PUNCT
ajlm-1720	230	4	color	color	NOUN
ajlm-1720	230	5	tube	tube	NOUN
ajlm-1720	230	6	with	with	ADP
ajlm-1720	230	7	dried	dry	VERB
ajlm-1720	230	8	antibody	antibody	NOUN
ajlm-1720	230	9	reagents	reagent	NOUN
ajlm-1720	230	10	for	for	ADP
ajlm-1720	230	11	the	the	DET
ajlm-1720	230	12	screening	screening	NOUN
ajlm-1720	230	13	of	of	ADP
ajlm-1720	230	14	hematological	hematological	ADJ
ajlm-1720	230	15	malignancies	malignancy	NOUN
ajlm-1720	230	16	.	.	PUNCT
ajlm-1720	231	1	int	int	PROPN
ajlm-1720	231	2	j	j	PROPN
ajlm-1720	231	3	lab	lab	NOUN
ajlm-1720	231	4	hematol	hematol	NOUN
ajlm-1720	231	5	.	.	PUNCT
ajlm-1720	232	1	2018;40(2):136–143	2018;40(2):136–143	X
ajlm-1720	232	2	.	.	PUNCT
ajlm-1720	232	3	https://doi.org/10.1111/ijlh.12753	https://doi.org/10.1111/ijlh.12753	PROPN
ajlm-1720	232	4	bouriche	bouriche	PROPN
ajlm-1720	232	5	l	l	NOUN
ajlm-1720	232	6	,	,	PUNCT
ajlm-1720	232	7	bernot	bernot	VERB
ajlm-1720	232	8	d	d	NOUN
ajlm-1720	232	9	,	,	PUNCT
ajlm-1720	232	10	nivaggioni	nivaggioni	ADJ
ajlm-1720	232	11	v	v	NOUN
ajlm-1720	232	12	,	,	PUNCT
ajlm-1720	232	13	arnoux	arnoux	NOUN
ajlm-1720	232	14	i	i	PRON
ajlm-1720	232	15	,	,	PUNCT
ajlm-1720	232	16	loosveld	loosveld	PROPN
ajlm-1720	232	17	m.	m.	NOUN
ajlm-1720	232	18	detection	detection	NOUN
ajlm-1720	232	19	of	of	ADP
ajlm-1720	232	20	minimal	minimal	ADJ
ajlm-1720	232	21	residual	residual	ADJ
ajlm-1720	232	22	disease	disease	NOUN
ajlm-1720	232	23	in	in	ADP
ajlm-1720	232	24	b	b	PROPN
ajlm-1720	232	25	cell	cell	NOUN
ajlm-1720	232	26	acute	acute	NOUN
ajlm-1720	232	27	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	232	28	leukemia	leukemia	NOUN
ajlm-1720	232	29	using	use	VERB
ajlm-1720	232	30	an	an	DET
ajlm-1720	232	31	eight	eight	NUM
ajlm-1720	232	32	-	-	PUNCT
ajlm-1720	232	33	color	color	NOUN
ajlm-1720	232	34	tube	tube	NOUN
ajlm-1720	232	35	with	with	ADP
ajlm-1720	232	36	dried	dry	VERB
ajlm-1720	232	37	antibody	antibody	NOUN
ajlm-1720	232	38	reagents	reagent	NOUN
ajlm-1720	232	39	.	.	PUNCT
ajlm-1720	233	1	cytometry	cytometry	PROPN
ajlm-1720	233	2	b	b	PROPN
ajlm-1720	233	3	clin	clin	PROPN
ajlm-1720	233	4	cytom	cytom	PROPN
ajlm-1720	233	5	.	.	PUNCT
ajlm-1720	234	1	2019;96(2):158–163	2019;96(2):158–163	NUM
ajlm-1720	234	2	.	.	PUNCT
ajlm-1720	234	3	https://doi.org/10.1002/cyto.b.21766	https://doi.org/10.1002/cyto.b.21766	PUNCT
ajlm-1720	235	1	bento	bento	NOUN
ajlm-1720	235	2	l	l	PROPN
ajlm-1720	235	3	,	,	PUNCT
ajlm-1720	235	4	correia	correia	PROPN
ajlm-1720	235	5	r	r	PROPN
ajlm-1720	235	6	,	,	PUNCT
ajlm-1720	235	7	de	de	PROPN
ajlm-1720	235	8	sousa	sousa	PROPN
ajlm-1720	235	9	f	f	PROPN
ajlm-1720	235	10	,	,	PUNCT
ajlm-1720	235	11	et	et	PROPN
ajlm-1720	235	12	al	al	PROPN
ajlm-1720	235	13	.	.	PUNCT
ajlm-1720	235	14	performance	performance	NOUN
ajlm-1720	235	15	of	of	ADP
ajlm-1720	235	16	eight	eight	NUM
ajlm-1720	235	17	-	-	PUNCT
ajlm-1720	235	18	color	color	NOUN
ajlm-1720	235	19	dry	dry	ADJ
ajlm-1720	235	20	antibody	antibody	NOUN
ajlm-1720	235	21	reagent	reagent	NOUN
ajlm-1720	235	22	in	in	ADP
ajlm-1720	235	23	the	the	DET
ajlm-1720	235	24	detection	detection	NOUN
ajlm-1720	235	25	of	of	ADP
ajlm-1720	235	26	minimal	minimal	ADJ
ajlm-1720	235	27	residual	residual	ADJ
ajlm-1720	235	28	disease	disease	NOUN
ajlm-1720	235	29	in	in	ADP
ajlm-1720	235	30	chronic	chronic	ADJ
ajlm-1720	235	31	lymphocytic	lymphocytic	ADJ
ajlm-1720	235	32	leukemia	leukemia	NOUN
ajlm-1720	235	33	samples	sample	NOUN
ajlm-1720	235	34	.	.	PUNCT
ajlm-1720	236	1	cytometry	cytometry	PROPN
ajlm-1720	236	2	b	b	PROPN
ajlm-1720	236	3	clin	clin	PROPN
ajlm-1720	236	4	cytom	cytom	PROPN
ajlm-1720	236	5	.	.	PUNCT
ajlm-1720	237	1	2020;98(6):529–535	2020;98(6):529–535	NUM
ajlm-1720	237	2	.	.	PUNCT
ajlm-1720	237	3	https://doi.org/10.1002/cyto.b.21875	https://doi.org/10.1002/cyto.b.21875	X
ajlm-1720	237	4	glencross	glencross	ADJ
ajlm-1720	237	5	dk	dk	PROPN
ajlm-1720	237	6	,	,	PUNCT
ajlm-1720	237	7	pretorius	pretorius	PROPN
ajlm-1720	237	8	m	m	PROPN
ajlm-1720	237	9	,	,	PUNCT
ajlm-1720	237	10	swart	swart	PROPN
ajlm-1720	237	11	l	l	PROPN
ajlm-1720	237	12	,	,	PUNCT
ajlm-1720	237	13	lawrie	lawrie	PROPN
ajlm-1720	237	14	d.	d.	PROPN
ajlm-1720	237	15	evaluation	evaluation	NOUN
ajlm-1720	237	16	of	of	ADP
ajlm-1720	237	17	the	the	DET
ajlm-1720	237	18	beckman	beckman	PROPN
ajlm-1720	237	19	coulter	coulter	PROPN
ajlm-1720	237	20	(	(	PUNCT
ajlm-1720	237	21	bc	bc	PROPN
ajlm-1720	237	22	)	)	PUNCT
ajlm-1720	237	23	clearllab	clearllab	PROPN
ajlm-1720	237	24	10c	10c	NUM
ajlm-1720	237	25	leukaemia	leukaemia	NOUN
ajlm-1720	237	26	/	/	SYM
ajlm-1720	237	27	lymphoma	lymphoma	NOUN
ajlm-1720	237	28	immunophenotyping	immunophenotype	VERB
ajlm-1720	237	29	panel	panel	NOUN
ajlm-1720	237	30	system	system	NOUN
ajlm-1720	237	31	in	in	ADP
ajlm-1720	237	32	a	a	DET
ajlm-1720	237	33	busy	busy	ADJ
ajlm-1720	237	34	,	,	PUNCT
ajlm-1720	237	35	high	high	ADJ
ajlm-1720	237	36	-	-	PUNCT
ajlm-1720	237	37	volume	volume	NOUN
ajlm-1720	237	38	academic	academic	ADJ
ajlm-1720	237	39	laboratory	laboratory	NOUN
ajlm-1720	237	40	in	in	ADP
ajlm-1720	237	41	johannesburg	johannesburg	PROPN
ajlm-1720	237	42	.	.	PUNCT
ajlm-1720	238	1	afr	afr	PROPN
ajlm-1720	238	2	j	j	PROPN
ajlm-1720	238	3	lab	lab	PROPN
ajlm-1720	238	4	med	me	VERB
ajlm-1720	238	5	.	.	PUNCT
ajlm-1720	239	1	2022;11(1):a1458	2022;11(1):a1458	X
ajlm-1720	239	2	.	.	PUNCT
ajlm-1720	239	3	https://doi.org/10.4102/ajlm.v11i1.1458	https://doi.org/10.4102/ajlm.v11i1.1458	AUX
ajlm-1720	239	4	rawstron	rawstron	VERB
ajlm-1720	239	5	ac	ac	PROPN
ajlm-1720	239	6	,	,	PUNCT
ajlm-1720	239	7	fazi	fazi	PROPN
ajlm-1720	239	8	c	c	NOUN
ajlm-1720	239	9	,	,	PUNCT
ajlm-1720	239	10	agathangelidis	agathangelidi	VERB
ajlm-1720	239	11	a	a	PRON
ajlm-1720	239	12	,	,	PUNCT
ajlm-1720	239	13	et	et	PROPN
ajlm-1720	239	14	al	al	PROPN
ajlm-1720	239	15	.	.	PUNCT
ajlm-1720	240	1	a	a	DET
ajlm-1720	240	2	complementary	complementary	ADJ
ajlm-1720	240	3	role	role	NOUN
ajlm-1720	240	4	of	of	ADP
ajlm-1720	240	5	multiparameter	multiparameter	NOUN
ajlm-1720	240	6	flow	flow	NOUN
ajlm-1720	240	7	cytometry	cytometry	NOUN
ajlm-1720	240	8	and	and	CCONJ
ajlm-1720	240	9	high	high	ADJ
ajlm-1720	240	10	-	-	PUNCT
ajlm-1720	240	11	throughput	throughput	NOUN
ajlm-1720	240	12	sequencing	sequencing	NOUN
ajlm-1720	240	13	for	for	ADP
ajlm-1720	240	14	minimal	minimal	ADJ
ajlm-1720	240	15	residual	residual	ADJ
ajlm-1720	240	16	disease	disease	NOUN
ajlm-1720	240	17	detection	detection	NOUN
ajlm-1720	240	18	in	in	ADP
ajlm-1720	240	19	chronic	chronic	ADJ
ajlm-1720	240	20	lymphocytic	lymphocytic	ADJ
ajlm-1720	240	21	leukemia	leukemia	NOUN
ajlm-1720	240	22	:	:	PUNCT
ajlm-1720	240	23	an	an	DET
ajlm-1720	240	24	european	european	ADJ
ajlm-1720	240	25	research	research	PROPN
ajlm-1720	240	26	initiative	initiative	NOUN
ajlm-1720	240	27	on	on	ADP
ajlm-1720	240	28	cll	cll	PROPN
ajlm-1720	240	29	study	study	NOUN
ajlm-1720	240	30	.	.	PUNCT
ajlm-1720	241	1	leukemia	leukemia	NOUN
ajlm-1720	241	2	.	.	PUNCT
ajlm-1720	242	1	2016;30(4):929–936	2016;30(4):929–936	X
ajlm-1720	242	2	.	.	PUNCT
ajlm-1720	243	1	https://doi.org/10.1038/leu.2015.313	https://doi.org/10.1038/leu.2015.313	PROPN
ajlm-1720	243	2	rawstron	rawstron	PROPN
ajlm-1720	243	3	ac	ac	PROPN
ajlm-1720	243	4	,	,	PUNCT
ajlm-1720	243	5	kreuzer	kreuzer	PROPN
ajlm-1720	243	6	ka	ka	PROPN
ajlm-1720	243	7	,	,	PUNCT
ajlm-1720	243	8	soosapilla	soosapilla	PROPN
ajlm-1720	243	9	a	a	NOUN
ajlm-1720	243	10	,	,	PUNCT
ajlm-1720	243	11	et	et	PROPN
ajlm-1720	243	12	al	al	PROPN
ajlm-1720	243	13	.	.	PROPN
ajlm-1720	243	14	reproducible	reproducible	VERB
ajlm-1720	243	15	diagnosis	diagnosis	NOUN
ajlm-1720	243	16	of	of	ADP
ajlm-1720	243	17	chronic	chronic	ADJ
ajlm-1720	243	18	lymphocytic	lymphocytic	ADJ
ajlm-1720	243	19	leukemia	leukemia	NOUN
ajlm-1720	243	20	by	by	ADP
ajlm-1720	243	21	flow	flow	NOUN
ajlm-1720	243	22	cytometry	cytometry	NOUN
ajlm-1720	243	23	:	:	PUNCT
ajlm-1720	243	24	an	an	DET
ajlm-1720	243	25	european	european	ADJ
ajlm-1720	243	26	research	research	PROPN
ajlm-1720	243	27	initiative	initiative	NOUN
ajlm-1720	243	28	on	on	ADP
ajlm-1720	243	29	cll	cll	PROPN
ajlm-1720	243	30	(	(	PUNCT
ajlm-1720	243	31	eric	eric	PROPN
ajlm-1720	243	32	)	)	PUNCT
ajlm-1720	243	33	&	&	CCONJ
ajlm-1720	243	34	european	european	ADJ
ajlm-1720	243	35	society	society	PROPN
ajlm-1720	243	36	for	for	ADP
ajlm-1720	243	37	clinical	clinical	ADJ
ajlm-1720	243	38	cell	cell	NOUN
ajlm-1720	243	39	analysis	analysis	NOUN
ajlm-1720	243	40	(	(	PUNCT
ajlm-1720	243	41	escca	escca	NOUN
ajlm-1720	243	42	)	)	PUNCT
ajlm-1720	243	43	harmonisation	harmonisation	NOUN
ajlm-1720	243	44	project	project	NOUN
ajlm-1720	243	45	.	.	PUNCT
ajlm-1720	244	1	cytometry	cytometry	PROPN
ajlm-1720	244	2	b	b	PROPN
ajlm-1720	244	3	clin	clin	PROPN
ajlm-1720	244	4	cytom	cytom	PROPN
ajlm-1720	244	5	.	.	PUNCT
ajlm-1720	245	1	2018;94(1):121–128	2018;94(1):121–128	X
ajlm-1720	245	2	.	.	PUNCT
ajlm-1720	246	1	https://doi.org/10.1002/cyto.b.21595	https://doi.org/10.1002/cyto.b.21595	X
ajlm-1720	246	2	roshal	roshal	PROPN
ajlm-1720	246	3	m	m	PROPN
ajlm-1720	246	4	,	,	PUNCT
ajlm-1720	246	5	flores	flores	PROPN
ajlm-1720	246	6	-	-	PUNCT
ajlm-1720	246	7	montero	montero	PROPN
ajlm-1720	246	8	ja	ja	PROPN
ajlm-1720	246	9	,	,	PUNCT
ajlm-1720	246	10	gao	gao	PROPN
ajlm-1720	246	11	q	q	PROPN
ajlm-1720	246	12	,	,	PUNCT
ajlm-1720	246	13	et	et	PROPN
ajlm-1720	246	14	al	al	PROPN
ajlm-1720	246	15	.	.	PUNCT
ajlm-1720	246	16	mrd	mrd	PROPN
ajlm-1720	246	17	detection	detection	NOUN
ajlm-1720	246	18	in	in	ADP
ajlm-1720	246	19	multiple	multiple	ADJ
ajlm-1720	246	20	myeloma	myeloma	NOUN
ajlm-1720	246	21	:	:	PUNCT
ajlm-1720	246	22	comparison	comparison	NOUN
ajlm-1720	246	23	between	between	ADP
ajlm-1720	246	24	mskcc	mskcc	PROPN
ajlm-1720	246	25	10	10	NUM
ajlm-1720	246	26	-	-	PUNCT
ajlm-1720	246	27	color	color	NOUN
ajlm-1720	246	28	single	single	ADJ
ajlm-1720	246	29	-	-	PUNCT
ajlm-1720	246	30	tube	tube	NOUN
ajlm-1720	246	31	and	and	CCONJ
ajlm-1720	246	32	euroflow	euroflow	VERB
ajlm-1720	246	33	8	8	NUM
ajlm-1720	246	34	-	-	PUNCT
ajlm-1720	246	35	color	color	ADJ
ajlm-1720	246	36	2	2	NUM
ajlm-1720	246	37	-	-	PUNCT
ajlm-1720	246	38	tube	tube	NOUN
ajlm-1720	246	39	methods	method	NOUN
ajlm-1720	246	40	.	.	PUNCT
ajlm-1720	247	1	blood	blood	NOUN
ajlm-1720	247	2	adv	adv	PROPN
ajlm-1720	247	3	.	.	PUNCT
ajlm-1720	248	1	2017;1(12):728–732	2017;1(12):728–732	NUM
ajlm-1720	248	2	.	.	PUNCT
ajlm-1720	249	1	https://doi.org/10.1182/bloodadvances.2016003715	https://doi.org/10.1182/bloodadvances.2016003715	NOUN
ajlm-1720	249	2	bossuyt	bossuyt	PROPN
ajlm-1720	249	3	pm	pm	PROPN
ajlm-1720	249	4	,	,	PUNCT
ajlm-1720	249	5	reitsma	reitsma	VERB
ajlm-1720	249	6	jb	jb	PROPN
ajlm-1720	249	7	,	,	PUNCT
ajlm-1720	249	8	bruns	bruns	PROPN
ajlm-1720	249	9	de	de	PROPN
ajlm-1720	249	10	,	,	PUNCT
ajlm-1720	249	11	et	et	PROPN
ajlm-1720	249	12	al	al	PROPN
ajlm-1720	249	13	.	.	PROPN
ajlm-1720	250	1	towards	towards	ADP
ajlm-1720	250	2	complete	complete	ADJ
ajlm-1720	250	3	and	and	CCONJ
ajlm-1720	250	4	accurate	accurate	ADJ
ajlm-1720	250	5	reporting	reporting	NOUN
ajlm-1720	250	6	of	of	ADP
ajlm-1720	250	7	studies	study	NOUN
ajlm-1720	250	8	of	of	ADP
ajlm-1720	250	9	diagnostic	diagnostic	ADJ
ajlm-1720	250	10	accuracy	accuracy	NOUN
ajlm-1720	250	11	:	:	PUNCT
ajlm-1720	250	12	the	the	DET
ajlm-1720	250	13	stard	stard	PROPN
ajlm-1720	250	14	initiative	initiative	NOUN
ajlm-1720	250	15	.	.	PUNCT
ajlm-1720	251	1	clin	clin	PROPN
ajlm-1720	251	2	chem	chem	NOUN
ajlm-1720	251	3	lab	lab	NOUN
ajlm-1720	251	4	med	me	VERB
ajlm-1720	251	5	.	.	PUNCT
ajlm-1720	252	1	2003;41(1):68–73	2003;41(1):68–73	X
ajlm-1720	252	2	.	.	PUNCT
ajlm-1720	253	1	https://doi.org/10.1515/cclm.2003.012	https://doi.org/10.1515/cclm.2003.012	PROPN
ajlm-1720	253	2	united	unite	VERB
ajlm-1720	253	3	kingdom	kingdom	PROPN
ajlm-1720	253	4	national	national	ADJ
ajlm-1720	253	5	external	external	ADJ
ajlm-1720	253	6	quality	quality	NOUN
ajlm-1720	253	7	assessment	assessment	NOUN
ajlm-1720	253	8	scheme	scheme	NOUN
ajlm-1720	253	9	(	(	PUNCT
ajlm-1720	253	10	u.k	u.k	PROPN
ajlm-1720	253	11	.	.	PROPN
ajlm-1720	253	12	neqas	neqas	PROPN
ajlm-1720	253	13	)	)	PUNCT
ajlm-1720	253	14	u.	u.	PROPN
ajlm-1720	253	15	leukaemia	leukaemia	PROPN
ajlm-1720	253	16	immunophenotyping	immunophenotype	VERB
ajlm-1720	253	17	part	part	NOUN
ajlm-1720	253	18	1	1	NUM
ajlm-1720	253	19	and	and	CCONJ
ajlm-1720	253	20	part	part	NOUN
ajlm-1720	253	21	2	2	NUM
ajlm-1720	254	1	[	[	NOUN
ajlm-1720	254	2	homepage	homepage	NOUN
ajlm-1720	254	3	on	on	ADP
ajlm-1720	254	4	the	the	DET
ajlm-1720	254	5	internet	internet	NOUN
ajlm-1720	254	6	]	]	PUNCT
ajlm-1720	254	7	.	.	PUNCT
ajlm-1720	255	1	[	[	X
ajlm-1720	255	2	cited	cite	VERB
ajlm-1720	255	3	2021	2021	NUM
ajlm-1720	255	4	aug	aug	NOUN
ajlm-1720	255	5	]	]	X
ajlm-1720	255	6	.	.	PUNCT
ajlm-1720	256	1	available	available	ADJ
ajlm-1720	256	2	from	from	ADP
ajlm-1720	256	3	:	:	PUNCT
ajlm-1720	256	4	http://www.ukneqasli.co.uk/eqa-pt-programmes/flow-cytometry-programmes/leukaemia-immunophenotyping-part-1-accredited/	http://www.ukneqasli.co.uk/eqa-pt-programmes/flow-cytometry-programmes/leukaemia-immunophenotyping-part-1-accredited/	PROPN
ajlm-1720	256	5	wang	wang	PROPN
ajlm-1720	256	6	hw	hw	PROPN
ajlm-1720	256	7	,	,	PUNCT
ajlm-1720	256	8	lin	lin	PROPN
ajlm-1720	256	9	p.	p.	PROPN
ajlm-1720	256	10	flow	flow	PROPN
ajlm-1720	256	11	cytometric	cytometric	ADJ
ajlm-1720	256	12	immunophenotypic	immunophenotypic	ADJ
ajlm-1720	256	13	analysis	analysis	NOUN
ajlm-1720	256	14	in	in	ADP
ajlm-1720	256	15	the	the	DET
ajlm-1720	256	16	diagnosis	diagnosis	NOUN
ajlm-1720	256	17	and	and	CCONJ
ajlm-1720	256	18	prognostication	prognostication	NOUN
ajlm-1720	256	19	of	of	ADP
ajlm-1720	256	20	plasma	plasma	NOUN
ajlm-1720	256	21	cell	cell	NOUN
ajlm-1720	256	22	neoplasms	neoplasm	NOUN
ajlm-1720	256	23	.	.	PUNCT
ajlm-1720	257	1	cytometry	cytometry	PROPN
ajlm-1720	257	2	b	b	PROPN
ajlm-1720	257	3	clin	clin	PROPN
ajlm-1720	257	4	cytom	cytom	NOUN
ajlm-1720	257	5	.	.	PUNCT
ajlm-1720	258	1	2019;96(5):338–350	2019;96(5):338–350	NUM
ajlm-1720	258	2	.	.	PUNCT
ajlm-1720	258	3	https://doi.org/10.1002/cyto.b.21844	https://doi.org/10.1002/cyto.b.21844	X
ajlm-1720	259	1	beckman	beckman	PROPN
ajlm-1720	259	2	coulter	coulter	PROPN
ajlm-1720	259	3	sa	sa	PROPN
ajlm-1720	259	4	.	.	PUNCT
ajlm-1720	260	1	duraclone	duraclone	NOUN
ajlm-1720	260	2	panels	panel	NOUN
ajlm-1720	260	3	2021	2021	NUM
ajlm-1720	261	1	[	[	X
ajlm-1720	261	2	homepage	homepage	NOUN
ajlm-1720	261	3	on	on	ADP
ajlm-1720	261	4	the	the	DET
ajlm-1720	261	5	internet	internet	NOUN
ajlm-1720	261	6	]	]	PUNCT
ajlm-1720	261	7	.	.	PUNCT
ajlm-1720	262	1	[	[	X
ajlm-1720	262	2	cited	cite	VERB
ajlm-1720	262	3	2021	2021	NUM
ajlm-1720	262	4	aug	aug	NOUN
ajlm-1720	262	5	]	]	X
ajlm-1720	262	6	.	.	PUNCT
ajlm-1720	263	1	available	available	ADJ
ajlm-1720	263	2	from	from	ADP
ajlm-1720	263	3	:	:	PUNCT
ajlm-1720	263	4	https://www.beckman.co.za/reagents/coulter-flow-cytometry/antibodies-and-kits/duraclone-panels	https://www.beckman.co.za/reagents/coulter-flow-cytometry/antibodies-and-kits/duraclone-panel	NOUN
ajlm-1720	263	5	campo	campo	NOUN
ajlm-1720	263	6	e	e	NOUN
ajlm-1720	263	7	,	,	PUNCT
ajlm-1720	263	8	harris	harris	PROPN
ajlm-1720	263	9	nl	nl	PROPN
ajlm-1720	263	10	,	,	PUNCT
ajlm-1720	263	11	jaffe	jaffe	PROPN
ajlm-1720	263	12	es	es	PROPN
ajlm-1720	263	13	,	,	PUNCT
ajlm-1720	263	14	et	et	PROPN
ajlm-1720	263	15	al	al	PROPN
ajlm-1720	263	16	.	.	PROPN
ajlm-1720	263	17	world	world	PROPN
ajlm-1720	263	18	health	health	PROPN
ajlm-1720	263	19	organization	organization	NOUN
ajlm-1720	263	20	(	(	PUNCT
ajlm-1720	263	21	who	who	PRON
ajlm-1720	263	22	)	)	PUNCT
ajlm-1720	263	23	classification	classification	NOUN
ajlm-1720	263	24	of	of	ADP
ajlm-1720	263	25	tumours	tumour	NOUN
ajlm-1720	263	26	of	of	ADP
ajlm-1720	263	27	haematopoietic	haematopoietic	ADJ
ajlm-1720	263	28	and	and	CCONJ
ajlm-1720	263	29	lymphoid	lymphoid	ADJ
ajlm-1720	263	30	tissues	tissue	NOUN
ajlm-1720	263	31	(	(	PUNCT
ajlm-1720	263	32	medicine	medicine	NOUN
ajlm-1720	263	33	)	)	PUNCT
ajlm-1720	263	34	.	.	PUNCT
ajlm-1720	264	1	geneva	geneva	PROPN
ajlm-1720	264	2	:	:	PUNCT
ajlm-1720	264	3	who	who	PRON
ajlm-1720	264	4	;	;	PUNCT
ajlm-1720	264	5	2017	2017	NUM
ajlm-1720	264	6	..	..	PUNCT
ajlm-1720	264	7	glencross	glencross	ADJ
ajlm-1720	264	8	dk	dk	PROPN
ajlm-1720	264	9	,	,	PUNCT
ajlm-1720	264	10	coetzee	coetzee	PROPN
ajlm-1720	264	11	lm	lm	PROPN
ajlm-1720	264	12	,	,	PUNCT
ajlm-1720	264	13	cassim	cassim	PROPN
ajlm-1720	264	14	n.	n.	PROPN
ajlm-1720	264	15	an	an	DET
ajlm-1720	264	16	integrated	integrate	VERB
ajlm-1720	264	17	tiered	tiere	VERB
ajlm-1720	264	18	service	service	NOUN
ajlm-1720	264	19	delivery	delivery	NOUN
ajlm-1720	264	20	model	model	NOUN
ajlm-1720	264	21	(	(	PUNCT
ajlm-1720	264	22	itsdm	itsdm	PROPN
ajlm-1720	264	23	)	)	PUNCT
ajlm-1720	264	24	based	base	VERB
ajlm-1720	264	25	on	on	ADP
ajlm-1720	264	26	local	local	ADJ
ajlm-1720	264	27	cd4	cd4	PROPN
ajlm-1720	264	28	testing	testing	NOUN
ajlm-1720	264	29	demands	demand	NOUN
ajlm-1720	264	30	can	can	AUX
ajlm-1720	264	31	improve	improve	VERB
ajlm-1720	264	32	turn	turn	NOUN
ajlm-1720	264	33	-	-	PUNCT
ajlm-1720	264	34	around	around	ADP
ajlm-1720	264	35	times	time	NOUN
ajlm-1720	264	36	and	and	CCONJ
ajlm-1720	264	37	save	save	VERB
ajlm-1720	264	38	costs	cost	NOUN
ajlm-1720	264	39	whilst	whilst	SCONJ
ajlm-1720	264	40	ensuring	ensure	VERB
ajlm-1720	264	41	accessible	accessible	ADJ
ajlm-1720	264	42	and	and	CCONJ
ajlm-1720	264	43	scalable	scalable	ADJ
ajlm-1720	264	44	cd4	cd4	PROPN
ajlm-1720	264	45	services	service	NOUN
ajlm-1720	264	46	across	across	ADP
ajlm-1720	264	47	a	a	DET
ajlm-1720	264	48	national	national	ADJ
ajlm-1720	264	49	programme	programme	NOUN
ajlm-1720	264	50	.	.	PUNCT
ajlm-1720	265	1	plos	plos	PROPN
ajlm-1720	265	2	one	one	NUM
ajlm-1720	265	3	.	.	PUNCT
ajlm-1720	266	1	2014;9(12):e114727	2014;9(12):e114727	NOUN
ajlm-1720	266	2	.	.	PUNCT
ajlm-1720	267	1	https://doi.org/10.1371/journal.pone.0114727	https://doi.org/10.1371/journal.pone.0114727	PROPN
ajlm-1720	267	2	glencross	glencross	PROPN
ajlm-1720	267	3	dk	dk	PROPN
ajlm-1720	267	4	,	,	PUNCT
ajlm-1720	267	5	janossy	janossy	NOUN
ajlm-1720	267	6	g	g	PROPN
ajlm-1720	267	7	,	,	PUNCT
ajlm-1720	267	8	coetzee	coetzee	PROPN
ajlm-1720	267	9	lm	lm	PROPN
ajlm-1720	267	10	,	,	PUNCT
ajlm-1720	267	11	et	et	PROPN
ajlm-1720	267	12	al	al	PROPN
ajlm-1720	267	13	.	.	PUNCT
ajlm-1720	268	1	large	large	ADJ
ajlm-1720	268	2	-	-	PUNCT
ajlm-1720	268	3	scale	scale	NOUN
ajlm-1720	268	4	affordable	affordable	ADJ
ajlm-1720	268	5	panleucogated	panleucogate	VERB
ajlm-1720	268	6	cd4	cd4	PROPN
ajlm-1720	268	7	+	+	PROPN
ajlm-1720	268	8	testing	testing	NOUN
ajlm-1720	268	9	with	with	ADP
ajlm-1720	268	10	proactive	proactive	ADJ
ajlm-1720	268	11	internal	internal	ADJ
ajlm-1720	268	12	and	and	CCONJ
ajlm-1720	268	13	external	external	ADJ
ajlm-1720	268	14	quality	quality	NOUN
ajlm-1720	268	15	assessment	assessment	NOUN
ajlm-1720	268	16	:	:	PUNCT
ajlm-1720	268	17	in	in	ADP
ajlm-1720	268	18	support	support	NOUN
ajlm-1720	268	19	of	of	ADP
ajlm-1720	268	20	the	the	DET
ajlm-1720	268	21	south	south	ADJ
ajlm-1720	268	22	african	african	ADJ
ajlm-1720	268	23	national	national	PROPN
ajlm-1720	268	24	comprehensive	comprehensive	PROPN
ajlm-1720	268	25	care	care	NOUN
ajlm-1720	268	26	,	,	PUNCT
ajlm-1720	268	27	treatment	treatment	NOUN
ajlm-1720	268	28	and	and	CCONJ
ajlm-1720	268	29	management	management	NOUN
ajlm-1720	268	30	programme	programme	NOUN
ajlm-1720	268	31	for	for	ADP
ajlm-1720	268	32	hiv	hiv	PROPN
ajlm-1720	268	33	and	and	CCONJ
ajlm-1720	268	34	aids	aids	PROPN
ajlm-1720	268	35	.	.	PUNCT
ajlm-1720	269	1	cytometry	cytometry	PROPN
ajlm-1720	269	2	b	b	PROPN
ajlm-1720	269	3	clin	clin	PROPN
ajlm-1720	269	4	cytom	cytom	PROPN
ajlm-1720	269	5	.	.	PUNCT
ajlm-1720	270	1	2008;74	2008;74	NUM
ajlm-1720	270	2	suppl	suppl	ADJ
ajlm-1720	270	3	1	1	NUM
ajlm-1720	270	4	:	:	PUNCT
ajlm-1720	270	5	s40	s40	NOUN
ajlm-1720	270	6	–	–	PUNCT
ajlm-1720	270	7	s51	s51	X
ajlm-1720	270	8	.	.	PUNCT
ajlm-1720	271	1	https://doi.org/10.1002/cyto.b.20384	https://doi.org/10.1002/cyto.b.20384	X
ajlm-1720	271	2	coetzee	coetzee	PROPN
ajlm-1720	271	3	lm	lm	PROPN
ajlm-1720	271	4	,	,	PUNCT
ajlm-1720	271	5	glencross	glencross	ADJ
ajlm-1720	271	6	dk	dk	PROPN
ajlm-1720	271	7	.	.	PROPN
ajlm-1720	271	8	performance	performance	NOUN
ajlm-1720	271	9	verification	verification	NOUN
ajlm-1720	271	10	of	of	ADP
ajlm-1720	271	11	the	the	DET
ajlm-1720	271	12	new	new	ADJ
ajlm-1720	271	13	fully	fully	ADV
ajlm-1720	271	14	automated	automate	VERB
ajlm-1720	271	15	aquios	aquio	NOUN
ajlm-1720	271	16	flow	flow	NOUN
ajlm-1720	271	17	cytometer	cytometer	NOUN
ajlm-1720	271	18	panleucogate	panleucogate	NOUN
ajlm-1720	271	19	(	(	PUNCT
ajlm-1720	271	20	plg	plg	NOUN
ajlm-1720	271	21	)	)	PUNCT
ajlm-1720	271	22	platform	platform	NOUN
ajlm-1720	271	23	for	for	ADP
ajlm-1720	271	24	cd4	cd4	PROPN
ajlm-1720	271	25	-	-	PUNCT
ajlm-1720	271	26	t	t	PROPN
ajlm-1720	271	27	-	-	PUNCT
ajlm-1720	271	28	lymphocyte	lymphocyte	NOUN
ajlm-1720	271	29	enumeration	enumeration	NOUN
ajlm-1720	271	30	in	in	ADP
ajlm-1720	271	31	south	south	PROPN
ajlm-1720	271	32	africa	africa	PROPN
ajlm-1720	271	33	.	.	PUNCT
ajlm-1720	272	1	plos	plos	PROPN
ajlm-1720	272	2	one	one	NUM
ajlm-1720	272	3	.	.	PUNCT
ajlm-1720	273	1	2017;12(11):e0187456	2017;12(11):e0187456	NOUN
ajlm-1720	273	2	.	.	PUNCT
ajlm-1720	274	1	https://doi.org/10.1371/journal.pone.0187456	https://doi.org/10.1371/journal.pone.0187456	PROPN
ajlm-1720	274	2	novakova	novakova	PROPN
ajlm-1720	274	3	m	m	PROPN
ajlm-1720	274	4	,	,	PUNCT
ajlm-1720	274	5	glier	glier	ADJ
ajlm-1720	274	6	h	h	NOUN
ajlm-1720	274	7	,	,	PUNCT
ajlm-1720	274	8	brdickova	brdickova	PROPN
ajlm-1720	274	9	n	n	CCONJ
ajlm-1720	274	10	,	,	PUNCT
ajlm-1720	274	11	et	et	PROPN
ajlm-1720	274	12	al	al	PROPN
ajlm-1720	274	13	.	.	PUNCT
ajlm-1720	275	1	how	how	SCONJ
ajlm-1720	275	2	to	to	PART
ajlm-1720	275	3	make	make	VERB
ajlm-1720	275	4	usage	usage	NOUN
ajlm-1720	275	5	of	of	ADP
ajlm-1720	275	6	the	the	DET
ajlm-1720	275	7	standardized	standardized	ADJ
ajlm-1720	275	8	euroflow	euroflow	NOUN
ajlm-1720	275	9	8	8	NUM
ajlm-1720	275	10	-	-	PUNCT
ajlm-1720	275	11	color	color	NOUN
ajlm-1720	275	12	protocols	protocol	NOUN
ajlm-1720	275	13	possible	possible	ADJ
ajlm-1720	275	14	for	for	ADP
ajlm-1720	275	15	instruments	instrument	NOUN
ajlm-1720	275	16	of	of	ADP
ajlm-1720	275	17	different	different	ADJ
ajlm-1720	275	18	manufacturers	manufacturer	NOUN
ajlm-1720	275	19	.	.	PUNCT
ajlm-1720	276	1	j	j	PROPN
ajlm-1720	276	2	immunol	immunol	NOUN
ajlm-1720	276	3	methods	method	NOUN
ajlm-1720	276	4	.	.	PUNCT
ajlm-1720	277	1	2019;475:112388	2019;475:112388	X
ajlm-1720	277	2	.	.	PUNCT
ajlm-1720	278	1	https://doi.org/10.1016/j.jim.2017.11.007	https://doi.org/10.1016/j.jim.2017.11.007	PROPN
ajlm-1720	278	2	flores	flores	PROPN
ajlm-1720	278	3	-	-	PUNCT
ajlm-1720	278	4	montero	montero	PROPN
ajlm-1720	278	5	j	j	PROPN
ajlm-1720	278	6	,	,	PUNCT
ajlm-1720	278	7	de	de	X
ajlm-1720	278	8	tute	tute	NOUN
ajlm-1720	278	9	r	r	NOUN
ajlm-1720	278	10	,	,	PUNCT
ajlm-1720	278	11	paiva	paiva	PROPN
ajlm-1720	278	12	b	b	PROPN
ajlm-1720	278	13	,	,	PUNCT
ajlm-1720	278	14	et	et	PROPN
ajlm-1720	278	15	al	al	PROPN
ajlm-1720	278	16	.	.	PROPN
ajlm-1720	278	17	immunophenotype	immunophenotype	NOUN
ajlm-1720	278	18	of	of	ADP
ajlm-1720	278	19	normal	normal	ADJ
ajlm-1720	278	20	vs.	vs.	ADP
ajlm-1720	278	21	myeloma	myeloma	PROPN
ajlm-1720	278	22	plasma	plasma	NOUN
ajlm-1720	278	23	cells	cell	NOUN
ajlm-1720	278	24	:	:	PUNCT
ajlm-1720	278	25	toward	toward	ADP
ajlm-1720	278	26	antibody	antibody	NOUN
ajlm-1720	278	27	panel	panel	NOUN
ajlm-1720	278	28	specifications	specification	NOUN
ajlm-1720	278	29	for	for	ADP
ajlm-1720	278	30	mrd	mrd	ADJ
ajlm-1720	278	31	detection	detection	NOUN
ajlm-1720	278	32	in	in	ADP
ajlm-1720	278	33	multiple	multiple	ADJ
ajlm-1720	278	34	myeloma	myeloma	NOUN
ajlm-1720	278	35	.	.	PUNCT
ajlm-1720	279	1	cytometry	cytometry	PROPN
ajlm-1720	279	2	b	b	PROPN
ajlm-1720	279	3	clin	clin	PROPN
ajlm-1720	279	4	cytom	cytom	NOUN
ajlm-1720	279	5	.	.	PUNCT
ajlm-1720	280	1	2016;90(1):61–72	2016;90(1):61–72	X
ajlm-1720	280	2	.	.	PUNCT
ajlm-1720	281	1	https://doi.org/10.1002/cyto.b.21265	https://doi.org/10.1002/cyto.b.21265	X
ajlm-1720	281	2	chen	chen	PROPN
ajlm-1720	281	3	f	f	PROPN
ajlm-1720	281	4	,	,	PUNCT
ajlm-1720	281	5	hu	hu	PROPN
ajlm-1720	281	6	y	y	PROPN
ajlm-1720	281	7	,	,	PUNCT
ajlm-1720	281	8	wang	wang	PROPN
ajlm-1720	281	9	x	x	PROPN
ajlm-1720	281	10	,	,	PUNCT
ajlm-1720	281	11	fu	fu	PROPN
ajlm-1720	281	12	s	s	PROPN
ajlm-1720	281	13	,	,	PUNCT
ajlm-1720	281	14	liu	liu	PROPN
ajlm-1720	281	15	z	z	PROPN
ajlm-1720	281	16	,	,	PUNCT
ajlm-1720	281	17	zhang	zhang	PROPN
ajlm-1720	281	18	j.	j.	PROPN
ajlm-1720	281	19	expression	expression	NOUN
ajlm-1720	281	20	of	of	ADP
ajlm-1720	281	21	cd81	cd81	PROPN
ajlm-1720	281	22	and	and	CCONJ
ajlm-1720	281	23	cd117	cd117	PROPN
ajlm-1720	281	24	in	in	ADP
ajlm-1720	281	25	plasma	plasma	NOUN
ajlm-1720	281	26	cell	cell	NOUN
ajlm-1720	281	27	myeloma	myeloma	NOUN
ajlm-1720	281	28	and	and	CCONJ
ajlm-1720	281	29	the	the	DET
ajlm-1720	281	30	relationship	relationship	NOUN
ajlm-1720	281	31	to	to	PART
ajlm-1720	281	32	prognosis	prognosis	VERB
ajlm-1720	281	33	.	.	PUNCT
ajlm-1720	282	1	cancer	cancer	NOUN
ajlm-1720	282	2	med	med	PROPN
ajlm-1720	282	3	.	.	PUNCT
ajlm-1720	283	1	2018;7(12):5920–5927	2018;7(12):5920–5927	NUM
ajlm-1720	283	2	.	.	PUNCT
ajlm-1720	284	1	https://doi.org/10.1002/cam4.1840	https://doi.org/10.1002/cam4.1840	NOUN
ajlm-1720	284	2	tsitsikov	tsitsikov	PROPN
ajlm-1720	284	3	e	e	NOUN
ajlm-1720	284	4	,	,	PUNCT
ajlm-1720	284	5	harris	harris	PROPN
ajlm-1720	284	6	mh	mh	PROPN
ajlm-1720	284	7	,	,	PUNCT
ajlm-1720	284	8	silverman	silverman	PROPN
ajlm-1720	284	9	lb	lb	NUM
ajlm-1720	284	10	,	,	PUNCT
ajlm-1720	284	11	sallan	sallan	ADJ
ajlm-1720	284	12	se	se	PROPN
ajlm-1720	284	13	,	,	PUNCT
ajlm-1720	284	14	weinberg	weinberg	PROPN
ajlm-1720	284	15	ok	ok	PROPN
ajlm-1720	284	16	.	.	PROPN
ajlm-1720	284	17	role	role	NOUN
ajlm-1720	284	18	of	of	ADP
ajlm-1720	284	19	cd81	cd81	PROPN
ajlm-1720	284	20	and	and	CCONJ
ajlm-1720	284	21	cd58	cd58	PROPN
ajlm-1720	284	22	in	in	ADP
ajlm-1720	284	23	minimal	minimal	ADJ
ajlm-1720	284	24	residual	residual	ADJ
ajlm-1720	284	25	disease	disease	NOUN
ajlm-1720	284	26	detection	detection	NOUN
ajlm-1720	284	27	in	in	ADP
ajlm-1720	284	28	pediatric	pediatric	ADJ
ajlm-1720	284	29	b	b	NOUN
ajlm-1720	284	30	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	284	31	leukemia	leukemia	NOUN
ajlm-1720	284	32	.	.	PUNCT
ajlm-1720	285	1	int	int	NOUN
ajlm-1720	285	2	j	j	PROPN
ajlm-1720	285	3	lab	lab	NOUN
ajlm-1720	285	4	hematol	hematol	NOUN
ajlm-1720	285	5	.	.	PUNCT
ajlm-1720	286	1	2018;40(3):343–351	2018;40(3):343–351	X
ajlm-1720	286	2	.	.	PUNCT
ajlm-1720	286	3	https://doi.org/10.1111/ijlh.12795	https://doi.org/10.1111/ijlh.12795	PROPN
ajlm-1720	286	4	zeidan	zeidan	PROPN
ajlm-1720	286	5	ma	ma	PROPN
ajlm-1720	286	6	,	,	PUNCT
ajlm-1720	286	7	kamal	kamal	PROPN
ajlm-1720	286	8	hm	hm	PROPN
ajlm-1720	286	9	,	,	PUNCT
ajlm-1720	286	10	el	el	PROPN
ajlm-1720	286	11	shabrawy	shabrawy	PROPN
ajlm-1720	286	12	da	da	PROPN
ajlm-1720	286	13	,	,	PUNCT
ajlm-1720	286	14	esh	esh	PROPN
ajlm-1720	286	15	am	be	AUX
ajlm-1720	286	16	,	,	PUNCT
ajlm-1720	286	17	sattar	sattar	PROPN
ajlm-1720	286	18	rh	rh	PROPN
ajlm-1720	286	19	.	.	PROPN
ajlm-1720	286	20	significance	significance	NOUN
ajlm-1720	286	21	of	of	ADP
ajlm-1720	286	22	cd34	cd34	PROPN
ajlm-1720	286	23	/	/	SYM
ajlm-1720	286	24	cd123	cd123	PROPN
ajlm-1720	286	25	expression	expression	NOUN
ajlm-1720	286	26	in	in	ADP
ajlm-1720	286	27	detection	detection	NOUN
ajlm-1720	286	28	of	of	ADP
ajlm-1720	286	29	minimal	minimal	ADJ
ajlm-1720	286	30	residual	residual	ADJ
ajlm-1720	286	31	disease	disease	NOUN
ajlm-1720	286	32	in	in	ADP
ajlm-1720	286	33	b	b	ADJ
ajlm-1720	286	34	-	-	PUNCT
ajlm-1720	286	35	acute	acute	ADJ
ajlm-1720	286	36	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	286	37	leukemia	leukemia	NOUN
ajlm-1720	286	38	in	in	ADP
ajlm-1720	286	39	children	child	NOUN
ajlm-1720	286	40	.	.	PUNCT
ajlm-1720	287	1	blood	blood	NOUN
ajlm-1720	287	2	cells	cell	NOUN
ajlm-1720	287	3	mol	mol	ADP
ajlm-1720	287	4	dis	dis	PROPN
ajlm-1720	287	5	.	.	PUNCT
ajlm-1720	288	1	2016;59:113–118	2016;59:113–118	NUM
ajlm-1720	288	2	.	.	PUNCT
ajlm-1720	289	1	https://doi.org/10.1016/j.bcmd.2016.05.005	https://doi.org/10.1016/j.bcmd.2016.05.005	PROPN
ajlm-1720	289	2	broome	broome	PROPN
ajlm-1720	289	3	he	he	PRON
ajlm-1720	289	4	,	,	PUNCT
ajlm-1720	289	5	rassenti	rassenti	PROPN
ajlm-1720	289	6	lz	lz	PROPN
ajlm-1720	289	7	,	,	PUNCT
ajlm-1720	289	8	wang	wang	PROPN
ajlm-1720	289	9	hy	hy	PROPN
ajlm-1720	289	10	,	,	PUNCT
ajlm-1720	289	11	meyer	meyer	PROPN
ajlm-1720	289	12	lm	lm	PROPN
ajlm-1720	289	13	,	,	PUNCT
ajlm-1720	289	14	kipps	kipps	PROPN
ajlm-1720	289	15	tj	tj	PROPN
ajlm-1720	289	16	.	.	PROPN
ajlm-1720	290	1	ror1	ror1	PROPN
ajlm-1720	290	2	is	be	AUX
ajlm-1720	290	3	expressed	express	VERB
ajlm-1720	290	4	on	on	ADP
ajlm-1720	290	5	hematogones	hematogone	NOUN
ajlm-1720	290	6	(	(	PUNCT
ajlm-1720	290	7	non	non	ADJ
ajlm-1720	290	8	-	-	ADJ
ajlm-1720	290	9	neoplastic	neoplastic	ADJ
ajlm-1720	290	10	human	human	ADJ
ajlm-1720	290	11	b	b	PROPN
ajlm-1720	290	12	-	-	PUNCT
ajlm-1720	290	13	lymphocyte	lymphocyte	ADJ
ajlm-1720	290	14	precursors	precursor	NOUN
ajlm-1720	290	15	)	)	PUNCT
ajlm-1720	290	16	and	and	CCONJ
ajlm-1720	290	17	a	a	DET
ajlm-1720	290	18	minority	minority	NOUN
ajlm-1720	290	19	of	of	ADP
ajlm-1720	290	20	precursor	precursor	NOUN
ajlm-1720	290	21	-	-	PUNCT
ajlm-1720	290	22	b	b	NOUN
ajlm-1720	290	23	acute	acute	ADJ
ajlm-1720	290	24	lymphoblastic	lymphoblastic	ADJ
ajlm-1720	290	25	leukemia	leukemia	NOUN
ajlm-1720	290	26	.	.	PUNCT
ajlm-1720	291	1	leuk	leuk	PROPN
ajlm-1720	291	2	res	re	NOUN
ajlm-1720	291	3	.	.	PUNCT
ajlm-1720	292	1	2011;35(10):1390–1394	2011;35(10):1390–1394	X
ajlm-1720	292	2	.	.	PUNCT
ajlm-1720	293	1	https://doi.org/10.1016/j.leukres.2011.06.021	https://doi.org/10.1016/j.leukres.2011.06.021	PROPN
ajlm-1720	293	2	kohnke	kohnke	PROPN
ajlm-1720	293	3	t	t	PROPN
ajlm-1720	293	4	,	,	PUNCT
ajlm-1720	293	5	wittmann	wittmann	PROPN
ajlm-1720	293	6	vk	vk	PROPN
ajlm-1720	293	7	,	,	PUNCT
ajlm-1720	293	8	bucklein	bucklein	ADV
ajlm-1720	293	9	vl	vl	PROPN
ajlm-1720	293	10	,	,	PUNCT
ajlm-1720	293	11	et	et	PROPN
ajlm-1720	293	12	al	al	PROPN
ajlm-1720	293	13	.	.	PUNCT
ajlm-1720	294	1	diagnosis	diagnosis	NOUN
ajlm-1720	294	2	of	of	ADP
ajlm-1720	294	3	cll	cll	PROPN
ajlm-1720	294	4	revisited	revisit	VERB
ajlm-1720	294	5	:	:	PUNCT
ajlm-1720	294	6	increased	increase	VERB
ajlm-1720	294	7	specificity	specificity	NOUN
ajlm-1720	294	8	by	by	ADP
ajlm-1720	294	9	a	a	DET
ajlm-1720	294	10	modified	modify	VERB
ajlm-1720	294	11	five	five	NUM
ajlm-1720	294	12	-	-	PUNCT
ajlm-1720	294	13	marker	marker	NOUN
ajlm-1720	294	14	scoring	scoring	NOUN
ajlm-1720	294	15	system	system	NOUN
ajlm-1720	294	16	including	include	VERB
ajlm-1720	294	17	cd200	cd200	PROPN
ajlm-1720	294	18	.	.	PUNCT
ajlm-1720	295	1	br	br	PROPN
ajlm-1720	295	2	j	j	PROPN
ajlm-1720	295	3	haematol	haematol	NOUN
ajlm-1720	295	4	.	.	PUNCT
ajlm-1720	296	1	2017;179(3):480–487	2017;179(3):480–487	NUM
ajlm-1720	296	2	.	.	PUNCT
ajlm-1720	297	1	https://doi.org/10.1111/bjh.14901	https://doi.org/10.1111/bjh.14901	PROPN
ajlm-1720	297	2	mora	mora	PROPN
ajlm-1720	297	3	a	a	PRON
ajlm-1720	297	4	,	,	PUNCT
ajlm-1720	297	5	bosch	bosch	ADJ
ajlm-1720	297	6	r	r	NOUN
ajlm-1720	297	7	,	,	PUNCT
ajlm-1720	297	8	cuellar	cuellar	ADJ
ajlm-1720	297	9	c	c	NOUN
ajlm-1720	297	10	,	,	PUNCT
ajlm-1720	297	11	et	et	PROPN
ajlm-1720	297	12	al	al	PROPN
ajlm-1720	297	13	.	.	PUNCT
ajlm-1720	298	1	cd200	cd200	PROPN
ajlm-1720	298	2	is	be	AUX
ajlm-1720	298	3	a	a	DET
ajlm-1720	298	4	useful	useful	ADJ
ajlm-1720	298	5	marker	marker	NOUN
ajlm-1720	298	6	in	in	ADP
ajlm-1720	298	7	the	the	DET
ajlm-1720	298	8	diagnosis	diagnosis	NOUN
ajlm-1720	298	9	of	of	ADP
ajlm-1720	298	10	chronic	chronic	ADJ
ajlm-1720	298	11	lymphocytic	lymphocytic	ADJ
ajlm-1720	298	12	leukemia	leukemia	NOUN
ajlm-1720	298	13	.	.	PUNCT
ajlm-1720	299	1	cytometry	cytometry	PROPN
ajlm-1720	299	2	b	b	PROPN
ajlm-1720	299	3	clin	clin	PROPN
ajlm-1720	299	4	cytom	cytom	NOUN
ajlm-1720	299	5	.	.	PUNCT
ajlm-1720	300	1	2019;96(2):143–148	2019;96(2):143–148	NUM
ajlm-1720	300	2	.	.	PUNCT
ajlm-1720	301	1	https://doi.org/10.1002/cyto.b.21722	https://doi.org/10.1002/cyto.b.21722	X